,id,ticker,title,category,content,date,provider,url,article_id
127605,349120,MCK,Stocks making the biggest moves premarket  JP Morgan  Delta  GameStop  Visa   more,news,Check out the companies making headlines before the bell Citigroup  C    Citi reported quarterly profit of  1 90 per share  6 cents a share above estimates  Revenue also came in above Wall Street forecasts  The bank said growth in Citi s consumer business and a strong fixed income performance helped drive results Wells Fargo  WFC    Wells Fargo missed estimates on both the top and bottom lines  saying its expenses are too high and that it needs to become more efficient JP Morgan Chase  JPM    The bank reported quarterly profit of  2 57 per share  beating the consensus estimate of  2 35 a share  Revenue also came in above estimates  boosted in part by strong results for fixed income Delta Air Lines  DAL    The airline beat estimates by 30 cents a share  with quarterly profit of  1 70 per share  Revenue topped forecasts as well  CEO Ed Bastian told CNBC that the airline had a very strong holiday season and that Delta has had good success in de commoditizing its business GameStop  GME    GameStop said holiday season sales fell more than 25  and the videogame retailer also forecast a larger than expected drop in same store sales for fiscal 2019 McKesson  MCK    McKesson raised its fiscal 2020 full year outlook to  14 60 to  14 80 per share from the prior  14 00 to  14 60 a share  The drug distributor cited continued positive momentum in its business  and will give further details on its outlook at the J P  Morgan Healthcare Conference in San Francisco today Amazon com  AMZN    Amazon will ask a judge to block Microsoft  MSFT  from working on a  10 billion Pentagon cloud computing contract  Amazon is disputing the awarding of the contract  accusing President Donald Trump of exerting improper pressure on the Defense Department to favor Microsoft Visa  V    Visa will buy privately held financial technology startup Plaid for  5 3 billion  Plaid s technology helps link bank accounts to mobile apps  and is behind popular services like Venmo Boeing  BA    Boeing is offering very large discounts in order to keep orders for its currently grounded 737 Max jet  according to Britain s Telegraph newspaper  The paper said the discounts amount to more than 50  Zumiez  ZUMZ    Zumiez reported holiday season comparable sales of 6 8   with the specialty apparel retailer also raising its fourth quarter guidance Apple  AAPL    Apple was downgraded to  underweight  from  neutral  at Atlantic Equities  which said Apple s services and wearables businesses aren t likely to provide material upside Sysco  SYY    Sysco was downgraded to  neutral  from  overweight  at Piper Sandler  following the announcement that the food distributor s CEO Tom Bene would step down on Jan  31 after two years in that role Wesco International  WCC    Wesco was upgraded to  outperform  from  sector perform  at RBC Capital  after the industrial products distributor won a bidding contest to buy networking products maker Anixter International  AXE  for  100 per share in cash and stock ,2020-01-14,CNBC,https://invst.ly/phu02,2058849
127606,349121,MCK,McKesson EPS beats by  0 32  beats on revenue,news,"McKesson  NYSE MCK   Q3 Non GAAP EPS of  3 81 beats by  0 32  GAAP EPS of  1 06 
Revenue of  59 17B   5 3  Y Y  beats by  70M 
Press Release",2020-02-04,Seeking Alpha,https://invst.ly/pquti,2075307
127607,349122,MCK,Uber  UBER  To Report Q4 Earnings  What s In The Offing ,opinion,Uber Technologies   NYSE UBER    which went public on May 10  2019  is scheduled to report fourth quarter 2019 results on Feb 6  after market close The Zacks Consensus Estimate for the December end quarter is currently pegged at a loss of 69 cents  indicating a deterioration from the consensus mark of a loss of 66 cents 90 days ago  Given this backdrop  let s delve into the factors that might have influenced the company s performance in the said period Alike the first three quarters of 2019  high costs are likely to have adversely impacted Uber s fourth quarter 2019 performance  With Uber spending significantly on promotions and driver incentives to cope with competition from rivals like Lyft   NASDAQ LYFT   for higher market share  escalating costs are expected to get reflected in the company s bottom line results In a bid to cut costs and improve efficiencies  Uber trimmed its workforce  In October 2019  Uber reduced its headcount by roughly 350 employees  As a result  the surge in costs might have been mitigated to some extent  Moreover  the Core Platforms unit is likely to have performed well on the back of upbeat ridesharing revenues Ridesharing revenues are likely to have been boosted by Uber s endeavors to expand its operations  In line with its expansion efforts  in October 2019  the company increased its market share in West Africa by virtue of a boat service in the Nigerian city of Lagos  The Zacks Consensus Estimate for revenues from rides for the fourth quarter is pegged at  2 978 million  higher than the  2 895 million  reported in third quarter 2019  The Zacks Consensus Estimate for fourth quarter 2019 Uber Eats revenues is pegged at  699 million  higher than the  645 million  reported in the September end quarter Uber Technologies  Inc  Price and EPS Surprise   Highlights of Q3 ResultsIn the last reported quarter  Uber incurred a loss of 68 cents per share  narrower than the Zacks Consensus Estimate of a loss of 83 cents  Moreover  the amount of loss decreased year over year  Total revenues of  3 813 million beat the Zacks Consensus Estimate of  3 746 4 million and also rose 29 5  year over year What the Zacks Model UnveilsOur proven Zacks model does not conclusively predict a beat for Uber this earnings season  The combination of a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of beating estimates  However  that is not the case here  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Uber has an Earnings ESP of 0 00   as the Most Accurate Estimate is in line with the Zacks Consensus Estimate Zacks Rank  Uber carries a Zacks Rank  3  which increases the predictive power of ESP Stocks to ConsiderHere are some companies with the right combination of elements to beat on earnings in their upcoming releases McKesson   NYSE MCK   carries a Zacks Rank  2 and has an Earnings ESP of  0 07   The company will announce its third quarter fiscal 2020  ended Dec 31  2019  results on Feb 4 Spirit Airlines   NYSE SAVE   carries a Zacks Rank  2 and has an Earnings ESP of  3 24   The company is expected to announce its fourth quarter 2019 results on Feb 5  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/uber-uber-to-report-q4-earnings-whats-in-the-offing-200504056,200504056
127608,349123,MCK,Why Earnings Season Could Be Great For McKesson  MCK ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and McKesson Corporation   NYSE MCK   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because McKesson is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for MCK in this report In fact  the Most Accurate Estimate for the current quarter is currently higher than the broader Zacks Consensus Estimate of  3 54 per share  This suggests that analysts have very recently bumped up their estimates for MCK  giving the stock a Zacks Earnings ESP of  0 07  heading into earnings season McKesson Corporation Price and EPS Surprise    Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that MCK has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see Clearly  recent earnings estimate revisions suggest that good things are ahead for McKesson  and that a beat might be in the cards for the upcoming report Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-mckesson-mck-200504048,200504048
127609,349124,MCK,Should Value Investors Buy McKesson  MCK  Stock ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Of these  value investing is easily one of the most popular ways to find great stocks in any market environment  Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large 
On top of the Zacks Rank  investors can also look at our innovative Style Scores system to find stocks with specific traits  For example  value investors will want to focus on the  Value  category  Stocks with high Zacks Ranks and  A  grades for Value will be some of the highest quality value stocks on the market today 
One stock to keep an eye on is McKesson  MCK   MCK is currently sporting a Zacks Rank of  2  Buy   as well as a Value grade of A  The stock is trading with P E ratio of 9 53 right now  For comparison  its industry sports an average P E of 19 33  Over the past 52 weeks  MCK s Forward P E has been as high as 10 22 and as low as 7 94  with a median of 9 31 
MCK is also sporting a PEG ratio of 1 35  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  MCK s industry currently sports an average PEG of 2  Over the last 12 months  MCK s PEG has been as high as 1 48 and as low as 1 13  with a median of 1 33 
Another valuation metric that we should highlight is MCK s P B ratio of 3 96  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  This stock s P B looks solid versus its industry s average P B of 4 43  Over the past 12 months  MCK s P B has been as high as 4 21 and as low as 2 29  with a median of 3 21 
Finally  investors should note that MCK has a P CF ratio of 15 11  This data point considers a firm s operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook  This stock s P CF looks attractive against its industry s average P CF of 37 65  Over the past 52 weeks  MCK s P CF has been as high as 16 05 and as low as 7 02  with a median of 8 81 
Value investors will likely look at more than just these metrics  but the above data helps show that McKesson is likely undervalued currently  And when considering the strength of its earnings outlook  MCK sticks out at as one of the market s strongest value stocks ",2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-buy-mckesson-mck-stock-200504004,200504004
127610,349125,MCK,McKesson  MCK  Tops Q3 Earnings Estimates,opinion,"McKesson  MCK  came out with quarterly earnings of  3 81 per share  beating the Zacks Consensus Estimate of  3 54 per share  This compares to earnings of  3 40 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 7 63   A quarter ago  it was expected that this prescription drug distributor would post earnings of  3 60 per share when it actually produced earnings of  3 60  delivering no surprise 
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
McKesson  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  59 17 billion for the quarter ended December 2019  missing the Zacks Consensus Estimate by 0 42   This compares to year ago revenues of  56 21 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
McKesson shares have added about 4  since the beginning of the year versus the S P 500 s gain of 0 6  
What s Next for McKesson 
While McKesson has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for McKesson was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 18 on  55 61 billion in revenues for the coming quarter and  14 68 on  228 58 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 46  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-tops-q3-earnings-estimates-200504354,200504354
127611,349126,MCK,McKesson  MCK  Q3 Earnings Beat Estimates  Revenues Miss,opinion,McKesson Corporation s   NYSE MCK   reported third quarter fiscal 2020 earnings of  3 81 per share  which beat the Zacks Consensus Estimate of  3 54 per share by 7 6   Further  the bottom line improved 12 1  on a year over year basis Revenues came in at  59 17 billion  which missed the Zacks Consensus Estimate by 0 4   However  the figure improved 5 3  year over year Q3 Segmental AnalysisRevenues at the U S  Pharmaceutical and Specialty Solutions segment totaled  46 92 billion  up 6  year over year  Per management  the upside was primarily driven by branded pharmaceutical price increases and higher volumes from retail national account customers  However  branded to generic conversions partially offset the upside At the European Pharmaceutical Solutions segment  revenues amounted to  6 93 billion  up 0 3  year over year  Further  the metric rose 3  at constant currency  cc  on the back of growth in the pharmaceutical distribution business Revenues at the Medical Surgical Solutions segment totaled  2 14 billion  up 6 4  year over year  Growth in the Primary Care business  driven by higher volume of pharmaceutical products and an early start to influenza season  drove the upside Revenues at the Other segment were  3 18 billion in the fiscal third quarter  improving 5 7  year over year and 5  at cc  Growth in the Canadian business primarily contributed to the upside McKesson Corporation Price  Consensus and EPS Surprise    MarginsGross profit in the reported quarter was  3 03 billion  up 2 1  on a year over year basis  Meanwhile  gross margin was 5 1  of net revenues  down 20 bps Operating income in the quarter was  360 million  which plunged 47 3  from the year ago quarter figure of  683 million The U S  Pharmaceutical and Specialty Solutions segment reported adjusted operating profit of  658 million  up 11  from the prior year quarter  Adjusted operating margin was 1 4  at the segment Adjusted operating profit at the European Pharmaceutical Solutions segment amounted to  80 million  up 16  from the year ago quarter  Meanwhile  the adjusted operating margin at the segment was 1 2  The Medical Surgical segment had adjusted operating profit of  184 million  which improved 8  from the year ago quarter  Adjusted operating margin was 8 6  at the segment Adjusted operating profit was  214 million at the Other segment  down 4  from the prior year quarter Financial UpdateIn the quarter under review  cash and cash equivalents came in at  2 07 billion  up 52 3  sequentially Cash flow from operating activities for the nine months ended as of Dec 31  2019  came in at   280  million  against the year ago quarter figure of 141 million Fiscal 2020 Guidance ReiteratedMcKesson has reiterated fiscal 2020 guidance  announced Jan 13  2020   For fiscal 2020  the company projects adjusted earnings per share in the range of  14 60  14 80 Company UpdatesOn Dec 12  2019  McKesson and Walgreens Boots Alliance  NASDAQ WBA  announced an agreement to form a joint venture  JV  that is anticipated to combine their respective pharmaceutical wholesale businesses in Germany On February 4  2020  McKesson s wholly owned subsidiary  PF2 SpinCo  Inc   filed a registration statement with the Securities and Exchange Commission  SEC  with regards to a potential exit of the company from its investment in the Change Healthcare JV Summing UpMcKesson exited the fiscal third quarter on a mixed note  wherein the bottom line beat the consensus mark while the top line missed the same  Strong fiscal third quarter show by the segments   U S  Pharmaceutical and Specialty Solutions  Medical Surgical Solutions and Other   instills investor optimism in the stock  Further  management remains optimistic about the McKesson and Walgreens Boots Alliance agreement to form a JV that is anticipated to combine their respective pharmaceutical wholesale businesses in Germany Meanwhile  contraction in gross margin adds to woes  Price fluctuation of generic pharmaceuticals and stiff competition in the MedTech space remain concerns Zacks RankCurrently  McKesson carries a Zacks Rank  2  Buy  Earnings of Other MedTech Majors at a GlanceSome other top ranked stocks which reported solid results this earning season are Stryker Corporation   NYSE SYK    Accuray Incorporated   NASDAQ ARAY   and AmerisourceBergen Corporation   NYSE ABC    You can see  Stryker delivered fourth quarter 2019 adjusted EPS of  2 49  outpacing the Zacks Consensus Estimate by 1 2   Fourth quarter reported revenues of  4 13 billion surpassed the Zacks Consensus Estimate by 0 7   The company carries a Zacks Rank  2 Accuray reported second quarter fiscal 2020 adjusted earnings per share  EPS  of a penny  improving from the Zacks Consensus Estimate of a loss of 7 cents  Net revenues of  98 8 million outpaced the Zacks Consensus Estimate by 0 3   The company sports a Zacks Rank  1 AmerisourceBergen reported first quarter fiscal 2020 adjusted EPS of  1 76  which beat the Zacks Consensus Estimate of  1 67 by 5 4   The company has an expected long term earnings growth rate of 7 4   AmerisourceBergen carries a Zacks Rank of 2 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ,2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-q3-earnings-beat-estimates-revenues-miss-200504395,200504395
127612,349127,MCK,McKesson Corp  MCK  Q3 2020 Earnings Call Transcript,news,"McKesson Corp  NYSE MCK Q3 2020 Earnings CallFeb 4  2020  8 00 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorGood day  and welcome to McKesso s Q3 Earnings Call   Operator Instructions  At this time  I d like to turn the call over to Holly Weiss  Please go ahead Holly Weiss    Senior Vice President of Investor RelationsThank you  Jack  Good morning  and welcome everyone to McKesson s Third Quarter Fiscal 2020 Earnings Call  Today  I m joined by Brian Tyler  our Chief Executive Officer  and Britt Vitalone  our Chief Financial Officer  Brian will lead off  followed by Britt  and then we will move to a question and answer session Today s discussion will include forward looking statements such as forecasts about McKesson s operations and future results  Please refer to the cautionary statements in today s press release and our Slide presentation and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward looking statements During this call  we will discuss non GAAP financial measures  Additional information about our non GAAP financial measures including a reconciliation of those measures to GAAP results is included in today s press release and presentation slides  which are available on our website at investor mckesson com With that  let me turn it over the Brian Brian S  Tyler    Chief Executive OfficerThank you  Holly  and good morning  and thank you everyone for joining us on our call this morning  Before I get into our third quarter results  I wanted to take a few minutes to provide a brief update on opioid litigation  As you know we ve been engaged in complex discussions with the State Attorneys General and others about a settlement framework with the goal of achieving a broad resolution of opioid related claims  Those discussions continue to narrow what s left to address to achieve resolution on all the items that remain However  to the extent our efforts to reach a broad resolution settlement framework are unsuccessful  McKesson continues to be prepared to litigate and vigorously defend the miss characterization that our company drove the demand for opioids in this country  McKesson remains firmly committed to being part of the broader solution to this crisis  given however  the discussions and litigation are ongoing  I ll be somewhat limited in what I can say  I do appreciate your understanding Now let s get to our business results  Today  we reported third quarter total company revenues of  59 2 billion  Our adjusted earnings per diluted share was  3 81  and I m pleased with our third quarter and year to date execution across the majority of our businesses in our fiscal 2020 Also today  we reaffirmed our fiscal 2020 full year outlook of  14 60 to  14 80 of adjusted earnings per diluted share  which we first provided on January 13th  This reflected    this update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions segment  primarily driven by specialty  strength in our Medical Surgical segment  lower than anticipated corporate expenses  and the benefit from share repurchase activity in the third quarter  Our US Pharmaceutical and Specialty Solutions segment performed well in the quarter reflecting stable macro fundamentals and good execution  and was aided by the continued strong growth across our specialty businesses Let me walk you through the recent trends from an industry fundamental standpoint  For the third quarter  we saw branded price increases tracking in line with our expectations  and we continue to assume mid single digit branded price increases year over year for fiscal  20  For Generics  we remain disciplined in our approach to the market we are sourcing effectively through our scaled sourcing venture and the sell side remains competitive  but stable I d like to take a moment to acknowledge how pleased we are that the VA announced in December  it had again selected McKesson to be the prime pharmaceutical vendor beginning in August 2020  We have been the VA s prime pharmaceutical vendor for veteran hospitals and the department s mail order pharmacies for more than 15 years  This is a great point of pride for McKesson  and we re dedicated to hiring veterans and helping them build their careers after their service At McKesson  we have many employee resource groups celebrating and leveraging the diversity of our workforce and McKesson Military Resource Group or MMRG  as we refer to it internally provides opportunities for all employees to recognize and welcome veterans and their families to McKesson  MMRG offers networking opportunities  facilitates personal and professional development  supports McKesson s recruitment  hiring and retention of veterans and sponsors events within our communities for active duty military and veterans  I want to thank McKesson s veterans and every veteran really for their service  We re very proud to serve the VA  and we look forward to continuing our long standing partnership Moving to specialty  As you ve heard me discuss at several recent event we have a differentiated portfolio of assets and capabilities that we ve built over time with targeted internal and external investments  first  we distribute specialty pharmaceuticals via the traditional wholesale model to retail and hospital pharmacies  and although these products are margin rate dilutive we benefit from this growth at the topline and in our gross profit dollars  Next  we distribute specialty products that are primarily infused in the community based settings and typically require special handling including temperature control  We also provide other services like group purchase organization activities  data and technology services in oncology and other multi specialty practices And then we have our leading practice management business  specifically  the US Oncology Network  which now includes more than 1 200 oncology physicians providing 12  to 13  of all community based oncology care  we handle all aspects of managing the practice  so that the physician can focus on treating the patient  In addition  we re active in clinical trials  research and formulary development  The practice management business combined with the wholesale distribution and specialty product distribution and services business  are the scaled channels we leverage to provide services and solutions to our many biopharma partners  including commercialization  hub and patient assistance services We help manufacturers find patients that are appropriate and relevant for care  help them get started on that therapy sooner and work to keep them adherent to that therapy for the course of their treatment  This results in a patient getting the best possible outcome from their treatment  These services  not only support better outcomes for patients  but they also provide tremendous value to our manufacturer partners  We re really pleased with the growth we re seeing across these businesses  and we remain focused on specialty as a key tenet of our strategic direction  We are also pleased that we are returning to growth in the US Pharmaceutical and Specialty Solutions segment in fiscal 2020  while continuing to invest in our future Now let me turn to Europe  In mid December McKesson and Walgreens announced a joint venture agreement that we expect will bring together our respective wholesale operations in Germany  After a review of our business in Germany  we believe this is the right course of action as the combined business will have large reach and scale  driving increased efficiency and performance in a market where scale is vitally important  The transaction is subject to merger clearance and approval and that process is expected to take at least six months from the time of the announcement  As such  this transaction will not have any impact on adjusted earnings in our current fiscal year In the UK  we continue to monitor the retail pharmacy funding dynamics  As we detailed earlier in the fiscal year  the retail pharmacy industry experienced underfunding by the NHS in our first quarter  While there was a modest improvement in our fiscal second quarter further upward revisions have not yet been implemented  We continue to monitor the situation in the UK closely and engage in active dialog with NHS related to industry funding and the role pharmacy can play in managing NHS  overall cost  quality and access challenges  Outside of the UK  we re continuing to see performance in line with our expectations for the other countries in this segment Next our Medical Surgical business again this quarter  we had good growth across multiple markets  such as our home care delivery business and product categories  including pharmaceutical sales into the primary care space  Customers are repeatedly choosing McKesson  because of our relentless focus on providing what they need to take care of their patients  we differentiate ourselves in the marketplace through innovation and a focus on operational excellence  breadth of product and service offerings along with one of the largest and most tenured sales forces in the industry  We also saw an early start to the influenza season in the third quarter  which we are continuing to monitor for severity and duration  In addition  our results continue to reflect the integration of the MSD acquisition  which we lapped during our first quarter and our focus is now on driving synergies  This acquisition continues to perform in line with its business case Turning to other  which primarily consist of Canada  McKesson Prescription Technology Solutions sometimes referred to as MRXTS and our investment in Change Healthcare  In Canada  we re now capturing the benefits of previous actions we ve taken including our investments in people and in reconfigured pharmacy formats as community pharmacy plays an important role in Canadian healthcare and market fundamentals are stable  which helped to drive growth in our wholesale operations year over year  In addition  McKesson Canada also has broad specialty assets and capabilities and we are well positioned to participate in the growth of specialty in the Canadian market Moving on to MRXTS  which is a key area of investment  We re making investments to ensure we have the right product and personnel resources in place to support the growth trajectory of these businesses and we re looking to launch new products that leverage our existing technologies and build upon them  As we look at how MRXTS is performing year to date  we re pleased with the growth in the business  which is net of several investments we are making to drive and support our future growth Let s move on to Change Healthcare  As we ve discussed previously  we continue to take the customary steps toward an exit of our investment in Change Healthcare  as part of the exit process registration statements were filed today with the SEC  The previously discussed timing  expectations are unchanged and this is simply a necessary step as we move through the process of exiting our investment in Change Healthcare Recently  you ve heard me talk about aligning McKesson under one vision to improve care in every setting one product  one partner  one patient at a time  We ve been transforming and energizing the culture of McKesson  We ve got a great collaborative workspace at our new headquarters in the Dallas area  we ve rolled out new enterprise behaviors  building on the already strong foundation of our ICARE and ILEAD values  and getting everyone aligned around our strategy and how we want to work together to execute it  We re looking to become a simpler  more focused and nimbler organization  we centralize some of our functions and are looking at ways to work more efficiently and to utilize technology for day to day tasks that can be automated  freeing up time to focused on strategy  work that drives value for the organization and better leverages our teams We re seeing great execution across the enterprise  including cost savings as we track toward our target of  400 million to  500 million in gross pre tax savings by the end of our fiscal 2021  Our organization has rallied around these efforts and it s showing in the culture and the results  but could not be prouder of the McKesson team  And with one quarter to go in fiscal  20  I m confident in our reaffirmed adjusted earnings outlook of  14 60 to  14 80 per diluted share  As we look forward  we re in the initial stages of planning for our fiscal 2021 Let me walk through some of the things we re thinking about  The timing and impact of the exit of our investment in Change Healthcare as exit activities are currently under way  For customer renewals  the VA contract goes into effect in August 2020  As a reminder  we ve stated that this new contract will not be a material headwind to our fiscal 2021 outlook  We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom line and a portion being reinvested for growth And finally  from a capital allocation perspective  we would anticipate benefits from share repurchases completed in fiscal 2020  As you think about the market and the macro perspective in the US we re entering an election year  and we ll make assumptions related to any potential impact we might expect based on our analysis  including related to drug pricing trends McKesson will continue to engage with policymakers and industry partners to ensure that any reforms support solutions to improve cost  quality and access  The policy landscape remains a dynamic environment and we remain confident in McKesson s path forward As it relates to the UK  we re continuing to monitor the market environment in NHS funding  as well as Brexit activities  We will review our businesses and expectations  including the impact of external factors and we ll provide our fiscal 2021 outlook in May  when we report fourth quarter and full year fiscal 2020 earnings Before I turn the call over to Britt  I want to take just a moment to thank Kathy McElligott  who just retired from McKesson and her role as Chief Information   Technology Officer  she helped McKesson increase its focus on data and analytics and accelerate our technology modernization  Kathy  thank you for your contributions to McKesson And on the flip side  I d like to also welcome Nancy Flores  who is succeeding Kathy as CIO and CTO  Nancy has a long track record of success in Healthcare IT  and we look forward to utilizing her experience as we remain focused on our mission to improve Healthcare in every setting by leveraging technology solutions for our company  our customers and our business partners And with that let me turn the call over to Britt to go through the financials Britt Vitalone    Executive Vice President and Chief Financial OfficerWell  Thank you  Brian  and good morning everyone  I m pleased to be here this morning to talk about a solid third quarter for McKesson s  I ll focus on our third quarter results and full year fiscal 2020 guidance  including changes you need to consider as you update your models Brian walk you through high level of puts and takes as we think about our fiscal  21 guidance and will provide detailed assumptions for fiscal  21 when we report fourth quarter and full year results in May  We re pleased with our adjusted operating profit and adjusted earnings per diluted share results in the third quarter  which were ahead of our expectations and represent solid execution  We continue to see momentum across the business  as we execute against our strategic initiatives As a result of this momentum and based on the confidence in our fourth quarter outlook on January 13th we raised and narrowed our fiscal 2020 adjusted earnings outlook to a range of  14 60 to  14 80 per diluted share from the previous range of  14 to  14 60 per diluted share  and today we re reaffirming that adjusted earnings per diluted share guidance  Updated guidance assumptions can be found in our third quarter earnings slide presentation  which is posted on our Investor Section of our website Before I provide more details on our third quarter adjusted results  I want to address one item that impacted our GAAP only results in the quarter  During the third quarter  we recorded a pre and post tax charge of  282 million for the remeasurement to fair value of the net assets and the majority of McKesson s German wholesale business  in relation to the expected formation of a new German wholesale joint venture with Walgreens Boots Alliance Moving now to the adjusted earnings results for the quarter  Our third quarter adjusted EPS was  3 81  an increase of 12  compared to the prior year  which was primarily driven by organic growth in US Pharmaceutical and Specialty Solutions segment  the Medical Surgical segment and the European segment  To better understand our third quarter results  let me remind you of two discrete events in our prior year s third quarter  both within our US Pharmaceutical and Specialty Solutions segment  first  the  60 million pre tax charge related to the bankruptcy of Shopko and second a pre tax benefit of approximately  17 million related to the reversal of accrued New York State Opioid Stewardship Act charges  If you normalize for these two items  Q3 s fiscal 2020 adjusted earnings per diluted share increased 7  Moving to the details of our consolidated results on Slide 4  Consolidated revenues for the third quarter increased 5  versus the prior period  primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment  driven by branded pharmaceutical price increases and higher retail national account volumes  We continue to anticipate mid to high single digit percent consolidated revenue growth for the full year Third quarter adjusted gross profit increased 4  year over year  principally due to organic growth in our Medical Surgical and US Pharmaceutical and Specialty Solutions segment  Third quarter adjusted operating expenses increased 3  year over year  driven by higher corporate expenses  which include planned technology investments  Adjusted income from operations was  958 million for the quarter  which was up 4  year over year or 5  on an FX adjusted basis  As a result of this solid performance and our updated outlook  we are guiding full year adjusted income from operations to increase to low single digit percent Interest expense of  64 million in the quarter declined 4   compared to the prior year and our adjusted tax rate was 17 1  for the quarter  which included discrete tax benefits of approximately  36 million  For the full year  our adjusted tax rate assumption remains approximately 18  to 19   Wrapping up our consolidated results  our third quarter diluted weighted average shares were  180 million  a decrease of 8  year over year  During the quarter we completed approximately  500 million of share repurchases  bringing our year to date total share repurchases to  1 9 billion  As a result we now expect diluted weighted average shares of approximately  183 million for the year Next  I ll review our segment results  which can be found on Slides 5 through 8  Before I start with my review of the segments  including updated full year guidance  I want to reiterate that we provide full year guidance and do not provide quarterly guidance  As a reminder  there are a number of items  particularly in our largest segment  US Pharmaceutical and Specialty Solutions that can cause fluctuations on a quarter to quarter basis  While  this can make comparing year over year results on a quarterly basis difficult  these items do tend to balance out over the course of the year  These items include customer volumes  customer and product mix  brand price increases and the timing of discrete tax items  We anticipate that there could be additional fluctuation in our fourth quarter results Let me now start with US Pharmaceutical and Specialty Solutions  Revenues were  46 9 billion for the quarter  up 6  driven by branded pharmaceutical price increases and continued growth by our largest retail national customers  partially offset by branded to generic conversions  Third quarter adjusted operating profit increased 11  to  658 million  primarily driven by the execution and growth in our differentiated portfolio of specialty businesses As I mentioned earlier  there were two discrete items included in our prior year third quarter results  a  60 million pre tax charge related to the bankruptcy of Shopko and a pre tax benefit of approximately  70 million related to the reversal of accrued New York State Opioid Stewardship Act charges  If you adjust for these two prior year items  the segment adjusted operating profit was up 3 5  year over year in the quarter Also as a reminder  this is the final quarter in which we are lapping the effects of the loss Shopko earnings  which was approximately  8 million per quarter in terms of operating profit  The segment adjusted operating margin rate was 140 basis points  an increase of 6 basis points  On a year to date basis  the segment adjusted operating profit is up 7   If you adjust for the prior year impact of the  60 million pre tax charge related to the bankruptcy of Shopko  and the prior year earnings contribution of approximately  24 million from three quarters of Shopko results  Segment adjusted operating profit increased 5  year to date For the third quarter  brand priced activity trended in line with our expectations  Additionally  based on manufacturer price actions taken in January  we are maintaining our full year fiscal 2020 assumptions of brand price increases to be in the mid single digit percent range  I would remind you that our branded pharmaceutical contracts are primarily fixed fee for service rate in nature  And as a result  our compensation with branded manufacturers is less impacted by price increases  when compared to several years ago  To wrap up the segment given the underlying strength in the quarter and the year to date performance  we have confidence that segment adjusted operating profit growth will be on the high end of the previously provided range of 3  to 5  growth for fiscal 2020 Next European Pharmaceutical Solutions  revenues were  6 9 billion for the quarter  which was flat year over year  On an FX adjusted basis  revenues increased 3   driven primarily by market growth in the Pharmaceutical Distribution business  Segment adjusted operating profit was up 16  to  80 million  driven in part by lower operating expenses as a result of actions previously taken to rationalize store footprint and streamline back office functions  The segment adjusted operating margin rate was 116 basis points on a constant currency basis  an increase of 16 points Moving now to Medical Surgical Solutions  revenues were  2 1 billion for the quarter  which was up 6   driven by organic growth led by the primary care business including higher pharmaceutical volumes and in earlier start to the influenza season  Segment adjusted operating profit for the quarter was  up 8  to  184 million  driven by organic growth  The segment adjusted operating margin rate was 859 basis points  an increase of 14 basis points Year to date  the segment adjusted operating profit growth is 18  as a result of the organic growth in this segment year to date  we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low double digit percent year over year  In finishing our business review with other  revenues were  3 2 billion for the quarter  which was up 6   driven primarily by organic growth in the Canadian wholesale business  Other adjusted operating profit was down 4  to  214 million in part driven by higher strategic product investment in our Prescription Technology Solutions business or MRXTS  partially offset by growth in our Canadian wholesale business Closing our segment review with Change Healthcare  Adjusted equity income from Change Healthcare was  51 million for the quarter  As a reminder  our equity investment ownership in Change Healthcare was approximately 58 5  in our fiscal third quarter 2020  as compared to 70  in the prior year  As Brian mentioned earlier registration statements were filed this morning with the SEC disclosing our intention to exit our investment in Change Healthcare via an exchange offer  This is the next step in the process to exit our investment in a tax efficient manner  I direct you to today s filing for additional information Next McKesson recorded a  178 million in adjusted corporate expenses  which was an increase of 29  year over year  driven primarily by planned technology investment  which included investments in data and analytic capabilities  For the third quarter  we reported net opioid related adjusted operating expenses of  36 billion and year to date  108 million  For fiscal 2020  we continue to anticipate that opioid related costs will approximately be  150 million We continue to make solid progress against our cost savings programs  which include a focus on our core operating expenses by leveraging the scale of our enterprise and the continued transformation of back office functions  We remain on track with our previously announced annual pre tax savings of  400 to  500 million  which is anticipated to be substantially delivered by the end of fiscal 2021 As we ve discussed a portion of these savings will be reinvested back into the business in line with our growth initiatives and the remaining will flow to the bottom line  As a result of our performance year to date  we now anticipate adjusted corporate expenses to be in the range of  660 million to  700 million Now that I ve wrapped up our results  let me discuss our updated fiscal 2020 outlook  We feel really good about our steady execution throughout fiscal 2020  The recent narrowing an increase to our fiscal 2020 adjusted earnings per diluted share to a range of  14 60 to  14 80 reflects the following  solid core performance in our US Pharmaceutical and Specialty Solutions segment  driven by continued strength across our differentiated portfolio of Specialty businesses  organic growth in our Medical Surgical segment  improved second half performance in our European segment  as compared to the prior year  lower corporate expenses and originally anticipated and a lower share count as a result of share repurchase activity year to date This solid performance was partially mitigated by continued planned investments and strategic initiatives  including incremental second half investment in our differentiated oncology in manufacturer services businesses  investment in our technology products and investment in technology infrastructure  including data and analytics  We remain confident that we are well positioned to execute in our fourth quarter Turning now to cash  which can be found on Slide 10  We ended the quarter with a cash balance of  2 1 billion  in the quarter McKesson used  121 million of cash flow from operations  after deducting  154 million in internal capital investments the customer had negative free cash flow of  275 million  I would remind you that our working capital metrics and resulting cash flow may be impacted by timing  including the day of the week that marks the close to the given quarter  it is not uncommon to experience net cash    net use of cash during our fiscal third quarter  primarily driven by the build in inventory for the holiday season In our fiscal fourth quarter  we typically generate more than two thirds of our annual operating cash flow  During the quarter  we repurchased approximately  500 million of common stock  We ve now repurchased approximately  1 9 billion in common stock for the first nine months of the fiscal year  The repurchase of our common stock underpins our belief that McKesson shares are undervalued combined with the confidence in our execution and our outlook  we view this as a prudent use of capital For the first nine months of the fiscal year  McKesson paid  97 million for acquisition and  222 million in dividends  We now expect internal capital investments to be in the range of  500 million to  600 million  we continue to anticipate free cash flow in the range of  2 8 billion to  3 billion In closing  we are pleased with the solid operational results of our fiscal third quarter and our performance year to date  we will build on our third quarter performance and we remain confident in our business as we focus on a strong finish to the year  which is reflected in our expected adjusted earnings per diluted share range of  14 60 to  14 80 for fiscal 2020  As I look at our performance over the past several quarters and our outlook for the remainder of fiscal  20  it clearly demonstrates focus and execution against our strategy  as well as continued steady improvement in our financial results With that  I ll turn the call over to the operator for your questions  In the interest of time I ask you to limit yourself to just one question and a brief follow up to allow others an opportunity to participate  Operator Questions and Answers OperatorThank you   Operator Instructions  And our first question will come from Charles Rhyee with Cowen  Your line is open Charles Rhyee    Cowen   Company    AnalystYes  Thanks for taking the question  Maybe Brian I can start with the    just on opioids real quickly  What are the remaining points that are being negotiated  You kind of said that the negotiates are going well or it seems to be progressing and some of the points are being resolved  Maybe you can give a sense of what are some of the remaining kind of sticking points  perhaps  And if I understand correctly  the framework is being discussed among    was being led by four state attorney general  During these kind of discussions are we    other constituents let s say the other states or some of the bigger municipalities that are in this lawsuit or part of this of multidistrict litigation  Are they able to sort of see the progress  as well and understand what is being negotiated  so that when we get to maybe a final framework  the process for them to review and to accept is kind of in tandem or is that    or is this kind of being done close    kind of  a close session and then opened up later Brian S  Tyler    Chief Executive OfficerThank you for the question  Charles  And I think the way you framed the question  naming the number of parties or counterparties or folks involved in this discussion helps to frame why it s moving at the cadence that it s moving  We do continue to be in constructive dialog with the AGs  The AGs have broadened their group and they continue to talk among themselves The good news from my perspective is the basic framework that we ve laid out is still the framework that s being discussed and the details for the many component parts of that are progressing well  There is still a long way to go with regard to ultimately getting as broad of AG support as we can  and then AGs themselves going to their subdivisions and extending that broad support  So there is a lot of work that is ongoing  The discussions are really continuous  it d be too early for me to try to project a timeline or where the finish line might be  but I am pleased that the framework that we ve been negotiating continues to be the framework  the details are progressing and I think you    as we get through the coming months we ll begin to assess what the various AG and sub municipality just positions are Charles Rhyee    Cowen   Company    AnalystGreat  If I could have a follow up just on the core business  obviously you increased your outlook on the core Pharmaceutical segment here  you know  it s seems a lot of things are moving in the right direction  Is there anything you d point to specifically that is going to driving the improved outlook here  Thank you Brian S  Tyler    Chief Executive OfficerMaybe I ll start  and then Britt might want to offer a few comments  I mean  I think if you think about the general kind of industry fundamentals  The brand price inflation has been in line with where we thought it would be  the generic market is continuing to behave in a way that we had forecast  and then by that I mean our sourcing  our skilled sourcing entity continues to produce are in line with our anticipation  We are going in the market with a very disciplined approach  reflective of the transition  our industry has been in  And we think that the competitive    the sell side in the generics market remained stable  I mean  it s competitive and there s pressures  but it s stable I think we re seeing the benefits of a lot of the work and planning that we ve been    the last several quarters  we ve been executing and implementing  And so combining that I think with the market fundamentals and our really good positions in specialty is driving the results that you see Britt Vitalone    Executive Vice President and Chief Financial OfficerMaybe I might just add  I think Brian you hit on it here  The focus and our execution against our differentiated assets particularly specialty and you talked a lot about that  I think is really driving a lot of this  And then I would just reiterate that our cost programs are really driving not only in our corporate line  but also across our segment and so that focus is not only on our core set of differentiated assets  but just the discipline and focus around cost for us not only our corporate segments  but our business segments Charles Rhyee    Cowen   Company    AnalystOkay  thank you Brian S  Tyler    Chief Executive OfficerThank you  Charles OperatorAnd next will be Brian Tanquilut with Jefferies Brian Tanquilut    Jefferies    AnalystHi  good morning and congrats on a good quarter  So I guess the question for me  as I think about Brian  you talked about the execution  and how are you guys seem really positive about it  So how do you think about the runway remaining in specialty as we head into fiscal   21 without going into guidance  specifically  And just how you re looking at the volume outlook from the key accounts  because it sounds like that s a volume driver that s been driving some upside as well  Thanks Brian S  Tyler    Chief Executive OfficerYes  I mean  we re really pleased with our specialty businesses  we talked a few weeks ago about  you know  the  core  the distribution of these products to hospitals and retail pharmacies is being our biggest segment  clearly we benefit there from the growth that these products have just in general and the pipeline  If you look at the pipeline of the innovative products coming they tend to look that way and as you know and we ve got established scaled channels across both of these segments  And then if you think about the community setting  oncology we have a clear leading stake we re a leader in many of the other multi specialties settings  they re going to benefit from that same pipeline And I also think  if you step up from a more macro view  if you think about the challenges that the cost of healthcare represent in this country  We have a fundamental belief that to get access  cost and quality  care needs to continue to shift in just their community based settings  So that s where our community provider business  I think from a macro standpoint is well positioned  And then our US oncology business we have particular depth and strength in oncology and if you look at the pipeline there that continues to be strong  So I would say  all of those things are what are giving us our confidence  but at the bottom    at the end of the day  it s really the execution of the business that led to capitalize on those macro trends and opportunities Brian Tanquilut    Jefferies    AnalystI guess my follow up Britt  you mentioned the cost cuts and the opportunities that you ve found there  So do you think there is a lot of runway left as we think about cost opportunities both in the corporate side and also on the operation side Britt Vitalone    Executive Vice President and Chief Financial OfficerOur cost program  Brian  What we talked about we would capture these cost savings at the end of fiscal  21  So we re still making progress not only in leveraging the scale of our enterprise across all of our business units  But some of the things that we ve talked about previously in terms of back office function  transformation  and there s still opportunities there as  you know  the size of our enterprise allows us to continue to work across and collaborate and drive additional cost synergies So I would say that  that program as we talked about is    we expect it to be substantially complete by the end of fiscal  21  However  as the business grows and our focus on execution in specialty continues there are still opportunities for us to leverage our scale and transform our back office functions Brian S  Tyler    Chief Executive OfficerI mean  efficiency    the core part of the way you have to run a business like this at this scale  So it is a program that we implemented a few years ago  but most importantly to me it s a mindset  it s part of the way we think about how we manage and run the business Brian Tanquilut    Jefferies    AnalystGot it  Thank you OperatorAnd next will be Robert Jones with Goldman Sachs Robert Jones    Goldman Sachs    AnalystGreat  thanks for the questions  I guess just to go back to the segment guidance and specifically the US Pharma segment  it seems like if I look at what s implied with 4Q  at the high end it seems like you re kind of calling for year over year flat EBIT there in that segment  I know there s a number of moving pieces Britt  But maybe could you just help us think about what the major swing factors are in 4Q  because you guys highlighted the business there in particular specialty seems to be performing well and there s some momentum  but it seems like 4Q you re implying at least the things could potentially slow a bit  So just want to make sure we had the moving pieces there correctly Britt Vitalone    Executive Vice President and Chief Financial OfficerYes  Sure  Bob  that s    you re right about the implied  What I would just going back to end point out is that I ve talked about in the business  the size of ours with customers that are growing and you have mix that is changing in terms of customer and product mix  We are going to see fluctuations from quarter to quarter  We ve seen that historically  I think we re seeing that a little bit more this year some of our larger retail national customers are growing a little bit faster  And I think  what we re pleased with though  as Brian talked about there s some stability in the pricing environment  particularly with branded pricing certainly continue to see good progress against generics But what you should expect as I talked about at the beginning is that we are going to see some items that are going to fluctuate from quarter to quarter  We don t manage our business that way  we manage our business for the long haul  we look at our business on an annual basis and these items do tend to balance out over the course of the year  We re very pleased that we started the year with being able to guide back to growth in this segment  And we re very pleased that given the momentum and the execution that Brian talked about particularly in our specialty business we could raise that guidance today to the upper end  So we re making good progress  but I think you should expect to continue to see some fluctuation in our quarterly results Robert Jones    Goldman Sachs    AnalystThat s fair  And then I guess  Brian  you opened the door to a little bit of preliminary 2021 thoughts  and so I know we ll get more detail in May  But if I heard you correctly  it sounds like court drivers playing out in line this year with your expectations  you guys have highlighted the VA is not a material headwind sounds like cost savings will continue  it could be a benefit from capital allocation  you know  all have seem pretty neutral to tailwinds  Is there any major headwinds  you would have us start to contemplate as we start to think about framing 2021 more specifically well Brian S  Tyler    Chief Executive OfficerWell  look  as    as we come to May  we ll try to be very thoughtful and share with you our view of the thinking  If I think about what could materialize as headwinds  I mean  the policy arena has been dynamic  Well  probably for most of my career  but certainly for my tenure as CEO  And yet while the clouds always seem to be gathering nothing has really materialize  I would suspect we ll hear some commentary tonight  I think as we come into the face of election year we ll be evaluating not only the policy proposals  but the politics that s around    that sort of set the framework for the likelihood of any of that really getting done  But to me that s just that s a normal part of being in healthcare  a normal part of being in this business I think our European business  it s coming off of a good quarter  but our experience there particularly in the NHS  as been challenges around being    having good line of sight into how the reimbursement mechanisms really play out  And so while we re encouraged that we have a five year macro agreement with NHS for the pharmacy community there  I think underneath the nuances of the timing and the different mechanisms that make up that framework  we ll have to continue to monitor and evaluate  So  I mean those are the two things that first pop to mind  Anything you want to add Britt Britt Vitalone    Executive Vice President and Chief Financial OfficerNo  I think you ve captured them correctly  Brian OperatorAnd next will be Lisa Gill with JPMorgan Lisa Gill    JPMorgan    AnalystGood morning  Brian  I just want to follow up on that last point  as you talk about the policy arena  Clearly  specialty has been a growth area  you ve talked the whole call about specialty  What are your thoughts around IPI and what it could mean to your specialty business And then secondly  as we think about the European markets  what have you learned from the European markets where it is a fixed cost environment versus here in the US Brian S  Tyler    Chief Executive OfficerGreat  Thanks  Lisa  I ll take the IPI business first    the question first  So IPI is    I guess there s been a lot of different constructs around getting to Part B  there s been discussions of caps or limiting ASP rates  future caps on allowable inflation  IPI would be a proposal to index what the US pays based on a basket of internationally referenced prices for various products  And I think there s even been some debate or discussion around MFN  our most favored nation  type clauses  So the proposals have really been very wide in the spectrum and without commenting on any of them specifically  I would say  first and foremost  we think any reform in Part B should be constructed and we work with industry  the government and our partners to advocate for this in a way that pushes care into the community  It s clearly the low cost  high access setting  and we believe it has extremely high quality as well  So it kind of hits all the three macro principles And so anything    any reform that were to happen  in our view should move care to the community  Anything that would move the opposite way would be counterproductive  really  for the US spend on healthcare in general  Now relative to IPI  if something were to occur the way I think about this is in most instances  in our core pharma distribution  in our community provider setting  This is an implication to our customer  so it will be a secondary effect really from a wholesaler perspective  The one place we would have some exposure would be in the US Oncology Network  where I remind you  through our partnership we share in the practice economics  So we continue to watch this very closely  I m not sure there has been a proposal that s had more commentary and more aligned commentary to kind of come out against it  because of the impact potentially the patients and patient access and cost of care  But I suppose we ll see what we hear tonight Lisa Gill    JPMorgan    AnalystGreat  And then just my follow up  I just    Britt  you talked about the change exit as being one of the key component to 2021  And you said it s consistent with what you ve said before  Can you just remind us what you ve said before on the timeline of the exit Britt Vitalone    Executive Vice President and Chief Financial OfficerSure  Lisa  So what we ve said previously  dating back to our Q2 earnings call from that point in time  we would expect to exit our transaction in six to 12 months  although that it could be before the end of our fiscal 2020  So I would reiterate that language today OperatorAnd next will be Ricky Goldwasser with Morgan Stanley  Your line is open Ricky Goldwasser    Morgan Stanley    AnalystYes  Hi  good morning  I have a follow up question on the cost cutting initiative  I think you reduced your corporate expense guidance by about  45 million  So part of it is flow through of cost savings to the bottom line and some timing of investments  By our calculations  it s about  0 18 to the EPS  So as we think about the ongoing benefit of cost cutting  can we just  kind of  like run rate that  45 million that you saw in the fourth quarter Britt Vitalone    Executive Vice President and Chief Financial OfficerYes  Let me answer that  Ricky  Certainly  we are pleased with the progress that we re making against our cost initiatives  And I d reiterate that we expect to generate  400 to  500 million of savings by the end of  21  So the cost programs are ongoing  As I called out at the beginning of the year  there were some additional investments that we were going to be making  particularly in the areas of information security management and data and analytics  We are continuing to make those investments  but we re seeing good efficiency across the organization  So I don t think you can necessarily take our performance this quarter and just run it out  We re continuing to make investments in the business  but we re also continuing along getting the efficiencies from scale in some of the back office functions  So we wanted to do today was to update our guidance based on some of the benefits that we ve seen in performance and execution  but we re continuing to make investments along as we generate those savings Ricky Goldwasser    Morgan Stanley    AnalystOkay  And then one follow up on Change  I mean  obviously  I understand that the exit is tax efficient  But can you just remind us directionally  kind of  like the mechanics  Should we expect Change    what should we expect in terms of impact  would it be neutral to EPS accretive or dilutive  And same  how should we think about  just directionally  the impact to cash Britt Vitalone    Executive Vice President and Chief Financial OfficerYes  So let me just remind you that today is a filing that is another step along our exit  We have nothing that is included in our FY 20 guidance related to Change  So there s no additional information that I can provide you on that  And in terms of when we exit  spending on    regardless of how we exit  there ll be no cash impact OperatorAnd next will be Elizabeth Anderson with Evercore Elizabeth Anderson    Evercore ISI    AnalystHi  good morning guys  I guess with a broader long term picture on the specialty side  How do we think about the    like  the ramp up in sort of additional specialty services you re providing  particularly on the US Oncology side  but maybe also in the core business and sort of    are there sort of key moments that cause either providers or other customers to sort of take up that services  Is it something gradual  I just sort of looking for like a longer term vision of that Brian S  Tyler    Chief Executive OfficerYes  it s a great question and it s obviously an area that we have some excitement about  And we have spent  really  a good part of the last 10 or 15 years building out some through internal development and some through acquisition  a set of capabilities that are really oriented around helping manufacturers identify which patients are appropriate and should be benefiting from their therapy  finding those patients and getting them started on that therapy  and then ensuring that they stay on that therapy through the full clinically appropriate course  so that they can get the best possible outcome So the first good news in that is that the patient gets the best outcome and we think it s good for the patient  it s good for the healthcare system  Obviously for our biopharma partners that can result in more patients benefiting from their products that has obvious benefit to them and that s a service therefore  they re quite interested in paying us for it  So as we think about building off of really our 20 year experience in this marketplace  building off of the sets of assets that we ve acquired for the commercialization of these products  there is opportunities to both refine and deepen and develop the tools we offer today  A few weeks ago  I shared an example of a program like that we re calling Access for More Patients  which fundamentally is getting at the same issue  but it s doing it in a more automated  efficient way that lets us get more    find more patients and get them on those therapies faster As we look at that as a core we think there are opportunities to extend downstream and to get earlier stage services to support pharmaceuticals and as we think about some of our provider segments there is opportunity to do some integration with providers downstream  So this is an area that we think as you look at the pipeline  as you look at the products  as you look at what s happening in terms of  you know  in the clinical trial space and the fragmentation of populations  that there s going to continue to be a good opportunity here for McKesson Elizabeth Anderson    Evercore ISI    AnalystPerfect  That s really helpful  Thank you OperatorAnd next will be Eric Coldwell with Baird Eric Coldwell    Robert W  Baird    AnalystThanks  good morning  So maybe just focus on the Med Surg segment for a second  you ve mentioned the early flu season consistent with peers  I m curious  if you could carve out for us what you think the incremental benefit of early flu was or heavy flu  And then I know it s probably a bit early and maybe evolving situation  but coronavirus any issues with sourcing out of the Asia Pac region or pricing changes  demand changes in the US as maybe some facilities pre stock on certain gloves  gowns  masks etc  Just any questions on    or answers on coronavirus impact so far would be interesting  Thanks so much Britt Vitalone    Executive Vice President and Chief Financial OfficerGood morning  Eric  This is Britt  I ll take the first one and let Brian comment on the second  As I talked about in my remarks we re really pleased with the performance of the medical business  We had good organic growth really across our business  but primarily in our primary care business  And I also called out higher pharmaceutical volumes as one of the drivers  We did see some modest impact from early flu season  I would remind you  though  that typically the flu season has a larger impact on our fourth quarter than our third quarter  We did plan the year for a normal flu season  So we saw a little earlier start than we had anticipated  But again  I would just remind you that the strong core organic growth across our primary care business  which is inclusive of higher pharmaceutical volumes  was really the driver for the performance Brian S  Tyler    Chief Executive OfficerI ll take the coronavirus  Maybe before that  we ve been around this business for a long time  And we chart every year with the flu season    influenza season looks like in the US and every season is it s own    has its own cycle or rhythm  if you will  And so I think we    it s fair to say we have seen an early start ultimately how that plays out will depend on the duration and the severity  and it s probably hard to predict that right now Relative to coronavirus  I guess let me start by first saying our thoughts and sympathies go out to those particularly in China  but really Asia that are obviously dealing with this in a very real time way  We at McKesson have really been working across industry partners  peers  trade associations  government agencies for the better part of three or four weeks  so we try to jump on these things early and get ahead of them  And so we re monitoring this very  very closely  I would remind everybody that we don t manufacture these products  we procure them  we sell them and we distribute them  And we do have a domestic supplier base  although the majority of the products  the masks and the disinfectants and the gowns  are sourced from Asia or China I guess  fortunately or unfortunately  depending on your perspective we ve had some experience with SARS and H1N1  And so what we re doing is implementing the protocols  the monitoring capabilities that we ve built up through these prior experiences and working in close coordination with government agencies and industry partners to make sure we can keep this continuity of supply  Now whether    what that ultimately looks like depends really on how does the virus continue to proliferate  Does it stay contained in a region  And so those are things that we just have to watch  But we wake up every day thinking about the markets that we serve and how we make sure we have product available for our customers that operate in those markets OperatorAnd next will be Michael Cherny with BofA Securities Michael Cherny    Bank of America Merrill Lynch    AnalystThanks so much for taking the question  I guess a lot of key topics have been asked  The one thing that did stand out  you highlighted the recent success of    on the transaction side  medical really rocking it  pretty low so far from an acquisition perspective  at least in terms of your historical spend year to date  As you re heading into fiscal  21 as you re getting rid of the Change position on the balance sheet and the ownership stake as you think forward of the portfolio  are there any macro trends that you think would drive some areas for opportunities for you to go and drive inorganic growth  Or anything from a broader picture perspective where your customers are really asking you to pursue an area that you may not be in or in a strong as you would like to be right now Brian S  Tyler    Chief Executive OfficerGreat  great question  I think we probably  if you think    look back over the past few years  we came through a cycle of pretty heavy M A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty biopharma manufacturer value prop and our oncology business or ecosystem  however you want to think about that  And as we ve done the work to integrate those  and it s a lot of work to integrate these things and to integrate them properly  In parallel  we ve really been refining our strategies and if you ve heard me    you ve probably heard me say this before all good M A follows a good strategy  And so as we put this strategy together  we ve identified the areas that we think we have differentiated capabilities  in markets that have good overall growth prospects  So when I think about capital deployment  so we ve obviously got to deploy capital to be invested in efficiency and compliant and safe  secure always on environments And then the second area we d look forward to growth  But those growth investments  meaning M A investments have to be closely aligned to the strategy  and I think that  that s what you should expect of us  So we like growth investments  we like growth capital either extend our capabilities or add scale to the places that we have capabilities  And what we always have to balance    I would say  your strategy can t be based on M A  because it takes a buyer and a seller that take a price that you can agree on  So as we ve looked at the market and looked at those trade offs  obviously the past 12 months or so  we ve been favoring to deploy our capital to buy back our shares  because we think those are a great investment  but we continue to be very active in looking for areas  we can inorganically help support the growth OperatorAnd next will be Stephen Baxter with Wolfe Research Stephen Baxter    Wolfe Research    AnalystHi  thanks for the question  So wanted to ask about the generics business  I mean  you guys have been very clear that gross profit is growing here  and that appears to be a pretty different result than the rest of the industry  So from a macro point of view  it looks to us like the broader market is relatively flat  I was hoping to better understand what s driving your growth here in bigger picture terms  Are you growing generic revenue against the backdrop of stable margins  stable revenue with improving margins  really any color you can add on how you re achieving this results  so we can better assess sustainability going forward would be appreciated  Thank you Britt Vitalone    Executive Vice President and Chief Financial OfficerGood morning  I ll start  and certainly Brian can add on  As we ve talked about previously  we re really pleased with a couple of dimensions that lead    that are around our generic business  First of all  we have a scaled and efficient sourcing operation  We think we source as well as anybody  and we continue to find opportunities from a sourcing perspective  We continue to be disciplined in a stable yet competitive environment  We think that  that is lead    those dynamics are leading to our ability to generate gross profit growth  We are seeing some growth in units and when you combine that with a scaled and stable sourcing operation and disciplined approach in a competitive  but stable market we think that those are dynamics that are really helping us be very successful in the generics area Holly Weiss    Senior Vice President of Investor RelationsOperator  we have time for one more question OperatorCertainly  that question will come from Eric Percher with Nephron Research  Your line is open Eric Percher    Nephron Research    AnalystThank you  Quick one on Europe  Loud and clear on expense reduction and a little benefit from the UK helping the uptick this quarter on op profit  Is it correct that the German business has not been moved to discontinued ops  So is that still flowing through and at some point  would we see that a benefit or may be a loss might be removed from that segment when the JV is struck or approved Britt Vitalone    Executive Vice President and Chief Financial OfficerGood morning  Eric  It is true  we have not moved it to discontinued operations as it doesn t qualify for discontinued operations  I did talk about a GAAP only charge that we took in the quarter and we have the assets as held for sale on our balance sheet Eric Percher    Nephron Research    AnalystOkay  And  can you state anything on whether that is in a loss position Britt Vitalone    Executive Vice President and Chief Financial OfficerI d just go back to my comments in terms of the loss that we recorded from a capital perspective in the quarter of  282 million Brian S  Tyler    Chief Executive OfficerOkay  Well  I think that runs us out of time  I want to thank everyone for your great questions and your continued interest in McKesson  I want to thank Jack for facilitating this call  To conclude McKesson continue to execute well in the third quarter and we remain confident in our fiscal 2020 outlook  I m extremely proud of how our employees are embracing the team McKesson culture and I want to thank them for everything they do day in and day out  not only to deliver these results  but most importantly to improve care in every setting we serve  Thanks again for your interest in McKesson  we will release fourth quarter earnings results in early May  Look forward to talking to you then  Goodbye Operator Operator Closing Remarks Duration  64 minutesCall participants Holly Weiss    Senior Vice President of Investor RelationsBrian S  Tyler    Chief Executive OfficerBritt Vitalone    Executive Vice President and Chief Financial OfficerCharles Rhyee    Cowen   Company    AnalystBrian Tanquilut    Jefferies    AnalystRobert Jones    Goldman Sachs    AnalystLisa Gill    JPMorgan    AnalystRicky Goldwasser    Morgan Stanley    AnalystElizabeth Anderson    Evercore ISI    AnalystEric Coldwell    Robert W  Baird    AnalystMichael Cherny    Bank of America Merrill Lynch    AnalystStephen Baxter    Wolfe Research    AnalystEric Percher    Nephron Research    Analyst
More MCK analysis
All earnings call transcripts",2020-02-05,The Motley Fool,https://invst.ly/pq-r1,2075794
127613,349128,MCK,Company News For Feb 5  2020,opinion,Royal Caribbean Cruises Ltd  s   NYSE RCL   shares gained 1 3  after reporting fourth quarter 2019 adjusted earnings per share of  1 42  beating the Zacks Consensus Estimate by a penny Ralph Lauren Corp    NYSE RL   jumped 9 2  after the company reported third quarter of fiscal 2020 adjusted earnings per share of  2 86  surpassing the Zacks Consensus Estimate of  2 45 Shares of Simon Property Group Inc    NYSE SPG   surged 3 4  after posting fourth quarter 2019 revenues of  1 49 billion  outpacing the Zacks Consensus Estimate of  1 47 billion McKesson Corp    NYSE MCK   soared 3 7  after the company posted third quarter of fiscal 2020 adjusted earnings per share of  3 81  above the Zacks Consensus Estimate of  3 54 ,2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-feb-5-2020-200504790,200504790
127639,349154,MCK,U S  regions hard hit by opioids to ditch class action  pursue own lawsuits,news,"By Tom Hals
WILMINGTON  Del Reuters    Local governments in regions hard hit by the U S  opioid epidemic have opted out of massive litigation taking aim at the drug industry over the crisis  potentially weakening a novel legal mechanism created to help settle thousands of lawsuits 
Overall  98  of some 34 000 local governments agreed to be bound by a class action against companies such as drug distributor McKesson Corp  N MCK   drugmaker Johnson   Johnson  N JNJ  and pharmacy chain Walgreens Boots Alliance Inc  O WBA   according to a Monday court filing 
However  the 541 local governments that opted out included Florida s Palm Beach County and counties in West Virginia  according to attorneys  raising the prospect that companies could face expensive trials even if they settled with the class  The two regions are among the hardest hit by the crisis  which has contributed to more than 400 000 deaths since 1997 
Officials from Houston s Harris County  one of the largest U S  counties  have said it would opt out  meaning they would pursue their own lawsuit and not receive funds from a nationwide settlement 
The court filing did not identify opt outs 
U S  Judge Dan Polster in Cleveland  who has been overseeing 2 600 consolidated opioid lawsuits  is pushing hard for a settlement to help get funds to those most in need in a timely fashion  He approved the novel  negotiation class  as a way to reassure companies that any deal to resolve the lawsuits would bind remaining governments and prevent them from filing a case 
The lawsuits generally allege that drugmakers improperly marketed opioids while distributors and pharmacy chains failed to stop suspicious orders  The defendants deny the allegations 
Typical class actions allow members to opt out after a settlement has been reached  but the negotiation class fixes the members first  Any settlement must be approved by 75  of the class 
Lawyers said towns and counties less affected by the crisis had little reason to opt out  while areas ravaged by opioids  like West Virginia  had more incentive to pursue and control their own lawsuit 
The number of opt outs represented around 20  of those that have already sued and could be significant if it included large cities  according to Elizabeth Burch  a professor at the University of Georgia School of Law 
 If I m trying to negotiate with a town of 80  that s very different from Houston   she said 
The negotiation class was opposed by some state attorneys general and drug distributors  and faces a legal challenge at the 6th U S  Circuit Court of Appeals in Cincinnati ",2019-12-03,Reuters,https://www.investing.com/news/stock-market-news/us-regions-hard-hit-by-opioids-to-ditch-class-action-pursue-own-lawsuits-2032839,2032839
127640,349155,MCK,AdaptHealth completes acquisition of Patient Care Solutions business,news,"AdaptHealth  NASDAQ AHCO  has closed the acquisition of the Patient Care Solutions  PCS  business from McKesson  NYSE MCK  and named Rodney Carson as President of the newly formed AdaptHealth Patient Care Solutions 
Mr  Carson most recently served as President and CEO of CCS Medical 
The PCS acquisition adds urological and ostomy products to AdaptHealth s HME product portfolio ",2020-01-03,Seeking Alpha,https://invst.ly/pd1l6,2051806
127641,349156,MCK,Morgan Stanley sees 15  upside in McKesson in premarket analyst action,news,"Aerie Pharmaceuticals  NASDAQ AERI  initiated with Neutral rating and  27  6  upside  price target at Bank of America 
Aurinia Pharmaceuticals  AUP CN  initiated with Buy rating and C 35 26  32  upside  price target at Jefferies  Shares up 3  premarket  NASDAQ AUPH  in U S 
BeyondSpring  NASDAQ BYSI  initiated with Buy rating and  34  111  upside  price target at Nomura Instinet  Shares up 3  premarket 
Cerecor  NASDAQ CERC  initiated with Outperform rating and  11  135  upside  price target at Oppenheimer 
Edwards Lifesciences  NYSE EW  initiated with Outperform rating and  280  20  upside  price target at Oppenheimer 
Elanco Animal Health  NYSE ELAN  initiated with Market Perform rating at Raymond James 
Exact Sciences  NASDAQ EXAS  resumed with Buy rating and  127  23  upside  price target at BTIG Research 
Haemonetics  NYSE HAE  initiated with Buy rating and  138  19  upside  price target at Needham 
IRhythm Technologies  NASDAQ IRTC  initiated with Outperform rating at William Blair 
Kadmon Holdings  NYSE KDMN  initiated with Buy rating and  10  117  upside  price target at Nomura  Shares up 3  premarket 
Relmada Therapeutics  NASDAQ RLMD  initiated with Outperform rating at SVB Leerink 
ResMed  NYSE RMD  initiated with Market Perform rating at Oppenheimer 
Soleno Therapeutics  NASDAQ SLNO  initiated with Buy rating and  8  181  upside  price target at Craig Hallum Capital 
Zoetis  NYSE ZTS  initiated with Market Perform rating at Raymond James 
Anika Therapeutics  NASDAQ ANIK  upgraded to Strong Buy with a  5  30  upside  price target at First Analysis 
Charles River Labs  NYSE CRL  upgraded to Buy with a  179  14  upside  price target at Goldman Sachs  Shares up 1  premarket 
McKesson  NYSE MCK  upgraded to Overweight with a  162  15  upside  price target at Morgan Stanley  Shares up 1  premarket 
Aduro BioTech  NASDAQ ADRO  downgraded to Market Perform at Cowen and Company  Shares up 1  premarket 
Aurora Cannabis  NYSE ACB  downgraded to Underweight with a C 1 31  46  downside risk  price target  Shares down  ACB  6  premarket in U S 
Portola Pharmaceuticals  NASDAQ PTLA  downgraded to Market Perform with a  17  31  downside risk  price target at Oppenheimer  Shares down 40  premarket on soft preliminary Q4 results 
PRA Health Sciences  NASDAQ PRAH  downgraded to Neutral with a  120  11  upside  price target at Goldman ",2020-01-10,Seeking Alpha,https://invst.ly/pgece,2056785
127642,349157,MCK,Is McKesson  MCK  A Profitable Stock For Value Investors ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value  One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put McKesson Corporation   NYSE MCK   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks  PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole  On this front  McKesson has a trailing twelve months PE ratio of 11 08  as you can see in the chart below   This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 79  If we focus on the long term PE trend  McKesson s current PE level puts it below its midpoint of 12 27 over the past five years   Further  the stock s PE also compares quite favorably with the Medical Market s trailing twelve months PE ratio  which stands at 23 54  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers   We should also point out that McKesson has a forward PE ratio  price relative to this year s earnings  of 10 68  which is lower than the current PE level  So  it is fair to say that a slightly more value oriented path may be ahead for McKesson stock in the near term too  P S Ratio Another key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings  Right now  McKesson has a P S ratio of about 0 13  This is quite lower than the S P 500 average  which comes in at 3 59x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years   Broad Value Outlook In aggregate  McKesson currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes McKesson a solid choice for value investors  What About the Stock Overall  Though McKesson might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of B and a Momentum Score of A  This gives MCK a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores   Meanwhile  the company s recent earnings estimates have been bullish  The current quarter has seen five estimates go higher in the past sixty days compared to no lower  while the full year estimate has seen six up and no down in the same time period  This has had a positive impact on the consensus estimate though as the current quarter consensus estimate has risen by 3 8  in the past two months  while the full year estimate has inched up by 1 3   You can see the consensus estimate trend and recent price action for the stock in the chart below McKesson Corporation Price and Consensus   This somewhat bullish trend is why the stock has a Zacks Rank  2  Buy  and it is the reason why we are looking for outperformance from the company in the near term  Bottom Line McKesson is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Despite a sluggish industry rank  Bottom 37  of 255 industries   a Zacks Rank  2 instils investors  optimism in the stock  However  over the past two years  the broader industry has clearly underperformed the broader market  as you can see below   We believe  despite an unsatisfactory past industry rank and performance  a good Zacks rank and bullish analyst sentiments signal that the stock is likely to benefit from favorable broader factors in the immediate future  Add to this robust value metrics  and we believe that we have a strong value contender in McKesson  Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020  Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/is-mckesson-mck-a-profitable-stock-for-value-investors-200501368,200501368
127660,349175,MCK,New Strong Buy Stocks For October 25th,opinion,"Here are 5 stocks added to the Zacks Rank  1  Strong Buy  List today 
Brunswick Corporation  BC   This company that designs  manufactures  and markets recreation products has seen the Zacks Consensus Estimate for its current year earnings increasing 0 2  over the last 60 days Brunswick Corporation Price and Consensus
    Clean Harbors  Inc   CLH   This company that provides environmental  energy  and industrial services has seen the Zacks Consensus Estimate for its current year earnings increasing 6 6  over the last 90 days Clean Harbors  Inc  Price and Consensus
    H E Equipment Services  Inc   HEES   This integrated equipment services company has seen the Zacks Consensus Estimate for its current year earnings increasing 0 4  over the last 90 days H E Equipment Services  Inc  Price and Consensus
    McKesson Corporation  NYSE MCK   MCK   This company that provides pharmaceuticals and medical supplies has seen the Zacks Consensus Estimate for its current year earnings increasing 0 1  over the last 60 days McKesson Corporation Price and Consensus
    IQVIA Holdings Inc   IQV   This company that provides advanced analytics  technology solutions  and contract research services has seen the Zacks Consensus Estimate for its current year earnings increasing 0 3  over the last 90 days IQVIA Holdings Inc  Price and Consensus
    You can see 
5 Stocks Set to Double
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth 
Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/new-strong-buy-stocks-for-october-25th-200478618,200478618
127661,349176,MCK,Integra LifeSciences   IART  Earnings Top Estimates In Q3,opinion,"Integra LifeSciences Holdings Corporation   NASDAQ IART   delivered adjusted earnings per share  EPS  of 68 cents in the third quarter of 2019  up 15 3  from a year ago  The metric surpassed the Zacks Consensus Estimate by 4 6  Reported loss per share during the third quarter was 32 cents against reported EPS of 15 cents in the prior year quarter Revenue DiscussionTotal revenues in the reported quarter inched up 3 6  year over year to  379 1 million  This figure beat the Zacks Consensus Estimate by 0 7   Excluding revenues from the current period acquisitions  product discontinuations and the effect of currency exchange rates  organic revenues rose 4 7  year over year Coming to product categories  revenues from the Codman Specialty Surgical segment rose 5 8  to  252 9 million  The upside was driven by continued positive customer reception of several new products like CereLink  CertasPlus and Integra DUO Integra LifeSciences Holdings Corporation Price  Consensus and EPS Surprise
    Orthopedics and Tissue Technologies revenues totaled  126 1 million in the third quarter  down 0 6  year over year owing to sales decline in the Private Label portfolio Margin Trend          In the reported quarter  gross profit totaled  236 5 million  Gross margin expanded 153 basis points  bps  to 62 4  on a 6 2  rise in gross profit  Selling  general and administrative expenses contracted 0 1  to  173 1 million in the quarter under review while research and development expenses fell 6 4  to  19 million  Operating profit came in at  44 4 million  up 53 2  year over year  Overall  adjusted operating margin saw a 379 bps expansion year over year to 11 7  Financial PositionIntegra LifeSciences exited the third quarter with cash and cash equivalents of  207 9 million  up from  176 1 million at the end of the second quarter  Year to date  net cash flow from operating activities in the third quarter was  142 2 million  down from  156 9 million a year ago 2019 OutlookIntegra LifeSciences has tightened its revenue guidance for 2019  The company expects 2019 revenues in the range of  1 517  1 522 billion versus the earlier range of  1 515   1 525 billion  Organic revenue growth projection has been reaffirmed at roughly 5   The Zacks Consensus Estimate for 2019 revenues is pegged at  1 52 billion  near the high end of the guided range The company has reaffirmed its adjusted EPS guidance at the band of  2 70 2 75  The Zacks Consensus Estimate for 2019 adjusted earnings stands at  2 74  within the company s guided range Our TakeIntegra LifeSciences exited the third quarter on a solid note as both adjusted EPS and revenues beat consensus marks  We are upbeat about the year over year revenue growth in the Codman Specialty Surgical segment  Expansion of both the margins is also encouraging as well The 2019 guidance for organic revenue growth and adjusted EPS appears strong  However  the drop in the Orthopedics and Tissue Technologies revenues is concerning Zacks Rank and Key PicksIntegra LifeSciences currently has a Zacks Ranks  3  Hold  A few better ranked stocks in the broader medical space are Mckesson   NYSE MCK    Stryker   NYSE SYK   and Syneos Health   NASDAQ SYNH    While McKesson carries a Zacks Rank  1  Strong Buy   the other two companies carry a Zacks Rank  2  Buy   You can see  The Zacks Consensus Estimate for McKesson s second quarter fiscal 2020 revenues is pegged at  54 94 billion  suggesting 3 5  growth from the prior year reported figure  The same for adjusted EPS stands at  3 59 The Zacks Consensus Estimate for Stryker s third quarter fiscal 2019 revenues is pegged at  3 58 billion  calling for a year over year increase of 10 5   The same for adjusted EPS stands at  1 91  indicating an increase of 13  from the year ago reported figure The Zacks Consensus Estimate for Syneos  third quarter fiscal 2019 revenues is pegged at  1 18 billion  suggesting 6 03  growth from the prior year reported figure  The same for adjusted EPS stands at 72 cents  implying a 5 3  improvement from the year ago reported number 5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/integra-lifesciences-iart-earnings-top-estimates-in-q3-200478541,200478541
127662,349177,MCK,ResMed s  RMD  Q1 Earnings Beat Estimates  Margins Expand,opinion,"ResMed Inc    NYSE RMD   announced first quarter fiscal 2020 adjusted earnings per share  EPS  of 93 cents  up 14 8  year over year  The metric also beat the Zacks Consensus Estimate by 6 9  Reported EPS was 83 cents for the quarter under review  reflecting an increase of 13 7  from the year ago period Revenues in the reported quarter increased 15 8  year over year  up 17  at constant exchange rate or CER  to  681 1 million  The figure surpassed the Zacks Consensus Estimate by 3 6  A Closer View of the Top LineGeographically  excluding Software as a Service  revenues in the United States  Canada and Latin America improved 13  over the prior year period to  370 3 million led by robust performance by its mask and device product portfolios 
Global revenues from Software as a Service in the quarter under consideration summed  86 9 million  representing an 83  jump year over year ResMed Inc  Price  Consensus and EPS Surprise
    Revenues in the combined EMEA and APAC region were  223 9 million  highlighting a 8  rise at CER from the year earlier tally MarginsGross margin for the fiscal first quarter was 59 5   translating to a 115 basis point  bps  expansion from the year ago number Selling  general and administrative expenses were up 13 7  year over year to  167 4 million  while research and development expenses increased 23 8  to  48 million  This  in turn  induced a 15 8  rise in adjusted operating expenses  which amounted to  215 5 million  However  adjusted operating margin in the reported quarter expanded 115 bps to 27 8  Financial UpdatesResMed exited the first quarter of fiscal 2020 with cash and cash equivalents of  172 2 million compared with  147 1 million at the end of fiscal 2019       Along with the earnings release  ResMed announced a regular quarterly dividend payout of 39 cents per share Our TakeResMed exited first quarter fiscal 2020 on a solid note with earnings and revenues beating the Zacks Consensus Estimate  It is encouraging to note that the company registered growth at CER across both its key operating segments   Total Sleep and Respiratory Care and Software as a Service  Mask sales were strong in Europe and Asia  Overall  the company achieved double digit global revenue growth in the reported quarter  led by strong sales at Software as a Service businesses as well as of new mask products and devices  Within Software as a Service  the company recorded continued momentum in the Brightree service portfolio and additional contribution from the MatrixCare buyout However  in the quarter  device sales in France and Japan were impacted as customers completed their connected device upgrade programs Zacks Rank and Other Key PicksResMed currently has a Zacks Ranks  2  Buy  A few other top ranked stocks in the broader medical space are Mckesson   NYSE MCK    Stryker   NYSE SYK   and Syneos Health   NASDAQ SYNH    While McKesson sports a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  You can see  The Zacks Consensus Estimate for McKesson s second quarter fiscal 2020 revenues is pegged at  54 94 billion  suggesting 3 5  growth from the prior year reported figure  The same for adjusted EPS stands at  3 59 The Zacks Consensus Estimate for Stryker s third quarter fiscal 2019 revenues is pegged at  3 58 billion  calling for a year over year increase of 10 5   The same for adjusted EPS stands at  1 91  indicating an increase of 13  from the year ago reported figure The Zacks Consensus Estimate for Syneos  third quarter fiscal 2019 revenues is pegged at  1 18 billion  suggesting 6 03  growth from the prior year reported figure  The same for adjusted EPS stands at 72 cents  implying a 5 3  improvement from the year ago reported number 5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/resmeds-rmd-q1-earnings-beat-estimates-margins-expand-200478497,200478497
127663,349178,MCK,McKesson  MCK  Q2 Earnings Meet Estimates,opinion,"McKesson  MCK  came out with quarterly earnings of  3 60 per share  in line with the Zacks Consensus Estimate  This compares to earnings of  3 60 per share a year ago  These figures are adjusted for non recurring items 
A quarter ago  it was expected that this prescription drug distributor would post earnings of  3 04 per share when it actually produced earnings of  3 31  delivering a surprise of 8 88  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
McKesson  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  57 62 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 4 88   This compares to year ago revenues of  53 08 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
McKesson shares have added about 35 2  since the beginning of the year versus the S P 500 s gain of 21 1  
What s Next for McKesson 
While McKesson has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for McKesson was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 39 on  57 90 billion in revenues for the coming quarter and  14 40 on  223 43 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the bottom 39  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-q2-earnings-meet-estimates-200480037,200480037
127683,349198,MCK,McKesson  MCK  Hits Fresh High  Is There Still Room To Run ,opinion,"Shares of McKesson  MCK  have been strong performers lately  with the stock up 4 5  over the past month  The stock hit a new 52 week high of  152 53 in the previous session  McKesson has gained 37 8  since the start of the year compared to the 0 3  move for the Zacks Medical sector and the 2 5  return for the Zacks Medical   Dental Supplies industry 
What s Driving the Outperformance 
The stock has a great record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on July 31  2019  McKesson reported EPS of  3 31 versus consensus estimate of  3 04 while it beat the consensus revenue estimate by 3 26  
For the current fiscal year  McKesson is expected to post earnings of  14 39 per share on  223 43 billion in revenues  This represents a 6 04  change in EPS on a 4 25  change in revenues  For the next fiscal year  the company is expected to earn  15 53 per share on  232 19 billion in revenues  This represents a year over year change of 7 92  and 3 92   respectively 
Valuation Metrics
McKesson may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself 
On this front  we can look at the Zacks Style Scores  as these give investors a variety of ways to comb through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style 
McKesson has a Value Score of A  The stock s Growth and Momentum Scores are D and C  respectively  giving the company a VGM Score of B 
In terms of its value breakdown  the stock currently trades at 10 6X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 5 1X versus its peer group s average of 11 4X  Additionally  the stock has a PEG ratio of 1 52  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to consider the stock s Zacks Rank  as this supersedes any trend on the style score front  Fortunately  McKesson currently has a Zacks Rank of  2  Buy  thanks to favorable earnings estimate revisions from covering analysts 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if McKesson passes the test  Thus  it seems as though McKesson shares could have a bit more room to run in the near term ",2019-10-20,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-hits-fresh-high-is-there-still-room-to-run-200475683,200475683
127684,349199,MCK,Cerner s  CERN  AbleVets Buyout To Boost Federal Services,opinion,Cerner Corporation   NASDAQ CERN   recently announced a definitive agreement to acquire AbleVets  which will help it to revamp its federal and military health IT systems  The transaction is expected to close in the fourth quarter of 2019  Terms of the deal have been kept under the wraps Following the announcement  shares of the Zacks Rank  3  Hold  company climbed 0 6  to  68 16 at close For investors  notice  AbleVets is a Washington DC based IT consulting and engineering firm  which has been Cerner s trusted partner in providing critical support to federal programs How Will Cerner Benefit With AbleVets  technical expertise  Cerner can provide integrated  seamless care for veterans  federal service members and their families The integration of Cerner s coveted electronic health records  EHR  platform reduces the time and risks associated with IT modernization efforts In fact  earlier this year  Cerner received  139 9 million as part of a task order from the Department of Veteran Affairs  VA   seeking support for the EHR interface part of VA s Cerner EHR platform A Brief Note on Cerner s Federal ProgramsCerner provides intelligent  secure solutions to government agencies for supporting their populations and improving the business of health care The company s collaboration with the VA to create a completely integrated health record platform to provide veterans a lifetime of seamless care also deserves a mention Cerner s other federal clients include the Federal Bureau of Prisons  Indian Health Service  U S  Centers for Disease Control and U S  Department of Defense Price PerformanceOver the past year  shares of Cerner have rallied 7 3  against the  s 3 3  decline  The performance compares favorably with the S P 500 index s 8 1  rise Key PicksA few better ranked stocks from the broader medical space are Nissan Chemical Corporation   OTC NNCHY    Straumann Holding AG  and McKesson Corporation   NYSE MCK    each carrying a Zacks Rank  2  Buy   You can see  Nissan Chemical has a long term earnings growth rate of 10  Straumann Holding has a long term earnings growth rate of 18  McKesson has a long term earnings growth rate of 6 9  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-21,Zacks Investment Research,https://www.investing.com/analysis/cerners-cern-ablevets-buyout-to-boost-federal-services-200476218,200476218
127685,349200,MCK,Thermo Fisher  TMO  Beats On Q3 Earnings  Lifts Guidance,opinion,"Thermo Fisher Scientific Inc  s   NYSE TMO   third quarter 2019 adjusted earnings per share  EPS  came in at  2 94  beating the Zacks Consensus Estimate by 2 1   The figure also improved from the year ago quarterly figure by 12 2   On a reported basis  EPS was  1 88  up 7 4  year over year Revenues in the quarter under review grossed  6 27 billion  up 5 9  year over year  The top line also beat the Zacks Consensus Estimate by 1 3  Quarter in DetailOrganic revenues in the reported quarter grew 7  year over year while currency translation affected total revenues by 1  Thermo Fisher operates under four business segments  Life Sciences Solutions  Analytical Instruments  Specialty Diagnostics and Laboratory Products and Services Revenues at the Life Sciences Solutions segment  27 1  of total revenues  improved 13 3  year over year to  1 70 billion while Analytical Instruments Segment sales  21 7   edged up 2 3  to  1 36 billion Thermo Fisher Scientific Inc  Price  Consensus and EPS Surprise
    Revenues at the Laboratory Products and Services segment  41 8   rose 6 1  to  2 62 billion  The Specialty Diagnostics segment  14   recorded a 1 1  drop from the year ago quarter to  0 88 billion Gross margin of 46  during the third quarter contracted 22 basis points  bps  year over year despite a 5 4  rise in gross profits  Adjusted operating margin for the quarter came in at 22 5   reflecting an expansion of 27 bps The company exited the third quarter of 2019 with cash and cash equivalents of  1 27 billion  compared with  2 29 billion in the second quarter  Year to date  net cash provided by operating activities was  3 06 billion compared with  2 74 billion a year ago 2019 GuidanceBanking on an improvement in operational performance  Thermo Fisher has raised its 2019 revenue and earnings guidance Revenue guidance has been raised to  25 34  25 50 billion from the earlier provided  25 30  25 50 billion  indicating revenue growth of 4  to 5  from 2018  The Zacks Consensus Estimate of  25 43 billion is within the guided range Adjusted EPS guidance for 2019 has also been raised to  12 28 to  12 34  previous range was  12 16 to  12 26   suggesting 10  to 11  growth from 2018  The Zacks Consensus Estimate of  12 25 falls below the guided range Bottom LineThermo Fisher ended the third quarter of 2019 on a solid note with both EPS and revenues beating the Zacks Consensus Estimate  We are encouraged that three of its four business segments witnessed strong year over year revenue growth During the reported quarter  the company launched a range of products like the TSQ Altis  the Quantis MD mass spectrometers and the Vanquish MD HPLC for clinical diagnostic laboratories  The company also broadened its global market reach by setting up a Biosciences Customer Exploration Center in Shanghai and expanding its clinical trials logistics facility in Suzhou  We are looking forward to the recently completed acquisition of an active pharmaceutical ingredient manufacturing facility in Cork  Ireland  of GlaxoSmithKline  Meanwhile  adjusted operating loss during the quarter is concerning Zacks Rank and Key PicksThermo Fisher currently has a Zacks Ranks  3  Hold  A few better ranked stocks in the broader medical space are Mckesson   NYSE MCK    ResMed   NYSE RMD   and Syneos Health   NASDAQ SYNH    While  ResMed has a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  Buy  You can see  The Zacks Consensus Estimate for ResMed s first quarter fiscal 2020 revenues is pegged at  657 2 million  calling for a year over year increase of 11 7   The same for adjusted EPS stands at 87 cents  indicating an increase of 7 4  from the year ago reported figure The Zacks Consensus Estimate for Syneos  third quarter fiscal 2019 revenues is pegged at  1 18 billion  suggesting 6 03  growth from the prior year reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 5 3  improvement from the year ago reported number The Zacks Consensus Estimate for McKesson s second quarter fiscal 2020 revenues is pegged at  54 94 billion  suggesting 3 5  growth from the prior year reported figure  The same for adjusted EPS stands at  3 59 Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-10-22,Zacks Investment Research,https://www.investing.com/analysis/thermo-fisher-tmo-beats-on-q3-earnings-lifts-guidance-200476963,200476963
127687,349202,MCK,Edwards Lifesciences  EW  Beats On Q3 Earnings  Ups EPS View,opinion,Edwards Lifesciences Corporation s   NYSE EW   third quarter 2019 adjusted earnings per share  EPS  came in at  1 41  outpacing the Zacks Consensus Estimate by 15 6   Moreover  the figure improved 31 8  year over year  primarily on growth in all businesses The company reported EPS of  1 30  which also increased 22 6  year over year Sales DetailsThird quarter net sales improved 20 7  year over year to  1 09 billion and surpassed the Zacks Consensus Estimate by 5 5   Additionally  underlying sales increased 19  Revenues were primarily driven by significant growth in Transcatheter Aortic Valve Replacement  TAVR   Transcatheter Mitral and Tricuspid Therapies  TMTT  sales and strong performance by the Surgical Structural Heart and Critical Care product lines Segmental DetailsIn the third quarter  sales in the TAVR product group amounted to  700 million  up 26  from the prior year reported figure  Further  TAVR underlying sales grew 27  in the quarter  Per management  this solid performance can be attributed to the strong therapy adoption across all geographies with notable strength in the United States Edwards Lifesciences Corporation Price  Consensus and EPS Surprise   In the United States  total TAVR procedures surged around 30  year over year  This was stronger than expected following the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems  In Europe  TAVR sales improved in the teens from the year ago quarter  Outside the United States and Europe  the company is experiencing a robust TAVR adoption  driven by SAPIEN 3 performance Surgical Structural Heart sales in the quarter totaled  204 million  up 11  from the prior year quarter s figure and 3  higher on an underlying basis  Growth in the reported quarter was boosted by sales of premium products  particularly through adoption of the INSPIRIS RESILIA aortic valve that drove the adoption of surgical aortic valve procedures Critical Care sales totaled  180 million in the third quarter  up 10  from the year ago quarter reportedly and 7  improvement came on an underlying basis  Per management  all the product categories contributed to this upside  bolstered by substantial growth in HemoSphere advanced monitoring platform sales TMTT sales totaled  10 million  primarily attributable to strong commercial sales of the PASCAL transcatheter mitral system in Europe  Notably  Edwards Lifesciences continues to invest in its transcatheter mitral and tricuspid portfolio as well as plans to achieve significant clinical and regulatory milestones in 2019  For 2019  Edwards Lifesciences now expects TMTT revenues to lie below  40 million MarginsIn the third quarter  gross margin contracted 200 bps to 73 3   Favorable impacts from foreign exchange rates and product mix were offset by spending in support of the new European device regulations and manufacturing variances SG A expenses rose 13 6  year over year to  306 2 million  induced primarily by increased transcatheter structural heart field personnel related expenses including expansion of the transcatheter mitral and tricuspid therapy field organization in Europe R D expenditures escalated 13 6  year over year to  306 2 million due to significant investments in transcatheter structural heart programs However  operating margin in the quarter expanded 155 bps to 17 3  on 32 6  rise in operating income to  189 million Cash PositionEdwards Lifesciences exited the third quarter of 2019 with cash and cash equivalents  and short term investments of  1 36 billion compared with  934 3 million at the end of the second quarter  Long term debt at the end of the third quarter was  594 2 million compared with  594 1 million at second quarter end Year to date cash flow from operating activities was  780 million compared with  633 8 million a year ago  Year to date capital expenditures rose to  182 9 million from  181 1 million a year ago Guidance ImpressiveFor 2019  Edwards Lifesciences has raised its adjusted EPS guidance to  5 50  5 65 from the earlier view of  5 20  5 40  The Zacks Consensus Estimate is pegged at  5 33  indicating a decline from the guided range The company now projects total revenues around the upper end of its earlier provided guidance of  4  4 3 billion  The Zacks Consensus Estimate of  4 23 billion falls within the expected range For fourth quarter 2019  the company forecasts total sales between  1 12 billion and  1 16 billion  The Zacks Consensus Estimate stands at  1 12 billion  which lies at the lower end of the envisioned range  Adjusted EPS is anticipated between  1 40 and  1 55  The Zacks Consensus Estimate of  1 40 comes in at the lower end of the guided range Our TakeEdwards Lifesciences exited the third quarter on a solid note  Globally  TAVR procedures delivered growth  According to the company  sales were significantly higher than expected following the sturdy PARTNER 3 trial evidence  leading to the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems  Moreover  lifted 2019 guidance increases investors  optimism on the stock However  gross margin contracted in the third quarter  Moreover  tough competition in the cardiac devices market and reimbursement issues raise concerns Zacks RankEdwards Lifesciences currently carries a Zacks Rank  3  Hold   You can see  Key PicksSome better ranked stocks in the broader medical space are Mckesson   NYSE MCK    ResMed   NYSE RMD   and Syneos Health   NASDAQ SYNH    While ResMed sports a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  Buy  each  You can see  The Zacks Consensus Estimate for McKesson s second quarter fiscal 2020 revenues is pegged at  54 94 billion  suggesting 3 5  growth from the prior year reported figure  The same for adjusted EPS stands at  3 59 The Zacks Consensus Estimate for ResMed s first quarter fiscal 2020 revenues is pegged at  657 2 million  indicating 11 7  increase from the prior year reported number  The same for adjusted earnings per share stands at 87 cents  implying a rise of 7 4  from the year ago reported figure The Zacks Consensus Estimate for Syneos  third quarter fiscal 2019 revenues is pegged at  1 18 billion  suggesting 6 03  growth from the year earlier reported figure  The same for adjusted earnings per share stands at 72 cents  implying a 5 3  improvement from the year ago reported number Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-ew-beats-on-q3-earnings-ups-eps-view-200477458,200477458
127688,349203,MCK,Align Technology  ALGN  Beats On Q3 Earnings  Margins Fall,opinion,Align Technology  Inc  s   NASDAQ ALGN   third quarter 2019 earnings per share  EPS  came in at  1 28  reflecting a 3 2  increase from a year ago  The figure beat the Zacks Consensus Estimate by 12 3  RevenuesRevenues grew 20 2  year over year to  607 3 million in the quarter  surpassing the Zacks Consensus Estimate by 2 5  The robust top line growth was led by a double digit increase in Invisalign case shipments from the year ago quarter  Moreover  increased revenues from iTero scanner contributed substantially Segments in DetailIn the third quarter  revenues at the Clear Aligner segment rose 20 9  year over year  Within the segment  Invisalign case shipments amounted to 385 000  up 20 7  year over year  The upside was primarily driven by continued adoption by teenage and younger patients as well as increased utilization among orthodontists and expansion of the company s global customer base During the quarter  Invisalign volumes were up 13  and 32 1  year over year in the Americas and International regions  respectively  Invisalign volume for teenage patients was 130 000 cases  up 31 5  year over year Align Technology  Inc  Price  Consensus and EPS Surprise    Revenues from Scanner and Services improved a significant 16 5  to  91 1 million on increased sales of iTero scanner and services MarginsGross margin in the quarter under review contracted 153 basis points  bps  year over year to 72  on account of a 27 2  rise in cost of net revenues During the quarter  Align Technology witnessed a 29 8  year over year increase in selling  general and administrative expenses to  277 5 million and a 21 3  rise in research and development  R D  expenses to  39 7million  Accordingly  adjusted operating margin contracted 496 bps to 19 8  in the quarter under review Financial DetailsAt the end of the third quarter  Align Technology had cash  cash equivalents and short term marketable securities of  782 4 million  compared with  720 9 million at the end of the second quarter In the reported quarter  Align Technology repurchased 1 1 million stocks for  200 million under its accelerated stock repurchase agreement  introduced last July  The company currently has approximately  200 5 million left under its May 2018 repurchase program Q4 GuidanceFor the fourth quarter of 2019  the company projects EPS of 1 35 to  1 42 on revenues to 640 million to  650 million  indicating 20 22  growth from a year ago   The company estimates Invisalign case shipments in the band of 400 000 407 000 suggesting a 20 22  rise from a year ago Meanwhile  the Zacks Consensus Estimate for fourth quarter EPS is pinned at  1 38 on revenues of  648 9 million  Both the earnings and revenue estimates lie within their respective projected bands Our TakeAlign Technology exited the third quarter of 2019 with better than expected results  We are upbeat about the continued momentum in Invisalign volumes across all geographies  We are also encouraged by the solid adoption of Invisalign treatment registered with record utilization  The expansion of Invisalign customer base  which totaled 63 000 active doctors worldwide in the third quarter  buoys optimism  The company is witnessing solid worldwide Invisalign volume growth for teenage patient cases  On the flip side  gross and operating margins contracted on escalating expenses Zacks Rank and Key PicksAlign Technology currently has a Zacks Ranks  4  Sell  A few better ranked stocks in the broader medical space are Mckesson   NYSE MCK    Stryker   NYSE SYK   and Syneos Health   NASDAQ SYNH    each carrying a Zacks Rank  2  Buy  You can see  The Zacks Consensus Estimate for McKesson s second quarter fiscal 2020 revenues is pegged at  54 94 billion  suggesting 3 5  growth from the prior year reported figure  The same for adjusted EPS stands at  3 59 The Zacks Consensus Estimate for Stryker s third quarter fiscal 2019 revenues is pegged at  3 58 billion  calling for a year over year increase of 10 5   The same for adjusted EPS stands at  1 91 cents  indicating an increase of 13  from the year ago reported figure The Zacks Consensus Estimate for Syneos  third quarter fiscal 2019 revenues is pegged at  1 18 billion  suggesting 6 03  growth from the prior year reported figure  The same for adjusted EPS stands at 72 cents  implying a 5 3  improvement from the year ago reported number Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/align-technology-algn-beats-on-q3-earnings-margins-fall-200477328,200477328
127696,349211,MCK,IBM  Walmart  Merck in blockchain collaboration with FDA,news," Reuters     IBM   NYSE IBM   Merck and Walmart  NYSE WMT  have been chosen for a U S  Food and Drug Administration pilot program that will explore using blockchain technology to improve the security of prescription drug supply and distribution  The companies said they would work with consultancy KPMG to create a shared blockchain network that will allow real time monitoring of products in the pharmaceutical supply chain  The project has been authorized under the U S  Drug Supply Chain Security Act  DSCSA  that was set up to increase regulatory oversight of counterfeit  stolen  contaminated or otherwise harmful drugs  The FDA has previously used the DSCSA to issue a warning letter to drug distributor McKesson Corp  NYSE MCK  for violations involving opioid medications   Opioids have been tied to thousands of overdose deaths and state and local governments across the United States have filed lawsuits seeking to hold pharmaceutical companies responsible for the epidemic of abuse  The new project is aimed at reducing the time needed to track and trace prescription drugs  improving access to reliable distribution information and ensuring products are handled appropriately and stored at the right temperature while being distributed  the companies said in a statement  Blockchain technology  originally conceived a decade ago as the basis for the cryptocurrency bitcoin  will help stakeholders establish a permanent record and can be integrated with existing systems used to trace products while they are distributed   
The project is scheduled to be completed in the fourth quarter of 2019 and results will be published in a report  the companies said ",2019-06-13,Reuters,https://www.investing.com/news/cryptocurrency-news/ibm-walmart-merck-in-blockchain-collaboration-with-fda-1896751,1896751
127697,349212,MCK,Beauty retailers fall after Amazon opens store for professionals,news," Reuters    Shares of a number of specialized beauty retailers fell on Monday after Amazon com Inc  NASDAQ AMZN  said it had started selling beauty products used by licensed stylists  barbers and beauticians  Shares of Sally Beauty Holdings  which targets industry professionals  sank 17   while those of Ulta Beauty Inc fell about 3    They are the just the latest to suffer from Wall Street s concern about moves by the world s largest retailer into a series of niche or more regulated markets  Last year  U S  pharmacy chains and drug wholesalers such as CVS  Walgreen and McKesson Corp  NYSE MCK  lost billions in market value when Amazon took its first step into online pharmacy by buying  small existing player PillPack  Amazon typically uses its scale and online profile to offer a wider range of products at lower prices  putting pressure on margins of existing players   Currently  stylists often travel to multiple cosmetology supply locations to get necessary supplies   Jefferies analysts said   We expect Amazon to quickly become an important enough channel for brands to carry their top offerings on the platform   Amazon said stylists would need to upload their state issued licenses and create a business account to buy products from the new store  which the company said would stock brands including Wella Professionals and OPI Professional  Its entry will directly threaten about 19  of Sally Beauty s operating profit and an additional 33  was likely see pressure from more competition  according to DA Davidson analysts   Ulta  however  will see lesser pain as it sells mostly cosmetics and styling tools  which account for only 19  of total sales  the analysts said  The companies did not immediately respond to multiple requests for comment  
Shares of the e commerce retailer were trading 0 2  higher at  1 913 16 ",2019-06-24,Reuters,https://www.investing.com/news/stock-market-news/amazons-new-beauty-store-for-professionals-pose-a-threat-to-beauty-retailers-1905905,1905905
127698,349213,MCK,Special Report  How judges added to the grim toll of opioids,news,"By Benjamin Lesser  Dan Levine  Lisa Girion and Jaimi Dowdell WELCH  West Virginia  Reuters    The opioid epidemic that has so far killed half a million Americans is routinely blamed on greedy drug makers  feckless doctors and lax regulators  But there s another group that has contributed to the depth and duration of the catastrophe  judges  Judges like Booker T  Stephens  Until his retirement in May  Stephens sat on the West Virginia Circuit Court in Welch  deep in Appalachian coal country  where addiction took early root among miners who were prescribed the blockbuster opioid OxyContin for the pain their jobs inflicted  And it was in his court where the first lawsuit filed by a state against OxyContin s maker  Purdue Pharma LP  landed in 2001  West Virginia accused Purdue of duping doctors into widely prescribing the drug by minimizing its risks  convincing them it was less addictive than other opioids because just one dose delivered steady relief for 12 hours  In the pretrial  discovery  phase of the case  Purdue sent thousands of pages of internal memos  notes from sales calls on doctors  marketing plans and other records to the state s lawyers who had requested them  That evidence was clearly compelling  In a 2004 ruling  Judge Stephens rejected Purdue s motion that he dismiss the case and sided with the state s assertion that the material could convince a jury that Purdue s sales pitch was full of dangerous lies  But Stephens sealed the evidence on which he relied in that ruling  And when Purdue and the state reached a settlement that year  before the case went to trial  the evidence remained hidden  out of sight to regulators  doctors and patients  Over the next few years  as OxyContin sales and opioid related deaths climbed  more than a dozen other judges overseeing similar lawsuits against Purdue took the same tack  keeping the company s records secret  It would be 12 years   and 245 000 overdose deaths   before evidence Stephens and other judges kept hidden was made public  and then only after it was leaked to a newspaper   What it showed was revelatory  OxyContin  the first billion dollar a year narcotic  was not the reliable 12 hour painkiller Purdue long claimed it was  Its effects often wore off much sooner  exposing patients to a relapse of pain  withdrawal  or both   suffering relieved only by the next pill  When doctors raised concerns  the documents showed  Purdue sales reps counseled them to put patients on bigger  more dangerous doses  The eventual release of the evidence reinforced the widely held view that OxyContin was a catalyst for the epidemic  which by then had expanded beyond prescription opioids to include illicit drugs such as heroin  The material also informed hundreds of new lawsuits seeking to force accountability on the entire opioid industry for its role in the addiction crisis  But for untold numbers of opioid users who had overdosed  it was too late   Heartbreaking and sickening  is how Congresswoman Katherine Clark  a Massachusetts Democrat who has been involved in investigating the causes of the opioid epidemic  described the early decisions to seal the Purdue evidence  In an interview  Clark said she believes that had the secrets come out earlier  doctors would have written fewer OxyContin prescriptions and fewer insurers would have covered the drug   We don t know how many lives we could have saved   she said  Stephens told Reuters he doesn t second guess his decision   It happened  and that s all that I can say about it   he said   It speaks for itself   CONTINUING THE TRADITION Today  15 years after Stephens protected Purdue s secrets  Federal Judge Dan Polster is providing the same cover for multiple opioid makers  distributors and retailers  He is presiding over a mass of litigation that seeks to hold the entire industry responsible for the epidemic  Life saving information contained in those cases  too  may remain under seal  as Polster has stuck to a strict secrecy playbook  Polster declined to comment for this article  The trail of hidden evidence running through the opioid crisis is emblematic of a pervasive and deadly secrecy that shrouds product liability cases in U S  courts  enabled by judges who routinely allow the makers of those products to keep information pertinent to public health and safety under wraps  And since nearly all such cases are resolved before trial  the evidence often remains secret indefinitely  robbing consumers of the chance to make informed choices and regulators of opportunities to improve safety  In an unprecedented analysis  Reuters found that over the past 20 years  judges sealed evidence relevant to public health and safety in about half of the 115 biggest defective product cases consolidated before federal judges in so called multidistrict litigation  or MDLs  Those cases comprised nearly 250 000 individual death and injury lawsuits  involving dozens of products used by millions of consumers  drugs  cars  medical devices and other products  And the numbers don t convey the full extent of information locked away because they don t include thousands of product liability cases heard in state courts  The impact is broad  Although secrecy makes complete analysis impossible  Reuters found that hundreds of thousands of people were killed or seriously injured by allegedly defective products after judges in just a handful of cases allowed litigants to file under seal  beyond public view  evidence that could have alerted consumers and regulators to potential danger  For example  beginning in the early 1980s  judge after judge kept under seal evidence that the trigger on Remington Arms Co s Remington 700 hunting rifle was prone to misfiring  In 2014  after decades of secrecy  a judge presiding over a class action lawsuit in Missouri refused to seal the trove of documents  which showed that the company had been aware of the defective trigger since the late 1940s  By then  nearly 200 people had died from accidental shootings blamed on the problem  The company then recalled the defective rifles  Thousands more people died in rollover accidents involving General Motors Co  NYSE GM  cars and trucks while judges agreed to hide records showing the company knew that reinforcing vehicle roofs would save lives  After a decade of lawsuits in which those records were kept secret  a Los Angeles judge released the information in 2004 at the request of plaintiffs who wanted to share it with regulators  In 2009  the federal government upgraded a decades old standard on roof strength  Remington declined to comment  In a statement emailed to Reuters  GM said   Advances in auto safety effectively addressed this concern many years ago   Also  it s fair for individuals or companies to be able to request that certain sensitive or personal information be safeguarded   THE LAW AND THE REALITY In fact  court records are presumed to be public as a matter of law  They can only be sealed for valid concerns about privacy  including personal medical records  and to protect company trade secrets  In most states and nearly all the 13 federal appellate circuits  judges are legally obliged to weigh any litigant s request that information be sealed against the broader public interest in making it public  They also must explain in the court record any decision in favor of secrecy  Judges incur no penalty for failing to do these things  In practice  secrecy has become so ingrained in the system that judges rarely question it  In 85 percent of the cases where Reuters found health and safety information under seal  judges provided no explanation for allowing the secrecy  Judge Stephens was bound by West Virginia law to weigh secrecy against transparency and provide in the court record his reasoning  Like many judges in his position  he did neither   This case was sealed because both sides agreed and asked me to seal it   he told Reuters  That reasoning explains why secrecy has become the norm  It makes things easier for everyone involved  Corporate lawyers want to protect their clients  reputations  Plaintiffs  lawyers want to avoid miring their clients  cases in lengthy courtroom wrangling over requests that filings be sealed or redacted  And judges want to keep the business of justice moving  Secrecy is amplified by the growing practice of consolidating similar lawsuits under a single judge  MDLs  which now cover as much as 40 percent of all lawsuits filed in federal courts  are meant to promote efficient resolutions  Each decision the judge makes applies to all of the consolidated lawsuits  Thus  with one sealing order  a judge can impose secrecy in thousands of cases  That is now happening in federal district court in Ohio  where Judge Polster is managing nearly 2 000 lawsuits filed against the opioid industry  Cities and counties across the country claim that companies up and down the supply chain   drug makers like Johnson   Johnson s Janssen Pharmaceuticals subsidiary and Teva Pharmaceutical Industries  NYSE TEVA  Ltd  as well as Purdue  distributors like McKesson Corp  NYSE MCK   and retailers like  Walgreen Co   NASDAQ WBA    contributed to the public health disaster by using misleading marketing and other ruses to boost sales at the expense of public safety  So far  Polster has imposed a draconian secrecy on the proceedings  The judge  a former federal prosecutor confirmed to the bench in 1998  has given the litigants broad discretion to determine what records remain secret  As a result  entire lawsuits have been filed under seal in his court  including supporting evidence drawn from millions of records that detail the industry s conduct over two decades  All the companies have denied the allegations  Teva and McKesson declined to comment for this article  Walgreens did not respond to a request for comment  Janssen said its marketing of opioids was  appropriate and responsible   Privately held Purdue  controlled by the Sackler family  said that OxyContin  has been deemed safe and effective for 12 hour dosing   that it has always given the U S  Food and Drug Administration  FDA  all information the agency requires  that protective orders are routine  and that any suggestion the company used court ordered secrecy to withhold relevant safety information about OxyContin is misleading and inflammatory  Purdue said it has spent more than  1 5 billion on efforts to solve the opioid crisis   These efforts  not the disclosure of Purdue s internal documents  will help solve the complex opioid abuse crisis   it said  A few states  including Texas and Florida  have adopted  sunshine  rules and laws that limit the sealing of health and safety records  At the federal level  corporate lobbying has stymied sunshine legislation for decades  Opponents of sunshine laws often cite a 1991 Harvard Law Review article in which New York University law professor Arthur Miller wrote that no hard evidence showed that court secrecy caused any harm to public health or safety   Research or statistical data is completely nonexistent   Miller wrote  In an interview  Miller said Reuters  analysis of court data helps fill that void and suggests that judges are not fulfilling their responsibility to guard the public interest   Certainly  anything relating to public health or things tied to social policy  you would want to have an explanation as to why something is sealed   he said   THAT S BANANAS  In the years following the Purdue case  Judge Stephens watched the wreckage of opioid addiction flow through McDowell County Circuit Court  burglaries  robberies  assaults  Thursdays in the hilltop courthouse in Welch were usually spent dealing with parents accused of child abuse and neglect  On one rainy Thursday last February  a clerk led a steady stream of mothers and fathers into Stephens s chambers  where he decided whether their children could remain with them   In almost every case  the parents are addicted   Stephens said later   We have parents who are now choosing drugs over their own children   When the state s suit against Purdue came before him in 2001  the cumulative U S  death toll from opioids since 1999 was 16 000  according to the National Institute on Drug Abuse  Stephens  who served for more than three decades on the McDowell County court before his May retirement  still counts it as his most high profile case  During the discovery process  each side was obliged to send information requested by the other   including the Purdue documents describing the company s development and marketing of OxyContin  That exchange is where secrecy gets its start in lawsuits  For decades  the rules of civil litigation required that evidence collected during discovery be logged with the court  open to public scrutiny  Secrecy was the exception  In the 1980s and 1990s  rule changes moved discovery out of the courthouse and thus out of public view  Instead  the material was to be swapped privately between the lawyers involved  Companies eager to keep their records confidential had pushed for the change  but it also served the interests of judges and court clerks inundated with increasingly complex product liability cases and huge caches of documents accompanying them  In the early 2000s  under the new discovery rules  Purdue s lawyers sent the company s documents directly to lawyers working for West Virginia  outside the court record and thus inaccessible to the public  This exchange occurred  as it almost always does  under the judge s protective order that the material remain confidential  Lawyers for Purdue filed a pretrial motion asking Judge Stephens to dismiss the case  West Virginia  to support its argument that the case should go to trial  submitted as evidence some of the documents Purdue had handed over in discovery  Such evidence entered into the court record to support a pretrial motion is generally the only way  short of a trial  that discovery material is made public   though that evidence often represents only a tiny fraction of what s produced in discovery  Here  too  secrecy prevailed  Lawyers for Purdue and the state agreed between themselves that the state would file its motion and supporting evidence under seal  Stephens did not evaluate the material to determine whether secrecy was warranted  as required by state law  and he provided no rationale   That s bananas   said Jennifer Oliva  a professor at West Virginia University College of Law   He s not allowed to do that without providing reasons   Judge Stephens was no rogue outlier  At least 16 other judges allowed internal documents produced by Purdue in lawsuits filed between 2001 and 2007 to be sealed without explanation  Court records make clear that evidence under seal pertained to Purdue s marketing  More broadly  in at least 31 of the 115 large federal product liability cases Reuters reviewed  judges sealed entire arguments that dealt directly with the strength of the evidence  Court rules frown on such broad sealing practices because truly confidential information rarely spans an entire legal brief  In most of those cases  nothing in the court record indicates that the judge conducted any analysis of whether secrecy was merited  Almost immediately after Stephens s 2004 ruling that the evidence against Purdue was sufficient for the case to proceed to trial  Purdue settled with West Virginia for  10 million  Stephens left his sealing order intact  The evidence was locked away in a vault in McDowell County Courthouse  By the end of that year  opioid deaths neared 65 000  Stephens told Reuters that he was simply honoring the litigants  wishes   Obviously when you settle a case of this magnitude and of this nature  Purdue Pharma would not want to let the world know they had engaged in deceptive marketing practices   he said  Frances Hughes  West Virginia s chief deputy attorney general at the time  said the state agreed to Purdue s sealing requests to get the evidence it needed and avoid a potentially lengthy court fight   We were doing something that is very much routine and necessary when you are involved in litigation with a major corporation   she said  Many plaintiffs  lawyers privy to evidence that could affect public health and safety told Reuters they had often employed a similar calculus  Bound by ethics rules to put their clients  interests first  they want access to records that can help their cases  Demanding transparency can cause protracted delays  Judges  while charged with guarding the public interest  also have large caseloads  At the federal level  their efficiency in handling those caseloads is measured by the Administrative Office of the U S  Courts  the federal judiciary s management agency  but judges aren t formally penalized for letting cases drag on  Many judges want to avoid getting bogged down in confidentiality battles  said Jeremy Fogel  who as a judge until last year managed the Federal Judicial Center in Washington  D C   an agency that helps educate judges   You re overburdened  You ve got limited bandwidth  You have lawyers fighting about everything  And so  when they finally agree on something  you re all too happy to accept that   said Fogel  now head of the Berkeley Judicial Institute at the University of California  As a result  he said   information that could have really made a difference sometimes doesn t come to light   LITTLE DATA  LITTLE SUNSHINE In the years following Stephens s ruling  Purdue benefited from the secrecy that had shrouded the West Virginia and similar cases  The U S  Department of Justice in 2007 brought criminal charges against Purdue  accusing it of lying in its marketing about how easy it was to abuse OxyContin by crushing the pills to get their full narcotic payload all at once  In a filing in federal court in Abingdon  Virginia  Purdue reasserted its 12 hour claim   When taken as directed  without tampering with the product s controlled release delivery system  OxyContin is indisputably safe and effective   Under a plea bargain  three Purdue executives admitted guilt but served no time  The company paid  600 million to resolve the case  The three executives later left the company  Company records that dribbled out over the years generated newspaper and government reports about aggressive sales tactics  But evidence undermining Purdue s claims about OxyContin remained locked away in courthouses across the country  And Purdue continued marketing its drug based on the contested 12 hour claim  OxyContin sales surged  topping  2 billion in 2008  Opioid deaths climbed to 135 000 by the end of 2008  The next year  Purdue s 80 milligram Oxycontin pill  the largest dose version  was the company s biggest moneymaker  That year  drugs   fueled by the spike in opioid overdoses   surpassed car accidents as a cause of death in the United States  By then  Mississippi lawyer Philip Thomas was trying to bring information about Purdue s marketing of OxyContin to the attention of regulators  Thomas represented Patricia Gwen Kiser  a nurse who alleged in a lawsuit against Purdue that her doctor had prescribed OxyContin for her fibromyalgia and arthritis pain based on the company s false claims about the drug s safety  Purdue turned over more than 250 boxes of records to Thomas  designating most of the evidence confidential  Thomas asked Purdue to share just 21 of the documents   emails  meeting minutes and the script Purdue asked sales reps to use when pitching OxyContin to doctors   with the FDA  Purdue declined  Thomas then asked Judge Linda Anderson  the judge hearing the case in federal court in Mississippi  to allow him to share the records with the regulator  Purdue resisted  arguing that the records were confidential trade secrets  Anderson  in a 2010 order  agreed with Purdue  Anderson did not respond to a request for comment  In its statement to Reuters  Purdue said it provided  all or most  of the documents to the agency  though they  do not contain the type of scientific information  the agency usually relies on  Some regulators have made efforts to counter the potential harm of court secrecy  In 2016  the National Highway Traffic Safety Administration  NHTSA  issued guidance for judges on allowing exemptions in secrecy orders so that lawyers can share health and safety records with the agency  The Consumer Product Safety Commission followed suit  The FDA has not  In a statement to Reuters  the agency said the current regulatory regime gives it  the tools to keep patients and consumers safe   The year after NHTSA issued its guidance  the agency opened an investigation into possible safety defects in Goodyear tires on thousands of motor homes  In its December 2017 announcement  the agency said the inquiry  which is continuing  was made possible  in part  only after an Arizona judge allowed the release of the tire maker s records  including insurance claims and complaints data  Goodyear declined to comment  as did NHTSA  In the absence of such exceptions  lawyers or anyone else with knowledge of confidential evidence put themselves at risk if they share that information outside the confines of court  David Egilman was an expert witness in a lawsuit alleging Eli Lilly  NYSE LLY    Co s antipsychotic drug Zyprexa could cause excessive weight gain and diabetes  Egilman  a clinical professor of family medicine at Brown University  made Lilly records he had reviewed in the case available to the New York Times  After the newspaper published articles  based on the documents  Lilly threatened to seek criminal sanctions against Egilman  In 2007  he agreed to pay  the drug maker  100 000 to resolve the matter  About a year later  Lilly pleaded guilty and agreed to pay  1 4 billion to resolve charges it had illegally marketed Zyprexa  Lilly declined to comment  Egilman had that earlier experience in mind when he sought to shine a light on OxyContin  which he had prescribed to a few patients in the drug s early days  While reviewing Purdue s records as an expert witness in a lawsuit against the company  Egilman became convinced that doctors were getting the wrong message about OxyContin  This time  he went to court to try to force Massachusetts Attorney General Martha Coakley to release evidence her office had gathered during an investigation into Purdue s sales practices  Massachusetts Superior Court Judge Linda Giles took a dim view of his petition  asking Egilman s lawyer during a 2012 hearing   What s his agenda   and  You want me to believe he s some noble citizen   Sensing the case wasn t going his way  Egilman said  he agreed to withdraw his petition rather than risk establishing an unfavorable precedent with a ruling that evidence collected in a state investigation was confidential   I could have stopped this   Egilman said in an interview   I am morally and ethically responsible  I took an oath to protect my patients  health  not corporate profits   Coakley and Giles declined to comment  By the end of 2012  the opioid death toll stood at 223 000  The evidence that OxyContin wasn t the benign pain reliever its maker said it was remained locked away until 2016  That year  the Los Angeles Times published a report  based on copies of sealed records  detailing how Purdue sold OxyContin as a 12 hour drug  even though the company knew it often didn t last that long  The report cited the company documents that Stephens and other judges had long kept under seal  revealing that OxyContin wore off early in Purdue test patients and that physicians complained to sales reps about the problem  Gaps in a narcotic s effect can cause bouts of pain  withdrawal and relief known to foster addiction  The sealed records further showed that despite what Purdue knew  it hired hundreds of sales reps to push OxyContin as a 12 hour drug because insurers would balk at paying top dollar for a pain reliever that was little different from cheaper alternatives  After the Los Angeles Times report  Judge Stephens began releasing the records he had sealed in 2004 to news organizations that requested them  including Reuters   I felt that it would be helpful to others who are going to pursue this type of litigation   he said  He was right  Many lawsuits against Purdue have cited the newspaper report and the original records  When the opioid epidemic landed on Judge Polster s docket in federal district court in Cleveland in late 2017  it had claimed 350 000 lives  Blame for the public health disaster was now directed at the entire industry   drug makers  distributors and retailers  The allegations in the hundreds of cases consolidated in Polster s court remained consistent  The companies hyped opioids for everyday pain relief  downplayed their addictiveness  and then blamed the people who used them for getting hooked   What s happening in our country with the opioid crisis is present and ongoing   Polster told a courtroom packed with lawyers for a Jan  9  2018  hearing   Since we re losing more than 50 000 of our citizens every year  about 150 Americans are going to die today  just today  while we re meeting   The judge said then  as he has said many times since  that he wanted the suits settled quickly so that communities ravaged by addiction can receive money to combat the crisis   I don t think anyone in the country is interested in a whole lot of finger pointing   Polster told the standing room only crowd   People aren t interested in depositions  and discovery  and trials   The tobacco industry settlement of 20 years ago  however  shows that when evidence is aired  it can have a big public impact  Under their landmark agreement with 46 states in 1998  cigarette makers paid  246 billion and divulged more than 26 million pages of records showing how they had manipulated nicotine to foster addiction and funded research to sway policy  That information formed the basis of public health initiatives and regulatory action in 160 countries  Since then  smoking rates in the U S  have plunged to historic lows  Citing the tobacco archives  public interest lawyers recently filed a brief in Polster s court asking that any resolution of the opioid litigation require the disclosure of all documents to promote research  changes in public policy  regulations and consumption  In Polster s court  as lawyers began fleshing out their cases against the opioid industry in amended complaints  they redacted details of the companies  conduct  In almost every instance  Polster failed to provide on the record his reason for allowing the secrecy  though the U S  Court of Appeals for the Sixth Circuit  which oversees his jurisdiction  has established precedent requiring that he do so  A few courts  recognizing the breadth of the opioid crisis  have recently signaled a less tolerant stance on secrecy  putting them at odds with Polster  Massachusetts Superior Court Judge Janet Sanders was presiding over a hearing in January on Purdue s request to maintain hundreds of redactions in a lawsuit filed against it by the state  News organizations  including Reuters  had petitioned Sanders to lift the redactions  Sanders reminded the lawyers that they were in the courthouse where records of child sexual abuse by Roman Catholic priests had been sealed   until the Boston Globe petitioned the court  for their release  That case  she said  showed that even if the litigants on both sides want to keep evidence secret  the  court has to separately make a determination   Purdue s lawyers argued that disclosure would stoke outrage and embarrass the company  Noting the  tremendous  public interest in the information  Sanders said   This material   some part of it or all of it   is going to come out one day  I m not sure why it shouldn t be sooner rather than later   Tony LaGreca  whose son fatally overdosed after becoming addicted to opioids prescribed for a football injury  was in the courtroom that day   She was pretty awesome   he said of Sanders  LaGreca said parents like him are eager for the world to see evidence placing some responsibility for addiction on the drug companies   It should be all made public   he said  In an emergency motion filed in Polster s Cleveland court  Purdue urged the judge to block Sanders from lifting the redactions  The Massachusetts lawsuit was full of details that could make the company look bad  a Purdue lawyer complained at a hearing  and the effort to get Judge Sanders in Boston to release them was an attempt to get around Polster s secrecy order  Polster sympathized   I m not very happy with the Massachusetts AG either   he said  But he decided he didn t have the power to overrule Sanders  The next day  an unredacted version of the Massachusetts lawsuit was made public  The state used excerpts of emails between Purdue executives and board members and details from other records to bolster its main allegation  Purdue s sales campaign was a  deadly and illegal scheme to deceive doctors and patients  that had contributed to at least 671 fatal overdoses in Massachusetts since 2009  The unredacted material supported allegations that  after pledging reforms in the 2007 plea agreement with federal prosecutors  Purdue pressed doctors to prescribe OxyContin to the elderly and military veterans  groups vulnerable to addiction  The state also alleged that Purdue sought to boost prescriptions for bigger doses  even though a 2012 internal analysis acknowledged that the more potent pills  very likely  carried heightened  dose related overdose risk   The underlying analysis remains under seal  Purdue denies the allegations  The unredacted material shows why doctors continued to write historically high numbers of OxyContin prescriptions even as deaths mounted  said Harvard Medical School professor Jerry Avorn   It helps patients and doctors understand why so much OxyContin is being used   Judge Sanders declined to comment on the case  In product liability cases generally   the public has very much right to know what s going on   she said   Transparency gives assurance that what s going on is fair   There s no hanky panky  There are no agreements between the parties that are contrary to the public interest   Polster has since ratcheted up the secrecy in his court  He signed a Feb  11 order that allows litigants to designate any document as  highly confidential   attorneys  eyes only information   That bars disclosure to anyone   even the mayors and other state and local officials the lawyers represent   without signed permission from Polster or the litigant who produced it  Last week  the Sixth U S  Circuit Court of Appeals rebuked Polster for his secrecy orders  after the Washington Post and the Gazette Mail of Charleston  West Virginia  appealed his sealing of government data on the flow of opioids around the country  The three judge panel unanimously agreed that Polster had not stated adequate reasons for allowing parties to file documents under seal  not just about the government data  but beyond  They ordered him to do so  Polster  is advised to bear in mind that the party seeking to file under seal must provide a  compelling reason  to do so   Judge Eric Clay wrote  
In the coming weeks  the plaintiffs will file their most extensive briefs yet about the opioid industry s conduct  It will be up to Polster to decide what the public will be allowed to see ",2019-06-25,Reuters,https://www.investing.com/news/stock-market-news/special-report-how-judges-added-to-the-grim-toll-of-opioids-1906852,1906852
127699,349214,MCK,Integer Holdings  ITGR  Boosts Product Line With New Buyout,opinion,Integer Holdings Corporation   NYSE ITGR   recently acquired certain assets of US BioDesign   a company manufacturing complex braided biomedical structures for disposable and implantable medical devices  The buyout is likely to add to Integer Holdings  already broad and robust product portfolio  thereby strengthening its position of being a partner of choice for advanced medical technologies Notably  US BioDesign caters to cardiovascular  neurovascular and general surgery markets with nitinol  stainless steel  polymer and other braided structures  These in turn have been enabling the next generation of structural heart  peripheral vascular  neurovascular and electrophysiology products Financial Terms of the AcquisitionAn upfront payment of  15 million and potential contingent payments in the future comprise as the terms of the agreement  Notably  the acquisition is expected to have a negligible impact on Integer Holdings  sales and adjusted EPS for the full year 2019 Benefits of the DealThe buyout is likely to add differentiated capability for complex braided and formed biomedical structures to Integer Holdings wide array of product portfolio  Moreover  the transaction will enable the company to partner with its customer base to aid patients by developing life saving medical devices  This in turn is likely to help Integer Holdings to stay ahead of the curve Consequently  the buyout will not only allow Integer Holdings to better serve its customers and patients worldwide but also accelerate growth Additionally  the acquisition is expected to provide a boost to Cardio and Vascular product line Market ProspectsPer a report by   the global medical devices market size accounted for  425 5 billion in 2018 and is anticipated to reach  612 7 billion by 2025 at a CAGR of 5 4  from 2018 2025   Increase in geriatric population  rising prevalence of chronic conditions and growth in surgical procedures are expected to drive the market during the aforementioned time period Notably  emerging markets hold great prospect for biomedical materials space Zacks Rank and Price PerformanceCurrently Integer Holdings has a Zacks Rank of 3  Hold   Shares of the company lost 4  on a year to date basis  compared with the  s decline of 6 9   Meanwhile  the S P 500 index rallied 16  in the same timeframe  Key PicksSome better ranked stocks from the broader medical space are Nissan Chemical Corporation   OTC NNCHY    Fresenius Medical Care AG   Co  KGaA   NYSE FMS   and McKesson Corporation   NYSE MCK    each currently carrying a Zacks Rank  2  Buy   You can see  Nissan Chemical has a long term earnings growth rate of 10  Fresenius Medical has a long term earnings growth rate of 5 9  McKesson has a long term earnings growth rate of 6 9  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/integer-holdings-itgr-boosts-product-line-with-new-buyout-200471874,200471874
127700,349215,MCK,Here s Why You Should Retain Cooper Companies  COO  Stock Now,opinion,"The Cooper Companies  Inc    NYSE COO   is well poised for growth on strong segmental performances  increasing penetration in international markets and solid gains from the core CooperVision   CVI   unit  However  foreign exchange related headwinds raise concerns The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of Cooper Companies have gained 13 5  against the  s decline of 6 6  on a year to date basis  Meanwhile  the S P 500 Index rallied 14 2  
 

What s Deterring the Stock Cooper Companies generates a significant part of revenues in foreign currencies  Fluctuations in foreign exchange rates may significantly mar its overseas revenues The company anticipates foreign exchange headwinds to have an adverse impact of 62 cents per share on earnings and  66 million on revenues on a year over year basis in 2019 What s Favoring the Stock Driven by a highly exclusive product portfolio  featuring the likes of Biofinity and Clariti  Cooper Companies has been able to maintain its leading position in specialty lens markets  Notably  the company s flagship silicone hydrogel lenses are anticipated to generate strong sales in the near term  We expect its MyDay and Clariti lenses to bolster prospects further Moreover  the company s CooperVision segment has been successful globally and is fortifying presence through developments such as Eye care professional  ECP  programs in Australia and New Zealand This apart  the aforementioned segment remains focused on multiple initiatives that will increase the adoption of its innovative MiSight 1 day product across major global markets For fiscal 2019  management expects revenues at CVI to grow 7 8  at pro forma Cooper Companies has been witnessing expansion at its CooperSurgical   CSI   business line s product portfolio  which has been benefiting the segment consistently  Notably  revenues from CSI are anticipated to range between  669 and  679 million Acquisitions play an important role in the company s long term growth prospects  CSI s acquisition of Incisive Surgical and CVI s buyout of Blanchard contact lenses are expected to prove beneficial for the respective segments  which in turn will fuel growth An upgraded fiscal 2019 guidance is also favoring the stock  Currently  the company expects revenues to be  2 635  2 655 million  calling for pro forma growth of 6 7   Its adjusted earnings per share  EPS  are expected to be  12 27  12 35 Which Way Are Estimates Headed For fiscal 2019  the Zacks Consensus Estimate for the company s revenues is pegged at  2 65 billion  suggesting an improvement of 4 5  from the year ago reported figure  The same for earnings stands at  12 32  indicating year over year growth of 7 1  Stocks to ConsiderSome better ranked stocks from the broader medical space are Nissan Chemical Corporation   OTC NNCHY    Fresenius Medical Care AG   Co  KGaA   NYSE FMS   and McKesson Corporation   NYSE MCK    each currently carrying a Zacks Rank  2  Buy   You can see  
Nissan Chemical has a long term earnings growth rate of 10  Fresenius Medical has a long term earnings growth rate of 5 9  McKesson has a long term earnings growth rate of 6 9  
5 Stocks Set to Double
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth 
Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-09,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-cooper-companies-coo-stock-now-200472241,200472241
127701,349216,MCK,Here s Why You Should Hold On To NextGen Healthcare For Now,opinion,NextGen Healthcare  Inc    NASDAQ NXGN   is well poised for growth on the back of growing RCM  Revenue Cycle Management  and electronic health record  EHR  markets  and solid demand for other NextGen solutions  However  intense competition in the healthcare information technology market remains a concern The stock carries a Zacks Rank  3  Hold  Price PerformanceShares of NextGen Healthcare have lost 23 5   compared with the  s decline of 7 3  in a year s time  Meanwhile  the S P 500 Index rallied 4 7  What s Deterring the Stock The company faces intense competition thanks to the highly competitive healthcare information technology  HCIT  market it operates in  This in turn will aggravate pricing pressure Further  the company has been witnessing margin pressure for a considerable period of time and is likely to persist in the near term What s Favoring the Stock Being a major player in the U S  RCM space  the company continues to benefit from this market  The global RCM market is anticipated to reach  73 2 billion by 2026 at a CAGR of 12 0  Given the popularity of the RCM solution  the company intends to expand into dental and hospital markets that will boost the top line On the basis of the latest trend of EHR services in the U S  MedTech space gaining prominence  the company is expected to benefit from the growing global EHR market According to Transparency Market Research  the global EHR market is estimated to reach  38 29 billion by 2025 at a CAGR of 5 7   Further  reports indicate that MedTech companies with significant exposure to big data automated EHRs will excel with respect to operations and margins Apart from RCM  NextGen Healthcare will continue to benefit from strong demand for its other NextGen solutions that include Hospitals  EHR and practice management  NextGen s Inpatient Clinicals  Lab and Patient Portal EHR solutions have also been gaining significant traction Strength in the company s NextGen division is significantly bolstering the company s revenues  Moreover  recurring revenue stream and growing base of physicians  dentists and hospitals are other tailwinds Which Way Are Estimates Headed For fiscal 2019  the Zacks Consensus Estimate for revenues is pegged at  541 8 million  indicating an improvement of 2 4  from the year ago period  The same for earnings stands at 85 cents per share  suggesting a decline of 1 2  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Nissan Chemical Corporation   OTC NNCHY    Straumann Holding AG  and McKesson Corporation   NYSE MCK    each currently carrying a Zacks Rank  2  Buy   You can see   Nissan Chemical has a long term earnings growth rate of 10  Straumann Holding has a long term earnings growth rate of 18  McKesson has a long term earnings growth rate of 6 9  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-nextgen-healthcare-for-now-200473615,200473615
127704,349219,MCK,Top Ranked Value Stocks To Buy For October 15th,opinion,"Here are four stocks with buy rank and strong value characteristics for investors to consider today  October 15th The Michaels Companies  Inc    MIK   This arts and crafts retail chain has a Zacks Rank  2  Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 1 7  over the last 60 days The Michaels Companies  Inc  Price and Consensus   Michaels has a price to earnings ratio  P E  of 4 02 compared with 9 80 for the industry  The company possesses a  of A 
The Michaels Companies  Inc  PE Ratio  TTM    Office Properties Income Trust  OPI   This real estate investment trust has a Zacks Rank  1  Strong Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 5 8  over the last 60 days 
Government Properties Income Trust Price and Consensus   Office Properties Income Trust has a price to earnings ratio  P E  of 5 17 compared with 22 80 for the industry  The company possesses a Value Score of B 
Government Properties Income Trust PE Ratio  TTM    McKesson Corporation  NYSE MCK   MCK   This provider of pharmaceuticals and medical supplies has a Zacks Rank  2  Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 0 3  over the last 60 days 
McKesson Corporation Price and Consensus   McKesson has a price to earnings ratio  P E  of 9 37 compared with 17 00 for the industry  The company possesses a Value Score of A 
McKesson Corporation PE Ratio  TTM    Fly Leasing Limited  FLY   This aircraft leasing company has a Zacks Rank  2  Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 43 8  over the last 60 days 
Fly Leasing Limited Price and Consensus   Fly Leasing has a price to earnings ratio  P E  of 3 35 compared with 10 80 for the industry  The company possesses a Value Score of A 
Fly Leasing Limited PE Ratio  TTM    See the 
Learn more about the  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-value-stocks-to-buy-for-october-15th-200473559,200473559
127712,349227,MCK,Here s Why You Should Add PRA Health To Your Portfolio Now,opinion,PRA Health Sciences  Inc    NASDAQ PRAH   is well poised for growth on the back of strong international expansion  improving Contact Research Organization  CRO  industry and favorable biopharmaceutical industry dynamics The stock currently carries a Zacks Rank  2  Buy  Price PerformanceShares of PRA Health Sciences have gained 5 2   against the  s decline of 16 9  on a year to date basis  Meanwhile  the S P 500 Index rallied of 18 1  in the same timeframe Factors to Boost PRA HealthThe CRO industry has been gaining traction of late on the back of worldwide increase in demand for outsourced clinical development solutions  Going by a CRO Market Size Projections report by Industry Standard Research  ISR   the size of the worldwide CRO market was approximately  32 billion in 2016 and is anticipated to hit  44 billion in 2021 at a CAGR of 7  International expansion has been and continues to be a major growth driver  This is because PRA Health is one of the largest CROs globally on the basis of revenues  focusing on executing clinical trials on a worldwide basis We note that  PRA Health s revenues from international operations is growing fast  currently Europe  Africa  and Asia Pacific region contributes more than 30  to total revenues  The company continues to gain from large pharmaceutical companies  which contributed to the top line in recent times Moreover  a solid 2019 outlook instills optimism in the stock  For 2019  PRA Health anticipates to achieve total revenues between  3 02 billion and  3 10 billion  representing reported growth of 5 8  and 6 8  at constant currency Adjusted EPS for 2019 is expected between  4 98 and  5 08  indicating growth of 16  to 19  from 2018 Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  3 06 billion  indicating an improvement of 9 3  from the year ago period  For adjusted earnings per share  the same is pinned at  5 07  suggesting growth of 18 5  year ago reported figure Other Stocks to ConsiderSome other top ranked stocks from the broader medical space are Nissan Chemical Corporation   OTC NNCHY    Straumann Holding AG  and McKesson Corporation   NYSE MCK    each currently carrying a Zacks Rank  2  You can see   Nissan Chemical has a long term earnings growth rate of 10  Straumann Holding has a long term earnings growth rate of 18  McKesson has a long term earnings growth rate of 6 9  7 Best Stocks for the Next 30 Days Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-add-pra-health-to-your-portfolio-now-200474519,200474519
127713,349228,MCK,Stocks   Tilray  Newell Brands Jump in Premarket  Walgreen s  Pier 1  ConAgra Fall,news,"Investing com   Stocks in focus in premarket trade Thursday 
  Walgreens Boots Alliance  NASDAQ WBA  fell 1 8  at 8 30 AM ET  13 30 GMT  after it reported quarterly sales that were a tad lower than expectations  The drugstore chain owner did reaffirm full year profit guidance 
  Tilray  NASDAQ TLRY  soared 12  on news the cannabis company is teaming up with Anheuser Busch Inbev  NYSE BUD  to research cannabis infused non alcoholic beverages 
  ConAgra Foods  NYSE CAG  slipped 5  after it issued full year profit guidance that was lower than consensus estimates  despite handily beating on the bottom line in its most recent quarter 
   Pier 1 Imports   NYSE PIR  plunged 10  after reporting a quarterly loss that was much wider than expected and also missed on sales  The retailer also appointed an interim CEO 
  Newell Brands  NASDAQ NWL  stock gained 5  after activist investor Carl Icahn revealed in a regulatory filing that he now owns 9 89  of the company  up from 8 1  
  Rite Aid  NYSE RAD  shares jumped 13  after the company reported earnings and sales in line with expectations and announced a 10 year pharmaceutical distribution deal with McKesson  NYSE MCK  ",2018-12-20,Investing.com,https://www.investing.com/news/stock-market-news/stocks--tilray-newell-brands-jump-in-premarket-walgreens-pier-1-conagra-fall-1727488,1727488
127714,349229,MCK,Dance off  Attempt to shame Ocasio Cortez with video backfires,news,"By Gina Cherelus  Reuters    An attempt to embarrass newly elected U S  Representative Alexandria Ocasio Cortez with a nine year old video showing her dancing while in college backfired when it drew a wave of support for the liberal lawmaker on social media  The widely shared video shows the 29 year old Democrat  the youngest woman ever elected to the U S  Congress  dancing on a roof with other students at Boston University as they recreate dance scenes from famous 1980 s films like  The Breakfast Club   The caption under the original Twitter post  which was reported to be uploaded by the now deactivated account  AnonymousQ1776  read   Here is America s favorite commie know it all acting like the clueless nitwit she is       Ocasio Cortez graduated from the university in 2011 with degrees in international relations and economics  A representative of the New York lawmaker  who rose to prominence last year after beating a 10 term incumbent in a Democratic primary  did not immediately respond to a request for comment   Ocasio Cortez was part of a wave of Democratic women congressional candidates elected in November aiming to put more support behind the liberal progressive wing of the party  Twitter comments broke down along partisan lines  with opponents describing the dance video as showing immaturity while supporters saw it as cute   Hey  AOC  just wanted to say that I thought the high school video of you dancing was awesome   wrote Twitter user David Weissman  a New York born columnist now living in Israel on Thursday  referring to Ocasio Cortez by her Twitter handle   It also shows your haters are desperate and pathetic  keep being you   The original posting meant to demean Ocasio Cortez incorrectly said she was in high school at the time the video was recorded   The video of  AOC dancing is so well done  And she s all joy in it  I can t believe they thought that was going to be some scandal   wrote DeRay McKesson  NYSE MCK   a U S  civil rights activist who was a leader of the Black Lives Matter wave of protests against police violence that swept U S  cities including Ferguson  Missouri  and Baltimore in 2014 and 2015  
The four minute  20 second mashup video was posted on YouTube in 2010 and was filmed at Boston University  University officials at the time said in a statement that about 20 students gathered to create a  high spirited music video  to pay homage ",2019-01-04,Reuters,https://www.investing.com/news/world-news/danceoff-attempt-to-shame-ocasiocortez-with-video-backfires-1737710,1737710
127715,349230,MCK,Dance off  Attempt to shame Ocasio Cortez with video backfires,news,"By Gina Cherelus  Reuters    An attempt to embarrass newly elected U S  Representative Alexandria Ocasio Cortez with a nine year old video showing her dancing while in college backfired when it drew a wave of support for the liberal lawmaker on social media  The widely shared video shows the 29 year old Democrat  the youngest woman ever elected to the U S  Congress  dancing on a roof with other students at Boston University as they recreate dance scenes from famous 1980 s films like  The Breakfast Club   The caption under the original Twitter post  which was reported to have been uploaded by the now deactivated account  AnonymousQ1776  read   Here is America s favorite commie know it all acting like the clueless nitwit she is       Ocasio Cortez graduated from the university in 2011 with degrees in international relations and economics  The New York lawmaker  who rose to prominence last year after beating a 10 term incumbent in a Democratic primary  posted on Twitter on Friday a brief video of herself dancing outside of her office with a huge grin while the song  War  by Edwin Starr is heard playing in the background    I hear the GOP thinks women dancing are scandalous   wrote Ocasio Cortez in the tweet   Wait till they find out Congresswomen dance too  Have a great weekend everyone    Ocasio Cortez was part of a wave of Democratic women congressional candidates elected in November aiming to put more support behind the liberal progressive wing of the party  Twitter comments broke along partisan lines  with opponents describing the dance video as showing immaturity while supporters saw it as cute   Hey  AOC  just wanted to say that I thought the high school video of you dancing was awesome   wrote Twitter user David Weissman  a New York born columnist now living in Israel on Thursday  referring to Ocasio Cortez by her Twitter handle   It also shows your haters are desperate and pathetic  keep being you   The original posting meant to demean Ocasio Cortez incorrectly said she was in high school at the time the video was recorded  
 The video of  AOC dancing is so well done  And she s all joy in it  I can t believe they thought that was going to be some scandal   wrote DeRay McKesson  NYSE MCK   a U S  civil rights activist who was a leader of the Black Lives Matter wave of protests against police violence that swept U S  cities including Ferguson  Missouri  and Baltimore in 2014 and 2015 ",2019-01-04,Reuters,https://www.investing.com/news/politics-news/danceoff-attempt-to-shame-ocasiocortez-with-video-backfires-1737709,1737709
127716,349231,MCK,UPS eyes in home health services with U S  vaccine project,news,"By Lisa Baertlein and Michael Erman LOUISVILLE  Ky     United Parcel  Service Inc  NYSE UPS  wants to get beyond U S  doorsteps with a new push into healthcare   The world s largest package delivery firm is preparing to test a U S  service that dispatches nurses to vaccinate adults in their homes  Reuters has learned  as the company and its healthcare clients work to fend off cost pressures and competitive threats from Amazon com  NASDAQ AMZN   UPS did not disclose which vaccines it would be using in the project  but drug and vaccine maker Merck   Co told Reuters it is looking at partnering with the company for the initiative  The project  previously unreported  shows how UPS is targeting a larger slice of the  85 billion outsourced healthcare logistics market  Deutsche Post s DHL Group dominates the market  which is expected to grow to  105 billion by 2021   Over the threshold services is where the world is headed   Chris Cassidy  who joined UPS last year from GlaxoSmithKline PLC to oversee global healthcare logistics strategy  told Reuters in an interview at UPS  Worldport facility in Louisville  Here is how the test  slated to launch later this year  will operate  Workers in UPS  1 7 million square foot healthcare complex at Worldport will package and ship the vaccine to one of the more 4 700 franchised U S  UPS stores  A home health nurse contracted by UPS  clinical trial logistics unit known as Marken will collect the insulated package  transport it the  last mile  to the patient s home and administer the vaccine  which will target a viral illness in adults  The aim of the test is to  see if we can connect all these dots   said Wes Wheeler  chief executive at Marken  which was purchased by UPS in 2016 and is overseeing the vaccine project  It comes as the parcel delivery industry braces for the impact of a cooling economy and competition from customer turned rival Amazon  which is building its own logistics network to contain the swelling cost of dropping millions of packages at shoppers  homes   UPS healthcare customers  facing political scrutiny over high drug prices and systemic waste  are also under pressure from Amazon  The world s biggest online retailer is teaming up with Berkshire Hathaway  NYSE BRKa  and JPMorgan Chase   Co  NYSE JPM  to lower prescription drug costs for their employees  And  it rocked the sector last year with its roughly  1 billion purchase of specialty online pharmacy PillPack  Experts say raising low U S  adult vaccination rates would reduce healthcare spending by curbing preventable illnesses that result in doctor visits and hospitalizations  Merck  a major UPS healthcare customer  has a portfolio of vaccines for viral illnesses ranging from shingles and hepatitis B to the flu  Spokeswoman Pamela Eisele said the company is considering the project as it looks for new ways to increase access to its medicines and vaccines and boost adult vaccine rates  Experts said the UPS project could also save money by having contract home nurses  rather than higher paid doctors  administer the vaccine  But the test  a first for a large U S  shipper  is not a guaranteed slam dunk for UPS  Marken s CEO said it must figure out how to get medical insurers to pay for the new service   NEW FRONTIERS UPS  DHL and specialty shippers have a smattering of home health projects around the world   mostly in countries with single payer health systems  DHL  the healthcare logistics leader with annual medical related revenue of more than 3 billion euros   3 4 billion   transports U K  patients from home to non emergency hospital appointments  Polar Speed  a U K  specialty logistics company UPS bought in 2014  has trained and background checked drivers who enter homes to drop off prescriptions  deliver and install medical refrigerators and infusion pumps  and remove waste such as used syringes and wound dressings  Pharmaceutical companies already pay Marken to give vaccines to patients testing their experimental drugs  Cathy Morrow Roberson  who founded consulting firm Logistics Trends   Insights after working for more than a decade as an analyst at Atlanta based UPS  said the vaccine project taps the assets and expertise the company has acquired since getting into healthcare in the early 2000s   They re reaping the benefits of all the acquisitions and investments they ve made   she said  The effort is designed to put even more distance between UPS and Amazon  which lacks the specialized warehouse  temperature controlled shipping and regulatory infrastructure that healthcare companies require  Amazon currently uses UPS and FedEx Corp  NYSE FDX  for PillPack home deliveries  Major insurers contacted by Reuters declined to say what they pay to have vaccines administered  But an analysis of 2010 MarketScan health claims data sheds some light on the subject   finding that the average cost of a shingles shot was  208 72 at a doctor s office and  168 50 at a pharmacy  Flu shots cost less than  30 at both locations  The provider of that data declined to update it  Delivering home vaccines at a competitive price may not be the only hurdle to the UPS project s success  said Stephen Buck  chief executive of Courage Health and a former vice president at McKesson Corp  NYSE MCK   
 Pharmacies and physicians may not be happy about a new player competing against them   Buck said ",2019-03-22,Reuters,https://www.investing.com/news/stock-market-news/ups-eyes-inhome-health-services-with-us-vaccine-project-1815013,1815013
127717,349232,MCK,Glenview s Larry Robbins says he s shorting 3M shares  likes healthcare stocks  Sohn,news," Reuters    Glenview Capital Management CEO Larry Robbins said at the Sohn Investment Conference on Monday that he s shorting shares of industrial conglomerate 3M  NYSE MMM  Co and is positive on healthcare stocks like  Cigna Corp   NYSE CI    Humana Inc   NYSE HUM  and UnitedHealth Group Inc  NYSE UNH   Despite his long call on HMO equities  Robbins said he does not like pharmaceutical stocks due to the political risk  with many Democratic presidential hopefuls   as well as President Donald Trump   opposed to lofty drug prices   In pharmaceuticals     the president can act unilaterally to reduce drug pricing   Robbins warned   The same drug in the United States costs three times as much as other  developed countries   Robbins said Glenview has three long and 16 short positions in the pharmaceutical space and recommends investors short any ETF that tracks the space  Long a fan of healthcare stocks  Robbins in 2018 picked Express Scripts Cigna  CVS Aetna and McKesson  NYSE MCK  as his winners in the field  
3M shares were down 2 2 percent in afternoon trading ",2019-05-06,Reuters,https://www.investing.com/news/stock-market-news/glenviews-larry-robbins-says-hes-shorting-3m-shares-likes-healthcare-stocks-sohn-1857839,1857839
127721,349236,MCK,MCK Vs  ALGN  Which Stock Is The Better Value Option ,opinion,"Investors looking for stocks in the Medical   Dental Supplies sector might want to consider either McKesson  MCK  or Align Technology  NASDAQ ALGN   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
McKesson and Align Technology are sporting Zacks Ranks of  2  Buy  and  4  Sell   respectively  right now  Investors should feel comfortable knowing that MCK likely has seen a stronger improvement to its earnings outlook than ALGN has recently  But this is just one factor that value investors are interested in 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
MCK currently has a forward P E ratio of 9 62  while ALGN has a forward P E of 34 99  We also note that MCK has a PEG ratio of 1 39  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  ALGN currently has a PEG ratio of 1 44 
Another notable valuation metric for MCK is its P B ratio of 3 17  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  ALGN has a P B of 10 65 
These metrics  and several others  help MCK earn a Value grade of A  while ALGN has been given a Value grade of D 
MCK stands above ALGN thanks to its solid earnings outlook  and based on these valuation figures  we also feel that MCK is the superior value option right now ",2019-09-01,Zacks Investment Research,https://www.investing.com/analysis/mck-vs-algn-which-stock-is-the-better-value-option-200460776,200460776
127722,349237,MCK,Looking For Value  Why It Might Be Time To Try McKesson  MCK ,opinion,Value investing is always a very popular strategy  and for good reason  After all  who doesn t want to find stocks that have low PEs  solid outlooks  and decent dividends Fortunately for investors looking for this combination  we have identified a strong candidate which may be an impressive value  McKesson Corporation   NYSE MCK   McKesson in FocusMCK may be an interesting play thanks to its forward PE of 9 6  its P S ratio of 0 1  and its decent dividend yield of 1 1   These factors suggest that McKesson is a pretty good value pick  as investors have to pay a relatively low level for each dollar of earnings  and that MCK has decent revenue metrics to back up its earnings McKesson Corporation PE Ratio  TTM    But before you think that McKesson is just a pure value play  it is important to note that it has been seeing solid activity on the earnings estimate front as well  For current year earnings  the consensus has gone up by 0 2  in the past 30 days  thanks to two upward revisions in the past one month compared to none lower This estimate strength is actually enough to push MCK to a Zacks Rank  2  Buy   suggesting it is poised to outperform  You can see  So really  McKesson is looking great from a number of angles thanks to its PE below 20  a P S ratio below one  and a strong Zacks Rank  meaning that this company could be a great choice for value investors at this time Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ,2019-09-03,Zacks Investment Research,https://www.investing.com/analysis/looking-for-value-why-it-might-be-time-to-try-mckesson-mck-200461005,200461005
127726,349241,MCK,Top Research Reports For Amgen  Cisco   Berkshire Hathaway,opinion,"Thursday  September 12  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Amgen  AMGN   Cisco  CSCO  and Berkshire Hathaway  BRK B   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Amgen s shares have outperformed the Zacks Biomedical and Genetics industry on a year to date basis  0 6  vs   1 4    The Zacks analyst thinks that while Amgen s newer drugs   Prolia  Xgeva  Blincyto  Kyprolis   will drive sales  biosimilar and brand competition for its legacy products will create pressure on sales in the second half 
Meanwhile  uptake of key drug  Repatha  has been slow due to payer restrictions  However  recently launched products  including Aimovig and Evenity  biosimilars and international expansion provide incremental growth opportunities  
Amgen is also progressing with its pipeline  In the past five years  Amgen has launched nine products  including two in new therapeutic areas  Amgen boasts a strong biosimilars pipeline  which could be an important long term growth driver  The company s restructuring plan is making it leaner and more cost efficient  Amgen s shares have outperformed the industry so far this year 
 You can  
Shares of Cisco have lost 4 9  in the past six months  outperforming the Zacks Computer Networking industry s fall of 5 2   The Zacks analyst believes that Cisco is benefiting from a solid security business  Strong contribution from Infrastructure Platforms and applications is a positive 
Moreover  order strength and improving traction of the subscription based business model are tailwinds  Further  a strengthening collaboration portfolio  which includes Webex Teams  bodes well  Additionally  the acquisitions of Voicea and CloudCherry hold promise  Notably  shares of the company have outperformed the industry in the past year 
However  weakness in service provider business in China remains a concern  Further  stiff competition from Arista and Juniper in switching and routing verticals is likely to create pricing pressure and impact profitability  Also  increasing investments in product enhancements are likely to limit margin expansion at least in the near term 
 You can   
BRK B s shares have gained 2 9  over the past six months  outperforming the Zacks Insurance   Property and Casualty industry s rise of 2 5  
The Zacks analyst believes that Berkshire Hathaway s inorganic growth story remains impressive with strategic acquisitions  A strong cash position supports earnings accretive bolt on buyouts  Demand for utilities is expected drive earnings growth  Continued insurance business growth also increases float  Its non insurance businesses are delivering improved results  A sturdy capital level provides further impetus 
However  exposure to catastrophe loss remains a concern as its property and casualty insurance business generates maximum return on equity  Huge capital expenses due to railroad operations pose concerns 
 You can   
Other noteworthy reports we are featuring today include Eaton  NYSE ETN   ETN   T  Rowe Price  TROW  and McKesson  MCK  
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better 

Mark VickerySenior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Amgen  AMGN  Counts on New Drugs to Drive Top line Growth


Security Business Aids Cisco  CSCO  Despite China Exposure


Solid Insurance Business Aid Berkshire  BRK B   Cat Loss Ail


Featured Reports
Extensive Market Reach  Product Innovation Aid Eaton  ETN 
Per the Zacks analyst Eaton s presence in around 175 countries across the globe and its consistent research and development aiding it to churn out new products is boosting performance 

Passenger Revenues Buoy Alaska Air  ALK  Amid High Costs
The Zacks analyst is impressed with Alaska Air s solid passenger revenues  up 4  in first half 2019  due to solid demand for air travel 

Action 2020 to Aid ArcelorMittal  MT  Amid Trade Tensions
While U S  China trade tensions may hurt some of the company s key markets including automotive  it should gain from efforts to boost margins through the Action 2020 initiative  per the Zacks analyst 

Medical Surgical Unit Aids McKesson  MCK   Pricing Ails
Per the Zacks analyst  robust Medical Surgical Solutions unit  fueled by growth in the Primary Care and Extended Care businesses  continues to boost McKesson 

Focus on Hospitality  New Galleries To Boost RH s  RH  Sales
Per the Zacks analyst  the company s core RH business  solid performance of new galleries  mainly RH New York   along with continued expansion of RH Hospitality will drive growth 

Skechers  SKX  Robust International Business to Drive Sales
Per the Zacks analyst  Skechers  international wholesale business remains a key sales driver 

TripAdvisor  TRIP  Non Hotel Drives Growth  Expense A Concern
The Zacks analyst believes that TripAdvisor s growth in non hotel business and expanding user base are positives  However  higher expenses   weakness in the Hotel business remain concerns 

New Upgrades
Strong C P Order Inflows to Boost National Oilwell  NOV 
The Zacks analyst believes that the significant improvement in order inflows for National Oilwell s Completion   Production  C P  Solutions unit will deliver impressive revenue growth 

Ciena  CIEN  Rides High on Holistic Growth Initiatives
Per the Zacks analyst  the buyout of Packet Design has expanded Ciena s Blue Planet software business and network capabilities with critical new features to support multilayer multivendor networks 

Growth in Europe to Keep Driving Guess    GES  Top Line
Per the Zacks analyst  Guess  is gaining from solid business progress in Europe  Management continues to invest in this region  wherein it expects revenues to rise high single digits in fiscal 2020 

New Downgrades
Weak Store Traffic to Weigh on Kirkland s  KIRK  Performance
Per the Zacks analyst  Kirkland s is reeling under weak comps  due to low traffic in brick and mortar stores  Such trends are likely to persist  which led management to trim fiscal 2019 earnings view 

Elevated Expenses and FX Movements Hurt T  Rowe Price  TROW 
Per the Zacks analyst  over dependence on investment advisory fees which can be adversely affected owing to market fluctuations and FX translations is a concern  Also  high costs act as a headwind 

Competition   China Exposure to Hurt ON Semiconductor  ON 
Per the Zacks analyst  ON Semiconductor is affected by stiff competition and weakness in majority of end markets  Further  the U S  China trade war and Huawei headwinds remain major concerns 
undefined undefined",2019-09-12,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-for-amgen-cisco--berkshire-hathaway-200464217,200464217
127729,349244,MCK,The Zacks Analyst Blog Highlights  Amgen  Cisco  Berkshire Hathaway  T  Rowe Price And McKesson,opinion,For Immediate ReleaseChicago  IL  September 13  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Amgen   NASDAQ AMGN    Cisco   NASDAQ CSCO    Berkshire Hathaway   T  Rowe Price   NASDAQ TROW   and McKesson   NYSE MCK   Here are highlights from Thursday s Analyst Blog Top Research Reports for Amgen  Cisco and Berkshire HathawayThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Amgen  Cisco and Berkshire Hathaway  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Amgen s shares have outperformed the Zacks Biomedical and Genetics industry on a year to date basis  0 6  vs   1 4    The Zacks analyst thinks that while Amgen s newer drugs   Prolia  Xgeva  Blincyto  Kyprolis   will drive sales  biosimilar and brand competition for its legacy products will create pressure on sales in the second half Meanwhile  uptake of key drug  Repatha  has been slow due to payer restrictions  However  recently launched products  including Aimovig and Evenity  biosimilars and international expansion provide incremental growth opportunities Amgen is also progressing with its pipeline  In the past five years  Amgen has launched nine products  including two in new therapeutic areas  Amgen boasts a strong biosimilars pipeline  which could be an important long term growth driver  The company s restructuring plan is making it leaner and more cost efficient  Amgen s shares have outperformed the industry so far this year  You can  Shares of Cisco have lost 4 9  in the past six months  outperforming the Zacks Computer Networking industry s fall of 5 2   The Zacks analyst believes that Cisco is benefiting from a solid security business  Strong contribution from Infrastructure Platforms and applications is a positive Moreover  order strength and improving traction of the subscription based business model are tailwinds  Further  a strengthening collaboration portfolio  which includes Webex Teams  bodes well  Additionally  the acquisitions of Voicea and CloudCherry hold promise  Notably  shares of the company have outperformed the industry in the past year However  weakness in service provider business in China remains a concern  Further  stiff competition from Arista and Juniper in switching and routing verticals is likely to create pricing pressure and impact profitability  Also  increasing investments in product enhancements are likely to limit margin expansion at least in the near term  You can   BRK B s shares have gained 2 9  over the past six months  outperforming the Zacks Insurance   Property and Casualty industry s rise of 2 5  The Zacks analyst believes that Berkshire Hathaway s inorganic growth story remains impressive with strategic acquisitions  A strong cash position supports earnings accretive bolt on buyouts  Demand for utilities is expected drive earnings growth  Continued insurance business growth also increases float  Its non insurance businesses are delivering improved results  A sturdy capital level provides further impetus However  exposure to catastrophe loss remains a concern as its property and casualty insurance business generates maximum return on equity  Huge capital expenses due to railroad operations pose concerns  You can   Other noteworthy reports we are featuring today include T  Rowe Price and McKesson Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-09-12,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-amgen-cisco-berkshire-hathaway-t-rowe-price-and-mckesson-200464470,200464470
127733,349248,MCK,Opioid Overdose Crisis In US Likely To Affect These 3 Stocks,opinion,Opioids are a diverse class of moderately strong  addictive and cheap painkillers  whose misuse claims more than 130 lives daily in the United States  Notably  the opioid epidemic began in the late 1990s and the death rates have increased manifold since then  Though  expects these deaths to drop in 2019  pharmaceutical giants are ending up facing increasing number of lawsuits for allegedly aggravating the opioid crisis Now this might raise the alarm for potential investors Opioid Lawsuit Wave Rattles IndustryAugust ended on a bitter note for the pharmaceutical industry as drug giant Johnson   Johnson   NYSE JNJ   was slapped with a penalty of  572 million in a landmark opioid trial  Notably  the company has been alleged to have spread highly addictive painkillers in the state of Oklahoma  Earlier this year  Oklahoma also settled disputes over opioid use with Teva Pharmaceutical   NYSE TEVA   for  85 million That s not all  Privately held Purdue Pharma  a maker of OxyContin  is offering  10  12 billion to settle more than 2 000 lawsuits  Notably  the lawsuits from various states  cities and counties have alleged the company of fostering the opioid crisis The scenario is clearer when we look at the total consumer spending on medicines in the United States  Spending totaled  482 billion in 2018  significantly up from  316 billion in 2010  per   Remedial Measures Likely to Baffle InvestorsIn the wake of the recent events  President Trump announced  1 8 billion in new grants earlier this month  to help fight the opioid epidemic  This  along with the FDA s latest stance on combating the epidemic  might further vex investors about the future of opioid makers and distributors Notably  the FDA suggested the consumption of a life saving drug called naloxone to reverse the effects of an overdose  In fact  most states have passed laws or made rules to allow pharmacists to provide over the counter naloxone to consumers  Although this creates a remedial scope for pharmaceutical companies  the glare of opioid lawsuits is likely to remain and impact drug manufacturers  pharmacy operators and distributors Stocks Likely to Bear the BruntGiven the present situation  we have zeroed down on three stocks which rake in billions from drug retailing and prescription drug monitoring  and thus might be impacted by the recent turn of events First on our list is Walmart Inc    NYSE WMT    This Arkansas based operator of retail stores and supermarkets carries a Zacks Rank  3  Hold   Walmart Pharmacy  a subsidiary of Walmart  is committed to providing affordable healthcare through initiatives like its  4 generic drug price program  Last October  the company joined a saver plan along with CVS Pharmacy to provide affordable access to more than 2 800 commonly used medications while offering an expanded preferred pharmacy network Also last year  the company planned to restrict acute opioid prescriptions to a seven day supply Over the past year  the stock has rallied 25 9   outperforming the  s 21 2  gain Next on our list is CVS Health Corporation   NYSE CVS    The Rhode Island based bigwig is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care  The company s Pharmacy Services segment provides a full range of pharmacy benefit management solutions  retail pharmacy network management services and mail order pharmacy  The segment also sells and distributes prescription drugs The company currently has a Zacks Rank  2  Buy   You can see Over the past year  the stock has slipped 20 5  compared with the  s 23  decline McKesson Corporation   NYSE MCK   comes next on our list  The California based health care services and information technology company distributes branded and generic pharmaceutical drugs along with other healthcare related products on a global basis worldwide through its Distributions Solutions segment  In addition  the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels In May  the Zacks Rank  2 company settled litigation with the State of West Virginia to resolve claims regarding McKesson s operations in the state  citing significant enhancements to how it monitors and controls the distribution of controlled substances Over the past year  the stock has rallied 8 1  against the  s 9  decline Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/opioid-overdose-crisis-in-us-likely-to-affect-these-3-stocks-200468310,200468310
127734,349249,MCK,Veeva Systems To Improve Patient Outcome With Crossix Buyout,opinion,"Veeva Systems Inc    NYSE VEEV   recently inked a deal to acquire Crossix Solutions  The buyout is likely to enable the company enhance its cloud based software technology  Moreover  the deal reinforces Veeva Systems  presence in the healthcare IT  HCIT  space Notably  Crossix   a pioneer in privacy safe patient data and analytics   will continue to operate as an independent business unit Financial Details of the AcquisitionVeeva Systems is set to acquire Crossix for a purchase price of  430 million in an all cash transaction  Additionally  few employees of Crossix will receive long term equity retention grants amounting to about  120 million in total  The buyout is anticipated to get completed in November this year Deal RationaleVeeva Systems is likely to leverage Crossix s analytics platform  which connects health and non health data for more than 300 million U S  patients  and provide improved patient outcomes  The buyout is the right step forward for Veeva Systems as it will take the company closer to its goal of a patient centric healthcare system Moreover  the company s cloud based software technology is likely to get a boost on the back of this buyout Veeva s Cloud Based Software Technology UpdateVeeva Systems recently released its advanced Veeva Commercial Cloud offering  Veeva CRM Engage Webinar  at the Veeva Commercial Summit Europe  The company also released Veeva Vault PromoMats Brand Portal   a new digital asset management capability that helps brand managers create portals  organize and showcase content within Veeva Vault PromoMats Market Holds PromisePer a report by   the Global Healthcare Analytics market is valued at  20 86 billion and is estimated to hit  108 01 billion by 2025 at a CAGR of 26 5  from 201 2025  Increasing pressure on the healthcare providers to boost the efficiency of healthcare and improvement in the patient s outcome is expected to fuel market growth Some other key players who have showed substantial progress in the healthcare analytics space are Cerner Corporation   NASDAQ CERN    Allscripts Healthcare Solutions Inc    NASDAQ MDRX   and McKesson Corporation   NYSE MCK   Cerner is one of the largest pure play HCIT companies and its broad presence  large reference able client base and composite array of solutions make it an ideal candidate for investors seeking an exposure to the HCIT industry Allscripts Healthcare provides information technology  IT  solutions and services to healthcare organizations  Moreover  Allscripts Sunrise is a fully integrated Electronic Health Record  HER  platform that connects all clinical and financial aspects of a hospital or health system for inpatient  emergency and outpatient care McKesson is a health care services and information technology company  Following a merger agreement with Change Healthcare Holdings  which is a leading provider of software and analytics  network solutions and technology enabled services  McKesson formed a new healthcare information technology company called Change Healthcare  The new company aspires to be a better healthcare system on the back of a broad set of complementary capabilities that will deliver wide ranging financial  operational and clinical benefits to payers  providers and consumers 
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  
Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/veeva-systems-to-improve-patient-outcome-with-crossix-buyout-200469944,200469944
127736,349251,MCK,McKesson goes ex dividend tomorrow,news,McKesson  NYSE MCK  has declared  0 34 share quarterly dividend  in line with previous Payable July 2  for shareholders of record June 1  ex div May 31 Now read ,2018-05-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/mckesson-goes-exdividend-tomorrow-1468782,1468782
127737,349252,MCK,McKesson declares  0 39 dividend,news,McKesson  NYSE MCK  declares  0 39 share quarterly dividend  in line with previous Forward yield 1 28 Payable Jan  2  for shareholders of record Dec  3  ex div Nov  30 See MCK Dividend Scorecard  Yield Chart    Dividend Growth Now read ,2018-10-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/mckesson-declares-039-dividend-1659437,1659437
127740,349255,MCK,Can McKesson  MCK  Keep The Earnings Surprise Streak Alive ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering McKesson  MCK   which belongs to the Zacks Medical   Dental Supplies industry 
When looking at the last two reports  this prescription drug distributor has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 4 85   on average  in the last two quarters 
For the most recent quarter  McKesson was expected to post earnings of  3 04 per share  but it reported  3 31 per share instead  representing a surprise of 8 88   For the previous quarter  the consensus estimate was  3 66 per share  while it actually produced  3 69 per share  a surprise of 0 82  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for McKesson lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
McKesson has an Earnings ESP of  2 82  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  2  Buy   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on October 30  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-03,Zacks Investment Research,https://www.investing.com/analysis/can-mckesson-mck-keep-the-earnings-surprise-streak-alive-200470744,200470744
127743,349258,MCK,Top Ranked Value Stocks To Buy For October 8th,opinion,Here are four stocks with buy rank and strong value characteristics for investors to consider today  October 8th Insight Enterprises  Inc   NSIT   This technology company has a Zacks Rank  1  Strong Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 5 6  over the last 60 days Insight Enterprises  Inc  Price and Consensus   Insight Enterprises has a price to earnings ratio  P E  of 11 17  compared with 11 40 for the industry  The company possesses a  of A Insight Enterprises  Inc  PE Ratio  TTM    Office Properties Income Trust  OPI   This real estate investment trust company has a Zacks Rank  1  and seen the Zacks Consensus Estimate for its current year earnings rising 5 8  over the last 60 days Government Properties Income Trust Price and Consensus   Office Properties Income Trust has a price to earnings ratio  P E  of 5 14  compared with 22 70 for the industry  The company possesses a Value Score of B Government Properties Income Trust PE Ratio  TTM    McKesson Corporation  NYSE MCK   MCK   This healthcare company has a Zacks Rank  2  Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 0 3  over the last 60 days McKesson Corporation Price and Consensus   McKesson has a price to earnings ratio  P E  of 9 08  compared with 17 90 for the industry  The company possesses a Value Score of A McKesson Corporation PE Ratio  TTM    Gran Tierra Energy Inc   GTE   This energy company has a Zacks Rank  2  and seen the Zacks Consensus Estimate for its current year earnings rising 55 6  over the last 60 days Gran Tierra Energy Inc  Price and Consensus   Gran Tierra Energy has a price to earnings ratio  P E  of 8 07 compared with 10 40 for the industry  The company possesses a Value Score of A Gran Tierra Energy Inc  PE Ratio  TTM    See the  Learn more about the  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-value-stocks-to-buy-for-october-8th-200471404,200471404
127751,349266,MCK,Glenview s Robbins says talk of Amazon s entering pharma is overblown,news,"NEW YORK  Reuters    Glenview Capital Management Chief Executive Larry Robbins said on Monday at the Sohn Investment Conference in New York that he still likes a trio of stocks he already owns  citing CVS Health Corp  N CVS   McKesson Corp  N MCK  and Express Scripts Holdings  O ESRX   He also said speculation that Amazon com Inc  O AMZN  might be looking to enter the pharmacy business and possibly threaten these companies  business is overblown   Amazon has not made significant hires in the pharmacy business and does not have the licenses needed to enter the business  Robbins said  Amazon s entry into the business of selling medications  is  neither imminent  assured  nor likely to succeed   he said  Speculation mounted late last year that the online retail giant might be ready to target pharmacies and the selling of drugs next after buying grocer Whole Foods earlier in 2017  The speculation about Amazon has weighed on CVS s stock price  But Robbins was confident his stock picks could rise  
Within two year  Robbins said  Express Scripts  stock could climb 69 percent while McKesson s stock could post returns of 136 percent and CVS could climb 96 percent   Amazon fears are dramatically overblown   he said ",2018-04-23,Reuters,https://www.investing.com/news/stock-market-news/glenviews-robbins-says-talk-of-amazons-entering-pharma-is-overblown-1409570,1409570
127753,349268,MCK,High profile investors bet on stocks tied to millennials  Sohn Conference,news,"By David Randall and Svea Herbst Bayliss NEW YORK  Reuters    Hedge fund managers at the high profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation  ranging from online food ordering to homebuilders  John Khoury  founder and managing partner of the  2 7 billion Long Pond Capital hedge fund  revealed a long position in U S  homebuilder D R  Horton Inc  which he said should rise as more millennials age into the first time home buyer market   D R  Horton  the country s largest homebuilder  has been increasingly focused on its entry level segment  which the company in January said should grow strongly over the next three years   Two investors pitched online food ordering companies  Alexander Captain  who runs Cat Rock Capital Management  introduced Netherlands based Takeaway com NV while Li Ran  who runs Half Sky Capital  pitched GrubHub Inc  the parent company of Seamless  She said GrubHub averages  30 per order and earns 15 percent of each order  with spending growth at restaurants outpacing spending at grocery stores    I like to call this chart  millennials can t cook   Ran said  to laughter   Millennials  a term for those born between 1981 and 1996  are expected to become the largest generation in the United States in 2019  according to estimates from Pew Research   Jeffrey Gundlach  one of the world s most closely watched investors  recommended a short position in social media giant  Facebook Inc   NASDAQ FB  and a long position in the SPDR S P Oil and Gas Exploration ETF   Facebook used to be a place people felt good going to   Gundlach said   Facebook has come under pressure as the company acknowledged misuse of users  data   RISING CONFIDENCE Investors were confident about their stock picks at a time when the broad S P 500 has been lagging and retail clients have expressed nervousness about the durability of the stock market s long running gains   Long Pond Capital s Khoury suggested that D R  Horton has more than 60 percent upside  while Ran of Half Sky Capital said GrubHub could hit  160 a share  up about 55 percent from its Monday closing price of  102 17   Among technology focused investors  Glen Kacher  founder and chief investment officer at Light Street Capital  announced a long position in online security company Palo Alto Networks Inc  which he said has a 164 percent upside through 2020   Chamath Palihapitiya  founder and chief executive officer at Social Capital LP  offered a bullish take on cloud management company Box Inc  predicting the stock could grow 10 fold over the next 10 years    If you believe in and if you care about A I   Artificial Intelligence  and its role in the world  be long Amazon  be long Google  NASDAQ GOOGL   but be long Box   Palihapitiya said  calling Box a  really interesting disruptive company   Shares of Box closed up nearly 11 percent on Monday  turning it positive for the year to date   Organizers of the Sohn Conference said they were expecting as many as 3 000 attendees at New York s Lincoln Center  making Sohn one of the most high profile investment conferences of the year   Against a background of more volatile markets and worries that some of the biggest hedge fund managers are nursing losses this year  many in the audience focused on the smaller  better performing investors like Oleg Nodelman   Nodelman  founder and managing director of EcoR1 Capital LLC  whose fund returned a reported 53 percent last year  announced a long bet on drug company Ascendis Pharma A S  Larry Robbins  of Glenview Capital Management LLC  threw cold water on the notion that Amazon com Inc  NASDAQ AMZN  will enter the drug distribution business and reiterated the bullish case for his existing positions in McKesson Corp  NYSE MCK   Express Scripts Holding Co and CVS Health Corp  NYSE CVS     Amazon doesn t always win   he said   David Einhorn  whose Greenlight Capital was down 14 percent in the first quarter  presented an existing short position in bond insurance company Assured Guaranty Ltd  The stock fell 6 percent in after hours trading  wiping out its gain for the year to date   
Assured Guaranty is  a melting ice cube that is paying out the drops while it still can   Einhorn said ",2018-04-23,Reuters,https://www.investing.com/news/stock-market-news/highprofile-investors-bet-on-stocks-tied-to-millennials-sohn-conference-1409044,1409044
127757,349272,MCK,Rite Aid  RAD  Down 23 5  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Rite Aid  RAD   Shares have lost about 23 5  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Rite Aid due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Rite Aid Incurs Loss in Q1  Revenues Decline Y YRite Aid incurred first quarter fiscal 2020 adjusted loss from continuing operations of 14 cents per share against the Zacks Consensus Estimate of earnings of 2 cents  In the year ago quarter  the company reported adjusted earnings of 2 cents per share Notably  the bottom line was hurt by a decline in adjusted EBITDA coupled with higher income tax expenses  somewhat offset by lower depreciation and amortization expense as well as lease termination and impairment charges Management stated that quarterly results lagged expectations owing to prescription reimbursement rate pressure in the Retail Pharmacy Segment  Also  margin compression in the company s Pharmacy Services Segment weighed on the company s performance However  operating efficiency in the Retail Pharmacy Segment along with higher Medicare Part D revenues and prescription count sales growth remain impressive  Management is also optimistic about its drug purchasing agreement with McKesson Corporation  NYSE MCK   which is likely to reinforce the company s Retail Pharmacy business  Additionally  the company remains confident about its  Path to the Future  transformation initiative Q1 in DetailRevenues dipped 0 3  to  5 372 6 million  almost in line with the Zacks Consensus Estimate  During the quarter  the Retail Pharmacy segment revenues slipped 0 8  owing to lower store count  somewhat offset by higher same store sales  At the Pharmacy Services segment  revenues edged up 1 5  owing to higher Medicare Part D revenues Retail Pharmacy same store sales inched up 1 4  owing to a 2 3  rise in pharmacy sales and 0 3  decrease in front end sales  Excluding cigarettes and tobacco products  front end same store sales inched up 0 3   Pharmacy sales included a negative impact of nearly 207 basis points  bps  from the introduction of new generic drugs  Further  prescription count at same store sales rose 3 7   Prescription sales constituted 66 9  of total drugstore sales  Notably  the company delivered the fourth straight quarter of same store prescription count growth Rite Aid s adjusted EBITDA fell 20 1  year over year to  110 3 million  with adjusted EBITDA margin contraction of 50 bps to 2 1   This downturn was due to lower adjusted EBITDA at the Retail Pharmacy and Pharmacy Services segments  offset by improvement in adjusted EBITDA selling  general and administrative   SG A   expenses  Improvement in SG A was due to reduction in salaries and benefits  more than offset the decrease in Transition Services Agreement  TSA  fee income from Walgreens Boots Alliance  NASDAQ WBA  Further  adjusted EBITDA at the Retail Pharmacy Segment totaled  84 million  depicting a 19 2  decline from the prior year quarter  At the Pharmacy Services Segment  the metric amounted to  26 3 million  reflecting 22 4  decline Store UpdateRite Aid remodeled 27 stores in the fiscal first quarter  bringing the company s total wellness store count to 1 787  Moreover  it opened one while shuttered 4 stores  taking the total store count to 2 466 as of Jun 1  2019 Financial StatusRite Aid ended the quarter with cash and cash equivalents of approximately  190 5 million  long term debt  net of current maturities  of  3 582 million and total shareholders  equity of  1 035 2 million Further  the company used cash from operating activities of  51 2 million in the fiscal first quarter OutlookRite Aid reaffirmed its outlook for fiscal 2020  This view includes the assumption of persistent decrease in prescription reimbursement rates  somewhat compensated with higher prescription count coupled with improvements in drug costs and SG A expenses Rite Aid continues to project sales of  21 5  21 9 billion for fiscal 2020 along with same store sales growth projection of 0 1  over fiscal 2019  Moreover  the company still anticipates adjusted EBITDA to be between  500 million and  560 million for fiscal 2020 Further  it estimates net loss of  170  220 million  Management envisions the bottom line between adjusted loss of 14 cents and earnings of 72 cents per share  Capital expenditures are likely to be roughly  250 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  46 15  due to these changes 
VGM Scores
At this time  Rite Aid has a great Growth Score of A  though it is lagging a lot on the Momentum Score front with a C  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  It s no surprise Rite Aid has a Zacks Rank  5  Strong Sell   We expect a below average return from the stock in the next few months ",2019-07-25,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-down-235-since-last-earnings-report-can-it-rebound-200445641,200445641
127758,349273,MCK,McKesson  MCK  Q1 Earnings And Revenues Top Estimates,opinion,"McKesson  MCK  came out with quarterly earnings of  3 31 per share  beating the Zacks Consensus Estimate of  3 04 per share  This compares to earnings of  2 90 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 8 88   A quarter ago  it was expected that this prescription drug distributor would post earnings of  3 66 per share when it actually produced earnings of  3 69  delivering a surprise of 0 82  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
McKesson  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  55 73 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 3 26   This compares to year ago revenues of  52 61 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
McKesson shares have added about 29  since the beginning of the year versus the S P 500 s gain of 20 2  
What s Next for McKesson 
While McKesson has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for McKesson was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 67 on  54 84 billion in revenues for the coming quarter and  14 17 on  221 21 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 38  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-q1-earnings-and-revenues-top-estimates-200448627,200448627
127761,349276,MCK,McKesson  MCK  Soars To 52 Week High  Time To Cash Out ,opinion,"Have you been paying attention to shares of McKesson  MCK   Shares have been on the move with the stock up 5 3  over the past month  The stock hit a new 52 week high of  149 99 in the previous session  McKesson has gained 34 2  since the start of the year compared to the 4  move for the Zacks Medical sector and the 17 6  return for the Zacks Medical   Dental Supplies industry 
What s Driving the Outperformance 
The stock has an impressive record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on July 31  2019  McKesson reported EPS of  3 31 versus consensus estimate of  3 04 while it beat the consensus revenue estimate by 3 26  
For the current fiscal year  McKesson is expected to post earnings of  14 2 per share on  221 93 billion in revenues  This represents a 4 64  change in EPS on a 3 55  change in revenues  For the next fiscal year  the company is expected to earn  15 42 per share on  230 08 billion in revenues  This represents a year over year change of 8 58  and 3 67   respectively 
Valuation Metrics
McKesson may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level 
On this front  we can look at the Zacks Style Scores  as they provide investors with an additional way to sort through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style 
McKesson has a Value Score of A  The stock s Growth and Momentum Scores are A and D  respectively  giving the company a VGM Score of A 
In terms of its value breakdown  the stock currently trades at 10 4X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 5X versus its peer group s average of 12 9X  Additionally  the stock has a PEG ratio of 1 51  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to consider the stock s Zacks Rank  as this supersedes any trend on the style score front  Fortunately  McKesson currently has a Zacks Rank of  2  Buy  thanks to rising earnings estimates 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if McKesson meets the list of requirements  Thus  it seems as though McKesson shares could have potential in the weeks and months to come ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-soars-to-52week-high-time-to-cash-out-200449967,200449967
127762,349277,MCK,MCK Vs  WST  Which Stock Is The Better Value Option ,opinion,"Investors with an interest in Medical   Dental Supplies stocks have likely encountered both McKesson  MCK  and West Pharmaceutical Services  WST   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
Currently  both McKesson and West Pharmaceutical Services are holding a Zacks Rank of   2  Buy   The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates  so investors should rest assured that both of these companies have improving earnings outlooks  But this is just one factor that value investors are interested in 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
MCK currently has a forward P E ratio of 10 20  while WST has a forward P E of 47 29  We also note that MCK has a PEG ratio of 1 48  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  WST currently has a PEG ratio of 4 13 
Another notable valuation metric for MCK is its P B ratio of 3 35  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  WST has a P B of 7 40 
These are just a few of the metrics contributing to MCK s Value grade of A and WST s Value grade of C 
Both MCK and WST are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that MCK is the superior value option right now ",2019-08-13,Zacks Investment Research,https://www.investing.com/analysis/mck-vs-wst-which-stock-is-the-better-value-option-200455133,200455133
127768,349283,MCK,Should Value Investors Consider McKesson  MCK  Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put McKesson Corporation   NYSE MCK   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  McKesson has a trailing twelve months PE ratio of 10 46  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 85  If we focus on the long term PE trend  McKesson s current PE level puts it below its midpoint of 12 62 over the past five years  Moreover  the current level stands well below the highs for the stock  suggesting that it can be a solid entry point Further  the stock s PE also compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 20 59  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should also point out that McKesson has a forward PE ratio  price relative to this year s earnings  of just 10 09  so it is fair to say that a slightly more value oriented path may be ahead for McKesson stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  McKesson has a P S ratio of about 0 13  This is a bit lower than the S P 500 average  which comes in at 3 15x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  McKesson currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes McKesson a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for McKesson is just 1 46  a level that is far lower than the industry average of 1 85  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Clearly  MCK is a solid choice on the value front from multiple angles What About the Stock Overall Though McKesson might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of D and a Momentum Score of B  This gives MCK a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen two estimates go higher in the past sixty days compared to two lower  while the full year estimate has seen eight up and none down in the same time period This has had a mixed impact on the consensus estimate though as the current quarter consensus estimate has dropped by 1 1  in the past two months  while the full year estimate has risen by 1 8   You can see the consensus estimate trend and recent price action for the stock in the chart below McKesson Corporation Price and Consensus   Apart from this somewhat mixed trend the stock has just a Zacks Rank  2  Buy  which is why we are looking for outperformance from the company in the near term Bottom LineMcKesson is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 29  of more than 250 industries  instills our confidence  However  over the past two years  the Zacks Medical   Dental Supplies industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ,2019-08-21,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-mckesson-mck-stock-now-200457623,200457623
127772,349287,MCK,McKesson  MCK  Hits 52 Week High  Can The Run Continue ,opinion,"Shares of McKesson  MCK  have been strong performers lately  with the stock up 4 9  over the past month  The stock hit a new 52 week high of  150 82 in the previous session  McKesson has gained 31 1  since the start of the year compared to the 0 8  move for the Zacks Medical sector and the 12 7  return for the Zacks Medical   Dental Supplies industry 
What s Driving the Outperformance 
The stock has an impressive record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on July 31  2019  McKesson reported EPS of  3 31 versus consensus estimate of  3 04 while it beat the consensus revenue estimate by 3 26  
For the current fiscal year  McKesson is expected to post earnings of  14 35 per share on  222 57 billion in revenues  This represents a 5 75  change in EPS on a 3 85  change in revenues  For the next fiscal year  the company is expected to earn  15 44 per share on  230 23 billion in revenues  This represents a year over year change of 7 65  and 3 44   respectively 
Valuation Metrics
McKesson may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself 
On this front  we can look at the Zacks Style Scores  as they provide investors with an additional way to sort through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style 
McKesson has a Value Score of A  The stock s Growth and Momentum Scores are D and C  respectively  giving the company a VGM Score of B 
In terms of its value breakdown  the stock currently trades at 10 1X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 4 9X versus its peer group s average of 11 2X  Additionally  the stock has a PEG ratio of 1 46  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to consider the stock s Zacks Rank  as this supersedes any trend on the style score front  Fortunately  McKesson currently has a Zacks Rank of  2  Buy  thanks to favorable earnings estimate revisions from covering analysts 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if McKesson meets the list of requirements  Thus  it seems as though McKesson shares could have potential in the weeks and months to come ",2019-08-25,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-hits-52week-high-can-the-run-continue-200458638,200458638
127773,349288,MCK,3 Stocks Set To Outperform As The U S  China Trade War Escalates,opinion,"Escalating worries related to the ongoing U S  China trade war are once again rattling Wall Street  after U S  President Donald Trump announced additional tariffs on  550 billion of Chinese imports last week  This salvo came in retaliation for Beijing s announcement of more tariffs of its own on  75 billion of U S  goods  
Investors  fearful that tariffs could tip the U S  economy into a recession  have dragged the  S P 500 down about 4  so far in August 





While most larger cap companies are finding it difficult to insulate themselves from the effects of the U S  China trade conflict  the three names below are likely to outperform in the months ahead since they re less at risk from any trade war fallout 
1  AT T  High Yield  Blue Chip Dividend Stock 
Shares of AT T  NYSE T   the world s largest telecommunications company  are up nearly 22  this year  The stock closed at  34 72 on Tuesday  within sight of a 52 week high of  35 50  touched on August 22  giving it a market cap of  253 7 billion 
With the trade war more likely to affect goods producers with significant revenue exposure to China  services companies that generate most of their sales domestically should suffer less than their multi national counterparts  which makes AT T a good bet going forward 

The Dallas  Texas based telecom and media giant posted upbeat second quarter results on July 24  AT T reported earnings per share  EPS  of  0 89  matching expectations  Sales in the quarter were  44 96 billion  up 15  from the same period a year earlier  and just ahead of expectations for revenue of  44 89 billion 
AT T s high dividend growth the company is currently paying out  0 51 per share per quarter implies an annualized dividend of  2 04 per share  This just enhances the appeal of both the company and the stock  Its dividend yield is currently 6 01   almost triple the implied yield for the S P 500  which is 2 04  
2  Visa  Credit Card Giant With Limited China Exposure
Visa is the second name on our radar  The world s largest payment processing company  with international operations in more than 200 countries  ranks the U S  as its largest market 
The company s limited exposure to the world s second largest economy makes it one of the top China proof names to consider as trade tensions accelerate 
Visa shares have gained almost 35  since the start of the year  making it the Dow s best performing component of 2019  The stock closed at  178 38 last night  not far from its recent 52 week high of  184 07  reached on July 29  At current valuations  the credit card giant is the seventh largest company in the world with a market cap of  387 5 billion 





The San Francisco based payments processor easily beat estimates on both the top and bottom lines when it released earnings for its fiscal third quarter on July 23  Earnings per share totaled  1 37 in the quarter ended June 30  surpassing expectations for EPS of  1 32 and up from  1 20 in the same period a year earlier  Revenue climbed 11 5  to  5 84 billion  above forecasts of  5 7 billion   
Total payments volume on a constant dollar basis rose 8 7  to  2 23 trillion  with the U S  accounting for about 8 8  of that 
3  McKesson  U S  Focused Healthcare Stock
Our final name comes from the healthcare sector  Like the two companies mentioned above  McKesson  NYSE MCK   widely considered to be the leading healthcare company for pharmaceutical distribution  also has limited revenue exposure to China and generates most of its sales within the U S 
The stock  which finished yesterday at  138 75  has gained 25  in 2019  giving it a market cap of  25 6 billion  On August 23 it hit a fresh 52 week high of  150 82 





The Irving  Texas based company announced earnings and revenue on July 31  which easily topped consensus estimates thanks in large part to its strong performance in its U S  domestic operations  Earnings per share totaled  3 31  much better than expectations of  3 03  while revenue climbed 6  from the same period a year earlier  to  55 7 billon  easily beating estimates for sales of  54 0 billion 
Its strongest performance came from the U S  Pharmaceutical and Specialty Solutions segment  which climbed 8  
The upbeat results prompted McKesson to boost its guidance for the remainder of the fiscal year  The drug distribution and wholesale specialist now expects EPS in a range between  14 00 to  14 60  up from its previously provided target of  13 85 to  14 45 ",2019-08-28,Jesse Cohen/Investing.com,https://www.investing.com/analysis/3-stocks-set-to-outperform-as-the-uschina-trade-war-escalates-200459207,200459207
127777,349292,MCK,Premarket analyst action   healthcare,news,Halozyme  NASDAQ HALO  initiated with Neutral rating at Goldman Catalent  NYSE CTLT  initiated with Buy rating and  50  14  upside  price target at Goldman McKesson  NYSE MCK  upgraded to Buy at Jefferies Juno Therapeutics  NASDAQ JUNO  downgraded to Equal Weight at  Barclays   LON BARC  Puma Biotechnology  NYSE PBYI  downgraded to Market Perform at Cowen and Company Now read ,2018-01-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1144787,1144787
127778,349293,MCK,Noble Energy declares  0 10 dividend,news,Noble Energy   NYSE NBL  declares  0 10 share quarterly dividend  in line with previous Forward yield 1 31 Payable Feb  26  for shareholders of record Feb  12  ex div Feb  9 Now read ,2018-01-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/noble-energy-declares-010-dividend-1171650,1171650
127779,349294,MCK,McKesson beats by  0 47  beats on revenue,news,McKesson  NYSE MCK   Q3 EPS of  3 41 beats by  0 47 Revenue of  53 62B   7 0  Y Y  beats by  1 64B Press ReleaseNow read ,2018-02-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/mckesson-beats-by-047-beats-on-revenue-1181203,1181203
127787,349302,MCK,Rite Aid  RAD  Incurs Loss In Q1  Revenues Decline Y Y,opinion,Rite Aid Corporation   NYSE RAD   incurred first quarter fiscal 2020 adjusted loss from continuing operations of 14 cents per share against the Zacks Consensus Estimate of earnings of 2 cents  In the year ago quarter  the company reported adjusted earnings of 2 cents per share Notably  the bottom line was hurt by a decline in adjusted EBITDA coupled with higher income tax expenses  somewhat offset by lower depreciation and amortization expense as well as lease termination and impairment charges Management stated that quarterly results lagged expectations owing to prescription reimbursement rate pressure in the Retail Pharmacy Segment  Also  margin compression in the company s Pharmacy Services Segment weighed on the company s performance However  operating efficiency in the Retail Pharmacy Segment along with higher Medicare Part D revenues and prescription count sales growth remain impressive  Management is also optimistic about its drug purchasing agreement with McKesson Corporation  NYSE MCK   which is likely to reinforce the company s Retail Pharmacy business  Additionally  this Zacks Rank  2  Buy  company remains confident about its  Path to the Future  transformation initiative  You can see  Q1 in DetailRevenues dipped 0 3  to  5 372 6 million  almost in line with the Zacks Consensus Estimate  During the quarter  the Retail Pharmacy segment revenues slipped 0 8  owing to lower store count  somewhat offset by higher same store sales  At the Pharmacy Services segment  revenues edged up 1 5  owing to higher Medicare Part D revenues Retail Pharmacy same store sales inched up 1 4  owing to a 2 3  rise in pharmacy sales and 0 3  decrease in front end sales  Excluding cigarettes and tobacco products  front end same store sales inched up 0 3   Pharmacy sales included a negative impact of nearly 207 basis points  bps  from the introduction of new generic drugs  Further  prescription count at same store sales rose 3 7   Prescription sales constituted 66 9  of total drugstore sales  Notably  the company delivered the fourth straight quarter of same store prescription count growth Rite Aid Corporation Price and EPS Surprise   Rite Aid s adjusted EBITDA fell 20 1  year over year to  110 3 million  with adjusted EBITDA margin contraction of 50 bps to 2 1   This downturn was due to lower adjusted EBITDA at the Retail Pharmacy and Pharmacy Services segments  offset by improvement in adjusted EBITDA selling  general and administrative   SG A   expenses  Improvement in SG A was due to reduction in salaries and benefits  more than offset the decrease in Transition Services Agreement  TSA  fee income from Walgreens Boots Alliance   NASDAQ WBA   Further  adjusted EBITDA at the Retail Pharmacy Segment totaled  84 million  depicting a 19 2  decline from the prior year quarter  At the Pharmacy Services Segment  the metric amounted to  26 3 million  reflecting 22 4  decline Store UpdateRite Aid remodeled 27 stores in the fiscal first quarter  bringing the company s total wellness store count to 1 787  Moreover  it opened one while shuttered 4 stores  taking the total store count to 2 466 as of Jun 1  2019 Financial StatusRite Aid ended the quarter with cash and cash equivalents of approximately  190 5 million  long term debt  net of current maturities  of  3 582 million and total shareholders  equity of  1 035 2 million Further  the company used cash from operating activities of  51 2 million in the fiscal first quarter OutlookRite Aid  which shares space with Herbalife Nutrition Ltd    NYSE HLF    reaffirmed its outlook for fiscal 2020  This view includes the assumption of persistent decrease in prescription reimbursement rates  somewhat compensated with higher prescription count coupled with improvements in drug costs and SG A expenses Rite Aid continues to project sales of  21 5  21 9 billion for fiscal 2020 along with same store sales growth projection of 0 1  over fiscal 2019  Moreover  the company still anticipates adjusted EBITDA to be between  500 million and  560 million for fiscal 2020 Further  it estimates net loss of  170  220 million  Management envisions the bottom line between adjusted loss of 14 cents and earnings of 72 cents per share  Capital expenditures are likely to be roughly  250 million Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-26,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-incurs-loss-in-q1-revenues-decline-yy-200435305,200435305
127788,349303,MCK,Rite Aid Expands In Northeast With Thrifty Ice Cream Brand,opinion,Rite Aid Corporation   NYSE RAD   recently announced the expansion of its premium Thrifty Ice Cream brand in select stores in Delaware  New York  Maryland  New Jersey and Pennsylvania  Available in 48 ounce containers  customers will have about eight different ice cream flavors to pick from This ice cream brand is currently available in 23 flavors across California  Notably  the Thrifty Ice Cream tradition started in 1940 when its production plant was introduced in Hollywood  CA  This award winning brand is made with Real California Milk to bring one of a kind ice cream experience to its customers Rite Aid Focuses on Omni Channel GrowthConcurrent to expansion of product categories  Rite Aid is enhancing home delivery through its partnership with Instacart as part of its initiatives to boost customer experience  The company also remains encouraged to partner with Amazon   NASDAQ AMZN   to bring Amazon Lockers in roughly 900 Rite Aid stores  This service will allow customers to pick up or return their Amazon packages  Recently  Rite Aid inked a partnership deal with Adobe  NASDAQ ADBE  to enhance digital solutions and marketing capabilities  This move is expected to improve customer analytics  content management and real time personalization Rite Aid has also shifted e commerce fulfillment from a third party provider to its own distribution network  This has reduced fulfillment lead time  lowered cost and helped increase online offering by 25   Further  the company s own brand program is supporting efforts to build tailored offerings that are specific to each local market  Backed by all these efforts  the company should strengthen its omni channel capabilities and provide increased convenience and value to customers Furthermore  the company renewed its drug purchasing agreement with McKesson Corporation   NYSE MCK    which will extend for another 10 years  As part of the agreement  McKesson will continue providing Rite Aid with sourcing and direct to store delivery for branded and generic pharmaceutical products through March 2029  The partnership will provide Rite Aid with a combination of competitive drug pricing and operational flexibility  This extension also represents a key step toward strengthening the pharmacy business  with continued focus on improving access to preferred and limited networks and executing key script growth initiatives Price PerformanceDespite these positives  shares of Rite Aid have lost 20 7  against the  s 0 2  growth in the past three months  The downside can be attributed to the company s first quarter fiscal 2020 results  wherein it incurred loss  Persistent weakness in the Retail Pharmacy segment also affected its performance  Nevertheless  Rite Aid  which shares space with Herbalife Nutrition Ltd    NYSE HLF    has a Zacks Rank  3  Hold   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-07-01,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-expands-in-northeast-with-thrifty-ice-cream-brand-200436511,200436511
127792,349307,MCK,Stock Charts To Watch  EIDX  KPTI  MCK  VG  ZIOP  ZYNE ,opinion,"Eidos Therapeutics  Inc   EIDX 
EIDX bounced 2 41  or 7   to 36 07  on 85 997 shares traded on Wednesday  It started the day out with a small pop to 33 98  pulled back to the low for the day at 33 52  rallied  worked its way up to the morning high at 34 96  It then looked like it platformed and wedged its way up  Just as the noon hour was beginning  it reached its second high at 35 65  It came down  popped slightly  formed a thrust that took it to 35 89  It rolled over  and then bounced to the high for the day at 36 27  pulled back slightly  and had a slight bounce that took it near the high for the day  Resistance is near 36 27  If it gets through that  targets are 38  and then 40 
Karyopharm Therapeutics Inc   KPTI 
KPTI on a drug approval for a cancer  closed up 2 36  or 36   to 8 90  on 14 2 million shares  and another 50 cents  6   in after hours taking it to 9 40  It opened to the upside at 6 46  moved along calmly with a few mild highs and lows  and then midmorning  when the approval was announced on Wednesday  it exploded on high volume to 8 85  pulled back slightly  platformed  had another spike up to the high for the day at 9 25  It platformed again  and then pulled back into the close not far from the highs for the day  This was an amazing day for this stock  Targets are 10  and 12 50 
McKesson Corporation
MCK jumped 4 88  or 3 1 2   to 140 74  on 1 5 million shares on Wednesday  MCK immediately gapped up to 136 99  pulled back to the day s low at 136 13  popped and pulled back  It made its way up to 142 12  rolled over  consolidated for the next hour  tested the high  and when it failed  it rolled over again  rallied slightly  and pulled back to 141 61  It then popped  started to stair step its way downward when it took a long slide down to close 1 5 points off the high  Not a bad day for this stock  Resistance is at 142 31  Targets are 145  147 50  and 150 
Vonage Holdings Corp   VG 
VG gained 71 cents  or 6   to 12 30  on 2 6 million shares on Wednesday  It gapped up  pulled back slightly  then coiled its way up to the morning high at 11 91  rolled over  worked its way down to the low for the day at 11 63  rallied to 12 18  pulled back  took a dip to 12 17  rallied back up  rolled over  made a nice thrust to the day s high at 12 40  moved down  and platformed into the close  If it can get through initial resistance 14 73  the target is 15 
ZIOPHARM Oncology  Inc   ZIOP 
ZIOP popped 59 cents  or 11   to 6 02  on 2 55 million shares  This stock had a very interesting day on Wednesday  It opened at 5 50  consolidated and formed coils as it channeled its way up to close at the high for the day  Resistance is at 6 30 and 6 70  If it can get through there  targets are 7 00 and 7 50 
Zynerba Pharmaceuticals  Inc   ZYNE 
ZYNE bounced 51 cents  or 4   to 14 75  on 1 1 million shares on Wednesday  It gapped up at the opening  pulled back sharply  popped again  There was some volatility as this stock stair stepped its way up  ZYNE has strong technicals  Resistance is at 16 47  If it can get through here  targets are 17 50 and 20 
All of these stocks had bullish closes  bullish channels  which varied  and good price action 
Watch Video Here ",2019-07-04,Harry Boxer,https://www.investing.com/analysis/eidx-kpti-mck-vg-ziop-zyne--stock-charts-to-watch-200436962,200436962
127794,349309,MCK,Amazon sheds light on pharmacy licenses,news,Amazon  NASDAQ AMZN  has told regulators it will not be using the pharmacy licenses it obtained from Tennessee and Indiana to sell prescriptions  but will instead use them to sell medical devices and supplies That could mean a more immediate threat to medical distribution companies  like McKesson  NYSE MCK  and  Cardinal Health   NYSE CAH   rather than to pharmacies and pharmacy benefits managers That said  most industry experts aren t ruling out the possibility of Amazon entering the prescription drug market  They maintain that it s a matter of if  not when Now read ,2017-11-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/amazon-sheds-light-on-pharmacy-licenses-855120,855120
127795,349310,MCK,Why The Earnings Surprise Streak Could Continue For McKesson  MCK ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  McKesson  MCK   which belongs to the Zacks Medical   Dental Supplies industry  could be a great candidate to consider 
This prescription drug distributor has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 3 87  
For the most recent quarter  McKesson was expected to post earnings of  3 66 per share  but it reported  3 69 per share instead  representing a surprise of 0 82   For the previous quarter  the consensus estimate was  3 18 per share  while it actually produced  3 40 per share  a surprise of 6 92  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for McKesson  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
McKesson currently has an Earnings ESP of  0 10   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on July 31  2019 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-mckesson-mck-200441580,200441580
127797,349312,MCK,Is McKesson  MCK  Stock Undervalued Right Now ,opinion,"Here at Zacks  our focus is on the proven Zacks Rank system  which emphasizes earnings estimates and estimate revisions to find great stocks  Nevertheless  we are always paying attention to the latest value  growth  and momentum trends to underscore strong picks 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors use tried and true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels 
In addition to the Zacks Rank  investors looking for stocks with specific traits can utilize our Style Scores system  Of course  value investors will be most interested in the system s  Value  category  Stocks with  A  grades for Value and high Zacks Ranks are among the best value stocks available at any given moment 
McKesson  MCK  is a stock many investors are watching right now  MCK is currently holding a Zacks Rank of  2  Buy  and a Value grade of A  The stock is trading with P E ratio of 9 63 right now  For comparison  its industry sports an average P E of 16 80  MCK s Forward P E has been as high as 9 98 and as low as 7 78  with a median of 9 08  all within the past year 
Investors will also notice that MCK has a PEG ratio of 1 37  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  MCK s industry has an average PEG of 1 74 right now  Over the past 52 weeks  MCK s PEG has been as high as 1 46 and as low as 1 12  with a median of 1 32 
We should also highlight that MCK has a P B ratio of 3 14  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  This stock s P B looks attractive against its industry s average P B of 3 16  Over the past year  MCK s P B has been as high as 3 25 and as low as 2 22  with a median of 2 67 
Finally  investors will want to recognize that MCK has a P CF ratio of 8 71  This metric focuses on a firm s operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook  MCK s P CF compares to its industry s average P CF of 15 84  MCK s P CF has been as high as 9 02 and as low as 6 39  with a median of 7 73  all within the past year 
These are just a handful of the figures considered in McKesson s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that MCK is an impressive value stock right now ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/is-mckesson-mck-stock-undervalued-right-now-200443077,200443077
127798,349313,MCK,MCK Vs  COO  Which Stock Is The Better Value Option ,opinion,"Investors interested in stocks from the Medical   Dental Supplies sector have probably already heard of McKesson  MCK  and Cooper Cos   COO   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
McKesson and Cooper Cos  are both sporting a Zacks Rank of   2  Buy  right now  This system places an emphasis on companies that have seen positive earnings estimate revisions  so investors should feel comfortable knowing that these stocks have improving earnings outlooks  But this is just one piece of the puzzle for value investors 
Value investors also tend to look at a number of traditional  tried and true figures to help them find stocks that they believe are undervalued at their current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
MCK currently has a forward P E ratio of 9 80  while COO has a forward P E of 27 14  We also note that MCK has a PEG ratio of 1 46  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  COO currently has a PEG ratio of 2 52 
Another notable valuation metric for MCK is its P B ratio of 3 21  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  For comparison  COO has a P B of 4 65 
These are just a few of the metrics contributing to MCK s Value grade of A and COO s Value grade of C 
Both MCK and COO are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that MCK is the superior value option right now ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/mck-vs-coo-which-stock-is-the-better-value-option-200443055,200443055
127803,349318,MCK,McKesson  MCK  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when McKesson  MCK  reports results for the quarter ended June 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on July 31  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This prescription drug distributor is expected to post quarterly earnings of  3 04 per share in its upcoming report  which represents a year over year change of  4 8  
Revenues are expected to be  53 97 billion  up 2 6  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 77  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for McKesson 
For McKesson  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 77  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that McKesson will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that McKesson would post earnings of  3 66 per share when it actually produced earnings of  3 69  delivering a surprise of  0 82  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
McKesson appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-reports-next-week-wall-street-expects-earnings-growth-200444013,200444013
127811,349326,MCK,Premarket analyst action   healthcare,news,AMAG Pharmaceuticals  NASDAQ AMAG  initiated with Overweight rating and  26  39  upside  price target by  Morgan Stanley   NYSE MS  LivaNova  NASDAQ LIVN  initiated with Buy rating and  76  20  upside  price target by Jefferies TherapeuticsMD  NYSEMKT TXMD  initiated with Equal Weight rating and  6  13  downside risk  price target by Morgan Stanley McKesson  NYSE MCK  upgraded to Buy by Needham citing stabilization of environment  although generic price deflation still an issue  NewLink Genetics   NASDAQ NLNK  upgraded to Buy with a  26  91  upside  price target by Jefferies U S  Physical Therapy  NASDAQ USPH  upgraded to Buy by Sidoti Fate Therapeutics  NASDAQ FATE  resumed with Outperform rating and  7  67  upside  price target by Leerink Axovant Sciences  NYSE AXON  resumed with Outperform rating and  30  43  upside  price target by Evercore ISI Catalent  NYSE CTLT  downgraded to Sector Weight by Keybanc GlaxoSmithKline  NYSE GSK  downgraded to Underweight by Morgan Stanley Now read ,2017-09-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-526872,526872
127812,349327,MCK,Premarket analyst action   healthcare coverage changes,news,McKesson  NYSE MCK  upgraded to Outperform with a  178  20  upside  price target by Baird citing attractive valuation Quidel  NASDAQ QDEL  upgraded to Overweight by Piper Jaffray Supernus Pharmaceuticals  NASDAQ SUPN  downgraded to Hold with a  47  5  downside risk  price target by Stifel citing valuation and risk in the Phase 3 study of SPN 810 since lower dose eliminated Adamas Pharmaceuticals  NASDAQ ADMS  price target raised to  48  129  upside  by Mizuho citing higher than expected Gocovri pricing and higher estimates for MS gait program  although launch expectations in 2018 lowered after conservative guidance Dimension Therapeutics  NASDAQ DMTX  downgraded to Sell by  Citigroup   NYSE C  citing a  small chance  of a higher bid topping Ultragenyx Pharma s  5 50 share offer  Shares are down 6  premarket on light volume Now read ,2017-09-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-coverage-changes-530391,530391
127814,349329,MCK,McKesson  MCK  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"McKesson  MCK  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on May 8  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This prescription drug distributor is expected to post quarterly earnings of  3 66 per share in its upcoming report  which represents a year over year change of  4 9  
Revenues are expected to be  53 35 billion  up 3 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for McKesson 
For McKesson  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 48  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that McKesson will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that McKesson would post earnings of  3 18 per share when it actually produced earnings of  3 40  delivering a surprise of  6 92  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
McKesson appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-30,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200414069,200414069
127815,349330,MCK,Can Core Business Unit Fuel McKesson  MCK  Q4 Earnings ,opinion,McKesson Corporation s   NYSE MCK   fourth quarter fiscal 2019 results are scheduled to release on May 8  In the last reported quarter  the company delivered a positive earnings surprise of 6 9   Further  it has an average four quarter positive surprise of 3 9  Let s take a look at how things are shaping up prior to this announcement Which Way Are Q4 Estimates Headed  The Zacks Consensus Estimate for McKesson s fiscal fourth quarter earnings is pegged at  3 66  indicating an improvement of 4 9  from the year ago quarter  The same for revenues stands at  55 35 billion  suggesting growth of 3 3  from the year ago reported figure  Core Business Unit to Drive Q4 ResultsMcKesson s U S  Pharmaceutical and Specialty Solutions segment is likely to act as a key catalyst in bolstering the company s fiscal fourth quarter results  Notably  the segment is likely to gain momentum on the back of its branded  generic and over the counter pharmaceuticals This apart  the business line is likely to be a major top line contributor in the to be reported quarter  driven by market growth  which might include better than expected results in oncology related pharmaceuticals and acquisitions McKesson Corporation Price and EPS Surprise    Other Factors at PlayEuropean Pharmaceutical Solutions The company is likely report higher European Pharmaceutical revenues in the fiscal fourth quarter possibly driven by better than expected performance outside the U K  However  currency rate movements might have a negative impact on the results  The Zacks Consensus Estimate for European Pharmaceutical s third quarter revenues is pegged at  7 03 billion  indicating a sequential improvement of 1 8  from the year ago quarter  Medical Surgical Solutions This segment is likely to exhibit a rise in revenues in the to be reported quarter  primarily on the back of strong market growth  incremental sale from the Medical Specialties Distributors  MSD  acquisition and benefits from an ongoing shift to lower cost sites of care   For the quarter to be reported  the Zacks Consensus Estimate for the segment s sales stands at  2 02 billion  suggesting a sequential improvement of 0 3  from the yar ago reported figure   Other Segment This segment  which includes McKesson Canada  McKesson Prescription Technology Solutions and Change Healthcare  is likely to witness better than expected performance in the fiscal fourth quarter  Expected organic growth and mitigation actions in Canada might have driven the anticipated improvement  However  price fluctuation of generic pharmaceuticals along with stiff competition in the MedTech space might impact the company s overall performance Further  the company estimates adjusted income from operations to decline in the low single digit on a year over year basis What Our Quantitative Model SuggestsOur proven model clearly indicates that a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to deliver a positive earnings surprise  This is the case here  Earnings ESP  McKesson has an Earnings ESP of  0 48   You can uncover the best stocks to buy or sell before they re reported with our   Zacks Rank  McKesson carries a Zacks Rank  3  Hold   Please note that we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions     Other Stocks Worth a Look Here are some other stocks worth considering from the broader medical space as these too have the right combination of elements to beat on earnings this time around  NanoString Technologies  Inc    NASDAQ NSTG   has an Earnings ESP of  3 08  and a Zacks Rank  3  Aurora Cannabis Inc    TO ACB   has an Earnings ESP of  55 88  and a Zacks Rank  3  STERIS plc   NYSE STE   has an Earnings ESP of  0 35  and a Zacks Rank  2  You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-05-03,Zacks Investment Research,https://www.investing.com/analysis/can-core-business-unit-fuel-mckesson-mck-q4-earnings-200416422,200416422
127816,349331,MCK,McKesson  MCK  Tops Q4 Earnings Estimates,opinion,"McKesson  MCK  came out with quarterly earnings of  3 69 per share  beating the Zacks Consensus Estimate of  3 66 per share  This compares to earnings of  3 49 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 0 82   A quarter ago  it was expected that this prescription drug distributor would post earnings of  3 18 per share when it actually produced earnings of  3 40  delivering a surprise of 6 92  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
McKesson  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  52 43 billion for the quarter ended March 2019  missing the Zacks Consensus Estimate by 1 73   This compares to year ago revenues of  51 63 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
McKesson shares have added about 13 8  since the beginning of the year versus the S P 500 s gain of 15 1  
What s Next for McKesson 
While McKesson has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for McKesson was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 13 on  54 64 billion in revenues for the coming quarter and  14 06 on  223 06 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 39  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-tops-q4-earnings-estimates-200418701,200418701
127817,349332,MCK,Company News For May 9  2019,opinion,Shares of Coty Inc    NYSE COTY   tumbled 5 5   after the company reported third quarter fiscal 2019 revenues of  1 99 billion  missing the Zacks Consensus Estimate of  2 05 billionShares of McKesson Corp    NYSE MCK   climbed 4 8  after the company posted fourth quarter fiscal 2019 adjusted earnings per share of  3 69  surpassing the Zacks Consensus Estimate of  3 66The Wendy s Co    NASDAQ WEN   shares surged 4  after posting first quarter 2019 adjusted earnings per share of  0 14  beating the Zacks Consensus Estimate of  0 12Shares of Qorvo  Inc    NASDAQ QRVO   soared 3 4  after posting fourth quarter fiscal 2019 adjusted earnings per share of  1 22  outpacing the Zacks Consensus Estimate of  1 06,2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-may-9-2019-200419662,200419662
127822,349337,MCK,U S  Supreme Court may limit where companies can be sued,news,By Andrew Chung WASHINGTON  Reuters    The U S  Supreme Court on Tuesday appeared poised to clamp down on where corporations can be sued  a potential setback for plaintiffs  lawyers who strive to bring cases in courts and locales they consider friendly   The nine justices in two separate cases heard appeals of lower court rulings allowing out of state injury lawsuits against drug maker Bristol Myers Squibb Co  N BMY  and BNSF Railway Co   Companies and plaintiffs are engaged in a fight over where lawsuits seeking financial compensation for injuries should be filed  Companies typically can be sued in a state where they are headquartered or incorporated  as well as where they have significant ties  They want to curtail plaintiffs  ability to  shop  for courts in states with laws conducive to such lawsuits  Bristol Myers was appealing a California Supreme Court ruling allowing that state s courts to hear claims related to its blood thinning medication Plavix even though most plaintiffs do not live in the state and the company is not based there  Based on questions asked during the argument  the court s conservative majority appeared to side with the companies  view while its liberals wondered how it would be unfair to add out of state claims to a case that would proceed anyway   Conservative Justice Anthony Kennedy expressed skepticism over California handling matters for residents of all other states   That s a very patronizing view of federalism   Kennedy told the plaintiffs  lawyer  Thomas Goldstein   California will tell Ohio   Oh  don t worry  Ohio  we ll take care of you    If suits involving out of state residents can be handled in every state  conservative Chief Justice John Roberts added   I don t see that it increases the efficiency at all    ALL OF THE ABOVE  Liberal Justice Elena Kagan suggested Bristol Myers did not want to face multiple trials in California specifically because of plaintiff friendly juries or the possibility of punitive damages    All of the above   the company s lawyer Neal Katyal said  adding that it is harder to get cases thrown out of court before trial in California   The underlying lawsuits filed in 2012 against Bristol Myers and California based drug distributor McKesson Corp  NYSE MCK  involved 86 California residents and 575 non Californians  alleging Plavix increased their risk of stroke  heart attack and internal bleeding   The California Supreme Court ruled in August 2016 that it could preside over the Plavix case because Bristol Myers Squibb conducted a national marketing campaign and sold nearly  1 billion of the drug in the state  Bristol Myers is incorporated in Delaware and headquartered in New York  The justices also appeared to be leaning toward Texas based railroad BNSF  The company is appealing a 2015 Montana Supreme Court ruling allowing out of state residents to sue there over injuries occurring anywhere in BNSF s nationwide network  The case focused on a federal law concerning railroads  but Roberts seemed skeptical that a ruling siding with the plaintiffs would be limited to that context  Roberts wondered whether other companies operating in multiple states including airlines and trucking companies could similarly be sued in states where they operate but are not based   How do you decide what other companies and industries are at home in Montana   Roberts asked the plaintiffs  lawyer  Rulings in both cases are due by the end of June  In an unusual twist  Justice Stephen Breyer s cellphone rang shortly after the Bristol Myers argument began  which he scrambled to turn off  Members of the public are forbidden from bringing electronic devices into the court s chamber  A court spokeswoman called Breyer s cellphone ringing an  oversight  ,2017-04-25,Reuters,https://www.investing.com/news/stock-market-news/u.s.-supreme-court-may-limit-where-companies-can-be-sued-477288,477288
127823,349338,MCK,QIAGEN Inks Distribution Deal With Mckesson Medical Surgical,opinion,QIAGEN N V    NYSE QGEN   recently announced that it has inked an agreement with McKesson Medical Surgical Inc  Mckesson Corporation s   NYSE MCK   affiliate will serve as the exclusive distributor of QIAGEN s QIAstat Dx syndromic testing solution in the acute market segment of U S  hospitals  which have 200 beds or less  Mckesson Medical Surgical will also distribute the solution in other select segments  This will enable QIAGEN to expand its reach within the healthcare market More About the AgreementThrough the agreement  McKesson becomes a non exclusive distributor for future expansion of QIAstat Dx into the non acute retail clinics in U S  retail pharmacies  The distribution relationship reinforces QIAGEN s sales and marketing focus on the growing syndromic market in the larger hospitals and clinical laboratories setting The agreement with McKesson comes after the QIAstat Dx syndromic testing system attained 510 k  approval from the FDA  The multiplex QIAstat Dx Respiratory Panel for simultaneous qualitative detection and identification of multiple respiratory viral and bacterial pathogens also received FDA s nod  This comprehensive respiratory panel identifies more than 20 pathogens and is the first test in a wide array of assays planned for QIAstat Dx in the United States  Moreover  this includes the addition of a comprehensive gastrointestinal panel later in 2019 Market prospectsThe smaller hospital segment is rapidly growing and includes one third of the estimated 6 000 hospitals in the United States  QIAGEN projects the total addressable market for respiratory and related syndromic testing in the acute segment at about 1 5 million tests per year  Hence  this distribution partnership has been forged at a strategic time Recent DevelopmentsCurrently  QIAGEN is investing in a few developments related to the QIAstat Dx syndromic testing solution In April  the company announced positive data outcomes of the QIAstat Dx Meningitis Encephalitis panel  The preliminary data showcases accurate diagnosis of the most predominant central nervous system pathogens with high analytical sensitivity and specificity levels  including the discrimination of clinically relevant strains and subtypes Price PerformanceThe company has outperformed the  in the past year  The stock has improved 12 3  compared with the industry s 17 6  fall Zacks Rank and Key PicksQIAGEN currently has a Zacks Rank  3  Hold  You can see  Two better ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN   and Bruker Corporation   NASDAQ BRKR    Each of these stocks carry a Zacks Rank  2  Buy  Cerner s long term earnings growth rate is expected to be 13 5  Bruker s long term earnings growth rate is estimated at 11 7  Will You Retire a Millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/qiagen-inks-distribution-deal-with-mckesson-medicalsurgical-200433188,200433188
127830,349345,MCK,Leerink not so impressed with McKesson s Q4 earnings beat  others have a different opinion  shares up 9  premarket,news,Leerink s David Larsen says McKesson s  NYSE MCK  fiscal Q4 results were  low quality  since most of the upside came from a lower tax rate and lower share count  The company would have missed consensus by  0 04 if these two items were excluded  He adds that its F18 non GAAP EPS outlook of  11 75   12 45 would have been  1 30 lower if it had not changed the definition of adjusted earnings  MARKET PERFORM  140  Investors appear to be unconcerned  Shares are up 9  premarket  albeit on light volume Source  The FlyNow read ,2017-05-19,Seeking Alpha,"https://www.investing.com/news/stock-market-news/leerink-not-so-impressed-with-mckesson's-q4-earnings-beat,-others-have-a-different-opinion,-shares-up-9-premarket-486469",486469
127833,349348,MCK,Supreme Court again limits where companies can be sued,news,"By Andrew Chung WASHINGTON  Reuters    The Supreme Court on Monday slapped limits on where injury lawsuits may be filed for the second time in three weeks  again siding with businesses that want to prevent plaintiffs from  shopping  for friendly courts for their cases  In an 8 1 ruling  the justices overturned a lower court s decision that had allowed hundreds of out of state patients who took Bristol Myers Squibb Co s  N BMY  blood thinning medication Plavix to sue the company in California  State courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there  the justices ruled  The Supreme Court on May 30 reached a similar conclusion in a separate case involving out of state injury claims against Texas based BNSF Railway Co  Businesses and plaintiffs are engaged in a battle over where lawsuits seeking financial compensation for injuries can be filed   Companies typically can be sued in a state where they are headquartered or incorporated  as well as where they have important ties  Businesses want to limit the ability of plaintiffs to shop for courts in states with laws conducive to such injury lawsuits  Plaintiffs contend that corporations are seeking to squeeze their access to compensation for injuries by denying them their day in state courts  The underlying lawsuits filed in 2012 against Bristol Myers and California based drug distributor McKesson Corp  NYSE MCK  involved 86 California residents and 575 non Californians  alleging Plavix increased their risk of stroke  heart attack and internal bleeding   Bristol Myers argued it should not face claims in California by plaintiffs who do not live in the state  The company is incorporated in Delaware and headquartered in New York  The California Supreme Court ruled in August 2016 that it could preside over the case because Bristol Myers conducted a national marketing campaign and sold nearly  1 billion of the drug in the state   
Writing for the Supreme Court majority on Monday  Justice Samuel Alito said the California court was wrong to rule that it could hear the case  without identifying any adequate link between the state and the nonresidents  claim   In a dissenting opinion  Justice Sonia Sotomayor predicted that the Supreme Court s ruling will make it harder to consolidate lawsuits against corporations in state courts and lead to unfairness for individual injury plaintiffs   There  is nothing unfair about subjecting a massive corporation to suit in a state for a nationwide course of conduct that injures  state residents and nonresidents alike  Sotomayor wrote ",2017-06-19,Reuters,https://www.investing.com/news/economy-news/supreme-court-again-limits-where-companies-can-be-sued-496980,496980
127834,349349,MCK,U S  Supreme Court ruling threatens massive talc litigation against JJ,news,"By Nate Raymond  Reuters    Johnson   Johnson  NYSE JNJ  is seizing upon a U S  Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer  New Jersey based J J has been battling a series of lawsuits over its talc based products  including Johnson s Baby Powder  brought by around 5 950 women and their families  The company denies any link between talc and cancer  A fifth of the plaintiffs have cases pending in state court in St  Louis  where juries in four trials have hit J J and a talc supplier with  307 million in verdicts  Those four cases and most of the others on the St  Louis docket involve out of state plaintiffs suing an out of state company  On Monday  the Supreme Court ruled 8 1 in a case involving Bristol Myers Squibb Co that state courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there  The ruling immediately led a St  Louis judge at J J s urging to declare a mistrial in the latest talc case  in which two of the three women at issue were from out of state  It also could imperil prior verdicts and cases that have yet to go to trial   We believe the recent U S  Supreme Court ruling on the Bristol Myers Squibb matter requires reversal of the talc cases that are currently under appeal in St  Louis   J J said in a statement  The question of where such lawsuits can be filed has been the subject of fierce debate  The business community has argued plaintiffs should not be allowed to shop around for the most favorable court to bring lawsuits  while injured parties claim corporations are trying to deny them access to justice  Along with talc cases  large scale litigation alleging injuries from Bayer  DE BAYGN  AG s Essure birth control device in Missouri and California and GlaxoSmithKline s antidepressant Paxil in California and Illinois are examples of other cases where defendants could utilize the Supreme Court decision  Although he declared a mistrial on Monday  St  Louis Circuit Judge Rex Burlison left the door open for the plaintiffs to argue they still have jurisdiction  Plaintiffs lawyer Ted Meadows said he would argue the St  Louis court still had jurisdiction based on a Missouri based bottler J J used to package its talc products  which he said would create a sufficient connection to the state   It s very disappointing to mistry a case because the Supreme Court changed the rules on us   said Meadows  The lawsuit decided by the high court on Monday involved claims against Bristol Myers and California based drug distributor McKesson Corp  NYSE MCK  by 86 California residents and 575 non Californians over the blood thinner Plavix  Beyond Monday s mistrial  the Supreme Court s ruling could bolster a pending appeal by J J of a  72 million verdict in favor of the family of Alabama resident Jacqueline Fox  who died in 2015  A Missouri appeals court had said in May it would wait until the Supreme Court issued its decision to decide the appeal  J J has won only one of the five trials so far in Missouri  It previously sought to move talc cases out of St  Louis  but the Missouri Supreme Court in January denied its bid  The company has also cast the St  Louis court as overly plaintiff friendly and has allowed evidence linking talc to cancer that was rejected by a New Jersey state court judge overseeing over 200 talc cases  The plaintiffs are appealing  The talc verdicts against J J led the business friendly American Tort Reform Association last year to declare the St  Louis state court the nation s top  Judicial Hellhole   Now J J could try to use the Supreme Court ruling to dismiss many of the cases it faces in Missouri  according to legal experts  Corporations facing a large volume of cases in venues chosen by plaintiffs will likely cite the Supreme Court to try to dismiss those claims  said Rusty Perdew  a defense lawyer at the law firm Locke Lord   You have a bunch of defendants who can go back and say   Judge  you got that wrong and you re going to have to dismiss claims by all those plaintiffs    he said  
 This story was corrected to show that Perdew was speaking about corporations in general  not J J  in next to last paragraph  ",2017-06-20,Reuters,https://www.investing.com/news/stock-market-news/u.s.-supreme-court-ruling-threatens-massive-talc-litigation-against-j-amp;j-497553,497553
127836,349351,MCK,McKesson to host Investor Day June 28,news,McKesson  NYSE MCK  will host an Investor Day on Wednesday  June 28  The presentation will be available live and archived on the company s website in the  Investors  section Now read ,2017-06-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/mckesson-to-host-investor-day-june-28-497974,497974
127837,349352,MCK,FDA to clear out Orphan Drug application backlog in 90 days,news,Consistent with his previously announced plan to reboot the FDA aimed at more timely reviews  Commissioner Scott Gottlieb  M D  unveils a new plan to eliminate the backlog of Orphan Drug requests in the next 90 days and establishing a benchmark of responding to new requests within 90 days of receipt  Currently  the agency has  200 applications pending review  Last year  it received 568 requests  more than double the amount received in 2012 The FDA s tactics will include a  Backlog SWAT team  of senior reviewers with significant expertise in the area  Requests will be reviewed on a FIFO basis  oldest ones reviewed first  In order to respond to new applications within 90 days  the review staff will be reorganized to improve efficiency and maximize expertise  A new Orphan Products Council will be established to help address scientific and regulatory issues to ensure a consistent approach in regulating orphan drugs and reviewing designation requests Selected tickers  BIB IBB XBI PBE CNCR PJP IHE XPH PPHNow read ,2017-06-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-to-clear-out-orphan-drug-application-backlog-in-90-days-500600,500600
127838,349353,MCK,Teamsters urge McKesson shareholders to vote against CEO pay,news,"By Michael Erman NEW YORK  Reuters    The International Brotherhood of Teamsters urged McKesson Corp s  N MCK  shareholders to vote against the company s executive pay practices and called for it to appoint an independent chairman as the union criticized the drug distributor for its role in the U S  opioid drug epidemic  McKesson Chief Executive John Hammergren was paid more than  20 million for the year ended March 31  despite the company s record  150 million settlement paid to resolve a U S  investigation into whether it failed to report suspicious orders of addictive painkillers   Recent pay decisions     send completely the wrong message to shareholders  regulators  lawmakers and the public about executive accountability   the Teamsters wrote in a letter to other shareholders filed with the U S  Securities and Exchange Commission on Monday  The union did not disclose how many McKesson shares it owns  but said it had substantial holdings in the company  It asked shareholders to vote against a proposal to approve executive compensation and for a proposal asking for an independent chairman  The  say on pay  proposal is an advisory  non binding vote  McKesson said in a statement the company has invested millions into and enhanced its controlled substances monitoring program  It also filed slides defending its pay practices  noting that Hammergren s pay had declined 27 percent over the past 4 years   McKesson and its shareholders have been well served during John Hammergren s service as both CEO and chairman of the board   the company said  McKesson s  150 million settlement with the U S  Justice Department earlier this year followed an earlier settlement with the company over similar violations in 2008  In addition to being McKesson investors  the Teamsters also represent some of McKesson s workers   
McKesson shares were up 44 cents  or 0 3 percent  to  165 12 in midday trading on the New York Stock Exchange ",2017-07-10,Reuters,https://www.investing.com/news/stock-market-news/teamsters-urge-mckesson-shareholders-to-vote-against-ceo-pay-503930,503930
127845,349360,MCK,Is McKesson  MCK  A Great Value Stock Right Now ,opinion,"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks  we also know that investors tend to develop their own individual strategies  With this in mind  we are always looking at value  growth  and momentum trends to discover great companies 
Of these  perhaps no stock market trend is more popular than value investing  which is a strategy that has proven to be successful in all sorts of market environments  Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued  leaving room for profits 
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits  For example  value investors will be interested in stocks with great grades in the  Value  category  When paired with a high Zacks Rank   A  grades in the Value category are among the strongest value stocks on the market today 
One company value investors might notice is McKesson  MCK   MCK is currently sporting a Zacks Rank of  2  Buy   as well as an A grade for Value  The stock has a Forward P E ratio of 9 63  This compares to its industry s average Forward P E of 16 13  MCK s Forward P E has been as high as 11 72 and as low as 7 78  with a median of 9 56  all within the past year 
MCK is also sporting a PEG ratio of 1 36  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  MCK s industry currently sports an average PEG of 1 80  MCK s PEG has been as high as 1 46 and as low as 1 12  with a median of 1 33  all within the past year 
Another valuation metric that we should highlight is MCK s P B ratio of 2 77  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  This company s current P B looks solid when compared to its industry s average P B of 2 92  Over the past 12 months  MCK s P B has been as high as 3 24 and as low as 2 22  with a median of 2 69 
Finally  investors will want to recognize that MCK has a P CF ratio of 8 81  This figure highlights a company s operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook  MCK s P CF compares to its industry s average P CF of 13 86  Over the past year  MCK s P CF has been as high as 10 07 and as low as 4 59  with a median of 7 81 
These are only a few of the key metrics included in McKesson s strong Value grade  but they help show that the stock is likely undervalued right now  When factoring in the strength of its earnings outlook  MCK looks like an impressive value stock at the moment ",2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/is-mckesson-mck-a-great-value-stock-right-now-200390130,200390130
127846,349361,MCK,Top Research Reports For Pfizer  Royal Dutch Shell   Celgene,opinion,"Wednesday  April 3  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Pfizer  PFE   Royal Dutch Shell  LON RDSa   RDS A  and Celgene  CELG   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Pfizer s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year  18 8  vs  13 3    Pfizer expects continued strong growth of key product franchises  including Ibrance  Eliquis  Xeljanz and Xtandi in 2019  However  loss of exclusivity on key drugs in the United States   mainly Lyrica and currency headwinds are expected to significantly hurt its 2019 sales 
Other top line headwinds are weak sales in the EH segment  pricing pressure and rising competition  To offset the threat of generic competition  Pfizer is strengthening its pipeline as well as oncology portfolio  Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years  which can drive long term growth  Bavencio  though currently approved for two small indications  is being considered a key long term growth driver for Pfizer if it can gain label expansion approvals 
 You can   
Shares ofbuy ranked Royal Dutch Shell have lost  8 2  in the last six months  underperforming the Zacks Integrated Oil industry s loss of  7 4  during the same period  However  the stock is poised for strong performance in 2019  The integrated behemoth s recent results have been driven by robust commodity prices and higher downstream earnings  Shell s upstream unit profit has rebounded strongly thanks to steady commodity price recovery  while the integrated gas business   consisting of BG Group activities   impressed on the back of pricing gains 
Importantly  the Anglo Dutch company s position as a key supplier of LNG should benefit its long term cash flow growth  Consequently  Shell is likely to offer substantial upside from the current price levels and is viewed as a preferred supermajor to own now 
 You can   
Celgene s shares have gained 10 1  in the last three months  outperforming the Zacks Biomedical and Genetics industry s increase of 7 5   Celgene s key growth driver  Revlimid continues to drive revenues  Robust performance of psoriasis drug  Otezla is also boosting performance  Investors are focusing on the company s recent merger agreement with Bristol Myers Squibb Company  NYSE BMY   Per the terms  Celgene shareholders will receive 1 0 share of Bristol Myers and  50 00 in cash for each share held 
Meanwhile  Celgene is also working on label expansion of drugs like Pomalyst Imnovid  Abraxane and Otezla  among others  The company is focused on the next cycle of innovation with five late stage candidates   ozanimod  fedratinib  luspatercept  liso cel and bb2121   all of which are expected to be launched by the end of 2020   
 You can   
Other noteworthy reports we are featuring today include Advanced Micro Devices  NASDAQ AMD   AMD   Occidental Petroleum  OXY  and The Blackstone  NYSE BX  Group  BX  
Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  

Mark VickerySenior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Pfizer  PFE  Boasts Solid Pipeline of Potential Blockbusters


Royal Dutch Shell  RDS A  to Gain from Growing LNG Demand


Celgene s  CELG  Revlimid Boosts Revenues Amid Setbacks


Featured Reports
High margin Area Output  Permian Focus Aid Occidental  OXY 
The Zacks analyst believes Occidental will continue to benefit from its high margin production and focus on resource rich Permian Resource region 

Schneider  SNDR  Aided by intermodal unit Amid Cost Woes
The Zacks analyst appreciates the solid performance of Schneider National s intermodal unit  Efforts to reward its shareholders are encouraging too 

Solid Industrial Tools Business  Buyouts to Aid Actuant  ATU 
Per a Zacks analyst  Actuant s  ATU  restructuring measures  aimed at making it a pure play industrial tool maker  will be a boon 

Hershey  HSY  Likely to Gain from Margin for Growth Program
Per the Zacks analyst  Hershey s Margin for Growth plan is set to improve the company s operating margin via supply chain optimization  a streamlined operating model and reduced administrative costs 

Prudent Land Investments Aid PulteGroup  NYSE PHM   Margins Low
Per the Zacks analyst  PulteGroup continues to benefit from its land acquisition strategies that have resulted in higher revenues and profitability 

Skyworks  NASDAQ SWKS  Rides on 5G Product Suite   LTE Solutions
Per Zacks analyst  Skyworks  growing clout in the connectivity solutions and 5G markets is a positive 

Omni Channel Efforts Aid Deckers  DECK   Sanuk Sales Hurt
Per the Zacks analyst  Deckers  focus on product innovation  brand assortments and omni channel distribution bode well 

New Upgrades
Debt free Position   Revenue Growth Aid T  Rowe Price  TROW 
Per the Zacks analyst  debt free position with substantial liquidity has assisted in strengthening T  Rowe Price s capital leverage  Further  revenue growth remains a key strength 

Strong Markets  New Products to Fuel Pentair s  PNR  Growth
Per the Zacks analyst  growth in segments aided by healthy end markets  introduction of products  acquisitions and productivity improvements will drive Pentair s results 

Higher Premiums Continue to Aid Reinsurance Group  RGA 
Per the Zacks analyst  improving premiums  on the back of sustained operational performance  will continue to bolster Reinsurance Group s bottom line 

New Downgrades
Economic Sluggishness in United Kingdom Ails McKesson  NYSE MCK  
McKesson s European Pharmaceutical Solutions witnessed softness due to challenges in the United Kingdom  The Zacks analyst is also apprehensive about stiff competition in the MedTech space 

Continuously Rising Expenses Hurt Blackstone s  BX  Profits
Per the Zacks analyst  elevated costs due to Blackstone s continued investment in franchise will likely hurt profits  Also  adverse effects of the on going volatility in the capital markets are a woe 

Highly Leveraged Balance Sheet   Competition Hurts AMD
Per the Zacks analyst  intensifying competition in the traditional PC market as well as GPU segment is a major headwind  Also  a highly leveraged balance sheet remains a concern ",2019-04-03,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-for-pfizer-royal-dutch-shell--celgene-200403703,200403703
127854,349369,MCK,McKesson in record  150 million U S  settlement over suspicious drug orders,news,"By Nate Raymond
 Reuters    McKesson Corp  NYSE MCK   one of the largest U S  distributors of pharmaceutical drugs  will pay a record  150 million to resolve a U S  investigation into whether it failed to report suspicious orders of addictive painkillers 
Tuesday s deal with the U S  Justice Department followed an earlier settlement with the company over similar violations in 2008  The latest accord came as U S  authorities continue to grapple with the nation s opioid drug epidemic 
 The consequences of McKesson s decision to circumvent its obligations are too devastating to ignore and warrant today s punishment   New Jersey U S  Attorney Paul Fishman  whose office was involved in the deal  said in a statement 
Under the settlement  San Francisco based McKesson must on a staggered basis suspend sales of controlled substances from distribution centers in Colorado  Ohio  Michigan and Florida for several years 
It will also be subject to new and enhanced compliance obligations and be required to hire an independent monitor to assess compliance  a first of its kind arrangement under a Controlled Substances Act civil penalty settlement 
McKesson in a statement said it has implemented significant changes to its monitoring and reporting processes and was committed to combating prescription drug diversion and abuse 
 We are committed to tackling this multi faceted problem in collaboration with all parties in the supply chain that share the responsibility for the distribution of opioid medications   McKesson Chief Executive Officer John Hammergren said in a statement 
Each day about 78 Americans die of an opioid overdose  according to authorities  Oxycodone  a big source of profit for drug dealers  is abused by over 13 million Americans annually  prosecutors say 
Tuesday s accord came after McKesson in 2008 reached a  13 25 million settlement resolving claims that it failed to design and implement an effective system to detect and report suspiciously large or frequent orders 
The Justice Department said that following that deal  from 2008 until 2013  McKesson supplied various pharmacies an increasing amount of oxycodone and hydrocodone pills  both opioid drugs that are frequently misused 
The Justice Department said the evidence showed that McKesson did not fully implement or adhere to its own compliance program designed after the 2008 settlement 
As one example  the Justice Department said that in Colorado  McKesson processed over 1 6 million orders for controlled substances from June 2008 through May 2013  yet only reported 16 as suspicious ",2017-01-17,Reuters,https://www.investing.com/news/stock-market-news/mckesson-in-record-$150-million-u.s.-settlement-over-suspicious-drug-orders-453762,453762
127857,349372,MCK,Trump health pick defends stocks  says Americans won t lose insurance,news,By Toni Clarke and Susan Cornwell WASHINGTON  Reuters    President elect Donald Trump s nominee to head the U S  Department of Health and Human Services defended his stock holdings and proposals to dismantle Obamacare on Wednesday  saying Americans would not suddenly lose health insurance  Representative Tom Price told the Senate Committee on Health  Education  Labor and Pensions  one of two that oversee the health department  that there was no connection between his purchase of certain health company stocks and his promotion of legislation that would have helped the companies  He said the stocks were bought on his behalf by a broker   I had no knowledge of those purchases   he said  Price owns a variety of healthcare stocks  including biotech firm  Amgen Inc   NASDAQ AMGN   pharma companies Bristol Myers Squibb Co  Eli Lilly   Co and drug distributor McKesson Corp  NYSE MCK   He has said he will divest health and other stocks that could be affected by his position as health secretary  Price  an orthopedic surgeon  said he did personally direct his broker to buy shares of Australian biotech company Innate Immunotherapeutics Ltd  He said he was made aware of the stock by Republican Congressman Chris Collins  who serves on Immunotherapeutics  board  but denied he had been given any inside information or broken any laws  He said he did his own due diligence on the company  A spokesman for Collins  Michael McAdams  said in a statement that Collins  relationship with Immunotherapeutics goes back more than 15 years  during which he has spoken with hundreds of people  including Price   Congressman Collins has never disclosed any nonpublic or improper information related to Innate Immunotherapeutics and has followed all ethical and legal standards required by the House of Representatives during his time in office   Senator Patty Murray  the top Democrat on the panel  said the purchase raised questions that need a full investigation before the Senate goes forward with his confirmation  Stephen Crimmins  an attorney with Murphy and McGonigle and former lawyer with the U S  Securities and Exchange Commission  said the chain of events described by Price does not suggest insider trading   What we re seeing so far is a tip from a company director  who happened to be another congressman   Crimmins said   It s a tip that the company was a good investment based on its ongoing public research on multiple sclerosis  That s not insider trading  whether Price bought in the market or in a private placement   Crimmins said the controversy illustrates the risk that all public officials take when they invest in individual stocks   The safe play to avoid such questions is to stick to fund investments   he said  Not everyone is as sanguine as Crimmins  James Cox  a securities law professor at Duke University School of Law  said Price appeared to have received the information about Immunotherapeutics by virtue of his public position   What I heard and thought he admitted to doing was abusing his position by using information that was not generally publicly available for private gain   he said  Price will face additional questioning the Senate Committee on Finance  which has set a confirmation hearing for Jan  24  Only members of the finance committee will vote on whether to send Price s nomination to the Senate floor for review  Questioned about President Obama s signature Affordable Care Act  Price said  nobody is interested in pulling the rug out from anyone  as Republicans in Congress work to repeal the law and replace it with an alternative system  Price said an overhaul of Obamacare will initially focus on individual health plans sold on online exchanges and the Medicaid program but would not tackle changes to Medicare  Trump has called for the immediate repeal of the law and its simultaneous replacement  Trump has said that he wants to keep some aspects of Obamacare  such as allowing young adults to be on their parents  insurance  but that he wants plans that use health savings accounts  He also advocates for insurance to be sold across state lines  Price said that with these new tools  and the rollout of new forms of high deductible so called catastrophic insurance  the government can expand healthcare coverage to more people  He also echoed Trump s recent call for  healthcare for all   saying that he wants more people to be covered after the ACA is repealed  The nonpartisan Congressional Budget Office on Tuesday said a repeal of Obamacare would increase the number of people without health insurance by 18 million in the first year and 32 million by the year 2026 ,2017-01-18,Reuters,https://www.investing.com/news/politics-news/trump's-health-pick-set-to-defend-investments-at-u.s.-senate-hearing-453891,453891
127858,349373,MCK,U S  top court to hear Bristol Myers out of state injury appeal,news,By Erica Teichert  Reuters    The U S  Supreme Court on Thursday agreed to hear an appeal by pharmaceutical company Bristol Myers Squibb Co  N BMY  in a dispute involving its blood thinning medication Plavix that could limit where corporations can be sued  the second such case it has taken up in the past week  The justices will review a California Supreme Court decision allowing that state s courts to hear claims over Plavix even though the plaintiffs did not live in the state and the company is not based there   Last Friday  the justices said they would decide a similar appeal by Texas based BNSF Railway Co of a 2015 Montana Supreme Court ruling allowing out of state residents to sue there over injuries that occurred anywhere in BNSF s nationwide network   Companies and plaintiffs are engaged in a fight over where lawsuits seeking compensation for injuries should be filed  Companies typically can be sued in a state where they are headquartered or incorporated  as well as where they have significant ties   The California Supreme Court ruled in August 2016 that it could preside over the Plavix case because Bristol Myers Squibb conducted a national marketing campaign and sold nearly  1 billion of the drug in the state  Bristol Myers and pharmaceutical industry groups argue that the ruling allows plaintiffs to bring lawsuits in states with more favorable laws  rather than where the company is based or where the alleged injury occurred  Bristol Myers is incorporated in Delaware and headquartered in New York  The eight underlying lawsuits filed in 2012 against Bristol Myers and California based drug distributor McKesson Corp  NYSE MCK  involve 84 California residents and 575 non residents  alleging Plavix increased their risk of stroke  heart attack and internal bleeding  The BNSF case involves a pair of lawsuits brought under the Federal Employers  Liability Act  which permits injured railroad employees to sue for compensation from their companies  BNSF  a subsidiary of  Berkshire Hathaway Inc   N BRKa   argued that the Montana courts did not have jurisdiction over the cases  The Montana Supreme Court in May ruled that state courts there can hear cases against BNSF without violating due process rights of the U S  Constitution because the company does business in the state ,2017-01-19,Reuters,https://www.investing.com/news/stock-market-news/u.s.-top-court-to-hear-bristol-myers-out-of-state-injury-appeal-454433,454433
127863,349378,MCK,U S  judge halts Arkansas plan for successive executions,news,"By Steve Barnes LITTLE ROCK  Ark   Reuters    A U S  judge in Little Rock on Saturday temporarily blocked plans by Arkansas to hold a rapid series of executions this month  after the inmates argued the state s rush to the death chamber was unconstitutional and reckless  Arkansas  which has not carried out an execution in 12 years  planned to begin the lethal injections of at least six convicted murderers on Monday  No state has ever executed as many inmates in as short a period since the U S  Supreme Court reinstated the death penalty in 1976   Arkansas had scheduled the fast paced series of executions in order to beat the expiration date on its batch of one of the three drugs used in its lethal injection cocktail  U S  District Judge Kristine Baker  in a 101 page ruling  found the state s plan would deny the inmates their legal rights by depriving them of adequate counsel by allowing only a single lawyer to be present at the execution   The court finds that plaintiffs are entitled to a preliminary injunction based on their challenge to  the state s  viewing policies  in their current form  as unreasonable restrictions of plaintiffs  right to counsel and right of access to the courts   Baker wrote  Arkansas Attorney General Leslie Rutledge vowed to appeal the temporary restraining order   It is unfortunate that a U S  District Judge has chosen to side with the convicted prisoners in one of their many last minute attempts to delay justice   Judd Deere  a spokesman for the attorney general  said in a statement   The injunction applies to nine condemned prisoners who petitioned the federal court  One of them was never put into the execution schedule for April  Two others won stays of execution from state courts  leaving six of the original petitioners   The state s mixture of drugs used in executions has brought legal challenges  Arkansas employs potassium chloride in combination with vecuronium bromide and midazolam  The latter drug is intended to render the inmate unconscious before the other two chemicals are administered to paralyze the lungs and stop the heart   Governor Asa Hutchinson has said the state must act quickly because the efficacy date for midazolam expires at the end of the month  But Arkansas circuit court Judge Wendell Griffen  an outspoken opponent of capital punishment  issued an order on Friday blocking the state from using a second drug  vecuronium bromide  after a petition from its maker  McKesson  NYSE MCK  Medical Surgical Inc  
The attorney general plans to appeal Griffen s order as well ",2017-04-15,Reuters,https://www.investing.com/news/world-news/arkansas-supreme-court-grants-stay-of-execution-for-one-condemned-inmate-474472,474472
127864,349379,MCK,J J s 3 4  post earnings decline leads healthcare lower  UNH a rare gainer,news,The company beat on the bottom line  but revenues fell short of estimates thanks a slowdown in pharmaceutical sales Speaking on the earnings call  CFO Dominic Caruso says J J  JNJ  3 5   continues to evaluate options for its diabetes unit  He sees pricing pressure and paying pressure for for Xarelto and Invokana  and is happy to see little impact from biosimilar competition on Remicade Weighing in on results  Cowen bull Joshua Jennings says the growth slowdown makes the Actelion acquisition more timely than previously thought  Source  Bloomberg s Tatiana Darie Other players  Merck  NYSE MRK   MCK  5 9    Bristol Myers  BMY  0 1    Gilead  GILD  1 5    Eli Lilly  LLY  1 1    AbbVie  ABBV  1 7   A rare green name in healthcare is UnitedHealth  UNH  1   after beating on both lines  Speaking on the earnings call  CEO Stephen Hemsley says Q2 results are likely to be inline with that seen in Q1 Other insurers  Aetna  AET  0 8    Humana  HUM  0 3    WellCare  WCG  0 4  Also at work is  Cardinal Health   NYSE CAH  s 11 6  plunge after its weak guidance The Health Care SPDR  XLV  1 4  ETFs  XLV  IYH  VHT  HQH  CURE  FXH  FHLC  RXL  THQ  RYH  RXD  SICK  BTEC  HCRF  JHMH  LNGR,2017-04-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/j-j's-3.4-post-earnings-decline-leads-healthcare-lower;-unh-a-rare-gainer-475084,475084
127865,349380,MCK,Company sues Arkansas  charging fraud over lethal injection drugs,news,"By Jon Herskovitz and Steve Barnes  Reuters    A major U S  pharmaceutical firm sued Arkansas again over capital punishment on Tuesday  claiming prison officials fraudulently obtained a muscle relaxant to administer in several executions and demanding the drug in question be confiscated from the state  Arkansas  which last carried out an execution a dozen years ago  has sought to resume capital punishment this month with a plan that originally called for putting eight inmates to death by lethal injection in 11 days  That tally would have marked the highest concentration of executions over such a short period in a single state since the U S  Supreme Court allowed reinstitution of capital punishment in 1976   However  three of the condemned killers headed for the death chamber this month have already won stays of execution in a flurry of legal challenges and criticism that Arkansas was acting recklessly  On Tuesday lawyers for all eight inmates filed a petition with the U S  Supreme Court seeking a reprieve for the entire group on the basis of such issues as alleged flaws in the state s execution procedures and inadequate access to legal counsel  Arkansas  death penalty push came as the number of U S  executions fell to a quarter century low in 2016   For a graphic on the number and method of U S  executions  see    Capital punishment in several states has been stymied by opposition of some global drug companies to the use of their products for executions and difficulties in finding effective replacements   Arkansas contends it must act quickly because its supply of one of the drugs in its lethal injection mix  the valium like sedative midazolam  expires at the end of April  In a repeat of its lawsuit against Arkansas  McKesson Medical Surgical  a unit of McKesson Corp  N MCK   said the state s correction department had acted deceitfully when it purchased another drug  vecuronium bromide  a commonly used muscle relaxant given in extreme doses in executions to paralyze the body and halt breathing  The state  intended to use this product in connection with executions  a fact that was never disclosed to McKesson   the company said in Tuesday s filing in state court in Little Rock  McKesson originally sued Arkansas last week but withdrew the complaint after a federal court on Saturday temporarily blocked the 11 day plan for eight executions  But that ruling was overturned on Monday by a federal appeals court  The company wants the drug supply in question impounded  Arkansas contends it has acted legally  Five inmates remain in line for the death chamber in the coming days  starting with Stacey Johnson and Ledell Lee on Thursday in what would be the first dual executions carried out anywhere in the United States in 17 years  
On Tuesday  a state judge refused Lee s petition seeking a stay to allow for DNA tests his lawyers say would prove his innocence  A federal judge later denied a reprieve for Johnson  who asserted his obesity and other medical conditions posed the likelihood that death by lethal injection would subject him to unconstitutional pain and suffering ",2017-04-18,Reuters,"https://www.investing.com/news/world-news/company-sues-arkansas,-charging-fraud-over-lethal-injection-drugs-475200",475200
127868,349383,MCK,Arkansas preps for first U S  double execution since 2000,news,"By Steve Barnes LITTLE ROCK  Ark   Reuters    Two Arkansas killers were scheduled on Monday to become the first pair of convicts put to death on the same day in the United States in 17 years  barring a last minute reprieve from the U S  Supreme Court  Jack Jones  52  and Marcel Williams  46  were scheduled for back to back executions by injection on Monday evening  Jones filed two applications with the U S  Supreme Court on Monday afternoon seeking to have his execution halted  while Williams was likely to file his appeal in the coming hours  Both men had previously asked for stays on the grounds that their obesity and related health conditions could expose them to unconstitutional pain and suffering if their death sentences were carried out  Both the Arkansas Supreme Court and the 8th U S  Circuit Court of Appeals in St  Louis rejected the men s requests  In addition to appealing the obesity issue to the Supreme Court  Jones separately argued that the Arkansas Supreme Court applied the wrong standard of review in 1997 when considering whether a jury properly determined his death sentence  The inmates  likelihood of success may have diminished with the recent appointment of conservative U S  Supreme Court Justice Neil Gorsuch  Last week  the high court cleared the way for Arkansas to hold its first execution in 12 years  and the state executed murderer Ledell Lee  The last time a state executed two inmates on the same day was 2000 in Texas  Jones  sentenced in 1996 for raping and strangling Mary Phillips and attempting to murder her 11 year old daughter  was scheduled to be put to death on Monday at 7 p m  CDT  0000 GMT at the Cummins  NYSE CMI  Unit prison  about 75 miles  120 km  southeast of the state capital  Little Rock  Jones also was convicted of rape and murder in Florida  Williams was tentatively scheduled to be executed at 8 15 p m  CDT  0115 GMT on Tuesday  for the 1997 kidnapping  rape and murder of Stacy Errickson  He also abducted and raped two other women  The condemned pair were among eight inmates that Arkansas had initially planned to execute in 11 days this month  a compressed schedule prompted by the impending expiration date of supplies of midazolam  the sedative used by the state for lethal injections  The drug was used in flawed executions in Oklahoma and Arizona  where witnesses said the inmates writhed in apparent pain on the gurney  No problems were reported in Lee s execution on Thursday  Four of the planned executions have been put on hold by court order  including two pending the outcome of a case heard on Monday by the U S  Supreme Court  The court s four liberal justices appeared sympathetic to the argument by Alabama death row inmate James McWilliams that he is entitled to a mental health assessment from an independent medical expert before he can be executed  Arkansas has scheduled a final execution for April on Thursday  
The unprecedented schedule generated a wave of criticism and legal challenges  including a lawsuit from the company that distributes one of the drugs  McKesson  NYSE MCK  Medical Surgical Inc claimed the state obtained its supplies under false pretenses  but the state s Supreme Court threw out that lawsuit last week ",2017-04-24,Reuters,https://www.investing.com/news/world-news/arkansas-plans-to-execute-two-convicts-monday-476583,476583
127870,349385,MCK,McKesson  MCK  Q3 Earnings And Revenues Beat Estimates,opinion,"McKesson  MCK  came out with quarterly earnings of  3 40 per share  beating the Zacks Consensus Estimate of  3 18 per share  This compares to earnings of  3 41 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 6 92   A quarter ago  it was expected that this prescription drug distributor would post earnings of  3 28 per share when it actually produced earnings of  3 60  delivering a surprise of 9 76  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
McKesson  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  56 21 billion for the quarter ended December 2018  surpassing the Zacks Consensus Estimate by 1 69   This compares to year ago revenues of  53 62 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
McKesson shares have added about 13 1  since the beginning of the year versus the S P 500 s gain of 7  
What s Next for McKesson 
While McKesson has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for McKesson was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 75 on  53 53 billion in revenues for the coming quarter and  13 41 on  214 42 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 41  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-01-31,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-q3-earnings-and-revenues-beat-estimates-200382275,200382275
127871,349386,MCK,Are Investors Undervaluing McKesson  MCK  Right Now ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large 
In addition to the Zacks Rank  investors looking for stocks with specific traits can utilize our Style Scores system  Of course  value investors will be most interested in the system s  Value  category  Stocks with  A  grades for Value and high Zacks Ranks are among the best value stocks available at any given moment 
One company to watch right now is McKesson  MCK   MCK is currently sporting a Zacks Rank of  2  Buy   as well as an A grade for Value  The stock is trading with a P E ratio of 9 15  which compares to its industry s average of 15 82  Over the past 52 weeks  MCK s Forward P E has been as high as 13 and as low as 7 78  with a median of 9 68 
Investors should also note that MCK holds a PEG ratio of 1 40  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  MCK s industry currently sports an average PEG of 1 76  Within the past year  MCK s PEG has been as high as 1 50 and as low as 1 12  with a median of 1 33 
We should also highlight that MCK has a P B ratio of 2 63  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  MCK s current P B looks attractive when compared to its industry s average P B of 2 85  Over the past year  MCK s P B has been as high as 3 24 and as low as 2 22  with a median of 2 68 
Finally  investors should note that MCK has a P CF ratio of 7 57  This metric takes into account a company s operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook  MCK s current P CF looks attractive when compared to its industry s average P CF of 13 55  Over the past year  MCK s P CF has been as high as 10 07 and as low as 4 59  with a median of 7 62 
These are just a handful of the figures considered in McKesson s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that MCK is an impressive value stock right now ",2019-02-03,Zacks Investment Research,https://www.investing.com/analysis/are-investors-undervaluing-mckesson-mck-right-now-200383230,200383230
127872,349387,MCK,MCK Vs  ALGN  Which Stock Should Value Investors Buy Now ,opinion,"Investors with an interest in Medical   Dental Supplies stocks have likely encountered both McKesson  MCK  and Align Technology  ALGN   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions  while our Style Scores work to identify stocks with specific traits 
Currently  McKesson has a Zacks Rank of  2  Buy   while Align Technology has a Zacks Rank of  3  Hold   The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates  so investors should rest assured that MCK has an improving earnings outlook  But this is only part of the picture for value investors 
Value investors also tend to look at a number of traditional  tried and true figures to help them find stocks that they believe are undervalued at their current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
MCK currently has a forward P E ratio of 9 49  while ALGN has a forward P E of 47 63  We also note that MCK has a PEG ratio of 1 45  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  ALGN currently has a PEG ratio of 2 21 
Another notable valuation metric for MCK is its P B ratio of 2 61  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  ALGN has a P B of 16 43 
These are just a few of the metrics contributing to MCK s Value grade of A and ALGN s Value grade of D 
MCK has seen stronger estimate revision activity and sports more attractive valuation metrics than ALGN  so it seems like value investors will conclude that MCK is the superior option right now ",2019-02-03,Zacks Investment Research,https://www.investing.com/analysis/mck-vs-algn-which-stock-should-value-investors-buy-now-200383200,200383200
127873,349388,MCK,Is McKesson Corporation  MCK  A Great Stock For Value Investors ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put McKesson Corporation   NYSE MCK   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  McKesson Corporation has a trailing twelve months PE ratio of 10 0  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 17 3  If we focus on the stock s long term PE trend  the current level puts McKesson Corporation s current PE ratio slightly below its midpoint  which is 13 5  over the past five years Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 17 7  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that McKesson Corporation has a forward PE ratio  price relative to this year s earnings  of just 9 9  so it is fair to say that a slightly more value oriented path may be ahead for McKesson Corporation s stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  McKesson Corporation has a P S ratio of 0 1  This is significantly lower than the S P 500 average  which comes in at 3 4 right now  Also  as we can see in the chart below  this is somewhat below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms    Broad Value OutlookIn aggregate  McKesson Corporation currently has a Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes MCK a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for McKesson Corporation is just 1 4  a level that is lower than the industry average of 2 1  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 4 8  which is considerably better than the industry average of 16 9  Clearly  MCK is a solid choice on the value front from multiple angles What About the Stock Overall Though McKesson Corporation might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of F and a Momentum score of D  This gives MCK a VGM score or its overarching fundamental grade of C   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen two estimates go higher in the past sixty days and three lower  while the full year estimate has seen eight upward and no downward revisions in the same time period This has had a noticeable impact on the consensus estimate  as the current quarter consensus estimate has fallen about 1 9  in the past two months  while the full year estimate has inched up 0 9   You can see the consensus estimate trend and recent price action for the stock in the chart below McKesson Corporation Price and Consensus    Despite this somewhat mixed trend  the stock has a Zacks Rank  2  Buy  on the back of its strong value metrics and this is why we are expecting above average performance from the company in the near term Bottom LineMcKesson Corporation is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Boasting a good industry rank  top 26  out of more than 250 industries  and a strong Zacks Rank  it is hard to get too excited about this company overall  Nonetheless  over the past one year  the sector has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates and analyst sentiment factors to turn favorable in this name first  but once that happens  this stock could be a compelling pick Zacks  Top 10 Stocks for 2019 In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/is-mckesson-corporation-mck-a-great-stock-for-value-investors-200388784,200388784
127887,349402,MCK,Wall Street loses gains as health stocks  oil prices slide,news,"By Abhiram Nandakumar  Reuters    Wall Street gave up early gains and were lower late on Monday morning  dragged down by health stocks and as crude prices slid further ahead of the start of the corporate earnings season  The S P materials and energy sectors were both off more than 1 percent  under pressure as oil prices fell for the sixth day in a row  U S  crude fell to  31 93  its lowest since 2003  The health sector fell the most  declining 1 38 percent  dragged down by Celgene  O CELG  and McKesson  N MCK   U S  stocks had opened higher  coming off their worst ever start to a year on mounting investor concerns about declining oil prices and a China led slowdown in global growth  Even strong December U S  nonfarm payrolls data failed to boost investor optimism   None of us know what the future is  but given this moment  where we ve gotten very conflicting data  it makes investors nervous   said Kim Forrest  senior equity research analyst at Fort Pitt Capital Group in Pittsburgh   I think the final coup de gr ce is the Federal Reserve and its tightening phase has made them even more nervous   At 11 04 a m  ET  1604 GMT   the Dow Jones industrial average was down 25 99 points  or 0 16 percent  at 16 320 46  The S P 500 was down 6 14 points  or 0 32 percent  at 1 915 89 and the Nasdaq Composite index was down 24 20 points  or 0 52 percent  at 4 619 43  The utilities sector s 0 7 percent gain led the three advancing S P sectors  Celgene fell 7 2 percent to  101 10 and McKesson dropped 9 5 percent to  165 10 after both companies gave disappointing profit forecasts  Alcoa is scheduled to report fourth quarter results after the close  unofficially starting the earnings season  The stock gave up early gains and was down 0 7 percent at  8 01  Energy and materials companies are expected to be main drivers behind U S  corporate earnings moving into a recession   two quarters of falling profits   in the quarter  Overall  fourth quarter corporate earnings are expected to decline 4 2 percent  according to Thomson Reuters I B E S  Apple was up 0 8 percent at  97 70 on reports that its music streaming service hit the 10 million subscriber mark in six months  The stock gave the biggest boost to the S P 500 and Nasdaq  Macy s was up 4 3 percent at  37 45 after Starboard Value urged the company to enter into joint ventures for its stores  Under Armour was down 8 percent to  69 01 after  Morgan Stanley   N MS  cut its rating and price target on the stock  Declining issues outnumbered advancing ones on the NYSE by 1 855 to 1 041  On the Nasdaq  1 648 issues fell and 965 rose  
The S P 500 index showed one new 52 week high and 81 new lows  while the Nasdaq recorded eight new highs and 283 lows ",2016-01-11,Reuters,"https://www.investing.com/news/stock-market-news/stock-futures-edge-up,-coming-off-worst-ever-start-to-a-year-379505",379505
127889,349404,MCK,Civil rights activist DeRay McKesson running for mayor of Baltimore,news, Reuters    U S  civil rights activist DeRay McKesson  N MCK   who was instrumental in the growth of the Black Lives Matter movement against police violence  is running for mayor of Baltimore  McKesson  who filed his paperwork minutes before Wednesday s deadline  is among more than a dozen Democrats heading to an April primary   The 30 year old son of two now recovered drug addicts  McKesson rose to prominence during the 2014 protests in Ferguson  Missouri  over the police killing of unarmed black teen Michael Brown and has become one of the nation s best known civil rights leaders  His distinctive blue Patagonia vest has been seen everywhere from street demonstrations in his native Baltimore to a recent appearance on  The Late Show with Stephen Colbert    I am not the silver bullet for the challenges of our city    no one individual is   McKesson said on Wednesday in a post on the blog publishing platform Medium    Together  with the right ideas  the right passion  the right people  we can take this city in a new direction   His rivals include former Baltimore Mayor Sheila Dixon and state Senator Catherine Pugh  The city has not elected a Republican mayor in more than 50 years  Current Mayor Stephanie Rawlings Blake said in September that she would not seek re election when her term ends  A website set up to collect contributions for McKesson s campaign had recorded 474 donations totaling  34 383 by midday Thursday  An alumnus of Maine s Bowdoin College  McKesson worked in Baltimore and Minneapolis schools before moving into full time activism   One political observer said working class Baltimore voters might hold his lack of political experience against him   The profile he has now  he s gotten from doing national work  not local work   said Lester Spence  associate professor of political science and African studies at Johns Hopkins University  Last year  the mainly black city of 600 000 people was torn by its worst riots in a half century following the death of Freddie Gray from injuries sustained while in police custody   Coming amid a string of controversial police killings across the United States  Gray s death proved a turning point when prosecutors brought charges against six officers within weeks  The first of those six trials  in which Officer William Porter faced charges including involuntary manslaughter  ended in a hung jury   That threw State s Attorney Marilyn Mosby s aggressive schedule into disarray  and a judge last month rejected prosecutors  request to order Porter to testify against his fellow officers while he awaits retrial ,2016-02-04,Reuters,https://www.investing.com/news/politics-news/u.s.-civil-rights-activist-deray-mckesson-running-for-mayor-of-baltimore-383298,383298
127892,349407,MCK,Theranos hires executives to lead regulatory and compliance push,news, Reuters    Theranos Inc hired two executives to oversee regulatory  quality and compliance standards  in a bid to turn around the struggling blood testing company after it received sanctions from U S  regulators  Dave Wurtz  who previously worked at Thermo Fisher Scientific Inc  N TMO   was appointed vice president  regulatory and quality  He will work on getting FDA clearances and approvals  marketing new products  and look into medical device quality systems  Daniel Guggenheim  who formerly served as assistant general counsel at McKesson Corp  N MCK   will be chief compliance officer  He will make sure that Theranos complies with all state and federal regulations  Theranos said its board had also created a compliance and quality committee  The company  once valued at  9 billion  was founded by Elizabeth Holmes in 2003 to develop an innovative blood testing device that would give quicker results using just one drop of blood  Its fortunes  however  waned after the Wall Street Journal published a series of articles starting in October last year that suggested the devices were flawed and inaccurate  Earlier this month  Holmes was barred from owning or operating a lab for at least two years ,2016-07-21,Reuters,https://www.investing.com/news/stock-market-news/theranos-hires-executives-to-lead-regulatory-and-compliance-push-415729,415729
127893,349408,MCK,U S  moves to block massive health insurer deals led by Anthem  Aetna,news,"By Caroline Humer and Carl O Donnell NEW YORK  Reuters    U S  antitrust officials on Thursday moved to block an unprecedented consolidation of the national health insurance market  filing suit against Anthem Inc s  N ANTM  proposed purchase of  Cigna Corp   N CI  and Aetna Inc s  N AET  planned acquisition of  Humana Inc   N HUM    The U S  Department of Justice said the two multibillion dollar mergers would reduce competition  raise prices for consumers and stifle innovation if the number of large  national insurers were to fall from five to three   It was the latest example of the Obama administration challenging massive combinations in major industries  from oilfield services to telecommunications   We will not hesitate to intervene  We will not shy away from complex cases   U S  Attorney General Loretta Lynch told a news conference on Thursday   We will protect the interests of the American people   The deals would hurt consumers in the different markets served by the four companies  from medical coverage provided by large corporations to their employees to Medicare Advantage plans for the elderly and insurance sold to individuals on exchanges created under President Barack Obama s healthcare reform law  the Justice Department said   We have no doubt that these mergers would reduce competition from what it is today   said Principal Deputy Associate Attorney General William Baer  who spearheaded the antitrust reviews  Merging Aetna s and Humana s Medicare Advantage businesses would create the largest U S  manager of the healthcare insurance for seniors and the disabled   The Anthem deal for Cigna would create the largest U S  health insurer by membership  with about 53 million members  surpassing UnitedHealth Group s  N UNH  45 9 million as of June 30  and make it the leader in employer based health insurance  Aetna and Anthem had each argued their proposed purchases would help lower prices for consumers by giving them greater leverage in negotiating with doctors and hospitals   AETNA VOWS LEGAL FIGHT Aetna and Humana said Thursday they plan  to vigorously defend the companies  pending merger   worth  33 billion  Aetna Chief Executive Mark Bertolini said the company has proposed divesting enough assets to ensure competition in markets where it overlaps with Humana   If we can t come to a negotiation on what markets to divest  although we have two very complete remedies in front of the Department of Justice now  I think I m willing to let a judge decide   Bertolini told business news channel CNBC   We ll go all the way we need to make this happen    Anthem had a more muted response  saying it was committed to working toward a settlement with the Justice Department for its  45 billion transaction  but would challenge the lawsuit if necessary  Cigna said it was evaluating its options  It does not believe a deal would close before 2017   if at all    After news of the lawsuit  Humana raised its 2016 earnings forecast  saying its core businesses  Medicare Advantage and Healthcare Services  are performing better than expected  Humana shares rose 8 3 percent  Cigna climbed 5 4 percent  Anthem closed up 2 6 percent and Aetna rose 1 6 percent  Speculation that the U S  government would block both deals had weighed on shares of all four insurers for several weeks  Humana s raised forecast  bodes well for the rest of the industry  Now you can expect the other guys to report good numbers and perhaps raise guidance as well   said Jeff Jonas  portfolio manager for Gabelli Funds  which holds Cigna and Humana shares   There s somewhat of a relief rally  too  given that this has been an overhang for so long  particularly with Anthem and Cigna   he said  CONCERN FOR DIFFERENT CONSUMERS  In the suit against Aetna  the Justice Department cited specific concerns about damage to 1 6 million people in 364 counties who are customers of Medicare Advantage  the program that serves older people   It also said there were issues for the individual plans sold on Obamacare exchanges  where the government has sought to spur competition and keep prices low  About 20 state insurance departments were required to review the Aetna Humana deal  Missouri came out firmly against it  while others  including California and New York  approved it after reaching a settlement  In the suit against Anthem Cigna  antitrust regulators said the combination would substantially lessen competition in an already consolidated industry  harming millions of Americans  doctors and hospitals  The Justice Department said it was concerned about the impact on the national corporate business  which serves large companies and which it said has only four competitors  It also said there were issues with local business markets  the individual Obamacare exchanges and the impact a combined company could have on contracts with doctors  Doctors and hospitals had urged the Justice Department to try to block the deal  and some large employers were also against the combination  Aetna and Anthem had each proposed asset sales to the regulators  but they did not adequately address the loss of market competition  Baer said  Eleven states and the District of Colombia joined the Justice Department suit against Anthem and Cigna  eight states and DC joined the suit against Aetna and Humana  If the government successfully scuttles the deals  Anthem would owe Cigna  1 85 billion in breakup fees  Aetna would have to pay Humana  1 billion  If the deals fail for other reasons  the breakup fees would be different  The unusual move against two deals in the same industry represents a repeat of history for Baer  who headed the department s Antitrust Division until a short time ago and is now the No  3 official in the Justice Department  
In March 1998  Baer asked a court to stop a major consolidation of the U S  drug wholesaling business  McKesson Corp  N MCK  had sought to buy AmeriSource Health Corp  and  Cardinal Health   N CAH  wanted to buy Bergen Brunswig Corp  A court granted the preliminary injunction ",2016-07-21,Reuters,"https://www.investing.com/news/stock-market-news/u.s.-regulators-to-block-anthem-cigna,-aetna-humana-deals-thursday:-source-415769",415769
127894,349409,MCK,Black Lives Matter activist sues Baton Rouge police over arrest,news," Reuters    A prominent activist in the Black Lives Matter movement  DeRay McKesson  NYSE MCK   on Thursday sued the chief of the Baton Rouge police department and other officials over the arrests of nearly 200 demonstrators during peaceful protests about police killings  In the federal civil rights lawsuit  which seeks class action status  McKesson and fellow protesters Kira Marrero and Gloria La Riva complained that police were unnecessarily aggressive in arresting them on July 9  The lawsuit covers arrests in the Louisiana capital between July 6 and July 11  The East Baton Rouge Parish Attorney s Office said they had no immediate comment on the lawsuit  The activists were protesting the July 5 shooting of a black man  Alton Sterling  outside a convenience store  one of a string of high profile police killings of black people by white officers over the past two years that were caught on video and reopened debate about race and discrimination in the United States  McKesson  known for his activism on social media and who ran in the 2016 Democratic Party primary for mayor of his hometown of Baltimore  Maryland  said in the lawsuit that demonstrators sought to have all arrest records expunged as well as unspecified damages  The allegations in the lawsuit include 16 violations of law by Baton Rouge police  excessive use of force  conspiracy to deprive protesters of their civil rights  negligence and arrests without probable cause   The 23 page complaint said charges of simple obstruction of a highway against nearly 200 protesters who were arrested were ultimately dropped by the local prosecutors office  though they still had to pay administrative and court fees    Throughout the protests  the Defendants responded in a militarized and aggressive manner   the complaint said   All class members now have criminal arrest records  which in this digital age could adversely affect their future employment  education  reputations  and professional licensing   A day after Sterling s death  another black man  Philando Castile  was shot to death by a policeman during a traffic stop near St  Paul  Minnesota  The back to back killings brought out protesters nationwide but after a rally in Dallas  Texas  a gunman shot dead five police officers in an ambush  Days later  three Baton Rouge police officers were also killed in an ambush   
Authorities said the shootings of officers by black gunmen were apparently in anger over the deaths of black people at the hands of police  but they were not connected to the peaceful protest movement ",2016-08-04,Reuters,https://www.investing.com/news/world-news/black-lives-matter-activist-sues-baton-rouge-police-over-arrest-418637,418637
127895,349410,MCK,McKesson FQ2 top line up 3  but shy of consensus  net income down 49   non GAAP EPS guidance lowered  shares off 11  after hours,news,McKesson  NYSE MCK  fiscal Q2 results   M   Revenues  49 957   2 5   Net Income  307   50 2    Non GAAP Net Income  393   49 4    EPS  1 36   48 9    Non GAAP EPS  1 72   48 0    CF Ops  6 mo    2 928   134 1   Fiscal 2017 Guidance  EPS   8 95   9 80  Non GAAP EPS   12 35   12 85 from  13 43   13 93 Consensus view was EPS of  3 05 on revenues of  51 2B Shares are down 11  after hours on increased volume ,2016-10-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/mckesson-fq2-top-line-up-3-but-shy-of-consensus;-net-income-down-49;-non-gaap-eps-guidance-lowered;-shares-off-11-after-hours-435408,435408
127896,349411,MCK,Drugmakers under fire for possible U S  price fixing,news,"By Deena Beasley  Reuters    Two prominent U S  lawmakers on Thursday called on federal antitrust regulators to probe whether Sanofi  PA SASY  SA  Eli Lilly and Co  Merck  NYSE MRK    Co Inc and  Novo Nordisk   CO NOVOb  A S colluded to set prices for insulin and other diabetes drugs  The request by U S  Senator Bernie Sanders and Representative Elijah Cummings follows a similar letter they sent last fall calling for an investigation into 14 drug companies over price increases of generic drugs  U S  prosecutors could file the first charges by the end of the year in their subsequent criminal investigation of generic drugmakers over suspected price collusion  Bloomberg reported on Thursday     A Justice Department spokesman declined to comment  In their latest letter to the Justice Department and Federal Trade Commission  Sanders  an independent  and Cummings  a Democrat  raised questions about skyrocketing prices for insulin  and included a chart showing that many of the price spikes appeared to occur in tandem  They noted that the original patent on insulin  a hormone used by diabetics to control blood sugar levels  expired 75 years ago  Sanofi spokeswoman Ashleigh Koss said in an emailed statement that  Sanofi sets the prices of our treatments independently   Novo Nordisk also said it sets prices  independently  and said it stands by its business practices  A spokeswoman for Merck said the company does not make insulin  Merck makes other products to treat diabetes  Eli Lilly  in an email  said it strongly disagrees with the accusations in the letter   The insulin market in the U S  is highly competitive   the pharmaceutical company said  Shares of several generic drugmakers fell on Thursday after the report of pending Justice Department charges  Mylan  NASDAQ MYL  N V  closed down 6 9 percent  Allergan  NYSE AGN pa  Plc fell 4 5 percent and Endo International Plc dropped 19 5 percent  Teva Pharmaceuticals Inc Ltd  which recently acquired Allergan s generics business  fell 9 5 percent   We do not think the major generic companies have likely participated in significant pricing collusion   A B Bernstein analyst Ronny Gal said in a research note   Several generic drugmakers  including Mylan  Allergan  Endo and Taro Pharmaceutical Industries Ltd  had previously disclosed that they were subpoenaed in connection with the antitrust investigation by the Justice Department  Bloomberg said the probe spans more than a dozen companies and about two dozen drugs  citing people familiar with the matter  Impax Laboratories Inc said earlier this year that the Justice Department had requested information on four drugs  blood pressure pill digoxin  asthma drug terbutaline sulfate  prilocaine lidocaine cream and calcipotriene solution  which is used to treat psoriasis  A spokesman from Teva said the company  is not aware of any facts that would give rise to an exposure to the company with respect to these subpoenas   Officials at Endo and Lannett Company Inc did not immediately respond to requests for comment  Aggressive drug pricing has come under intense scrutiny after Democratic presidential candidate Hillary Clinton tweeted her intent to tackle high prices last year  An August report from the Government Accountability Office found that more than 300 of 1 441 generic drugs analyzed had at least one price increase of 100 percent or more between the first quarter of 2010 and the first quarter of 2015  In February  Sanders and Cummings asked the U S  Department of Health and Human Services  enforcement arm to investigate generic drug price increases  Recent price hikes that have drawn fire included Turing Pharmaceuticals  decision in 2015 to raise by 5 000 percent the price of a decades old treatment for a dangerous parasitic infection  Generic drugmakers  possibly reacting to the political headwinds  reined in price hikes this year   Guggenheim Securities  citing polling of generic drugmakers  last month estimated that overall U S  generic drug prices would dip by a percentage in the mid single digits this year  
The price erosion has been felt by drug wholesalers like McKesson Corp  NYSE MCK  and Amerisource Bergen Corp  which rely on price fluctuations for part of their profit margins ",2016-11-03,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-under-fire-for-possible-u.s.-price-fixing-437519,437519
127897,349412,MCK,Is McKesson  MCK  A Suitable Stock For Value Investors Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put McKesson Corporation   NYSE MCK   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  McKesson has a trailing twelve months PE ratio of 9 5  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 9  If we focus on the long term PE trend  McKesson s current PE level puts it below its midpoint over the past five years  Moreover  the current level is fairly below the highs for this stock  suggesting it might be a good entry point Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 18 1  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that McKesson has a forward PE ratio  price relative to this year s earnings  of 9 5  which is in line with the current level  Hence the forward earnings estimates are already incorporated in the company s current share price P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  McKesson has a P S ratio of about 0 1  This is significantly lower than the S P 500 average  which comes in at 3 2 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  MCK is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  McKesson currently has a Zacks Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes McKesson a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for McKesson is just 1 4  a level that is lower than the industry average of 2 1  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 4 5  which is far better than the industry average of 18 8  Clearly  MCK is a solid choice on the value front from multiple angles What About the Stock Overall Though McKesson might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of B and a Momentum score of B  This gives MCK a Zacks VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current fiscal quarter has seen no estimates go higher in the past sixty days compared to six lower  while the fiscal full year estimate has seen seven upward and zero downward revisions in the same time period As a result  the current fiscal quarter consensus estimate has fallen by 2 2  in the past two months  while the fiscal full year estimate has inched up by 0 8   You can see the consensus estimate trend and recent price action for the stock in the chart below McKesson Corporation Price and Consensus    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineMcKesson is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Moreover  a strong industry rank  Top 37  out of more than 250 industries  further supports the growth potential of the stock However  with a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past three years  the industry has underperformed the broader market  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/is-mckesson-mck-a-suitable-stock-for-value-investors-now-200363974,200363974
127898,349413,MCK,Rite Aid  RAD  Stock Up On Q3 Earnings Beat  FY19 View Down,opinion,Rite Aid Corporation   NYSE RAD   reported third quarter fiscal 2019 results  wherein the top and bottom lines improved on a year over year basis  Also  earnings came ahead of the Zacks Consensus Estimate but sales lagged the same  Further  management lowered its guidance for fiscal 2019  Nevertheless  shares of the company increased almost 10  during the after market trading session on Dec 19 Q3 in DetailIn the reported quarter  Rite Aid s adjusted earnings came in at 1 cent per share  which outpaced the Zacks Consensus Estimate of a loss of 2 cents  The bottom line also came ahead of the break even earnings per share reported a year ago Revenues improved 1 8  to  5 450 1 million but missed the Zacks Consensus Estimate of  5 484 million  At the Retail Pharmacy segment  third quarter revenues rose 0 4  on account of an increase in same store sales  partly offset by store closures  At the Pharmacy Services segment  the same metric increased 5 6  owing to increased Medicare Part D membership Rite Aid Corporation Price  Consensus and EPS Surprise   Retail Pharmacy same store sales improved 1 6   courtesy of a 3 1  increase in pharmacy sales and a 1 5  decrease in front end sales  Notably  Pharmacy sales included a negative impact of nearly 108 basis points  bps  from the introduction of new generic drugs  Further  prescription count at comparable stores advanced 2 4   Prescription sales constituted 67 6  of total drugstore sales Backed by increased pharmacy gross profit owing to rise in script count  Rite Aid s adjusted EBITDA improved 0 5  year over year to  142 8 million  This was offset by lower front end gross profit and rise in distribution costs related with the divestiture of a distribution center to Walgreens Boots Alliance   NASDAQ WBA    Meanwhile  adjusted EBITDA margin declined almost 10 basis points to 2 6  Further  adjusted EBITDA at the Retail Pharmacy Segment totaled  101 2 million depicting a 0 5  decline from the prior year quarter s tally  At the Pharmacy Services Segment  the same amounted to  41 6 million  reflecting a rise of almost 3  Store UpdateRite Aid that shares space with CVS Health Corporation   NYSE CVS    renovated 21 stores in the fiscal third quarter  bringing the company s total wellness store count to 1 748  Further  it shuttered one store during the reported quarter  consequently taking the store count to 2 525 as of Dec 1  2018 Other DevelopmentsIn a separate press release  Rite Aid and McKesson Corporation   NYSE MCK   announced an agreement to continue the pharmaceutical sourcing and distribution partnership for an additional 10 years through March 2029  Per the terms of the deal  McKesson will continue providing Rite Aid with sourcing and direct to store delivery for brand and generic pharmaceutical products  The partnership will provide Rite Aid with a combination of competitive drug pricing and operational flexibility  which will enhance shareholder value Financial StatusRite Aid ended the fiscal third quarter with cash and cash equivalents of approximately  410 million  long term debt  net of current maturities  of  3 394 5 million and total shareholders  equity of  1 453 4 million Further  the company generated cash of  351 1 million from operating activities as of Dec 1  2018 OutlookRite Aid lowered its sales  same store sales  adjusted EBITDA and earnings view and reiterated its capital expenditure forecasts for fiscal 2019  The company lowered its net loss expectations as well For fiscal 2019  Rite Aid continues to estimate sales of  21 8  21 95 billion  with comps anticipated to increase in the range of 0 5 1   Adjusted EBITDA is projected to be  545  570 million  The company continues to anticipate capital expenditure of nearly  250 million for the fiscal year Earlier  Rite Aid had anticipated fiscal 2019 sales of  21 7  22 1 billion  with comps anticipated in the range of flat to up 1   Adjusted EBITDA was projected to be  540  590 million Rite Aid now projects adjusted net  loss  income per share between a loss of 3 cents and loss of 1 cent compared with the prior guidance of adjusted net loss per share of 3 cents to income of 1 cent Price PerformanceIn the past three months  this Zacks Rank  3  Hold  stock has plunged 35 1   underperforming the  s 5 7  decline You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-stock-up-on-q3-earnings-beat-fy19-view-down-200369866,200369866
127899,349414,MCK,Genpact  G  Extends Multiyear Relationship With McKesson,opinion,Genpact Limited   NYSE G   and McKesson   NYSE MCK   yesterday announced the extension of their existing relationship  McKesson has been receiving support for financial operations for several years through this relationship Through the renewed tie up  Genpact will deploy digitally enabled advanced technologies such as Artificial Intelligence  AI  and machine learning to simplify and standardize McKesson s finance operations  Genpact s technology contribution will be reflected in McKesson s Order to Cash  Record to Report  Contract Management  Master Data Management  and Source to Pay processes The broader goal is to accelerate McKesson s operating model and cost structure program redesign that are parts of the company s multi year strategic growth initiative  The companies will jointly implement the redesigns We observe that Genpact shares have declined 7 4  in the past three months compared with the 14 2  decline of the  Our TakeThe relationship is based on a combination of Genpact s deep operations optimization experience and McKesson s operational excellence Genpact Limited Revenue  TTM    It is a prime example of how Genpact is utilizing strong position in analytics and digital technologies and deep domain expertise to improve and expand offerings  Expansion of the relationship is likely to help expand Genpact s offerings to the healthcare industry Zacks Rank   Other Stocks to ConsiderCurrently  Genpact carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader  sector are Republic Services   NYSE G   and Waste Connections   NYSE WCN    each carrying a Zacks Rank  2  You can see  Long term expected EPS  three to five years  growth rate for Republic Services and Waste Connections is 10 7  and 11 7   respectively Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/genpact-g-extends-multiyear-relationship-with-mckesson-200373675,200373675
127900,349415,MCK,Why McKesson  MCK  Could Beat Earnings Estimates Again,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering McKesson  MCK   which belongs to the Zacks Medical   Dental Supplies industry 
When looking at the last two reports  this prescription drug distributor has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 5 05   on average  in the last two quarters 
For the last reported quarter  McKesson came out with earnings of  3 60 per share versus the Zacks Consensus Estimate of  3 28 per share  representing a surprise of 9 76   For the previous quarter  the company was expected to post earnings of  2 89 per share and it actually produced earnings of  2 90 per share  delivering a surprise of 0 35  
Price and EPS Surprise

For McKesson  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
McKesson currently has an Earnings ESP of  2 76   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  4  Sell  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on January 31  2019 
With the Earnings ESP metric  it s important to note that a negative value reduces its predictive power  however  a negative Earnings ESP does not indicate an earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-01-09,Zacks Investment Research,https://www.investing.com/analysis/why-mckesson-mck-could-beat-earnings-estimates-again-200374535,200374535
127901,349416,MCK, Here s Why Investors Should Hold McKesson  MCK  Stock Now,opinion,McKesson Corporation   NYSE MCK   is expected to benefit from the multi year strategic growth initiative for generating approximately  300  400 million in annual pre tax gross savings  However  regulatory headwinds in the United Kingdom and Canada have been strong deterrents Over the past year  shares of this Zacks Rank  3  Hold  company have lost 24 8   wider than the  s decline of 14 6   The current level is also more than the S P 500 index s decline of 6 4  only Here we take a quick look at the primary factors that have been plaguing McKesson and henceforth  discuss the company s prospects that ensure the stock s near term recovery Global Concerns Weigh on McKessonIn Canada  McKesson s Rexall business faced some challenges in the recent past  Developmental actions taken last year are not materializing as fast as the company anticipated  thereby resulting in a weak performance Per management  reimbursement and minimum wage headwinds impact the entire Canadian supply chain and retail pharmacy operations extensively  Similar woes prevail in the United Kingdom  which have affected the company s fiscal 2019 performance Moreover  the company apprehends the hindrances to persist in the quarters ahead  In fact  the company s European Pharmaceutical Solutions revenues were  6 6 billion for the second quarter of fiscal 2019  down 2  due to a negative impact of  68 million from currency rate movements Why Should Investors Hold McKesson McKesson is a major player in the pharmaceutical and medical supplies distribution market The company s distribution solutions segment kept up its performance in fiscal 2018 despite lower pricing trends and customer consolidation  The Distribution Solutions segment caters to a wide range of customers and businesses and stands to benefit from an increased generic utilization  inflation in generics  driven by several patent expirations in the next few years and an aging population At the end of second quarter fiscal 2019  Plasma and Biologics distribution business witnessed solid growth  As a whole  revenue uptick from distribution solutions business rose significantly  contributing to the company s entire revenue stream  The upside is attributable to market growth and acquisitions Which Way are Estimates Headed For the third quarter of fiscal 2019  the Zacks Consensus Estimate for earnings is pegged at  3 17 per share  Same for the revenues is pegged at  55 27 billion  showing a 3 1  improvement year over year For fiscal 2019  the Zacks Consensus Estimate for revenues stands at  214 42 billion  reflecting a year over year rise of 2 9   Same for earnings is pegged at  13 41  reflecting growth of 6 3  year over year McKesson Corporation Price and Consensus    Key PicksA few better ranked stocks in the broader medical space are Veeva Systems Inc   NYSE VEEV    Integer Holdings Corporation   NYSE ITGR   and OPKO Health  Inc   NASDAQ OPK   Veeva Systems  long term earnings growth rate is projected at 19 5   The stock currently sports a Zacks Rank  1  Strong Buy   You can see  Integer surpassed the Zacks Consensus Estimate in the trailing four reported quarters  the average being 9 7   It currently carries a Zacks Rank  2  Buy  OPKO Health s long term earnings growth rate is predicted at 12   The stock has a Zacks Rank of 1 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2019-01-13,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-hold-mckesson-mck-stock-now-200375275,200375275
127902,349417,MCK,Rite Aid  RAD  Up 14 2  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Rite Aid  RAD   Shares have added about 14 2  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Rite Aid due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Rite Aid Q3 Earnings Beat  FY19 View NarrowedRite Aid Corporation reported third quarter fiscal 2019 results  wherein the top and bottom lines improved on a year over year basis  Also  earnings came ahead of the Zacks Consensus Estimate but sales lagged the same  Further  management narrowed its guidance for fiscal 2019 Q3 in DetailIn the reported quarter  Rite Aid s adjusted earnings came in at 1 cent per share  which outpaced the Zacks Consensus Estimate of a loss of 2 cents  The bottom line also came ahead of the break even earnings per share reported a year ago Revenues improved 1 8  to  5 450 1 million but missed the Zacks Consensus Estimate of  5 484 million  At the Retail Pharmacy segment  third quarter revenues rose 0 4  on account of an increase in same store sales  partly offset by store closures  At the Pharmacy Services segment  the same metric increased 5 6  owing to increased Medicare Part D membership Retail Pharmacy same store sales improved 1 6   courtesy of a 3 1  increase in pharmacy sales and a 1 5  decrease in front end sales  Notably  Pharmacy sales included a negative impact of nearly 108 basis points  bps  from the introduction of new generic drugs  Further  prescription count at comparable stores advanced 2 4   Prescription sales constituted 67 6  of total drugstore sales Backed by increased pharmacy gross profit owing to rise in script count  Rite Aid s adjusted EBITDA improved 0 5  year over year to  142 8 million  This was offset by lower front end gross profit and rise in distribution costs related with the divestiture of a distribution center to Walgreens Boots Alliance  NASDAQ WBA   Meanwhile  adjusted EBITDA margin declined almost 10 basis points to 2 6   Further  adjusted EBITDA at the Retail Pharmacy Segment totaled  101 2 million depicting a 0 5  decline from the prior year quarter s tally  At the Pharmacy Services Segment  the same amounted to  41 6 million  reflecting a rise of almost 3  Store UpdateRite Aid renovated 21 stores in the fiscal third quarter  bringing the company s total wellness store count to 1 748  Further  it shuttered one store during the reported quarter  consequently taking the store count to 2 525 as of Dec 1  2018 Other DevelopmentsIn a separate press release  Rite Aid and McKesson Corporation  NYSE MCK  announced an agreement to continue the pharmaceutical sourcing and distribution partnership for an additional 10 years through March 2029  Per the terms of the deal  McKesson will continue providing Rite Aid with sourcing and direct to store delivery for brand and generic pharmaceutical products  The partnership will provide Rite Aid with a combination of competitive drug pricing and operational flexibility  which will enhance shareholder value Financial StatusRite Aid ended the fiscal third quarter with cash and cash equivalents of approximately  410 million  long term debt  net of current maturities  of  3 394 5 million and total shareholders  equity of  1 453 4 million Further  the company generated cash of  351 1 million from operating activities as of Dec 1  2018 OutlookRite Aid narrowed its sales  same store sales  adjusted EBITDA and earnings view and reiterated its capital expenditure forecasts for fiscal 2019  The company narrowed its net loss expectations as well For fiscal 2019  Rite Aid now estimates sales of  21 8  21 95 billion  with comps anticipated to increase in the range of 0 5 1   Adjusted EBITDA is projected to be  545  570 million  The company continues to anticipate capital expenditure of nearly  250 million for the fiscal year Earlier  Rite Aid had anticipated fiscal 2019 sales of  21 7  22 1 billion  with comps anticipated in the range of flat to up 1   Adjusted EBITDA was projected to be  540  590 million Rite Aid now projects adjusted net  loss  income per share between a loss of 3 cents and loss of 1 cent compared with the prior guidance of adjusted net loss per share of 3 cents to income of 1 cent 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  400  due to these changes 
VGM Scores
Currently  Rite Aid has a great Growth Score of A  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Rite Aid has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-up-142-since-last-earnings-report-can-it-continue-200377082,200377082
127903,349418,MCK,Earnings Preview  McKesson  MCK  Q3 Earnings Expected To Decline,opinion,"Wall Street expects a year over year decline in earnings on higher revenues when McKesson  MCK  reports results for the quarter ended December 2018  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on January 31  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This prescription drug distributor is expected to post quarterly earnings of  3 18 per share in its upcoming report  which represents a year over year change of  6 7  
Revenues are expected to be  55 27 billion  up 3 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 09  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for McKesson 
For McKesson  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 08  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that McKesson will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that McKesson would post earnings of  3 28 per share when it actually produced earnings of  3 60  delivering a surprise of  9 76  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
McKesson doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-23,Zacks Investment Research,https://www.investing.com/analysis/earnings-preview-mckesson-mck-q3-earnings-expected-to-decline-200378943,200378943
127925,349440,MCK,Police swarm home in St Louis suburb after  ambush  of two officers,news,"By Kate Munsch FERGUSON  Mo   Reuters    The shooting of two police officers in Ferguson  Missouri  during a protest rally sparked an intense manhunt on Thursday and ratcheted up tensions in a city at the center of a national debate over race and policing  U S  President Barack Obama and Attorney General Eric Holder condemned the attack on the men  who were treated at a local hospital and released  as law enforcement officers in tactical gear swarmed a home in the St  Louis suburb  looking for a suspect  Television images showed officers on the roof breaking into the attic with heavy tools  Shawn McGuire  a St  Louis County police spokesman  said people were taken from the house but there have been no arrests so far  He would not confirm media reports that two men and a woman were led away  Long simmering tensions between African Americans and Ferguson s mostly white police force came to a boil in August when a white policeman killed an unarmed black teenager  The shooting of 18 year old Michael Brown led to a coast to coast wave of demonstrations last year  The rally on Wednesday evening was called hours after the resignation of Ferguson s long criticized police chief  Tom Jackson  but activists demanded more changes  Jackson quit in the wake of a scathing U S  Justice Department report released last week finding his force was rife with racial bias   Around midnight  gunfire rang out  leaving a 41 year old St  Louis County Police officer with a shoulder wound and a 32 year  old officer from nearby Webster Groves Police Department with a bullet lodged near his ear  St  Louis County Police Chief Jon Belmar said   This is really an ambush  is what it is   Belmar said   You can t see it coming  You don t understand that it s going to happen   The shootings were  inexcusable and repugnant   Holder said in a statement   Such senseless acts of violence threaten the very reforms that nonviolent protesters in Ferguson and around the country have been working towards   The White House sent a Tweet that read   Violence against police is unacceptable  Our prayers are with the officers in MO  Path to justice is one all of us must travel together   Belmar told a news conference authorities had possible leads in finding whoever was responsible  He said the shooter used a handgun and shell casings had been recovered   This is No  1 priority of St  Louis County police to identify that individual or individuals   said Belmar  who leads the police force in the county that includes Ferguson  Officers did not return fire but may shoot back in future  he said   I have said all along that we cannot sustain this forever without problems   he said  referring to festering tensions in the city since Brown s death  The shooting incident came less than three months after a man ambushed and killed two New York City patrolmen  saying he sought to avenge the killings of Brown and an unarmed black man in New York City  In both cases  grand juries decided against bringing criminal charges   We reject any kind of violence directed toward members of law enforcement   Brown s family said in a statement   We specifically denounce the actions of stand alone agitators who unsuccessfully attempt to derail the otherwise peaceful and non violent movement that has emerged throughout this nation to confront police brutality   Police and protesters appeared to disagree about where the shots came from  with Belmar asserting they came from the middle of the crowd gathered in front of police headquarters   I don t know who did the shooting      but somehow they were embedded in that group of folks   Belmar said  Protesters at the scene insisted on social media that the shots came from further away   The shooter was not with the protesters  The shooter was atop the hill   activist DeRay McKesson  NYSE MCK  said on Twitter   I was here  I saw the officer fall  The shot came from at least 500 feet away from the officers   he said  A string of Ferguson officials quit after the Justice Department report  which found the city used police as a collection agency  issuing traffic citations to black residents to boost its coffers  resulting in a  toxic environment   McKesson said many were not satisfied with the police chief s resignation and wanted Ferguson Mayor James Knowles to step down too  
After the report  Holder said the federal government would demand police reforms in Ferguson  including possibly dismantling the department ",2015-03-12,Reuters,https://www.investing.com/news/world-news/gunfire-heard-at-protest-outside-ferguson-police-department-332010,332010
127926,349441,MCK,U S  CEO retirement packages  Bigger than yours ,news,"By Mark Miller CHICAGO  Reuters    Most fast food workers do not earn enough to retire with much of a pension  Then there is David Novak  executive chairman of YUM Brands  N YUM   the conglomerate that runs Taco Bell  Pizza Hut  and KFC outlets  Novak s total retirement holdings  including deferred compensation  are worth  234 million   more than any other Fortune 500 chief executive  Novak tops the list of Fortune 500 CEOs with the largest retirement nest eggs  according to a study from two progressive think tanks   the Center for Effective Government and the Institute for Policy Studies  Their data comes from Security   Exchange Commission filings for the 500 largest public companies  The figures are stunning and cast a harsh and troubling light on soaring retirement inequality  The report offers yet another indication that runaway income inequality is producing grossly unfair retirement outcomes  The top CEO retirement accounts are worth a combined  4 9 billion   equal to the total retirement account savings of the 41 percent of all American households with the lowest retirement wealth  according to the study  Among all Fortune 500 CEOs  the typical value is  17 7 million  That includes the present value of defined benefit pensions  401 k  account balances and other deferred compensation  John Hammergren  CEO of drug wholesaler McKesson Corp  N MCK    which froze its employee pension fund in 1996   has the largest Fortune 500 pension account  valued at  114 million   McKesson declined to comment  A spokeswoman for YUM noted its stock appreciated 900 percent during Novak s tenure   THE REST OF US The CEO numbers are a stark contrast to the rest of us  In 2013  pre retirement households  age 55 64  with annual income below  39 000 had median total retirement savings of  13 000 in 401 k  and IRA accounts  according to the Center for Retirement Research  Middle class households  income from  61 000 to  100 000  had median savings of  100 000  Only in the highest income band   138 000 or more  were accumulations significant  at a median of  452 000  Changes in our retirement benefit structure play a big role in account balances   especially the sharp decline in the share of private sector workers receiving traditional defined benefit pensions   In the past decade  54 Fortune 500 companies changed their defined benefit pension plans  according to the Pension Rights Center   either reducing benefits  freezing plans or closing them to new hires  or terminating them altogether   Growth in CEO pay itself is one factor  along with the shift of employees out of defined benefit plans to less costly 401 k  plans  which have less risk for the employer   says Scott Klinger  director of revenue and spending policies at the Center for Effective Government and co author of the report  The growing mountain of evidence on retirement inequality is adding to momentum to change national retirement policies in favor of middle and lower income households  The starting point should be an expansion of Social Security to boost benefits for middle  and lower income workers  an idea embraced by people like Democratic presidential candidate Bernie Sanders  Nothing else would have a broader  bigger impact   Beyond that  we need to make access to workplace retirement saving universal  The Obama administration s recent move to clear the path for states to create their own universal auto IRA plans is a good start  The financial services industry opposes these programs on ideological grounds   mainly because they are seen as government mandates   MANDATORY SAVING Even so  opposition is loosening a bit  That was clear in a remarkable speech this month by Tony James  president of Blackstone  N BX    one of the world s largest private equity firms  James issued a call for a universal  mandatory system of saving for all workers who do not currently have access to a workplace plan   Specifically  he endorsed the Guaranteed Retirement Account  GRA   which is the brainchild of Teresa Ghilarducci  a labor economist at the New School for Social Research in New York City  The GRA calls for mandatory worker and employer contributions to a low cost  professionally managed account    There is really no alternative  it has to be mandated   James said   I know that can be a politically loaded word these days  but I assure you that nothing short of a mandate will provide future generations of Americans enough income for a secure retirement   Blackstone is not run by fire breathing liberals  Its founders are deficit hawk in chief Peter Peterson and Stephen Schwarzman  who several years ago infamously compared an Obama plan to raise taxes on carried interest taxes to the 1939 Nazi invasion of Poland  
Even Ghilarducci thinks positive movement might be coming   I never thought 25 years ago we d be talking about Social Security expansion   but here we are  ",2015-10-28,Reuters,https://www.investing.com/news/stock-market-news/u.s.-ceo-retirement-packages:-bigger-than-yours-368354,368354
127927,349442,MCK,McKesson Stock Price And Research  NYSE  MCK   Strong Buy,opinion,"McKesson  NYSE MCK  is a large cap company that operates within the health care providers and services industry  Its market cap is  30 billion today and the total one year return is 2 87  for shareholders 
McKesson stock is underperforming the market  It s beaten down  but it reports earnings soon  So is it a good time to buy  To answer this question  we ve turned to the Investment U Stock Grader  Our research team built this system to diagnose the financial health of a company 
Our system looks at six key metrics 
  Earnings per Share   EPS  Growth  McKesson reported a recent EPS growth rate of 50 17   That s above the health care providers and services industry average of 21 85   That s a great sign  McKesson s earnings growth is outpacing competitors 
  Price to Earnings   P E   The average price to earnings ratio of the health care providers and services industry is 33 17  And McKesson s ratio comes in at 18 45  It s trading at a better value than many of its competitors 
  Debt to Equity   The debt to equity ratio for McKesson stock is 65 59   That s below the health care providers and services industry average of 67 17   That s a good sign  McKesson s debt levels are not out of control 
  Free Cash Flow per Share Growth   McKesson has decreased its FCF per share over the last year relative to its competitors  That s not good for investors  In general  if a company is growing its FCF  it will be able to pay down debt  buy back stock  pay out more in dividends and or invest money back into the business to help boost growth 
  Profit Margins   The profit margin of McKesson comes in at 1 68  today  And generally  the higher  the better  We also like to see this ratio above competitors  McKesson s profit margin is above the health care providers and services average of  2 93   So that s a positive indicator for investors 
  Return on Equity   Return on equity gives us a look at the amount of net income returned to shareholders  The ROE for McKesson is 49 43  and that s above the industry average ROE of 13 13  
McKesson stock passes five of our six key metrics today  That s why our Investment U Stock Grader gives it a Strong Buy ",2018-05-09,Investment U,https://www.investing.com/analysis/mckesson-stock-price-and-research-nyse-mck-200314494,200314494
127928,349443,MCK,Company News For May 25  2018,opinion,Hormel Foods Corporation s   NYSE HRL   shares declined 1 1  after reporting fiscal second quarter 2018 adjusted earnings of  0 44 per share  missing the Zacks Consensus Estimate of  0 45 per shareShares of Medtronic plc   NYSE MDT   surged 2  after reporting fiscal fourth quarter 2018 adjusted earnings  1 42 per share  beating the Zacks Consensus Estimate of  1 38 per shareMcKesson Corporation s   NYSE MCK   shares fell 3  after reporting fourth quarter fiscal 2018 earnings of  3 49 per share  missing the Zacks Consensus Estimate of  3 54 per shareShares of Williams Sonoma  Inc    NYSE WSM   increased 5 7  after reporting first quarter fiscal 2018 adjusted earnings of  0 67 per share  surpassing the Zacks Consensus Estimate of  0 57 per share,2018-05-24,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-may-25-2018-200319344,200319344
127929,349444,MCK,Why Is Allscripts Healthcare  MDRX  Up 9 8  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Allscripts Healthcare Solutions  Inc    NASDAQ MDRX    Shares have added about 9 8  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is MDRX due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsAllscripts Healthcare posted first quarter 2018 adjusted earnings per share of 16 cents per share  missing the Zacks Consensus Estimate by a penny  However  earnings improved from the year ago figure of 13 cents Revenues came in at  519 million  lagging the Zacks Consensus Estimate by 2 3   However  revenues improved 25  year over year In the quarter under review  bookings grew 6 3  to  304 million Segment DetailsSoftware delivery  Support and MaintenanceRevenues in this segment totaled  329 8 million  up 23  on a year over year basis  Per management  recurring software revenues consisting of subscriptions  recurring transactions  support and new maintenance increased 30   year over year  A large partof this growth was driven by consolidation of the EIS business Client servicesRevenues in the segment came in at  184 2 million  up 26 8   Recurring service revenues increased 20  year over year  driven by the addition of EIS  revenue cycle services and other multiyear service offerings MarginsGross margin in the first quarter was 47 3   compared with47 5  in the prior year quarter Total operating expenses was  182 million  up 29  on a year over year basis  The rise can be attributed to the EIS business acquisition from McKesson Corporation  NYSE MCK   Additionally  the company recorded  24 million of legal  transaction related and other costs in the quarter under review Adjusted EBITDA totaled  96 million in the first quarter Financial ConditionAllscripts exited the quarter with a cash flow of  58 million  compared with 76 million in the year ago quarter  Free cash flow totaled  17 million  down 37  on a year over year basis Stock Repurchase UpdateStock repurchases totaled  58 million in the first quarter of 2018 GuidanceFor 2018  Allscripts anticipates revenues between  2 15 billion and  2 25 billion  up 17 22  from2017  The Zacks Consensus Estimate for 2018 revenues is pegged at  2 2 billion  within the expected range Earnings per share areexpected between 72 cents and 82 cents  which reflects an increase of 16 32  year over year  The Zacks Consensus Estimate for earnings is pinned at 77 cents  within the guidedrange Adjusted EBITDA is expected in the range of  420 460 million  up 12 23  year over year 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been two revisions higher for the current quarter compared to eight lower Allscripts Healthcare Solutions  Inc  Price and Consensus    VGM Scores
At this time  MDRX has a nice Growth Score of B  though it is lagging a lot on the momentum front with a D  The stock was also allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Zacks  style scores indicate that the company s stock is suitable for value and growth investors 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  MDRX has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-allscripts-healthcare-mdrx-up-98-since-its-last-earnings-report-200321782,200321782
127946,349461,MCK,The Zacks Analyst Blog Highlights  Lockheed Martin  Mastercard  Colgate  Electronic Arts And McKesson,opinion,For Immediate ReleaseChicago  IL   February 5  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Lockheed Martin   NYSE LMT    Mastercard   NYSE MA    Colgate   NYSE CL    Electronic Arts   NASDAQ EA   and McKesson   NYSE MCK   Here are highlights from Friday s Analyst Blog  Top Stock Reports for Lockheed Martin  Mastercard and ColgateThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Lockheed Martin  Mastercard and Colgate  These research reports have been hand picked from the roughly 70 reports published by our analyst team today Strong Buy rated Lockheed Martin s shares have gained  40 4  over the last one year  underperforming the Zacks Aerospace Defense sector  which has gained  60 8  over the same period  However  Lockheed Martin ended 2017 on a solid note  Its fourth quarter earnings as well as revenue figures comfortably exceeded expectations The recent tax reform adopted by the U S  government had an adverse impact on the company s year over year earnings growth  while revenues reflected an uptick  The Zacks analyst emphasizes that being the largest defense contractor in the world  Lockheed Martin experiences strong demand for high end military equipment in both domestic as well as overseas markets Strong order growth has been a primary growth driver for this company  The latest  7 billion deal for the sustainment of F 22 air vehicle is one such order  Lockheed Martin continues to be a strong cash generator  helping it to take important cash deployment decisions  However  the F 35 program  despite being a prime defense project for the U S  government  has been facing criticism for being overtly expensive  for past few years Shares of Mastercard have gained  62 3  over the past one year  outperforming the Zacks Financial Transaction Services industry which has gained  43 3  over the same period  Mastercard s fourth quarter earnings beat expectations  driven by higher switched transactions  increase in cross border volume and gross dollar volume as well as gains from acquisitions  An increase in rebates and incentives from the prior year quarter was a partial dampener The Zacks analyst likes Mastercard s solid market position  ongoing expansion and digital initiatives  Further  there are significant opportunities from the secular shift toward electronic payments  The acquisitions of VocaLink and NuData Security complement the company s efforts to participate in new payment flows and enhance its safety and security offerings  However  it continues to face increasing costs  Also  higher incentives and rewards will put pressure on the bottom line Colgate s shares are up  11 2  over the last one year  outperforming the Zacks Consumer Staples sector  which has gained  10 5  over the same period  The Zacks analyst likes the progress on the Global Growth and Efficiency Program along with additional savings anticipated from the recent expansion of the program Moreover  the company has been infamous with investors for its meet or beat earnings track record  Notably  it delivered in line earnings for the third consecutive quarter in fourth quarter 2017  However  margins continue to be strained due to higher raw material and packaging costs  as well as advertising expenses  It anticipates advertising costs to remain high in 2018  which should hurt operating margin Colgate expects the backdrop to remain challenging in 2018 due to uncertain global markets and slowing category growth worldwide  Nonetheless  it remains confident of the brand building and productivity maximization initiatives  which are likely to boost results Other noteworthy reports we are featuring today include Electronic Arts and McKesson Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2018-02-04,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-lockheed-martin-mastercard-colgate-electronic-arts-and-mckesson-200287020,200287020
127948,349463,MCK,Cerner Centrus Health To Collaborate  HealtheIntent In Focus,opinion,In a bid to improve healthcare delivery and cost efficiency across the Kansas City community  Cerner Corporation   NASDAQ CERN   will collaborate with Centrus Health Centrus Health will leverage on Cerner s HealtheIntent population health management platform to coordinate and manage healthcare across Kansas City  Notably  Centrus Health is a clinically integrated  physician led network  which comprises more than 1 600 physicians across Kansas City Lately  Cerner has been dominating the headlines owing to its efforts to digitize electronic health record systems  Cerner follows a strategy of acquiring and collaborating with complementary businesses that enable the company to expand solutions  device offerings and services as well as grow market share and client base In this regard  the company s recent collaboration with Salesforce  the global leader in customer relationship management  CRM  deserves a mention  read more    Cerner Corporation Price    HealtheIntent in FocusCerner s HealtheIntent is a big data platform  which provides the company with significant exposure to the ongoing Artificial Intelligence  AI  trends in the medical world HealthIntent can fetch data from any electronic health record systems and other data sources like pharmacy benefits managers or insurance claims  This population health management platform also facilitates high performing networks to empower health care stakeholders globally  It is completely cloud based At the end of the fourth quarter  management announced that developments like these are likely to increase the company s operating costs  The company expects higher R D investments as well Market PotentialUndoubtedly  Cerner has been banking on its Population Health platform a lot to gain solid traction in MedTech and the HCIT  Healthcare   Information Technology  markets  Per a research report by Markets And Markets  the population health management market is estimated to reach  42 54 billion by 2021  at a CAGR of 25 2  in the next five years  2016 2021   Other than Cerner  McKesson Corporation   NYSE MCK   is a major player in the space However  the market for HCIT solutions  devices and services is intensely competitive  fast evolving and subject to rapid technological change  Intense competition in the space may dent the company s pricing and margins Price PerformanceIn the past year  Cerner s shares have gained 17 8  compared with the  s rally of 18 3   Regulatory headwinds and cutthroat competition have dented the performance Zacks Rank   Key PicksCerner has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are MEDNAX  Inc    NYSE MD   and athenahealth  Inc    NASDAQ ATHN    The stocks sport a Zacks Rank  1  Strong Buy   You can see athenahealth has a projected long term growth rate of 20 7   The stock delivered a positive earnings surprise of 73 4  in the last quarter MEDNAX has an expected long term growth rate of 10   The stock delivered a positive earnings surprise of 3 6  in the last quarter Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-06,Zacks Investment Research,https://www.investing.com/analysis/cernercentrus-health-to-collaborate-healtheintent-in-focus-200296342,200296342
127949,349464,MCK,Is McKesson Corporation  MCK  A Suitable Value Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put McKesson Corporation   NYSE MCK   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  McKesson has a trailing twelve months PE ratio of 11 3  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 9  If we focus on the long term PE trend  McKesson s current PE level puts it below its midpoint over the past five years  with the number having fallen over the past few months  Moreover  the current level is fairly below the highs for this stock  suggesting it might be a good entry point Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 18 9  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that McKesson has a forward PE ratio  price relative to this year s earnings  of 11 2  so it is fair to say that a slightly more value oriented path may be ahead for McKesson stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  McKesson has a P S ratio of about 0 1  This is significantly lower than the S P 500 average  which comes in at 3 4 right now  Also  as we can see in the chart below  this is below the highs for this stock in particular over the past few years If anything  MCK is almost in line with the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  McKesson currently has a Zacks Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes McKesson a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for McKesson is 1 4  a level that is lower than the industry average of 1 8  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 8 0  which is far better than the industry average of 12 4  Clearly  MCK is a solid choice on the value front from multiple angles What About the Stock Overall Though McKesson might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of C and a Momentum score of C  This gives MCK a Zacks VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current fiscal quarter has seen two estimates go higher in the past sixty days compared to five lower  while the fiscal full year estimate has seen nine upward and zero downward revisions in the same time period As a result  the current fiscal quarter consensus estimate has fallen by 2 5  in the past two months  while the fiscal full year estimate has risen by 3 7   You can see the consensus estimate trend and recent price action for the stock in the chart below McKesson Corporation Price and Consensus    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineMcKesson is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  among the bottom 17   and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past two years  its industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates  analyst sentiment and broader factors to turn around in this name first  but once that happens  this stock could be a compelling pick Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-03-22,Zacks Investment Research,https://www.investing.com/analysis/is-mckesson-corporation-mck-a-suitable-value-stock-now-200300305,200300305
127970,349485,MCK,CVS Health s  CVS  Outlook For 2018 Cheered By Investors,opinion,"Shares of CVS Health   NYSE CVS   rose 2 64  in the last trading session to close at  75 13  following the company s announcement of a promising 2018 earnings outlook Per management  banking on solid growth in scripts and claims  increasing purchasing power due to the Red Oak venture  and rising net benefits from the company s reorganization initiative  CVS Health expects to witness net revenue growth in the range of 0 75 2 5  for full year 2018  However  the Zacks Consensus Estimate for 2018 revenues is pegged at  192 07 billion  which signifies growth of 4 4  year over year Segment Wise OutlookCVS Health has also been striving to return to growth in the Retail LTC business  Management claims that the company is focused on working with all payers to drive volumes and capture market share in 2018 and beyond  Notably  it has been expanding partnerships with PBMs and health plans  and increasing participation as a preferred pharmacy in a larger number of Medicare Part D networks  Thus  for 2018  the company projects revenue growth in the range of 2 5 4  in this space  led by growth of 6 7  in the same store script  Moreover  CVS Health estimates same store sales to vary in the range of 2 3 5  CVS Health expects to witness revenue growth of 1 5 3 5  in the Pharmacy Services segment with growth of roughly 8   However  management of rebates for Aetna s Medicare Part D business  a projected rise in generic specialty introductions  prevalent pricing pressures and decreased levels of brand inflation are expected to adversely impact this segment in 2018 2018 Operating Profit ForecastThis leading provider of integrated services across the entire spectrum of pharmacy care expects adjusted consolidated operating profit growth in the band of 1 4  in 2018  Notably  the company expects to record low single digit adjusted operating profit growth in Retail  Long Term Care  LTC  segment  along with a low  to mid single digit growth in the Pharmacy Services business However  the operating profit growth in 2018 might be adversely impacted by around 125 basis points  bps  due to the costs associated with the following two deals inked by the company of late  To begin with  the company s divestiture of the provider of tailored services to pharmaceutical and biotechnology manufacturers   RxCrossroads   to McKesson Corporation   NYSE MCK   for a cash deal valued around  735 million  Secondly  the company recently inked a five year agreement with Anthem  Inc  to provide services  including claims processing and prescription fulfillment to support IngenioRx  a new PBM  Notably  the agreement will be implemented on Jan 1  2020  and will run through Dec 31  2024 However  this guidance assumes the company s major Aetna   NYSE AET   acquisition deal to close at the end of 2018 instead of the second half  subject to approval by the company s shareholders  regulatory bodies as well as fulfillment of certain other customary closing conditions  Thus  all the takeover related expenses will not be included in the company s adjusted figures Notably  during the announcement of this  69 billion deal  the company projected  750 million of near term synergies  with low  to mid single digit accretion in the second year post closure of the transaction  Many view the merger as a vertical integration instead of a horizontal one which will lead to efficiency gains and solid cost cutting at CVS Health s pharmacy benefit management  PBM  business CVS Health Corporation Price and EPS Surprise    Benefits from the Latest U S  Tax ReformThe latest U S  tax legislation  which slashes corporate tax rates from 35  to 21   is anticipated to benefit the company with an effective tax rate of 27  and an increased cash flow of around  1 2 billion in 2018 Revised Outlook for Q4CVS Health now expects to report a mid teens Pharmacy Services segment s adjusted operating profit growth rate in fourth quarter 2017 and around 4  for full year 2017  largely due to weaker margin performance in the PBM client and retail network claims administration process  However  the company still expects fourth quarter operating loss from its Retail LTC segment to be at the lower end of the previously provided range of 1 0  to 3 5   Also  the company estimates adjusted EPS and consolidated operating profit growth at the low end of the previously provided ranges of  1 88  1 92 and 5 75 8   respectively Zacks Rank and Key PickCVS Health currently carries a Zacks Rank  3  Hold  A better ranked stock in the broader medical sector is Bio Rad Laboratories  Inc    NYSE BIO   
Bio Rad Laboratories flaunts a Zacks Rank  1  Strong Buy   The company has a long term expected earnings growth rate of 25  and has gained 32 5  over the past year  You can see Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/cvs-healths-cvs-outlook-for-2018-cheered-by-investors-200277955,200277955
127973,349488,MCK,Mckesson  MCK  To Report Q3 Earnings  A Beat In The Cards ,opinion,"McKesson Corporation   NYSE MCK   is scheduled to release third quarter fiscal 2018 results on Feb 1  before the market opens Last quarter  earnings of  3 28 per share beat the Zacks Consensus Estimate of  2 78  In the trailing four quarters  McKesson s earnings beat the same with the average being 4 9  Meanwhile  the Zacks Consensus Estimate for revenues for the third quarter is pegged at  52 billion  which improved 3 7  year over year  Let s see how things are shaping up prior to this announcement Why a Likely Positive Surprise Our proven model shows that McKesson is likely to beat estimates because it has the perfect combination of two key ingredients Zacks ESP  The company has an  of  0 16   A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  McKesson currently carries a Zacks Rank  2  Buy   Note that stocks with a Zacks Rank  1  Strong Buy   2 or 3  Hold  have a significantly higher chance of beating earnings estimates We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions McKesson Corporation Price and Consensus     
What s Driving the Better Than Expected Earnings McKesson Specialty Health unit is likely to drive the company s top line in the third quarter  The unit is likely to benefit from the closing of the intraFUSION acquisition and the recent BDI Pharma buyout The company expects to witness solid performance in its Canadian business in the third quarter  Last quarter  McKesson Canada closed the Uniprix banner acquisition and strengthened independent pharmacies  Per management  Uniprix integration activities are progressing well Further  McKesson Prescription Technology Solutions business continues to make progress on the CoverMyMeds integration Coming to the Technology Solutions segment  the company divested its Enterprise Information Solutions or EIS business  recently  This marks another important step in the strategic shift to realign the company s business focus on Distribution Solutions  following the creation of Change Healthcare earlier this year McKesson s strong guidance for fiscal 2018 looks encouraging  The upside is expected to be driven by market growth  acquisitions and divestitures  McKesson expects GAAP earnings per share in the range of  4 80  6 90 for the fiscal year ending Mar 31  2018  Adjusted earnings for the same are expected in the range of  11 80  12 50 Recently  McKesson announced that it has entered into an agreement to buy RxCrossroads from CVS Health  NYSE CVS  for  735 million Other Stocks to ConsiderHere are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  1  You can see  Luminex   NASDAQ LMNX   has an Earnings ESP of  14 29  and a Zacks Rank  3 The Cooper Companies   NYSE COO   has an Earnings ESP of  10 75  and a Zacks Rank  3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-to-report-q3-earnings-a-beat-in-the-cards-200283537,200283537
127975,349490,MCK,Medical Device Stocks Earnings Due On Feb 1  BSX  BAX   More,opinion,"The fourth quarter 2017 earnings season is gaining momentum with 133 S P 500 participants having already released financial numbers as of Jan 26  Per the latest   the reporting cycle was off to an encouraging start with above average proportion of companies edging past the top and bottom line expectations Total earnings for these members have improved 11 6  on 6  increase in revenues With results of roughly 121 members slated to be announced this week  per the Zacks data  estimates for the period are gradually trending upward across the board for nine of the 16 Zacks sectors  The  as one in the bracket  is expected to witness a 2 1  earnings rise in the fourth quarter on 2  revenue growth projection What s in Store for Medical Device Industry The medical device space within the broader Medical sector somewhat displays a mixed bag of sorts  As part of the tax overhaul  corporate tax rates have been slashed down to 21  from the previous 35   thus lending a huge relief to the MedTech mammoths However  ahead of the industry s fourth quarter earnings release  a section of analysts expect this new tax law to negatively impact the industry due to a possible cut in overall Medicare spending  if certain criteria are not fulfilled by a specific date  The Congressional Budget Office apprehends that in absence of any alternative to meet the fiscal deficit from the huge tax reduction  automatic cut backs worth  136 billion including  25 billion in Medicare cuts from the mandatory budget of spending in 2018  could be triggered Amid tax reform related concerns  the news of Congress delaying the medical device tax for another two years came as a huge boost to industry players and investors  This 2 3  tax was earlier delayed by Congress in 2015 for a couple of years  The deferral will once again largely propel R D activities within this space Let s take a sneak peek at the performance of five major medical device companies  waiting to report earnings on Feb 1 Boston Scientific Corporation   NYSE BSX    We are optimistic about the company s gradually improving performance in Interventional Cardiology  led by an innovative portfolio and robust commercial teams  globally  More specifically  The WATCHMAN platform is expected to experience another excellent quarter on consistent global momentum as Boston Scientific s multiple market development efforts continue to push for growth The company has a positive  of  1 07  and a Zacks Rank  3  Hold   While a favorable Zacks ESP indicates a likely positive surprise  a bullish Zacks Rank  1  Strong Buy   2  Buy  or 3 increases the predictive power of ESP Conversely  Sell rated stocks   4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions    Read More   Boston Scientific Corporation Price and EPS Surprise   Baxter International Inc    NYSE BAX    In the fourth quarter of 2017  Baxter International is anticipated to gain from strong Hospital Products  driven by solid sales in the U S  Fluid Systems business as well as robust demand for injectable pharmaceuticals  Within the Hospital Products segment  we expect Fluid Systems to maintain the momentum  evident from the Zacks Consensus Estimate of  634 million for the to be reported quarter  which reflects a 3 3  improvement from the year ago period Banking on solid prospects  our quantitative model also shows a beat for the company  given the combination of a Zacks Rank of 3 and an Earnings ESP of  1 28   You can uncover the best stocks to buy or sell before they re reported with our   Read more    Baxter International Inc  Price and EPS Surprise   McKesson Corporation   NYSE MCK    This major player in the pharmaceutical and medical supplies distribution market expects to witness a solid performance in its Canadian business in the third quarter of fiscal 2018  Also McKesson Specialty Health unit is likely to drive the company s top line in the same time frame  The unit is likely to benefit from the closing of the intraFUSION acquisition and the recent BDI Pharma buyout We are unable to conclude whether McKesson is likely to beat on earnings this quarter  The stock carries a Zacks Rank  2  which increases the predictive power of ESP and an Earnings ESP of  0 66   However  we need to have a positive ESP to be confident about an earnings surprise  You can see   Read More   McKesson Corporation Price and EPS Surprise   Edwards Lifesciences Corporation   NYSE EW    This leading cardiovascular product maker is expected to grow on robust Transcatheter Heart Valve Therapy segment in the fourth quarter of 2017  On the back of a continued therapy adoption across all geographies  with notable strength in the United States  the company is likely to retain its bullish run in the period to be reported Edwards Lifesciences is a Zacks  3 Ranked player and has an  of  1 29   While a positive Zacks ESP denotes a likely earnings surprise  a favorable Zacks Rank of the company raises the predictive power of ESP  Read More   Edwards Lifesciences Corporation Price and EPS Surprise

   IDEXX Laboratories  Inc    NASDAQ IDXX    Repeating its preceding quarter s success as if  IDEXX is estimated to gain from a strong global footprint in Companion Animal Group Diagnostics with recurring revenues in the fourth quarter  We are also upbeat about IDEXX enhancing its commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics The company is a  3 Ranked player but has an Earnings ESP of  0 23   Therefore  we are unable to conclude whether IDEXX is likely to beat on earnings this quarter  However  IDEXX s trailing 12 month average beat is 9 35   Read More  IDEXX Laboratories  Inc  Price and EPS Surprise   The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/medical-device-stocks-earnings-due-on-feb-1-bsx-bax--more-200285426,200285426
127994,349509,MCK,Is McKesson  MCK  A Great Stock For Value Investors ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put McKesson Corporation   NYSE MCK   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  McKessonhas a trailing twelve months PE ratio of 13  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 49  If we focus on the long term PE trend  McKesson s current PE level puts it below its midpoint over the past five years  with the number having risen rapidly over the past few months Further  the stock s PE also compares favorably with the broader sector s trailing twelve months PE ratio  which stands at 19 5  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that McKesson has a forward PE ratio  price relative to this year s earnings  of just 12 8  so it is fair to say that a slightly more value oriented path may be ahead for McKesson stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  McKesson has a P S ratio of about 0 2  This is significantly lower than the S P 500 average  which comes in at 3 2x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  MCK is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  McKesson currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes McKesson a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for McKesson is just 1 6  a level that is far lower than the industry average of 2 2x  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate What About the Stock Overall Though McKesson might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of C and a Momentum Score of B  This gives MCK a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been favorable  The current quarter has seen six estimates go lower in the past sixty days  while the full year estimate has seen five up and three down in the same time period This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has risen by 1 1  in the past two months  while the full year estimate has inched upper by 0 1   You can see the consensus estimate trend and recent price action for the stock in the chart below McKesson Corporation Price and Consensus
    Notably  the stock has just a Zacks Rank  3  Hold  and we are looking for in line performance from the company in the near term Bottom LineMcKesson is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  among Bottom 29  of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past two years  broader industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-01,Zacks Investment Research,https://www.investing.com/analysis/is-mckesson-mck-a-great-stock-for-value-investors-200216480,200216480
127995,349510,MCK,MedTech Stock Q3 Earnings Roster For Oct 26  BSX  RMD   More,opinion,The latest  depicts a bullish run in the ongoing reporting cycle  Till Oct 20  87 S P 500 members  24 7  of the total market cap  reported their numbers  Total earnings for these members have gone up 9 4  on 7 3  higher revenues However  investors are concerned about the Medical sector  one of the 16 Zacks sectors  that saw a lot of struggle during the first nine months of the year  thanks to the political change and the ongoing policy restructuring related battle The ensuing lack of visibility has roiled the favorable trend that this sector maintained in the trailing few quarters  For the third quarter  the expected earnings growth rate stands at a mere 2 2  on a 4 8  revenue growth projection  In comparison  the second quarter earnings growth was quite impressive at 7  on 4 4  revenue growth What s in Store for the Medical Product Space While twists and turns continue to unfold at Capitol Hill  the scenario within the  space  an important part of the medical device subcategory within the broader Medical sector  is getting gloomier  The latest executive order released by the Republicans points to a shrinking customer base  indicating a cut in demand for expensive medical procedures and devices  This may lead to major supply demand disequilibrium within this space However  major medical device players have been pinning hopes on the abolition of the infamous 2 3  medical device sales tax  though its elimination is far from reality Considering these tax issues  investors interested in the Medical Product space eagerly await earnings reports of MedTech bigwigs throughout this week  Let s take a look at the major Medical products stocks slated to release their quarterly reports on Oct 26 Per our quantitative model  when stocks with a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  are combined with a positive   then chances of beating estimates are always high  You can uncover the best stocks to buy or sell before they re reported with our  Boston Scientific Corporation   NYSE BSX    We are upbeat about this medical device stalwart s gradually improving performance in Interventional Cardiology  IC   led by an innovative portfolio and robust commercial teams  globally  The company while gaining a fair share in a few cardiovascular segments and DES  Drug Eluting Stent   continues to build momentum worldwide However  ahead of this earnings release  the quarter s IC business is likely to be grossly impacted by the company s product recall issue within Europe  While the downbeat IC business tangled under product recall issue will possibly gain some boost from the company s recent  435 million acquisition of Switzerland based Symetis SA  a full recovery may take time  The Zacks Consensus Estimate for third quarter IC revenues is currently pegged at  580 million  lower than the sequentially last quarter s reported number of  603 million Boston Scientific Corporation Price and EPS Surprise    Notably  the company s earnings have outpaced the Zacks Consensus Estimate by an average of 0 84  in the trailing four quarters  Further  the Zacks Consensus Estimate for third quarter earnings of 31 cents per share has remained unchanged over the last three months  However  it has shown a rally of 14 8  from the year ago reported figure  The Zacks Consensus Estimate for the company s revenues is pegged at  2 2 billion for the yet to be reported quarter  an 11 5  improvement from the year ago reported number of  2 06 billion Boston Scientific has an Earnings ESP of  0 20   It also carries a Zacks Rank  2   ResMed Inc    NYSE RMD    This renowned worldwide provider of generators  masks and related accessories for the treatment of sleep disordered breathing  SDB  is expected to gain in its first quarter fiscal 2018 from strong performances on the domestic and international fronts  The company s revenues in the domestic domain were driven by solid growth in devices as well as low double digit software sales growth in the previous quarter  Internationally  the company s receipt of French reimbursement approval for telemonitoring buoys optimism The Zacks Consensus Estimate for domestic revenues  including the contributions from Brightree  of  334 million reflects an increase of 10 9  from the year ago quarter  Also  the Zacks Consensus Estimate for international revenues of  177 million indicates a rise of 7 5  from the year ago quarter  Overall  fiscal first quarter total revenues are projected at  501 million  up 7 7  from the prior year quarter ResMed Inc  Price and EPS Surprise    Notably  the company s earnings have outpaced the Zacks Consensus Estimate by an average of 1 7  in the trailing four quarters  ResMed carries a Zacks Rank  4  Sell  and has an Earnings ESP of 0 00   You can see   Read More   Align Technology Inc    NASDAQ ALGN    We are upbeat about Align Technology s strategic initiatives like international expansion  ensuring Invisalign treatment for a growing base of patients  Also  the last quarter s huge increase in international teen cases by 40 5  year over year encourages the investors  This figure reflects a rise in demand  In the quarter to be reported  the company reached a new benchmark of 1 million teen patients who had adopted the Invisalign treatment Management also anticipates consistent growth in the Asia Pacific region  In a bid to flourish in this region  the company opened a new Invisalign Treatment Planning Facility in China Align Technology  Inc  Price and EPS Surprise    Notably  the company s earnings have outpaced the Zacks Consensus Estimate by an average of 16 7  in the trailing four quarters  While Align has an Earnings ESP of  0 21   it carries a Zacks Rank  3 The stock has seen the Zacks Consensus Estimate for third quarter earnings of 82 cents per share being revised a penny upward over the last 7 days  It has also shown an improvement of a significant 60 8  from the year ago tally  The Zacks Consensus Estimate for the company s revenues is pegged at  360 million for the soon to be reported quarter as compared to the year ago reported figure of  273 million  reflecting a 31 8  gain   Read More   Cerner Corporation   NASDAQ CERN    Cerner is expected to show steady growth in system sales  a major revenue component  While this could primarily drive third quarter earnings  an expected improvement in revenues at all other segments should also help the company generate solid results this season The Zacks Consensus Estimate for systems sales stands at  337 million for the third quarter  This reflects a rally of almost 12  from the year ago quarter  Growth across acute and ambulatory EHR plus sales of Population Health and Revenue Cycle solutions and services hold promise for Cerner Cerner Corporation Price and EPS Surprise    Last quarter  management at Cerner announced that the company expects 3 4  growth within the Support  Maintenance   Services segment for the remaining year  In fact  the Zacks Consensus Estimate for this segment s revenues stands at  933 million  up 8 4  on a year over year basis and 1 7   sequentially Notably  the company s earnings have outpaced the Zacks Consensus Estimate by an average of 0 01  in the trailing four quarters  The Zacks Consensus Estimate for third quarter earnings of 62 cents per share has remained unchanged over the last two months  However  it has improved by 3 3  from the year ago figure  The Zacks Consensus Estimate for the company s revenues is pegged at  1 29 billion for the yet to be reported quarter  a 4  improvement from the year ago number of  1 24 billion Cerner has an Earnings ESP of  0 32   It also carries a Zacks Rank of 2  Read More   Stryker Corporation   NYSE SYK    In August  Stryker announced a voluntary recall of the Oral Care line up  offered by the company s Sage Products unit  Added to the voluntary recall  the company had placed a temporary hold on certain cloth based products  While this might mar third quarter results  an expected improvement in revenues at the major revenue segments might help the company generate solid results this season Stryker Corporation Price and EPS Surprise    Stryker delivered positive earnings surprises in the past four quarters  the average beat being 1 3   The Zacks Consensus Estimate for third quarter revenues stands at  2 97 billion  up 4 9  on a year over year basis  Also  the Zacks Consensus Estimate for earnings stands at  1 50 per share  up 8 1  year over year Stryker has an Earnings ESP of  0 72   It carries a Zacks Rank of 3 as well  Read More   McKesson Corporation   NYSE MCK    McKesson  a major player in the pharmaceutical and medical supplies distribution market  expects to gain from a gradually stabilizing generic and branded market  The company s distribution solutions segment performed favorably in the recent times  despite weak pricing trends and customer consolidation The Zacks  3 Ranked company s earnings have underperformed the Zacks Consensus Estimate by an average of 0 46  in the trailing four quarters  McKesson has an Earnings ESP of  0 72  McKesson Corporation Price and EPS Surprise    The stock has seen the Zacks Consensus Estimate for third quarter earnings of  2 78 per share being revised 2 cents downward over the last 30 days  It has also shown a decline of 8 9  from the year ago reported figure  The Zacks Consensus Estimate for the company s revenues is pegged at  51 6 billion for the yet to be reported quarter as compared to the year ago figure of  51 3 million   Read More   Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/medtech-stock-q3-earnings-roster-for-oct-26-bsx-rmd--more-200221048,200221048
127996,349511,MCK,Should You Buy McKesson Corporation  MCK  Ahead Of Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and McKesson Corporation   NYSE MCK   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because McKesson is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for MCK in this report In fact  the Most Accurate Estimate for the current quarter is currently at  2 80 per share for MCK  compared to a broader Zacks Consensus Estimate of  2 78 per share  This suggests that analysts have very recently bumped up their estimates for MCK  giving the stock a Zacks Earnings ESP of  0 72  heading into earnings season McKesson Corporation Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that MCK has a Zacks Rank  3  Hold  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for McKesson  and that a beat might be in the cards for the upcoming report Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-mckesson-corporation-mck-ahead-of-earnings-200220954,200220954
127997,349512,MCK,McKesson  MCK  Beats On Earnings And Sales In Q2,opinion,"Headquartered in San Francisco  California  McKesson Corporation   NYSE MCK   is a global provider of healthcare supply chain management solutions  retail pharmacy  community oncology cum specialty care  and healthcare information technology Currently  McKesson has a Zacks Rank  3  Hold  but that could change following its second quarter fiscal 2018 earnings report which has just released   You can see   We have highlighted some of the key details from the just released announcement below Earnings  McKesson s adjusted earnings of  3 28 per share came above the Zacks Consensus Estimate of  2 78 and increased from  2 96 in the year ago quarter Revenues  McKesson posted sales of  52 1 billion  beating the Zacks Consensus Estimate for revenues of  51 6 billion  This was up from  50 0 billion last year Key Stats  Distribution Solutions sales increased 5  at cc  while Technology Solutions decreased 82  from the year ago quarter  McKesson Corporation Price and EPS Surprise   Major Factors   Performance improved due to higher profits owing to market growth and acquisitions  Lower profit in Technology Solutions segment was driven primarily by the contribution of the majority of the businesses to Change Healthcare JV 
 McKesson expects GAAP earnings per diluted share between  4 80 to  6 90 for the fiscal year ending Mar 31  2018  Adjusted Earnings for the same are expected in the range of  11 80 to  12 50 per diluted share Check back later for our full write up on this McKesson report later  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-beats-on-earnings-and-sales-in-q2-200221241,200221241
128016,349531,MCK,Quest Diagnostics Closes Deal To Acquire 2 Labs In Texas,opinion,Well ahead of the expected time of completion  Quest Diagnostics   NYSE DGX   closed the earlier announced deal to acquire two laboratory businesses in Lewisville  TX  namely  Med Fusion and Clear Point  This is in line with the company s plan to fast expand in the high growth cancer diagnostic market The businesses jointly provide a complete range of diagnostic services to physicians and provider networks  This acquisition will allow Quest Diagnostics to establish a center of excellence to provide diagnostic services for the detection and management of cancer  Baylor Scott   White Health  BSWH   The US Oncology Network or the Network  supported by McKesson  NYSE MCK  Specialty Health   Texas Oncology and Pathologists Bio Medical Laboratories  PBM  are co owners of one or both the businesses Quest Diagnostics will team up with McKesson Specialty Health  The Network and Texas Oncology to enhance Med Fusion s model  which has been created to standardize next generation gene sequencing panels to help in selecting the therapy and monitoring of cancer After completion of the deal  Quest Diagnostics is now a preferred provider of advanced oncology diagnostics for The Network and Texas Oncology Primarily  Quest Diagnostics will offer services to 12 BSWH hospitals in North Texas and 400 independent  community based physicians nationally that are affiliated with The Network  including Texas Oncology We believe that the deal is perfectly aligned with Quest Diagnostics  goal to capture the high potential global oncology diagnostic market  On account of the data provided by American Cancer Society  nearly 1 7 million people are likely to be diagnosed with cancer in the U S  in 2017  In this regard  Quest Diagnostics is taking strategic steps to capture the market According to Markets and Markets  the global cancer diagnostics market is expected to reach a worth of  13 1 billion by 2020  and is poised to see a CAGR of 12 9  during the of 2015 to 2020 period  The company clearly has bountiful opportunities in this niche market Over the last three months  Quest Diagnostics has been observed to outperform the Zacks categorized industry  As per the latest share price movement  the company has gained 6 4   as compared to the 5 7  gain of the broader industry Recent DevelopmentsRecently  Quest Diagnostics announced plans to acquire the outreach laboratory services business of Cape Cod Healthcare  CCHC    Notably  CCHC provides healthcare services to residents and visitors of Cape Cod   The deal  if concluded  is expected to provide quality  affordable and convenient laboratory services to Cape Cod residents Within its advanced diagnostics business  Quest Diagnostics  along with its onchology francise partner Memorial Sloan Kettering  has teamed up with IBM  NYSE IBM  to form IBM Health Watson  With about 70  of the oncology prospects being in community healthcare centers instead of large urban centers  this is a huge opportunity for the companies Zacks Rank   Key PicksQuest Diagnostics currently carries a Zacks Rank  3  Hold   A few better ranked medical stocks are Mesa Laboratories  Inc    NASDAQ MLAB    INSYS Therapeutics  Inc    NASDAQ INSY   and Align Technology  Inc    NASDAQ ALGN    Notably  INSYS Therapeutics sports a Zacks Rank  1  Strong Buy   while Mesa Laboratories and Align Technology carry a Zacks Rank  2  Buy   You can see Mesa Laboratories has a positive earnings surprise of 2 84  for the last four quarters  The stock has added roughly 8 9  over the last three months INSYS Therapeutics has a long term expected earnings growth rate of 20   The stock has gained around 24 3  over the last three months Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock has added roughly 34 5  over the last three months 3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-07-19,Zacks Investment Research,https://www.investing.com/analysis/quest-diagnostics-closes-deal-to-acquire-2-labs-in-texas-200202364,200202364
128017,349532,MCK,Med Products  Q2 Earnings Roster For Jul 27  ALGN  BSX   More,opinion,With the second quarter earnings season gaining momentum  the broader picture no longer looks as bright as it was expected to be  Putting together all the 128 S P 500 members  released results as of Jul 25  constituting 36  of the index s total membership  we note that earnings growth pace is less than the last quarter  However  it is more or less in line with the trailing four quarter average earnings growth and exceeds the trailing 12 quarter average Per the latest second quarter scorecard  total earnings increased 7  year over year on 4 2  higher revenues  While earnings beat ratio remains at 77 3   revenue beat ratio is at 70 3    For more information  please consult our   What s in Store for the Medical Space Investors are concerned about the healthcare space  a sector that has been seen through a lot of struggle during the past half year  thanks to the political power change and the ongoing policy restructuring related battle While yesterday  it was finally President Donald Trump s win with the Republican healthcare bill passing one more barrier by a very narrow margin  investors are however not much optimistic about this development  Per a Vox article today  in its effort to repeal and replace Obamacare   President Donald Trump continues to make bold promises about what that bill would do   promises that all available analysis suggests the bill will not keep  While there are still chances that the Senate will amend the latest bill  its extent still remains unclear  Accordingly  uncertainty within the medical space is towering high  Investors are currently adopting a wait and see policy about this space Let s sneak a peek into the performance of five major Medical   Products companies within the broader  space expected on Jul 27 Align Technology  Inc    NASDAQ ALGN    We are upbeat about Align Technology s execution of strategic initiatives like international expansion  which ensured Invisalign treatment for a growing base of patients  In this context  the company strengthened its foothold internationally by acquiring the Invisalign distributors in the highly lucrative Europe  Middle East and Africa  EMEA  region as well as Brazil in February  This is likely to drive the company s results in the soon to be reported quarter Align is expected to beat expectations when it reports second quarter 2017 results before the market opens  as it has the right combination of two key ingredients  The stock currently carries a Zacks Rank  1  Strong Buy  and has an  of  2 74   We note that  while a positive Zacks ESP serves as a leading indicator of a likely positive earnings surprise  a bullish Zacks Rank increases the predictive power of the ESP  You can uncover the best stocks to buy or sell before they re reported with our   Read More   Align Technology  Inc  Price and EPS Surprise    Boston Scientific Corporation   NYSE BSX    We believe  this medical device major s second quarter performance will be grossly impacted by the company s product recall issue within Europe  On the other hand  the company s downbeat interventional cardiology business may get some sort of a boost with the company s  435 million acquisition of Switzerland based Symetis SA Boston Scientific is scheduled to report second quarter 2017 results after the market closes  The company currently carries a Zacks Rank  4  Sell  and has an Earnings ESP of 0 00   Hence  we are unable to conclude whether Boston Scientific is likely to beat on earnings this quarter  Note that all Sell rated stocks   4 or 5  should never be considered going into an earnings announcement    Read More   Boston Scientific Corporation Price and EPS Surprise    Cerner Corporation   NASDAQ CERN    We believe  Cerner s strong sales performance as well as its solid portfolio and strategic initiatives have positioned it well for stellar growth  Cerner announced that it has been chosen by the U S  Department of Veterans Affairs to develop an electronic health record  EHR  system  Department of Veterans Affairs will use the same system the company is developing for the U S  Department of Defense  which began its operation at its first site in February  This system will facilitate the exchange of data between military care facilities and civilian health providers  where current and former service members receive care This leading healthcare information technology  HCIT  company is scheduled to report second quarter 2017 earnings after the market closes  The company currently carries a Zacks Rank  2 and an Earnings ESP of  1 75   Hence it is expected to beat expectations this quarter  You can see   Read More   Cerner Corporation Price and EPS Surprise   Stryker Corporation   NYSE SYK    For the second quarter of 2017  this renowned medical device maker expects adjusted earnings per share in the range of  1 48  1 52  Notably  this indicates a rise of 6 5  9 4  on a year over year basis  We believe that the growing adoption of MAKO robots will drive sales in the orthopedic and reconstructive surgery market  Additionally  Stryker is well poised on the acquisitions of both Sage and Physio Control in the past The company also expects to beat expectations when it reports second quarter 2017 results after the closing bell  This is because the stock currently carries a Zacks Rank  3  Hold  and an Earnings ESP of  0 66    Read More   Stryker Corporation Price and EPS Surprise    McKesson Corporation   NYSE MCK    This major player in the pharmaceutical and medical supplies distribution market expects to gain from a gradually stabilizing generic and branded market  The company s distribution solutions segment performed favorably in fiscal 2017 despite weak pricing trends and customer consolidation We are unable to conclude whether McKesson is likely to beat on earnings this quarter  The stock carries a Zacks Rank  3  which increases the predictive power of ESP and an Earnings ESP of 0 00   We need to have a positive ESP to be confident about an earnings beat  Read More   McKesson Corporation Price and EPS Surprise   The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-07-25,Zacks Investment Research,"https://www.investing.com/analysis/med-products'-q2-earnings-roster-for-jul-27:-algn,-bsx---more-200203687",200203687
128018,349533,MCK,McKesson  MCK  Misses Earnings Estimates In Q1  Raises View,opinion,"McKesson Corporation   NYSE MCK   reported first quarter fiscal 2018  ended Jun 30  2017  earnings of  2 46 per share  missing the Zacks Consensus Estimate of  2 81  Earnings also lagged the year ago figure of  3 15  Performance was muted owing to branded to generic conversions and steep competition in its pharmacy business 
Revenues improved 3  year over year to  51 1 billion but failed to meet the Zacks Consensus Estimate of  51 2 billion 
Quarter in Detail
McKesson operates through two segments  Distribution Solutions and Technology Solutions  All growth rates given below are on a year over year basis 
At Distribution Solutions  revenues increased 5  to  50 9 billion  North America pharmaceutical distribution and services reported sales of  43 0 billion  up 5  on market growth and acquisitions  Revenues were hit by branded to generic conversions  Revenues from International pharmaceutical distribution and services were up 6  to  6 4 billion  Medical Surgical distribution and services generated sales of  1 5 billion  up 4  
However  revenues from the Technology Solutions business fell from  724 million in the year ago quarter to  120 million  This was due to the bifurcation of the Technology Solutions businesses to the Change Healthcare joint venture on Mar 1  The segment reflects only the numbers from the Enterprise Information Solutions business McKesson Corporation Price  Consensus and EPS Surprise
 

   Financial Condition
As of Jun 30  McKesson had  2 3 million in cash and cash equivalents against  2 8 million as of Mar 31  During the reported quarter  ended Jun 30  2017   the company generated cash amounting to  741 million from operations  Also in fiscal 2017  McKesson paid  1 5 billion for acquisitions  repurchased  250 million of its common stock  repaid approximately  541 million in long term debt and paid  62 million in dividends 
Fiscal 2018 Outlook
McKesson expects GAAP earnings per diluted share of  7 10 to  9 00 for the fiscal ending Mar 31  2018  Adjusted earnings for the same period are expected in the range of  11 80 to  12 50 per diluted share  Distribution Solutions business revenue growth is expected to increase by mid single digits year over year  The upside is expected to be driven by market growth and acquisitions  Revenues from Technology Solutions are expected to be down on a year over year basis 
Zacks Rank   Key Picks
McKesson currently carries a Zacks Rank  3  Hold   A few better ranked medical stocks are Mesa Laboratories  Inc    NASDAQ MLAB    INSYS Therapeutics  Inc    NASDAQ INSY   and Align Technology  Inc    NASDAQ ALGN    Notably  INSYS Therapeutics sports a Zacks Rank  1  Strong Buy   while Mesa Laboratories and Align Technology carry a Zacks Rank  2  Buy   You can see  
INSYS Therapeutics has a long term expected earnings growth rate of 20   The stock has gained around 5 7  over the last three months 
Mesa Laboratories has a positive earnings surprise of 2 84  for the last four quarters  The stock has added roughly 4 1  over the last three months 
Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock has added roughly 32 1  over the last three months 
More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-27,Zacks Investment Research,"https://www.investing.com/analysis/mckesson-(mck)-misses-earnings-estimates-in-q1,-raises-view-200204049",200204049
128021,349536,MCK,McKesson  MCK  Misses On Earnings And Sales In Q1,opinion,"Headquartered in San Francisco  California  McKesson Corporation   NYSE MCK   is a global provider of healthcare supply chain management solutions  retail pharmacy  community oncology cum specialty care  and healthcare information technology Currently  McKesson has a Zacks Rank  3  Hold  but that could change following its first quarter fiscal 2018 earnings report which has just released   You can see    We have highlighted some of the key details from the just released announcement below Earnings  McKesson s adjusted earnings of  2 46 per share missed the Zacks Consensus Estimate of  2 81 and decreased from  3 15 in the year ago quarter Revenues  McKesson posted sales of  51 05 billion  marginally missing the Zacks Consensus Estimate for revenues of  51 17 billion  This was up from  49 73 billion last year McKesson Corporation Price and EPS Surprise
    Key Stats  Distribution Solutions sales increased 5  at cc  while Technology Solutions decreased 83  from the year ago quarter 
 Major Factors   Performance was affected due to lower profits owing to increased price competition in pharmacy business and weaker pharmaceutical manufacturer pricing trends in U S  Lower profit in Technology Solutions segment was driven primarily by the contribution of the majority of the businesses to Change Healthcare JV McKesson expects GAAP earnings per diluted share between  7 10 to  9 00 for the fiscal year ending Mar 31  2018  Adjusted Earnings for the same are expected in the range of  11 80 to  12 50 per diluted share Check back later for our full write up on this McKesson report later More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artifical intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future  Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-27,Zacks Investment Research,https://www.investing.com/analysis/mckesson-(mck)-misses-on-earnings-and-sales-in-q1-200203939,200203939
128022,349537,MCK,McKesson Banks On Distribution Business Amid Pricing Woes,opinion,On Aug 14  we issued an updated research report on San Francisco  CA based McKesson Corporation   NYSE MCK    a health care services and information technology company   McKesson posted disappointing results in first quarter fiscal 2018  wherein adjusted earnings and revenues missed the Zacks Consensus Estimate  The company currently has a Zacks Rank  3  Hold  The quarter saw strong performance by the Distribution Solutions segment  The segment is expected to keep up its performance in fiscal 2018 despite weak pricing trends and customer consolidation  To boost growth  the company recently acquired CoverMyMeds for approximately  1 1 billion Coming to guidance  the Distribution Solutions business revenue growth is expected to witness robust growth on a year over year basis  The upside is expected to be driven by market growth and acquisitions McKesson expects GAAP earnings per diluted share of  7 10  9 00 for the fiscal ending Mar 31  2018  Adjusted earnings for the same period are expected in the range of  11 80  12 50 per diluted share On the flipside  pricing pressure in the independent retail pharmacy channel is a headwind  McKesson entered fiscal 2018 with an assumption of branded inflation in the mid single digits and its first quarter slightly surpassed expectations McKesson has been witnessing increased price competition in the independent retail pharmacy channel  which eventually resulted in reduced volumes  The company continues to see a competitive market for selling generic pharmaceuticals in the U S  However  McKesson expects to overcome the independent pharmacy sell side pricing impact by the end of second quarter fiscal 2018 Furthermore  cutthroat competition in the niche markets  currency headwinds and reimbursement issues remain challenges Stock Performance and Estimate Revision TrendOver the last three months  McKesson has been trading above the broader industry  The company has gained 5 1   comparing favorably with the  industry s return of just 4   The current level is also higher than the S P 500 s return of only 4 6  over the same time frame The estimate revision trend for McKesson has been unfavorable at the moment  For the current quarter  six analysts moved south compared to no movement in the opposite direction over the last two months  As a result  magnitude of full year estimates fell 4 8  to  2 76 over the same time frame Key PicksA few better ranked stocks in the broader medical sector are Edwards Lifesciences Corporation   NYSE EW    Masimo Corporation   NASDAQ MASI   and IDEXX Laboratories  Inc    NASDAQ IDXX   Notably  Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   while IDEXX Laboratories and Masimo Corporation have a Zacks Rank  2  Buy   You can see  Edwards Lifesciences has a long term expected earnings growth rate of 15 2   Notably  the stock has returned 2 7  over the last three months Masimo yielded a strong return of 26 6  year to date  The stock has a long term expected earnings growth rate of 11 1  IDEXX Laboratories has a long term expected earnings growth rate of 19 8   Additionally  the stock represents an impressive one year return of 39 6  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-08-15,Zacks Investment Research,https://www.investing.com/analysis/mckesson-banks-on-distribution-business-amid-pricing-woes-200207664,200207664
128023,349538,MCK,Quality Systems  QSII  Completes EagleDream Health Buyout,opinion,NextGen Healthcare Information Systems  a wholly owned subsidiary of Irvine  CA based Quality Systems  Inc    NASDAQ QSII    recently completed the acquisition of EagleDream Health Inc  for roughly  26 million in cash EagleDream Health is a cloud based analytics that optimizes understanding across clinical  financial and administrative data to enhanced practice performance Following the acquisition  NextGen Healthcare will gain facilities to provide enriching care experience and accelerate patient engagement for ambulatory clinics and health systems  Management further expects to achieve per capita cost efficiency as well as enhanced work life balance for clinicians and staff Interestingly  the company has been in on an acquisition spree for long  Earlier this year  NextGen Healthcare had acquired Entrada  Inc   provider of cloud based solutions for healthcare   for  34 million  The company has already started gaining from this deal  Per the first quarter fiscal 2018 results  Subscription revenues were significantly up on strength in Entrada  We believe the EagleDream Health acquisition will also prove accretive to the company Notably  the company has successfully added Revenue Cycle Management  RCM  solutions  Analytics  Patient Management and Regulatory and Clinical tools to its product portfolio through acquisitions  We believe that the company will continue to pursue strategic acquisitions that will not only expand its product portfolio but also strengthen its competitive position Per a report byMedGadget  the healthcare information systems market is expected to reach a value of  53 2 billion by 2019  at a CAGR of 7 1  Considering the market potential and Quality Systems  current developments  this acquisition seems to be a strategic one Quality Systems has been gaining investor confidence on consistent positive results  Over the past three months  the company s share price has outperformed the   The stock has gained 13 1   higher than the industry s gain of 4 6   The company has also outperformed the 4 3  gain of the S P 500 market over the same time frame However  the healthcare information systems and services market is highly competitive  Also  the industry is exceedingly fragmented and includes numerous players like athenahealth  Inc    NASDAQ ATHN   and McKesson Corporation   NYSE MCK    among others  Zacks Rank   A Key PickQuality Systems currently has a Zacks Rank  3  Hold   A better ranked medical stock is Edwards Lifesciences Corporation   NYSE EW    with a Zacks Rank  1  Strong Buy   You can see Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has gained around 28 8  over the last six months One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/quality-systems-qsii-completes-eagledream-health-buyout-200207854,200207854
128049,349564,MCK,McKesson  MCK  Q4 Earnings  Will The Stock Disappoint ,opinion,"McKesson Corporation   NYSE MCK    one of the largest healthcare services providers  is scheduled to report fourth quarter fiscal 2017 results on May 18 McKesson s track record has not been impressive  with the company missing estimates in two of the trailing four quarters  In the last reported quarter  it delivered a positive earnings surprise of 2 71   However the four quarter average surprise is  3 84   Let s see how things are shaping up prior to this quarter Pricing War to Impact Results This QuarterMcKesson has been facing challenging conditions over the last few quarters owing to lower generic launches  pricing challenges and customer transitions  The company expects performance to be affected by softness in pricing of drugs  Not only did the company experience fewer drugs with price increases  it also suffered much lower rates of price increases compared with fiscal 2016 Customer consolidation in the industry has resulted in further losses for the company  Fewer generic launches also affected business  Consequently  McKesson expects branded pharmaceutical pricing trends to be below than those experienced in fiscal 2016  In particular  competitive pricing is hurting the pharmaceutical distribution business in the U S Moreover  reimbursement cuts imposed by the U K  government to retail pharmacy rates as well as U K s decision to exit the EU has unfavorably impacted Celesio s operating performance  Accounting for the competitive customer pricing and softness in brand inflation  McKesson projects its earnings for fiscal 2017 in the range of  9 80 to  10 30  Revenues from Distribution Solutions are projected to grow in the mid single digits  However  revenues from Technology Solutions are expected to be down slightly on a year over year basis McKesson Corporation Price and EPS Surprise
    What Our Model IndicatesOur proven model does not conclusively show that McKesson will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  3 04  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  McKesson carries a Zacks Rank  4  Sell  which decreases the predictive power of ESP  Also  the company s ESP of 0 00  makes surprise prediction difficult We caution against stocks with a Zacks Ranks  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks That Warrant a LookHere are some companies you may want to consider instead as our model shows that they have the right combination of elements to post an earnings beat Best Buy Co  Inc    NYSE BBY   has an Earnings ESP of  12 50  and a Zacks Rank  3  On average  the stock delivered a positive surprise of almost 27 70  in the last four quarters Global Partners LP   NYSE GLP   delivered a positive surprise of almost 96 55  in the trailing four quarters  It has an Earnings ESP of  233 33  and a Zacks Rank  1  You can see Raymond James Financial  Inc    NYSE RJF   has an Earnings ESP of  3 45  and a Zacks Rank  1  The stock delivered a positive surprise of almost 14 4  in the trailing four quarters 
Sell These Stocks  Now  
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-05-12,Zacks Investment Research,https://www.investing.com/analysis/mckesson-(mck)-q4-earnings:-will-the-stock-disappoint-200188783,200188783
128050,349565,MCK,Book Review  The CEO Pay Machine,opinion,"Everybody  except perhaps the CEOs themselves and their compensation committees  know that CEO pay in the U S  is out of control  At large firms the CEO to worker compensation ratio  20 to 1 in 1965 and 26 to 1 in 1978  is now more than 300 to 1  perhaps as high as 700 to 1   In Japan the ratio is 16 to 1  in Denmark 48 to 1  and in the UK 84 to 1   How did CEO pay in the U S  become so untethered to the wages of average workers and what can be done to bring it back in line  if indeed doing so would be in the best interests of the companies themselves and the economy as a whole 
Steven Clifford  formerly CEO of King Broadcasting Company and National Mobile Television and a director of 13 companies  tackles these questions with wit and compelling logic in The CEO Pay Machine  How It Trashes America and How to Stop It  Blue Rider Press Penguin Random House  2017   He sets out to show  how the sausage is made how the Pay Machine actually works  how its parts interact  and how every step in the process pushes CEO pay to higher and higher levels  
He starts with a fairy tale about a loan officer at the Midwest Bank who asks his fairy godmother to help him get a promotion because his  75 000 salary isn t enough  Ah  she replies  she can do better than that  She can get him more money for the same job  Applying CEO compensation practices to the loan officer s pay package  the fairy godmother steers him  wide eyed step by wide eyed step  from his modest  75 000 salary to a whopping  5 845 000  In the process  the author sketches out the inner workings of the CEO Pay Machine 
Excessive CEO pay  the author argues  harms companies  shareholders  and the economy and undermines democracy  Not just because it is excessive but also because of the way in which it is typically structured  For instance  it usually misaligns CEO incentives with effective corporate practices and goals 
Clifford lays the blame for the emergence of the Pay Machine at the feet of  three totally unrelated actors  Michael Jensen  Milton Rock  and Bill Clinton    They were not attempting to overpay CEOs and might be stunned and insulted to be grouped together as causal agents   Jensen s basically sound recommendations  that CEOs own a significant amount of company stock and be paid in part for performance  were largely misapplied 
Rock and his fellow compensation consultants introduced the idea of using peer groups to calibrate executive pay and benchmarking  usually above average  to the salaries of the peer group CEOs  It s easy to see that  the above average benchmarking of pay within peer groups creates a relentless upward spiral in pay a game of CEO leapfrog  Every time a CEO leaps  he establishes a higher compensation base for the next CEO in the group to leap over   By the way  at this year s annual Berkshire Hathaway  NYSE BRKa  meeting  Charlie Munger said  I have avoided all my life compensation consultants  I hardly can find the words to express my contempt   He did  however  find the words at the 2012 meeting when he said  for  compensation consultants  prostitution would be a step up   Warren Buffett added at this year s meeting   If the board hires a compensation consultant after I go  I will come back mad  
The last culprit  Bill Clinton  executing on his campaign promise to clamp down on excessive executive compensation  set out to eliminate tax deductions for executive pay  at first above a certain level and then  in a compromise move  above a certain level that wasn t performance based  Business was still unhappy  so he agreed to exempt stock options from this cap   Boards could now pay unlimited amounts as long as they could pass it off as  performance based  and could grant unlimited stock options with no performance requirements  
Clifford examines the pay packages and performance of the highest paid executives of 2011 thru 2014 the CEOs of UnitedHealth Group  NYSE UNH   McKesson  NYSE MCK   Cheniere Energy  and Discovery Communications  NASDAQ DISCA   The disconnect should come as no surprise 
By way of a solution  Clifford proposes a simple  blunt instrument   For every dollar above  6 million that the companies pay their CEO or any other executive  and this includes all forms of compensation   they would pay a dollar in luxury tax  It would not be tax deductible   Punkt  No loopholes  And  he realizes  no way it would ever get through this Congress  But maybe someday  ",2017-05-14,Brenda Jubin,"https://www.investing.com/analysis/clifford,-the-ceo-pay-machine-200188989",200188989
128051,349566,MCK,McKesson  MCK  Beats Earnings Estimate In Q4  Revenues Miss,opinion,"McKesson Corporation   NYSE MCK   reported fourth quarter fiscal 2017  ended Mar 31  2017  earnings of  3 39 per share  beating the Zacks Consensus Estimate of  3 04  Earnings also came above the year ago figure of  2 44 Revenues improved 4  year over year to  48 7 billion but failed to meet the Zacks Consensus Estimate of  49 7 billion Stock PerformanceIn the last three months  the company s stock has gained 1 16   comparing unfavorably with the Zacks classified  sub industry s gain of 3 13   However  a long term expected earnings growth rate of 6 28  instills confidence in investors Quarter in DetailMcKesson operates through two segments   Distribution Solutions and Technology Solutions  All growth rates given below are on a year over year basis At Distribution Solutions  revenues increased 5  to  48 2 billion  North America pharmaceutical distribution and services reported sales of  40 6 billion  up 5   reflecting market growth and acquisitions  Revenues were hit by branded to generic conversions  Revenues from International pharmaceutical distribution and services were up 12  to  6 1 billion  Medical Surgical distribution and services generated sales of  1 6 billion  up 9  However  revenues from the Technology Solutions business fell from  734 million in the year ago quarter to  512 million  Quarterly revenues were affected by the decline in hospital software business  McKesson Corporation Price  Consensus and EPS Surprise
    Financial ConditionAs of Mar 31  2017  McKesson had  2 8 million in cash and cash equivalents against  24 2 million as of Dec 31  2016  During full fiscal 2017  ended Mar 31  2017  the company generated cash amounting to  4 7 billion from operations  Also in fiscal 2017  McKesson paid  4 2 billion for acquisitions  repurchased  2 3 billion of its common stock  repaid approximately  1 6 billion in long term debt  and paid  253 million in dividends Fiscal 2018 OutlookMcKesson expects earnings per share in the range of  11 75 to  12 45 for fiscal 2018  Distribution Solutions business revenue growth is expected to increase by mid single digits year over year  The upside is expected to be driven by market growth and acquisitions  Revenues from Technology Solutions are expected to be down on a year over year basis Zacks Rank   Key PicksMcKesson currently carries a Zacks Rank  5  Strong Sell   Better ranked stocks in the broader medical sector include Luminex Corporation   NASDAQ LMNX    Hologic  Inc    NASDAQ HOLX   and Inogen Inc   NASDAQ INGN    Notably  Inogen and Luminex sport a Zacks Rank  1  Strong Buy   while Hologic carries a Zacks Rank  2  Buy   You can see Inogen promises a long term adjusted earnings growth of almost 17 5   The stock returned 84 1  in the last one year Luminex has an expected long term adjusted earnings growth of almost 16 3  and the company s stock added roughly 17 6  in the last three months Hologic has a long term expected earnings growth rate of 11 33   The stock has a solid one year return of roughly 28 8  
 Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy  You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-05-18,Zacks Investment Research,"https://www.investing.com/analysis/mckesson-(mck)-beats-earnings-estimate-in-q4,-revenues-miss-200190273",200190273
128052,349567,MCK,Quest Diagnostics To Buy 2 Labs  Grow In Oncology Space,opinion,In order to accelerate growth in the cancer diagnostic segment  Quest Diagnostics   NYSE DGX   recently announced agreements to acquire two laboratory businesses in Lewisville  Texas  namely Med Fusion and Clear Point  The businesses jointly provide a complete range of diagnostic services to physicians and provider networks These deals are aimed at establishing a center of excellence for providing diagnostic services to detect and manage cancer for oncologists and patients all over the country  Baylor Scott   White Health  BSWH   The US Oncology Network or the Network  supported by McKesson  NYSE MCK  Specialty Health   Texas Oncology and Pathologists Bio Medical Laboratories  PBM  are co owners of one or both the businesses Post the deal closure  Quest Diagnostics will become a preferred provider of advanced oncology diagnostics for The Network and Texas Oncology  The company will provide genomic and pathology testing solutions for oncologists to select and monitor treatment so that they can predict disease progression appropriately Quest Diagnostics Incorporated Price    Also  Quest Diagnostics will be a preferred provider of a complete range of inpatient and outpatient diagnostic services for 12 hospitals of Baylor Scott   White Health in North Texas  Post the deal  Quest Diagnostics and PBM will also have a preferred provider relationship for various services Per management  partnering with McKesson Specialty Health and The Network will make Quest Diagnostics  advanced genomic analysis readily available to community oncologists everywhere  The company is also hoping to work with BSWH to offer wider access to high quality and high value services The deal is expected to be closed in the third quarter of 2017  subject to certain conditions The deal is in sync with Quest Diagnostics  goal to gain traction in the high potential global oncology diagnostic market  On account of data provided by American Cancer Society  nearly 1 7 million people are expected to be diagnosed with cancer in the U S  in 2017 According to Markets and Markets  the global cancer diagnostics market is expected to reach a worth of  13 1 billion by 2020 at a CAGR of 12 9  during 2015 to 2020  The company clearly has bountiful opportunities in this niche market Recent DevelopmentsWithin its advanced diagnostics business  Quest Diagnostics  along with its onchology francise partner Memorial Sloan Kettering  has teamed up with IBM  NYSE IBM  to form IBM Health Watson  With about 70  of the oncology prospects being in community healthcare centers instead of large urban centers  this is an opportunity for all the three companies to gain a significant portion of the market Zacks Rank   Key PicksQuest Diagnostics currently carries a Zacks Rank  2  Buy   Other top ranked medical stocks are Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    Notably  Align Technology and Inogen sport a Zacks Rank  1  Strong Buy   while Accelerate Diagnostics carries a Zacks Rank  2  You can see Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock added roughly 32 8  over the last three months Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 80  Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock added roughly 12  over the last three months Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-06-13,Zacks Investment Research,"https://www.investing.com/analysis/quest-diagnostics-to-buy-2-labs,-grow-in-oncology-space-200194883",200194883
128053,349568,MCK,Should Value Investors Consider McKesson  MCK  Stock ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put McKesson Corporation   NYSE MCK   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  McKesson has a trailing twelve months PE ratio of 12 67  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 34  If we focus on the long term PE trend  McKesson s current PE level puts it below its midpoint of 15 57 over the past five years  Moreover  the current level stands well below the highs for the stock  suggesting that it could be a solid entry point Further  the stock s PE also compares favorably with the Zacks classified Medical sector s trailing twelve months PE ratio  which stands at 19 90  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should also point out that McKesson has a forward PE ratio  price relative to this year s earnings  of 13 25  so it is fair to expect an increase in the company s share price in the near future P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  McKesson has a P S ratio of about 0 18  This is significantly lower than the S P 500 average  which comes in at 3 15 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  MCK is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  McKesson currently has a Zacks Value Style Score of  A   putting it into the top 20  of all stocks we cover from this look  This makes McKesson a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for McKesson is just 1 91  a level that is lower than the industry average of 2 11  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 5 68  which is far better than the industry average of 13 92  Clearly  MCK is a solid choice on the value front from multiple angles What About the Stock Overall Though McKesson might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of  A  and a Momentum score of  C   This gives MCK a Zacks VGM score or its overarching fundamental grade of  C    You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been quite mixed  The current quarter has seen two upward and downward estimate revisions each in the past sixty days  while the full year estimate has seen seven upward and no downward revisions in the same time period This has had a somewhat positive impact on the consensus estimate  as the current quarter consensus estimate is the same as it was two months ago  while the full year estimate has increased 4 6   You can see the consensus estimate trend and recent price action for the stock in the chart below McKesson Corporation Price and Consensus    However  this somewhat bullish trend has likely not yet been reflected in the stock  as we have just a Zacks Rank  3  Hold   which indicates expectations of in line performance in the near term  Nonetheless  the bullish analyst sentiment indicates that the stock s future prospects look good Bottom LineMcKesson is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  While this Zacks Rank  3 stock belongs to the Zacks categorized Medical Dental   Supplies industry that has underperformed the broader market in the last two years   the industry ranks among the Top 29  of the Zacks industries  This hints at favorable broader prospects  alongside signaling chances of revival So  value investors might want to wait for analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-mckesson-(mck)-stock-200196860,200196860
128078,349593,MCK,How Is Fidelity Select Health Care Services Portfolio Fund  FSHCX  Performing ,opinion,"Fidelity Select Health Care Services Portfolio Fund     a Zacks Rank  1  Strong Buy  was incepted in June 1986 and managed by the Fidelity Group  The objective of this health fund is to seek capital appreciation  FSHCX normally invests at least 80  of assets in common stocks of companies principally engaged in the ownership or management of hospitals  nursing homes  health maintenance organizations  and other companies specializing in the delivery of health care services

	This Sector   Health product  as of the last filing  allocates their fund in three major groups  Small Growth  Intermediate Bond and Large Value  Further  as of the last filing  UnitedHealth Group Inc  NYSE UNH   McKesson Corp  NYSE MCK  and Cigna Corp  NYSE CI  were the top holdings for FSHCX 

	The Fidelity Select Health Care Services Portfolio fund  managed by   carries an expense ratio of 0 77   Moreover  FSHCX requires a minimal initial investment of  2 500 

	FSHCX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 13 4  and 5 year 17 2   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

	FSHCX s performance  as of the last filing  when compared to funds in its category was in the top 42  over the past 1 year  in the top 35  over the past 3 years  and in the 73  over the past 5 years 

Want key mutual fund info delivered straight to your inbox 

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-11-09,Zacks Investment Research,https://www.investing.com/analysis/how-is-fidelity-select-health-care-services-portfolio-fund-(fshcx)-performing--200163868,200163868
128079,349594,MCK,Cerner Hurt By Low System Sales And Intense Competition,opinion,On Nov 25  we issued an updated research report on North Kansas City  MO based Cerner Corporation   NASDAQ CERN     a leading global provider of healthcare information technology solutions  HCIT   The stock currently carries a Zacks Rank  4  Sell  Cerner represents a negative return of 13 3  for the last one month  much lower than the S P 500 s almost 3 5  over the same time frame  In fact  over the last 30 days  the Zacks Consensus Estimate for full year 2016 earnings decreased by 6 cents to  2 14 per share  with one estimate moving down Notably  the stock recorded a negative earnings surprise of almost 1 8  in the last reported quarter On this note  Cerner ended third quarter 2016 on a dismal note  missing the Zacks Consensus Estimate for both the top and the bottom line  Also  the lowered revenue guidance for 2016  owing to reduced hardware revenues  is a dampener In the quarter  while System sales decreased 7 3  on a year over year basis there was a 21  decline in technology resale and 12  drop in licensed software  All these are likely to mar prospects for Cerner going ahead Coming to the HCIT space  of late the niche market has been gaining prominence  courtesy of latest technologies like EMR  Electronic Medical Record  and Electronic Health Record  EHR  Cerner  a major player in this space  has been facing cut throat competition from reputed names such as Allscripts Healthcare Solutions  Epic Systems  GE Healthcare Technologies  McKesson Corp  NYSE MCK   Quality Systems among others  This has impacted the company s pricing and margins to a great extent  Stringent hospital budgets exert further pressure on pricing As a result  Cerner s projected sales growth is now pegged at 8 65   much lower than the industry average of 18 5  However  we are upbeat about Cerner s Revenue Cycle management and Population Health platforms  The platforms posted strong results in the quarter  courtesy of solid sales  inclusion in new EHR deals and solid contribution from RevWorks services  revenue management services  Additionally  a long term expected earnings growth rate of 14 7  instills some confidence among investors Key PicksBetter ranked stocks in the broader medical space include HMS Holdings Corp    NASDAQ HMSY    Medidata Solutions Inc    NASDAQ MDSO   and IDEXX Laboratories  Inc    NASDAQ IDXX    Notably  HMS Holdings and Medidata Solutions carry a Zacks Rank  2 while IDEXX Laboratories sports a Zacks Rank  1  Strong Buy   You can see  HMS Holdings Corp has a long term expected growth rate of 14 26   Notably  the company has a solid one year return of roughly 58 8  Medidata Solutions has a strong one year return of roughly 18 22   The stock represents a long term expected growth rate of 22 33  IDEXX Laboratories represents a solid one year return of almost 70 09   The company has a long term expected growth rate of almost 14 96  Zacks  Best Private Investment Ideas In addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ,2016-11-28,Zacks Investment Research,https://www.investing.com/analysis/cerner-hurt-by-low-system-sales-and-intense-competition-200166895,200166895
128080,349595,MCK,MedTech Sails Through Macro Woes  Stocks In Focus,opinion,"Three full quarters of 2016 are behind us and  as expected  the trend has hardly changed for the bullish MedTech sector even amid severe economic instability surrounding one of the most controversial political power changes in history  This is because some powerful long term tailwinds like mergers   acquisitions  M A   emerging market expansion  positive demographic trends and new product innovation are the vital forces behind the continued uptrend in the sector s performance 
In addition  the recent change in consumer demand and market dynamics led to a dramatic transformation in the healthcare system  This is evident from the growing prevalence of minimally invasive surgeries  rising demand for liquid biopsy tests  use of IT for ensuring efficient patient care and the shift of the payment system to a value based model 
Let s go through some of the major long term tailwinds of the MedTech sector 
Major M As
By now we know how Medtronic  NYSE MDT   MDT  knocked Johnson   Johnson  NYSE JNJ   JNJ  from its indisputable position as the top firm in the medical devices space  thanks to its  43 billion Covidien merger  It s really amazing how a single mega consolidation shook up the dynamics of the entire medical devices space 
And after that the industry hasn t taken a breather with strategic mega consolidations continuing to pour in  Deals like Zimmer Biomet  ZBH   Johnson   Johnson Synthes  Thermo Fisher Life Technologies and many more gave birth to unprecedented leaders in their respective niche markets 
Although going by the last available EvaluateGroup data  the first half of 2016 witnessed a slump is mergers and acquisitions on a very tough year ago comparison  there are a number of sector changing deals in the pipeline  Most notable among these is Abbott Laboratories   ABT  impending consolidation with St  Jude Medical for a deal value of  25 billion  Post completion  this will create a leader in high growth cardiovascular markets 
Apart from this deal  Abbott has inked a number of deals this year which include its  5 8 billion agreement to acquire Alere  ALR  which should strengthen its presence and leadership in the global diagnostics market  As per EvaluateGroup data  following the completion of these deals  the company will capture the third place in company rankings in 2022  with potential sales of around  22 billion 
Also  Zimmer Biomet s impending acquisition of LDR Holding Corp  for a total deal value of  1 billion is expected to boost the spine portfolio of the former 
Other recently completed significant acquisitions are 
Thermo Fisher  TMO  Affimetrix  The acquisition of Affymetrix for  1 3 billion is expected to boost Thermo Fisher s biosciences and genetic analysis portfolio 
Thermo Fisher FEI Company  Thermo Fisher acquired FEI Company for  4 2 billion  FEI s industry leading high performance electron microscopy platform used for protein study will facilitate Thermo Fisher s life science research 
Medtronic  MDT  HeartWare  Recently  Medtronic acquired this company for a total value of  1 1 billion  This acquisition is expected to significantly boost Medtronic s cardiac rhythm and heart failure business  alongside providing a strong foothold in the global market 
Divestments 
Medical device majors continue to offload their non core business segments  specifically to focus on the main segments and to divest assets that are similar to the ones acquired through mergers  as required by the U S  Federal Trade Commission  FTC  and other international anti trust regulators  This restricts the chance of monopoly practice in the market 
Let s take a look at some of the significant divestments of recent times 
Abbott announced that it will divest its eye care business Abbott Medical Optics to Johnson   Johnson for about  4 33 billion in order to better streamline its newly added businesses 
Wright Medical s  WMGI  recent divestment of its large joints  hip knee  business to CorinOrthopaedics is an example of the company s focus on its core businesses 
On the other hand  in its motto to reduce and refine its portfolio and repay its debts  Community Health Systems  Inc   CYH  has decided to divest its Rockwood Health System and associated assets to MultiCare Health System 
Emerging Market Openings
As per recent data from Euromonitor International  the global medical device production value is likely to register strong growth of almost 6  in 2016  to reach  315 billion  While the traditional market continues to be plagued by difficulties like growing regulatory scrutiny and pricing pressure  it s the Asia Pacific region on which all bets are being placed this year 
The MedTech market in Asia Pacific grew the fastest at a CAGR of 10  during 2008 2014 and is expected to continue to grow rapidly over 2016 as well  According to the report  China and India s healthcare service revenues are expected to grow by 12  and 9   respectively  in 2016 alone 
Abbott continues to lead the emerging market investment trend with about 50  of sales from this region  In the third quarter of 2016  sales in key emerging markets climbed in double digits driven by growth in India  China and Latin America 
At Medtronic  emerging markets demonstrated strong growth in its second quarter of fiscal 2017  contributing 120 basis points  bps  to the company s overall revenue growth  Boston Scientific Corp   NYSE BSX  achieved 19  organic growth in emerging markets in the third quarter  driven by 26  growth in China and 21  growth in Latin America 
R D  Innovations
According to a survey by KPMG  the number of medical device companies that expect to spend more than 6  of revenue on R D innovation is rising and is fast exceeding the number of companies spending on R Ds in other manufacturing industries 
Edwards Lifesciences   EW  SAPIEN or its competitive product Medtronic s CoreValve transcatheter heart valve or surgical aortic valves are one of the most appropriate examples of such breakthrough innovations  As the global heart valves market is projected to grow at a CAGR of 14 28  during the period 2016 2020  according to the latest Market Research Report   it is needless to say how impactful these breakthroughs are for the Medtech market for it to remain on its growth trajectory 
Strongest Links
Among the medical product stocks  Nxstage Medical  Inc   NXTM  looks attractive  sporting a Zacks Rank  1  Strong Buy  and with a VGM score B  We note that  stocks with a  of A or B and a Zacks Rank of  1 or  2 have highest probability of success 
Other medical product stocks fitting the criteria are Cardiovascular Systems  Inc   CSII   Eagle Pharmaceuticals  Inc   EGRX  and Haemonetics Corp   HAE  among others with a Zacks Rank  2 and VGM Score B 
In the medical instrument space  we are positive on Cogentix Medical  Inc   CGNT  with a Zacks Rank  1 and VGM score B  AngioDynamics  Inc   ANGO  with a Zacks Rank  2 and VGM score B and Natus Medical Inc   BABY  with a Zacks Rank  2 and VGM score A 
Weaker Stocks
Coming to the weakest links in the MedTech sector  we advise investors to stay away from names that offer little growth opportunity in the near term  These include companies for which estimate revision trends reflect a bearish sentiment 
Stocks which do not look inspiring are Abaxis  Inc   ABAX   BioScrip  Inc   BIOS   Illumina  NASDAQ ILMN   Inc   ILMN   ResMed Inc   RMD  and Steris Plc  STE   each carrying a bearish Zacks Rank  4  Sell   Meridian Bioscience  Inc   VIVO  and McKesson Corp  NYSE MCK    MCK  bear a Zacks Rank  5  Strong Sell  ",2016-12-02,Zacks Investment Research,https://www.investing.com/analysis/medtech-sails-through-macro-woes:-stocks-in-focus-200168069,200168069
128081,349596,MCK,Inovalon Holdings Inc Shares Crash Down On Lower Guidance Numbers,opinion,"Inovalon Holdings Inc  NASDAQ INOV 
Inovalon Holdings  Inc   INOV   announced yesterday reported that they are updating their Full year 2016 Financial guidance numbers  Inovalon has updated their Non GAAP net income per share to be  0 32 to  0 33 per share which is lower than their previous guidance of  0 39 to  0 46 per share  Inovalon updated their full year revenue numbers to be in between  426 to  428 million which is down from previous guidance of  470 to  490 million 
Inovalon Holdings  Inc  CEO s Comments

Keith Dunleavy  M D   Chief Executive Officer and Chairman of the Board of Inovalon commented   While this is certainly not the situation we expected or desired  it does demonstrate the level of market opportunity for our platform capabilities  the significance of value that can be driven by those capabilities  and the size and scale at which Inovalon is being called upon to partner and deliver them   

INOV Technical Analysis

INOV opened trading yesterday at  15 05 which was exactly the same as the previous day s trading close  INOV closed trading yesterday at  14 85 and crashed down after market to  9 95  equivalent to a 33  decrease from the closing price  Taking a look at the daily chart we can see that we are in unchartered territory as INOV is now trading at all time lows  Taking a closer look at the daily chart we can see that before the spike down INOV had already been in an overall downward trend dating back to November 25th when it traded at highs of  16  INOV has a float of 53 81 million shares and traded below the normal daily trading volume on Monday  For trading purposes  I would like to see INOV open trading on Tuesday below  11 50 and if it does I would be looking to take a short position at the bell  My stop loss would be  0 30 from my entry position fearing anything more than that and the stock would start to fill in the gap down 
Company Profile
Inovalon Holdings  Inc   incorporated on September 11  2014  is a technology company  The Company combines advanced cloud based data analytics and data driven intervention platforms to provide services for health plans  hospitals  physicians  patients  pharmaceutical companies and researchers  The Company operates through developing cloud based data analytics and data driven intervention platforms segment and provides related services to its clients  The Company s datasets  integration technologies  predictive analytics and subject matter expertise allows the Company to provide platforms  Its analytics platforms identify gaps in care  quality  data integrity and financial performance in its clients  datasets  The Company s data analytics and intervention platforms consist of four primary components  data integration  advanced analytics  intervention platforms and business processing  The Company integrates data into its systems through its Extract  Transform  Load  ETL  tools and processes 
This system manages the process of defining and configuring thousands of industry data feeds from its clients and partners  such as electronic health records  EHR   laboratory  pharmacy  patient reported  claims  paper based medical records  biometric and hospital data feeds respectively  manages the data processing workflow  and monitors the ongoing provision and quality of data through the application of approximately 2 000 data integrity checks  In addition  to being maintained and tagged within client specific data lakes  data the Company receives in the course of providing its services are statistically de identified and stored in its MORE2 Registry  The MORE2 Registry includes information about demographics  enrollment  diagnoses  procedures  pharmacy  laboratory results and deep medical record clinical data  and presents a representative mix of commercial  HIX Marketplace  Medicare Advantage and managed Medicaid care plan patients The Company competes with Oracle  NYSE ORCL   Dell  SAP  SAS  IBM  NYSE IBM   Accenture plc  NYSE ACN   Deloitte Consulting  McKesson  NYSE MCK   OptumHealth  Truven  Verisk  DST Health  The Advisory Board  Alere  Altegra  Matrix  edifecs and Silverlink ",2016-12-13,Warrior Trading,"https://www.investing.com/analysis/inovalon-holdings,-inc.-$inov-stock-shares-crash-down-on-lower-guida-200169645",200169645
128110,349625,MCK,McKesson Corp  MCK  Stock Down Over 24  Today ,opinion,"On Friday  pharmaceutical giant McKesson Corp   NYSE MCK   experienced a 24  drop in their stock price  down to  124 57  as of 3 15pm central  This comes after the release of their 2nd quarter fiscal 2017 earnings 
MCK reported revenue of  49 96B and earnings of  2 94 per share  These figures are lower than expectations  which projected earnings of  3 04 per share and revenue of  51 2B  MCK CEO John Hammerger explained how the company needed to lower drug prices in order to reciprocate competition  This explains the sudden drop in stock price  as investors displayed uncertainty in MCK s future earnings 
Hammerger displayed annoyance while discussing competition and the drop in prices  saying   What we began to see more recently is competitive activity that is broader than our original expectations  more aggressive  and across several areas of our U S  pharmaceutical business  When a competitor significantly undercuts our existing pricing  we are compelled to respond  
The hope for MCK is that investors will see value in their impressive track record  Historically  the company has been able to post notable growth on both revenue and EPS  and recently  McKesson separated its technology sector from its other businesses  According to Zacks  MCK analysis summary page  McKesson  has been actively pursuing deals and acquisitions to drive growth  The separation of its Technology business into a new healthcare information technology that will enable the company to concentrate on the primary pharmaceuticals distribution business  
This explains why Zacks Rank had Value  Growth and VGM all rated at  A  as of October 27  2016  The company is showing growth and focus on their most profitable sector  However  with its current standing  it s clear to why the stock was downgraded from a  3  Hold  to a  4  Sell  on the Zacks Rank 
Interested in the other top stories of the week  Listen to Zacks Friday Finish Line to catch up on the week s financial and investment news 


Stocks that Aren t in the News Yet
You are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street  They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015  with a stellar average gain of  26  per year ",2016-10-28,Zacks Investment Research,https://www.investing.com/analysis/mckesson-corp-(mck)-stock-down-over-24-today-200161478,200161478
128111,349626,MCK,Q3  16 S P 500 Earnings Look Healthy  With Or Without Energy ,opinion,"The headline on this week s Thomson Reuters  This Week in Earnings  is that S P 500 earnings are  3 6  after 300 of the S P 500 companies have reported their 3rd quarter  2016  results 
Ex Energy  S P 500 have grown  6 7  
About a month ago  this blog predicted   based on historical surprise factors 
Now here is the catch  Exxon  NYSE XOM  and Chevron  NYSE CVX  reported their Q3  16 financial results Friday morning  October 28th  2016  while Thomson Reuters cuts off the data as of Thursday night  and with XOM s revenue miss  we could see different data as soon as Monday  October 31  16 
In other words  with XOM being  by far  the biggest component of the Energy space and Energy being the largest expected delta within the S P 500 over the next few quarters  the revisions for XOM and CVX matter 
Monday or Tuesday night  look for an update on Energy estimates on this blog  for Q4  16 and forward quarters 
Thomson Reuters by the data  as of Thursday  10 27 16
Forward 4 quarter estimate   128 97 vs last week s  129 16
P E ratio  16 5 x 
PEG ratio  4 4 x 
S P 500 earnings yield  6 07  vs last week s 6 03   Usually an S P 500 earnings yield above 6  has triggered a decent rally 
Year over year growth rate of forward estimate   3 74  vs last week s 3 83    Most recent high from late 2014 was over 7   Readers can see the dramatic effect the Energy collapse has had on S P 500 earnings  
Conclusion  This requires a separate blog post later this weekend  but for Q4  16  Technology and Financials are the two sectors seeing higher upward revisions  versus the current Q3  16 results  Again  it bears repeating many times for readers  but the trend in revisions at this time for forward quarters is usually downward  so to see upward revisions for a sector is an important tell 
The takeaway today is that Q3  16 earnings look very healthy  The financial media will crow how Q3  16 is the first quarter of positive earnings growth in the last 3 4 5 quarters  but that was easy to see coming just from the S P 500 earnings  surprise  factor  On average the S P 500 actual results usually come in 3    5  higher than the expected growth rate on Jan 1  April 1  July 1 and October 1 
Health Care was ugly this week  and again  because McKesson  NYSE MCK  and Amgen  NASDAQ AMGN  reported Thursday night  and Friday morning  10 28 16  the revisions following those numbers are NOT in the Thomson Reuters data as of this weekend 
Our two largest sector overweights for clients are Technology and Financials  the rationale for the weightings was that these two sectors saw their bear markets last decade and thus all the valuation excess and optimism was flushed entirely from these sectors  which also happen to be the two largest sectors of the S P 500 comprising about 35  of the S P 500 by market cap   Health Care may now be the 2nd largest weighting in the S P 500 by market cap   now that real estate has been spun out from Financial s  but the out performance in Financial s since Q3 started and now with Health Care woes the last 8 weeks  might have narrowed some of the differential  
Just 9  of Health Care stocks are trading above their respective 50 day moving averages  per a chart from Bespoke published Thursday  and that may have gotten worse on Friday  10 28 given the McKesson  MCK  and Amgen  AMGN  results ",2016-10-30,Brian Gilmartin,https://www.investing.com/analysis/q3-16-sp-500-earnings-3.6;-ex-energy-6.7-200161490,200161490
128112,349627,MCK,Moving Average Crossover Alert  McKesson  MCK ,opinion,McKesson Corporation   NYSE MCK   could be a stock to avoid from a technical perspective  as the firm is seeing unfavorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for MCK broke out below the 200 Day Simple Moving Average  suggesting short term bearishness This has already started to take place  as the stock has moved lower by 18  in the past four weeks  And with the recent moving average crossover  investors have to think that more unfavorable trading is ahead for MCK stock If that wasn t enough  McKesson isn t looking too great from an earnings estimate revision perspective either  It appears as though many analysts have been reducing their earnings expectations for the stock lately  which is usually not a good sign of things to come Consider that in the last 30 days  7 estimates have been reduced  while none has moved higher  Add this in to a similar move lower in the consensus estimate  and there is plenty of reason to be bearish here That is why we currently have a Zacks Rank  5  Strong Sell  on this stock and are looking for it to underperform in the weeks ahead  So either avoid this stock or consider jumping ship until the estimates and technical factors turn around for MCK  You can see  Confidential from Zacks Beyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-02,Zacks Investment Research,https://www.investing.com/analysis/moving-average-crossover-alert:-mckesson-(mck)-200162655,200162655
128140,349655,MCK,McKesson s IT Business To Merge With Change Healthcare,opinion,"McKesson Corporation   NYSE MCK   announced that it will collaborate with Change Healthcare Holdings to create a new healthcare information technology company  We note that Change Healthcare is a leading provider of software and analytics  network solutions and technology enabled services  with Blackstone  NYSE BX  Group as its largest stockholder  
Structure of the New Entity
As per the terms of the agreement  McKesson will offer majority of its Technology Solutions businesses  The company will  however  retain RelayHealth Pharmacy and Enterprise Information Solutions  EIS  
On the other hand  Change Healthcare will contribute all of its businesses to the new company  excluding its pharmacy switch and prescription routing units  which will be owned separately by the current stockholders of the company 
McKesson and Change Healthcare will own approximately 70  and 30   respectively  of the new company 
This new entity has received funding of  6 1 billion  via funded debt  which will be used to repay existing debt of approximately  2 7 billion of Change Healthcare  make cash payments of  1 25 billion to McKesson and  1 75 billion to Change Healthcare 
What to Expect from the Transaction
The transaction is slated to close in the first half of 2017  As per the agreement  McKesson and Change Healthcare will make efforts to launch an initial public offering post closure  The combination of Change Healthcare s business with the majority of McKesson s Technology Solutions business will create a diverse portfolio of technological solutions which should help lower healthcare costs  improve patient access and outcomes  and make it simpler for payers  providers and consumers to manage the transition to value based care  
The new entity  with combined annual revenues of  3 4 billion  is expected to generate synergies in excess of  150 million by the second year of closing deal  Since the separate entity will focus solely on healthcare technology and technology enabled services  it should be able to respond more efficiently to customer needs and better deliver next generation innovations  while addressing the three important areas   cost  quality and outcomes   across the healthcare sector MCKESSON CORP Price
   Our Take
McKesson s Technology Business has been facing challenging conditions for quite some time now as revenues continued to decline  Hence  a spin off of the business was around the corner as the company was looking to focus on its core distribution business 
We believe that the separation is a positive for the company as it can now concentrate on its primary pharmaceuticals distribution business  This business has also been facing headwinds in the form of pricing trends and negative impact from customer consolidation in the healthcare supply chain 
Meanwhile  the company is exploring strategic alternatives for the EIS division and we believe a divestiture of this business is coming up 
McKesson currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Co    NYSE BMY   and Johnson   Johnson   NYSE JNJ    While Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Johnson   Johnson is a Zacks Rank  2  Buy  stock ",2016-06-29,Zacks Investment Research,https://www.investing.com/analysis/mckesson's-it-business-to-merge-with-change-healthcare-200139108,200139108
128141,349656,MCK,McKesson Raises View Due To Accounting Changes  Stock Up,opinion,"Shares of McKesson Corporation   NYSE MCK   were up 3 83  after the company announced an increase in its guidance for fiscal 2017 
The company now expects earnings per share in the range of  13 43 13 93  up from the previous expectation of  13 30  13 80  The new guidance excludes charges of approximately 12 cents to 15 cents relating to the cost alignment plan undertaken by management earlier this year 
McKesson raised its fiscal 2017 guidance due to the early adoption of Accounting Standards Update 2016 09  as released by the Financial Accounting Standards Board  The standards primarily relate to stock based compensation and the impact of foreign currency exchange effects  related in particular to British pound sterling denominated activities following the UK s exit from the European Union 
Meanwhile  the company continues to expect growth in the high single digits at the Distribution Solutions segment  driven by market expansion and acquisitions in fiscal 2017  On a constant currency basis  the Pharmaceutical distribution and services business in North America is projected to grow in the high single digits as well  while international Pharmaceutical distribution and services revenues increase in the low double digits  Revenues at the Medical Surgical distribution and services division are projected to grow in the mid single digits MCKESSON CORP Price
   We note that McKesson has been facing challenging business conditions  Branded drug price trends in the U S  market are expected to be modestly below 2016 levels in the U S  The company expects a nominal contribution from price increase of generic pharmaceuticals in fiscal 2017  Contributions from the launch of new oral generic pharmaceuticals in the U S  market are also expected to decrease year over year 
Earlier this week  McKesson announced that it will collaborate with Change Healthcare Holdings to create a new healthcare information technology company  McKesson will offer majority of its Technology Solutions businesses for the new company  It will  however  retain RelayHealth Pharmacy and Enterprise Information Solutions 
McKesson s Technology Business has been facing challenging conditions for quite some time now as revenues continued to decline  Hence  a spin off of the business was around the corner as the company was looking to focus on its core distribution business   Read here   
McKesson currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Co    NYSE BMY   and Johnson   Johnson   NYSE JNJ    While Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Johnson   Johnson is a Zacks Rank  2  Buy  stock 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-30,Zacks Investment Research,"https://www.investing.com/analysis/mckesson-raises-view-due-to-accounting-changes,-stock-up-200139379",200139379
128142,349657,MCK,McKesson  MCK  Q1 Earnings  Stock Likely To Beat ,opinion,"McKesson Corporation   NYSE MCK   is scheduled to report first quarter fiscal 2017 results on Jul 27  after the market closes 
The company has beaten estimates in three out of the last four quarters with an average earnings surprise of 0 45   Let s see how things are shaping up for this announcement 
Factors Influencing This Quarter
McKesson is a major player in the pharmaceutical and medical supplies distribution market  The company s distribution solutions segment recorded steady growth on the back of a robust performance of the U S  pharmaceutical business over the last few quarters 
Although the company faced challenges related to a shift in generic pharmaceutical pricing trends and customer consolidation in the pharmaceuticals business in the U S   McKesson expects the business to perform strongly   In Jun 2016  management raised its fiscal 2017 guidance due to the early adoption of Accounting Standards Update 2016 09  as released by the Financial Accounting Standards Board  The standards primarily relate to stock based compensation 
The company also updated its guidance to reflect the impact of foreign currency exchange effects  related particularly to the British pound sterling denominated activities following the UK s exit from the European Union  The company continues to expect growth in the high single digits at the Distribution Solutions segment driven by market expansion and acquisitions in fiscal 2017 
On a constant currency basis  the pharmaceutical distribution and services business in North America is projected to grow in the high single digits as well  while international Pharmaceutical distribution and services revenues witness low double digit growth  Revenues at the  Medical Surgical distribution and services division are projected to grow in the mid single digits 
The company acquired Biologics and Vantage Oncology in Apr 2016 in a bid to expand specialty pharmaceutical distribution  oncology focused pharmacy offerings  and solutions for manufacturers and payers 
In Jan 2016  McKesson undertook a review of its cost structure and planned to realign its business model for better efficiency  value and innovation 
On the other hand  McKesson collaborated with Change Healthcare Holdings to create a new healthcare information technology company  McKesson will offer majority of its Technology Solutions businesses for the new company  It will  however  retain RelayHealth Pharmacy and Enterprise Information Solutions 
McKesson s Technology Business has been facing challenging conditions for quite some time now as revenues continued to decline  Hence  a spin off of the business was around the corner as the company was looking to focus on its core distribution business  The company is also evaluating strategic alternatives for its Enterprise Information Solutions business MCKESSON CORP Price and EPS Surprise
   What Our Model Indicates
Our proven model shows that McKesson is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates and McKesson has the right mix 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 20   This is because the Most Accurate estimate is pegged at  3 38  while the Zacks Consensus Estimate stands at  3 34 
Zacks Rank  McKesson currently carries a Zacks Rank  2  The combination of McKesson s favorable Zacks Rank and positive ESP makes us reasonably confident of a positive surprise this season 
Conversely  we caution against Sell rated stocks   4 or  5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks That Warrant a Look
Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter 
Ironwood Pharmaceuticals   NASDAQ IRWD   has an Earnings ESP of 13 3  and a Zacks Rank  2  The company is expected to report earnings on Aug 4 
Bristol Myers Squibb Co    NYSE BMY   has an Earnings ESP of  1 49  and a Zacks Rank  1  The company is scheduled to report second quarter results on Jul 28 
Exelixis  Inc    NASDAQ EXEL   has an Earnings ESP of 3 70  and a Zacks Rank  3  The company is scheduled to report results on Aug 3 ",2016-07-25,Zacks Investment Research,https://www.investing.com/analysis/mckesson-(mck)-q1-earnings:-stock-likely-to-beat-200144019,200144019
128175,349690,MCK,UDG Healthcare  Scope To Grow Faster With Sale Of Drug Distribution ,opinion,"UDG Healthcare  London UDG  plans to divest its drug distribution and travel health businesses to McKesson  NYSE MCK  for  408m  At 11 5x 12 month trailing EBITDA  the sales multiple looks attractive in view of McKesson paying 10 5x EBITDA for Celesio in 2014  The deal concludes UDG s transformation from low growth  low margin drug distribution to more dynamic and profitable healthcare outsourcing services  Our forecasts and valuation are under review 
We estimate the planned sale of Supply Chain Services  SCS  and MASTA travel clinics will accelerate UDG s pro forma operating profit CAGR FY16 20e from 6  to 8   The deal will reduce regulatory and pricing pressures  which have depressed SCS s operating profit from  46m in FY13 to  33m in FY15e  while joint operating profits in Sharp and Ashfield have grown from  48m to  87m 
Based on  27m divested EBITA   3m reduced interest costs and  1 2m lower corporate overhead  we estimate the deal will initially dilute earnings by c 20   2015e pro forma   However  we forecast UDG s pro forma FY15e financial firepower will rise from  130m to a minimum  380m  based on 2 5x debt EBITDA  excluding both  35m EBITDA in sold businesses and extra borrowing capacity from acquired EBITDA   as well as net cash of  103m after the deal  At 11x EBITA  UDG bought KP360 at 9x   UDG could buy  35m EBITA and offset the initial earnings dilution even including  12m interest costs  External and accelerated organic growth in Ashfield and Sharp may spur EBITA growth to a double digit level 
UDG announced that COO Brendan McAtamney will take over from CEO Liam Fitzgerald in March 2016  concluding a well flagged leadership transition process 
To Read the Entire Report Please Click on the pdf File Below ",2015-09-21,Edison,https://www.investing.com/analysis/scope-to-grow-faster-with-sale-of-drug-distribution-265709,265709
128176,349691,MCK,UDG Healthcare ,opinion,"Drug distribution disposal boosts growth potentialUDG s  L UDG  proposed sale of its drug distribution units should improve growth and reduce operating risk  With a solid track record in M A  it is well placed to create shareholder value by reinvesting in its fast growing Ashfield and Sharp divisions  Our DCF valuation is 503 631p per share 

Sole focus on commercial healthcare outsourcingThe disposal of the low growth and low margin drug wholesaling and MASTA travel clinics activities to McKesson  N MCK  for  408m leaves UDG solely focused on high growth healthcare outsourcing  With  700m in financial resources and a strong track record with recent investments  UDG is now better placed to create shareholder value through acquisitions in Ashfield and increased capex in Sharp  respectively 
To Read the Entire Report Please Click on the pdf File Below",2015-11-13,Edison,https://www.investing.com/analysis/udg-healthcare-271228,271228
128177,349692,MCK,McKesson  MCK  Q4 Earnings  Stock Likely To Disappoint,opinion,McKesson Corporation   NYSE MCK   is scheduled to report fourth quarter fiscal 2016 results on May 4  after the market closes McKesson has an impressive track record  having beaten estimates comfortably in all of the last four quarters with an average earnings surprise of 6 91   Let s see how things are shaping up for this announcement Factors Influencing This QuarterMcKesson is a major player in the pharmaceutical and medical supplies distribution market  The company s distribution solutions segment recorded steady growth on the back of robust performance at the U S  Pharmaceutical business over the last few quarters Concurrent with the fiscal third quarter call  McKesson affirmed its guidance for fiscal 2016  ending Mar 31  2016   which was originally provided on Jan 11  Generic pricing trends are projected to remain weak in the second half of the year  Generic pricing and customer transitions are anticipated to adversely impact fiscal 2017 results  The ongoing customer consolidation is also expected to impact its business Meanwhile  McKesson has been actively pursuing deals and acquisitions to drive growth  After acquiring Celesio in 2014  the company recently took over Vantage Oncology and Biologics Inc  to further strengthen its specialty pharmaceutical distribution scale and broaden its oncology focused pharmacy offerings  and solutions for manufacturers and payers  Moreover  the recently announced acquisition of Rexall Health will strengthen McKesson s pharmaceutical supply chain in Canada  Furthermore  the buyout of Sainsbury s pharmacies will add 281 new pharmacies to the Lloyd s Pharmacy brand in the UK In Mar 2016  the company announced a restructuring plan to lower its operating costs  Per the plan  the company will reduce its workforce and realign its business process initiatives in three years  McKesson expects to record charges  pre tax  of approximately  300 million to  330 million as a result of the restructuring plan  Of these expenses  approximately  250  275 million will be incurred in the fourth quarter of fiscal 2016  while the remainder will be recognized by the end of fiscal 2019  Majority of these charges will comprise severance and employee related costs  while remaining expenses will be on account of exit related costs  asset impairment and accelerated depreciation What Our Model IndicatesOur proven model does not conclusively show that McKesson is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  which is not the case here Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  20 81   This is because the Most Accurate estimate is  2 36  while the Zacks Consensus Estimate stands at  2 98 Zacks Rank  McKesson carries a Zacks Rank  4  Sell   As it is  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing a negative estimate revision momentum Stocks That Warrant a LookHere are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter Jazz Pharmaceuticals plc   NASDAQ JAZZ   has an Earnings ESP of  4 58  and a Zacks Rank  3  The company is expected to release first quarter results on May 10 Impax Laboratories Inc    NASDAQ IPXL   has an Earnings ESP of  8 89  and a Zacks Rank  3  The company is expected to release first quarter results on May 10 Intrexon Corporation   NYSE XON   has an Earnings ESP of  17 39  and a Zacks Rank  3  The company is expected to release first quarter results on May 10 ,2016-05-01,Zacks Investment Research,https://www.investing.com/analysis/mckesson-(mck)-q4-earnings:-stock-likely-to-disappoint-200127236,200127236
128178,349693,MCK,Wal Mart Ties Up With McKesson To Boost Pharmacy Offerings,opinion,Retail giant  Wal Mart Stores Inc    NYSE WMT   has been looking to strengthen its health related business as well as cut costs in its pharmacy operations As a part of this initiative  the company has inked a sourcing agreement for generic pharmaceuticals and an expanded long term distribution agreement with healthcare service company McKesson Corporation   NYSE MCK    Under this  the companies will collaborate on sourcing generic pharmaceuticals for their U S  operations  adding scale and value to both the companies Wal Mart and McKesson have been working together for years in the pharmaceutical category and this latest sourcing agreement strengthens the ties between the companies Wal Mart will benefit from McKesson s demonstrated strength and expertise in the global pharmaceutical industry  Meanwhile  McKesson will benefit from Wal Mart s brand name as well as its commitment to deliver health and wellness services at a low price The new agreement is expected to provide Wal Mart the opportunity to counter the headwinds it has been facing  The company has been facing intense competition on all fronts  ranging from dollar stores to traditional grocery store chains and online business  Its international operations are also under pressure with a stronger dollar affecting sales  At the same time  Wal Mart projects slower growth in small format Express stores due to price competition from local grocers in some markets The Bentonville  AR based company is facing severe challenges and showing signs of weakness  Wal Mart expects to incur huge e commerce expenses  In an effort to compete with the biggest online retailer Amazon com   NASDAQ AMZN   and to improve customer service  Wal Mart is aggressively investing in its e commerce business  Wal Mart s focus on e commerce will in turn lower profit margin  considering shipping costs and price competition Wal Mart is slated to report first quarter fiscal 2017 results  before the opening bell on May 19  Last quarter  this retail giant posted a positive earnings surprise of 2 05  Wal Mart carries a Zacks Rank  3  Hold   A better ranked stock in the retail sector is The Kroger Company   NYSE KR   with a Zacks Rank  2  Buy  ,2016-05-17,Zacks Investment Research,https://www.investing.com/analysis/wal-mart-ties-up-with-mckesson-to-boost-pharmacy-offerings-200130738,200130738
128210,349725,MCK,Top Trade Ideas   Week Of November 17  2014  Aetna  McKesson And More,opinion,"Here are the Rest of the Top 10 
Aetna  Ticker  AET
Aetna  NYSE AET  pulled back with the market  making a lower low and breaking below the 200 day SMA for the first time since November 2012  The recovery finds it back at resistance and consolidating  As it does  the RSI is in the bullish zone but looking a little tired and the MACD is leveling  A break higher could reignite the trend up 
Altera  Ticker  ALTR
Altera  NASDAQ ALTR  pulled back to the November 2013 lows with the market but has been on fire since  The stair step higher finds it consolidating over the SMA s and attempting a break higher Friday  Both the RSI and MACD support more upside 
Alliance Resource Partners  Ticker  ARLP
Alliance Resource Partners  NASDAQ ARLP  also did the  V  thing with the market  quickly recovering to the prior high  A quick pullback and then move higher Friday is starting to look like an Inverse Head and Shoulders pattern  should it break the neckline at about 49  The RSI is bullish and turning back higher and the MACD is flat but positive 
McKesson  Ticker  MCK
McKesson  NYSE MCK  had a strong trend higher until it made the  V   Now it is recovering from a small pullback  and testing trend resistance after holding at 200  The RSI is in the bullish zone and rising with a MACD that averted a cross down and is rising now as well 
Valeant Pharmaceuticals  Ticker  VRX
Valeant Pharmaceuticals  NYSE VRX  came back from the October  V  to prior resistance and a new higher high  Recently a mini V sees it back at that high  and 6 month resistance  There is a complex Inverse  bashed in  Head and Shoulders at work as well  The RSI is rising and bullish while the MACD is about to cross up giving a bullish signal 
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into the last full week before the Holiday season and November Options Expiration  sees the equity markets continuing to look better on the longer timeframe than on the daily  Elsewhere look for Gold to continue the bounce in its downtrend while Crude Oil heads lower  The US Dollar Index looks to continue to move sideways with a chance of a pullback while US Treasuries are level in their pullback  The Shanghai Composite may consolidate in the uptrend while Emerging Markets muddle along sideways with a slight upward bias  Volatility looks to remain subdued keeping the bias higher for the equity index ETF s SPDR S P 500  ARCA SPY   iShares Russell 2000 Index  ARCA IWM  and PowerShares QQQ  NASDAQ QQQ   Their charts are not as firm in that regard though  with the IWM in consolidation mode short term and the SPY and QQQ stronger but also looking better in the longer timeframe  Use this information as you prepare for the coming week and trad em well 
Disclosure  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-11-16,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas---week-of-november-17,-2014:-aetna,-mckesson-and-more-232649",232649
128211,349726,MCK,Top Trade Ideas For The Week Of April 20  2015  The Rest,opinion,"Here are the Rest of the Top 10 
Aetna  NYSE AET 
Aetna  AET  moved out of a  W  like consolidation in November and has just kept going  Currently it is taking a breather  as it consolidates between 105 and 110  While the MACD is resetting lower during the consolidation the RSI is holding in the bullish zone  Look for a break of the zone for the next leg higher or a retrace below 100 
Jd Com Inc Adr  NASDAQ JD 
JD com  JD  rose out of its IPO to a peak in September  Since then it has pulled back and then reversed in a rounded pattern  a Cup  Currently it is consolidating over the prior high  As it does so  the RSI is working off a technically overbought condition while the MACD is starting to roll over  The Handle may be forming in this consolidation or it may pullback to form it  The move higher out of it is what will make it interesting 
McKesson  NYSE MCK 
McKesson  MCK  has been trending higher since the October pullback with the market  What makes it interesting now is that the recent price action since late February shows consolidation of that move and a touch back at the rising trend support line  The RSI is now moving back higher  after holding in the bullish zone on the pullback  and the MACD crossed up last week  giving a buy signal 
Phillips 66  NYSE PSX 
Phillips 66  PSX  had a choppy pullback over the back half of 2014  But since the bottom in January it has recovered and is bouncing off of resistance at 80  The higher lows show some strength as it tightens against resistance  The RSI has held bullish and over the mid line during the consolidation while the MACD rest lower and is now flirting with a bullish cross 
Visa Inc  NYSE V 
Visa  V  is moving in a falling wedge as it pulls back from a top in early March  This is often a bullish pattern on the break of the wedge  As it moves lower the RSI is nearing the oversold region while the MACD has reset to levels where price has reversed in the past 
If you like what you see sign up for more ideas and deeper analysis using the Get Premium button above 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into next week sees the equity markets remaining positive in the longer run but mixed with a bit of trepidation in the short term 
Elsewhere look for Gold to continue to hold around 1200 while Crude Oil continues its short term bounce  The US Dollar Index looks to continue to consolidate sideways while US Treasuries are biased higher if they break their consolidation range  The Shanghai Composite is on fire and frothy but who know when it will stop while Emerging Markets consolidate their recent move higher 
Volatility looks to remain subdued keeping the bias higher for the equity index ETF s ARCA SPY  ARCA IWM and NASDAQ QQQ  Their charts suggest that the longer term view remains stronger while in the short term the IWM continues to be the strongest but with some short term trepidation and the SPY and QQQ with a decent possibility to start the week lower  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2015-04-20,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-april-20,-2015:-the-rest-248922",248922
128244,349759,MCK,Caterpillar Earnings and M A Stories Send Markets Higher  FTSE Rallies to 200 Day EMA,opinion,The Euro gave back some its recent gains overnight as macro data released today is forecasted to show declines in French and German consumer confidence data and markets prepare for the next EU summit meeting on Wednesday   The drop in the Euro was the start of some moderate US Dollar strength during the session  which was aided by intervention comments from the Japanese Finance Minister and weaker macro data out of Australia brought some buying back into the US Dollar In Asia  equities are mixed with Japanese stocks lower on negative corporate earnings  with Nissan being the primary example  and Chinese markets higher on forecasted improvements for September s manufacturing data   US stock futures are little changed  as markets await today s macro data  which will come in the form of the Case Shiller Home Price report and the Federal Reserve s Richmond Manufacturing survey Market attention is slowly starting to shift to corporate earnings reports  as this will be key for gauging sentiment going forward   Today s releases will be seen from UPS  3M  Amazon com and McKesson Corp   In Europe  the main earnings releases will come from UBS and Deutsche Bank Yesterday s main earnings story came from Netflix  which dropped more than 27  in the aftermarket session after the company released a statement lowering its fourth profit forecasts   The main positives during the New York session came from Caterpillar  which is generally thought of as a leading proxy for the US economic activity   Oracle  and a steady slow of M   A stories which helped the S P close higher on the day and brought some support back to the high yielding currencies Macro data out of Australia yesterday showed that the national Conference Board s survey of leading economic indicators saw a moderate drop to 120 5 and this was matched by consumer inflation data out of New Zealand  which showed a drop to 0 4   from 1 0  previously    Both of these releases support the idea that the RBA and RBNZ will continue expressing a dovish bias at their policy meetings   The turn from the previous tightening cycle from both central banks should continue to be a key factor in the currencies for both regions and suggests that longer term tops are in place at the highs seen earlier this year ,2011-10-25,Spread Betting,https://www.investing.com/analysis/caterpillar-earnings-and-m-a-stories-send-markets-higher;-ftse-rallies-to-200-day-ema-103426,103426
128245,349760,MCK,24 Of Warren Buffett s Most Wanted Dividend Stocks ,opinion,Warren Buffett is an American investor  Chairman and CEO of Berkshire Hathaway  BRK A   He is the third richest man in the world according to Forbes and one of the most influential people in the world  As an investor he generates nearly USD 1 billion in free cash flow per month and has additional USD 37 8 billion in cash for takeover projects  As of Q4 2011  Warren s portfolio had a worth of USD 66 15 billion   Recently  Bloomberg analyst s made a screen of stocks with some classical Buffett target criteria     Market Capitalization from  20 Billion to  40 Billion   Capital Expenditures   Net Fixed Assets   10    5 Year Average Growth in ROIC in Highest 50    5 Year Average Operating Cash Flow Growth in Highest 50    P E Ratio   Average Company Value in Home Market  24 companies worldwide remained  of which 14 are U S  listed  Four of the results have a yield over three percent and twelve are currently recommended to buy Deere   Company  NYSE DE  has a market capitalization of  31 73 billion  The company employs 61 300 people  generates revenues of  32 012 50 million and has a net income of  2 799 20 million  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  5 903 20 million  Because of these figures  the EBITDA margin is 18 44 percent  operating margin 13 19 percent and the net profit margin finally 8 74 percent   Financial Analysis  The total debt representing 55 16 percent of the company s assets and the total debt in relation to the equity amounts to 391 01 percent  Due to the financial situation  a return on equity of 42 76 percent was realized  Twelve trailing months earnings per share reached a value of  6 73  Last fiscal year  the company paid  1 52 in form of dividends to shareholders  Market Valuation  Here are the price ratios of the company  The P E ratio is 11 73  P S ratio 0 99 and P B ratio 4 72  Dividend Yield  2 33 percent  The beta ratio is 1 52  Tyco International  NYSE TYC  has a market capitalization of  25 49 billion  The company employs 100 000 people  generates revenues of  17 355 00 million and has a net income of  1 567 00 million  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  3 437 00 million  Because of these figures  the EBITDA margin is 19 80 percent  operating margin 12 21 percent and the net profit margin finally 9 03 percent   Financial Analysis  The total debt representing 15 49 percent of the company s assets and the total debt in relation to the equity amounts to 29 25 percent  Due to the financial situation  a return on equity of 11 07 percent was realized  Twelve trailing months earnings per share reached a value of  3 02  Last fiscal year  the company paid  0 99 in form of dividends to shareholders  Market Valuation  Here are the price ratios of the company  The P E ratio is 18 23  P S ratio 1 46 and P B ratio 1 80  Dividend Yield  1 82 percent  The beta ratio is 1 13  McKesson Corporation  NYSE MCK  has a market capitalization of  21 12 billion  The company employs 37 700 people  generates revenues of  122 734 00 million and has a net income of  1 403 00 million  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  2 474 00 million  Because of these figures  the EBITDA margin is 2 02 percent  operating margin 1 75 percent and the net profit margin finally 1 14 percent   Financial Analysis  The total debt representing 12 03 percent of the company s assets and the total debt in relation to the equity amounts to 58 26 percent  Due to the financial situation  a return on equity of 19 97 percent was realized  Twelve trailing months earnings per share reached a value of  5 60  Last fiscal year  the company paid  0 80 in form of dividends to shareholders  Market Valuation  Here are the price ratios of the company  The P E ratio is 16 03  P S ratio 0 17 and P B ratio 3 08  Dividend Yield  0 89 percent  The beta ratio is 0 80  Here is the complete list of targets off the screen Apache Corp   APA Covidien Plc  COV Cummins Inc   CMI Deere   Co   DE Deutsche Post AG  DPW DE Dominion Resources Inc   D Goldcorp Inc   GG Henkel AG  HEN DE ITC Ltd   ITC Kia Motors Corp   KIMTF PK Kumba Iron Ore Ltd   KUI BE McKesson Corp   MCK Mosaic Co   MOS Newmont Mining Corp   NEM NovaTek OAO  NVTK ME OAO GMK Norilsk Nickel  GMKN ME Potash Corp  of Saskatchewan  POT TO Prudential Plc  PRU PT Astra International  PTAIF PK SAIC Motor Corp   600104 SS Sasol Ltd   SSL Seven   I Holdings Co   SVNDF PK  Softbank Corp   SFT DE Tyco International Ltd   TYC   Take a closer look at the full table of Warren Buffett s most wanted takeover targets  The average price to earnings ratio  P E ratio  amounts to 16 18 and forward P E ratio is 10 55  The dividend yield has a value of 2 11 percent  Price to book ratio is 2 50 and price to sales ratio 2 16  The operating margin amounts to 24 11 percent  Related stock ticker symbols SSL  D  PUK  NEM  DE  ITC  TYC  COV  GG  CMI  POT  MOS  MCK  APA,2012-05-11,Dividend Yield,https://www.investing.com/analysis/24-of-warren-buffetts-most-wanted-dividend-stocks-122878,122878
128246,349761,MCK,What The Market Wants  More Waiting,opinion,September s first trading day opened flat but later gave way to volatility as the market retreated rather sharply on the heels of slightly weak economic data  Manufacturing ISM fell further below the neutral line of 50  to 49 6  despite forecasts that it would move ahead to 50 after last month s tepid 49 8 reading  That makes three consecutive down months for manufacturing  The market s downward momentum accelerated with the announcement that Construction Spending fell  0 9    much worse than the expected growth of  0 5  and last month s growth of  0 4   Fortunately  Motor Vehicle Sales late in the day helped continue a rally begun by Apple s invitations to a September 12 anticipated showcasing of iPhone 5  Auto sales were up  6 4  year over year and truck sales higher by a similar amount The market rallied into positive territory late in the day before succumbing to concerns about this week s ECB meeting and whether or not President Draghi can sell his three year sovereign debt purchases to assist Greece  Spain  and Italy  That meeting will be followed  about a week later  by the September Fed meeting which  hopefully  will reveal whether QE3 is ready for primetime or simply another tease from Bernanke  All of this uncertainty  coupled with our Presidential election and dysfunctional Congress  are likely to keep equity buyers on the sidelines  Our opinion is that current equity prices are reasonable  if not a tad on the cheap side  unless of course none of the above action items turn out positive for investors  The U S  economy could probably survive without QE3  however  Draghi s task is of particular concern  The amount of European sovereign debt held by banks could be disastrous if Greece  Spain  and Italy collapse  A decline in the euro would lead to downward EPS revisions in U S  equities and place them on an overvalued shelf With so few alternatives sellers are likely to be timid  Bond yields are so low that the downside risk is great if interest rates were to rise  Real estate is risky  precious minerals are expensive  and currency is a dangerous game to trade  The picture for equities remains the most enticing  unless no one acts to get world economies moving ahead faster 4 Stock Ideas for this MarketThis week  I created a custom search in MyStockFinder that picked stocks with strong GARP characteristics in the sectors and market caps favored in Sabrient s Market Stats  namely Cyclicals and Small caps  Here are four you may find interesting  including two Small caps and one Cyclical Consumer Globecomm Systems  Inc   GCOM  TechnologyEnergy Partners Ltd   EPL    EnergyMcKesson Corporation  MCK  HealthcareCooper Tire   Rubber Co   CTB  Cyclical Consumer,2012-09-05,David Brown,https://www.investing.com/analysis/what-the-market-wants:-more-waiting-135190,135190
128247,349762,MCK,McKesson Corp  Stock Research Analysis ,opinion,This article is going to look at Fortune 500 company McKesson Corp  MCK  through the lens of FAST Graphs   fundamentals analyzer software tool  which shows us 18 leading analysts reporting to Capital IQ forecast McKesson Corp s long term earnings growth at 13   The prudent growth and dividend investor may want to do their own due diligence into this company further for a possible addition to their portfolio   McKesson Corporation  currently ranked 14th on the FORTUNE 500  is a healthcare services and information technology company dedicated to making the business of healthcare run better  We partner with payers  hospitals  physician offices  pharmacies  pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting  McKesson helps its customers improve their financial  operational  and clinical performance with solutions that include pharmaceutical and medical surgical supply management  healthcare information technology  and business and clinical services   Earnings Determine Market Price  The following earnings and price correlated  clearly illustrates the importance of earnings  The Earnings Growth Rate Line or True Worth  Line  orange line with white triangles  is correlated with the historical stock price line  On graph after graph the lines will move in tandem  If the stock price strays away from the earnings line  over or under   inevitably it will come back to earnings   Earnings   Price Correlated Fundamentals at a Glance A quick glance at the historical earnings and price correlated FAST Graphs  on McKesson Corp shows a picture of undervaluation based upon the historical earnings growth rate of 14 1   orange circle  and a current PE of 13 2  Analysts are forecasting the earnings growth to continue at about 13   and when you look at the forecasting graph below  the stock appears undervalued   it s inside of the value corridor of the five orange lines   based on future growth   McKesson Corp  Historical Earnings  Price  Dividends and Normal PE Since 2003Performance Table McKesson CorpThe associated performance results with the earnings and price correlated graph  validates the principles regarding the two components of total return  capital appreciation and dividend income  Dividends are included in the total return calculation and are assumed paid  but not reinvested  When presented separately like this  the additional rate of return a dividend paying stock produces for shareholders becomes undeniably evident  In addition to the 12 8  capital appreciation  green circle   long term shareholders of McKesson Corp  assuming an initial investment of  1 000  would have received an additional  136 16 in dividends  blue highlighting  that increased their total return from 12 8  to 13 3  per annum versus 6 7   red circle  in the S P 500 The following graph plots the historical PE ratio  the dark blue line  in conjunction with 10 year Treasury note interest  Notice that the current price earnings ratio on this quality company is as normal as it has been since 2003 A further indication of valuation can be seen by examining a company s current price to sales ratio relative to its historical price to sales ratio  The current price to sales ratio for McKesson Corp is  17 which is historically normal  Looking to the FutureExtensive research has provided a preponderance of conclusive evidence that future long term returns are a function of two critical determinants 1  The rate of change  growth rate  of the company s earnings2  The price or valuation you pay to buy those earningsForecasting future earnings growth  bought at sound valuations  is the key to safe  sound  and profitable performance The Estimated Earnings and Return Calculator Tool is a simple yet powerful resource that empowers the user to calculate and run various investing scenarios that generate precise rate of return potentialities  Thinking the investment through to its logical conclusion is an important component towards making sound and prudent commonsense investing decisions The consensus of 18 leading analysts reporting to Capital IQ forecast McKesson Corp s long term earnings growth at 13   orange circle   McKesson Corp has medium long term debt at 31  of capital  red circle   McKesson Corp is currently trading at a P E of 13 2  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  McKesson Corp s True Worth  valuation would be  196 02 at the end of 2017  brown circle on EYE Chart   which would be a 16 4  annual rate of return from the current price  yellow highlighting  Earnings Yield EstimatesDiscounted Future Cash Flows  All companies derive their value from the future cash flows  earnings  they are capable of generating for their stakeholders over time  Therefore  because Earnings Determine Market Price in the long run  we expect the future earnings of a company to justify the price we pay Since all investments potentially compete with all other investments  it is useful to compare investing in any prospective company to that of a comparable investment in low risk Treasury bonds  Comparing an investment in McKesson Corp to an equal investment in 10 year Treasury bonds  illustrates that McKesson Corp s expected earnings would be 8 3  purple circle  times that of the 10 Year T Bond Interest   See EYE chart below   This is the essence of the importance of proper valuation as a critical investing component Summary   ConclusionsThis report presented essential  fundamentals at a glance  illustrating the past and present valuation based on earnings achievements as reported  Future forecasts for earnings growth are based on the consensus of leading analysts  Although  with just a quick glance you can know a lot about the company  it s imperative that the reader conducts their own due diligence in order to validate whether the consensus estimates seem reasonable or not Disclosure   No position at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation  A comprehensive due diligence effort is recommended ,2012-09-14,F.A.S.T. Graphs,https://www.investing.com/analysis/mckesson-corp:-stock-research-analysis-136445,136445
128248,349763,MCK,McKesson Corp  In Value Stock Based On Historical Earnings ,opinion,Before analyzing a company for investment  it s important to have a perspective on how well the business has performed  Because at the end of the day  if you are an investor  you are buying the business  The FAST Graphs  presented with this article will focus first on the business behind the stock  The orange line on the graph plots earnings per share since 2002  A quick glance vividly reveals the historical operating record of the company McKesson Corporation  MCK  is a healthcare services and information technology company This article will reveal the business prospects of McKesson Corp through the lens of FAST Graphs   fundamentals analyzer software tool  Therefore  it is offered as the first step before a more comprehensive research effort  Our objective is to provide companies that have excellent historical records and appear reasonably priced based on past  present and future data and expectations  A quick glance at the graph itself and the orange earnings justified valuation line will tell the readers volumes about how well the company has historically been managed and performed as an operating business  Simply put  the reader should ask whether this example is worthy of a greater investment of their time and effort based on the data as presented and organized  The FAST Graphs  unique advantage is the graphical articulation of the price value proposition  Earnings Determine Market Price  The following earnings and price correlated FAST Graphs  clearly illustrates the importance of earnings  The Earnings Growth Rate Line or True Worth  Line  orange line with white triangles  is correlated with the historical stock price line  On graph after graph the lines will move in tandem  If the stock price strays away from the earnings line  over or under   inevitably it will come back to earnings  Earnings and Price Correlated Fundamentals at a GlanceA quick glance at the historical earnings and price correlated FAST Graphs  on McKesson Corp shows a picture of in value based upon the historical earnings growth rate of 13 6  and a current P E of 14 9  Analysts are forecasting the earnings growth to continue at about 15   and when you look at the forecasting graph below  the stock appears in value  it s inside of the value corridor of the five orange lines   based on future growth  McKesson Corp  Historical Earnings  Price  Dividends and Normal P E Since 2002Performance Table McKesson CorpThe associated performance results with the earnings and price correlated graph  validates the principles regarding the two components of total return  capital appreciation and dividend income  Dividends are included in the total return calculation and are assumed paid  but not reinvested  When presented separately like this  the additional rate of return a dividend paying stock produces for shareholders becomes undeniably evident  In addition to the 9 7  capital appreciation  green circle   long term shareholders of McKesson Corp  assuming an initial investment of  1 000  would have received an additional  115 53 in dividends  blue highlighting  that increased their total return from 9 7  to 10 1  per annum versus 3 8  in the S P 500 The following graph plots the historical P E ratio  the dark blue line  in conjunction with 10 year Treasury note interest  Notice that the current price earnings ratio on this quality company is as normal as it has been since 2002 A further indication of valuation can be seen by examining a company s current P S ratio relative to its historical P S ratio  The current P S ratio for McKesson Corp is  20 which is historically normal  Looking to the FutureExtensive research has provided a preponderance of conclusive evidence that future long term returns are a function of two critical determinants 1  The rate of change  growth rate  of the company s earnings2  The price or valuation you pay to buy those earningsForecasting future earnings growth  bought at sound valuations  is the key to safe  sound and profitable performance The Estimated Earnings and Return Calculator Tool is a simple yet powerful resource that empowers the user to calculate and run various investing scenarios that generate precise rate of return potentialities  Thinking the investment through to its logical conclusion is an important component towards making sound and prudent commonsense investing decisions The consensus of 18 leading analysts reporting to Capital IQ forecast McKesson Corp s long term earnings growth at 15    McKesson Corp has medium long term debt at 34  of capital  McKesson Corp is currently trading at a P E of 14 9  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  based upon forecasted earnings growth of 15   McKesson Corp s share price would  211 98 at the end of 2018  brown circle on EYE Chart   which would represent a 15 4  annual rate of total return which includes dividends paid  yellow highlighting  Earnings Yield EstimatesDiscounted Future Cash Flows  All companies derive their value from the future cash flows  earnings  they are capable of generating for their stakeholders over time  Therefore  because Earnings Determine Market Price in the long run  we expect the future earnings of a company to justify the price we pay Since all investments potentially compete with all other investments  it is useful to compare investing in any prospective company to that of a comparable investment in low risk Treasury bonds  Comparing an investment in McKesson Corp to an equal investment in 10 year Treasury bonds illustrates that McKesson Corp s expected earnings would be 7 1  purple circle  times that of the 10 year T bond interest  see EYE chart below   This is the essence of the importance of proper valuation as a critical investing component Summary   ConclusionsThis report presented essential  fundamentals at a glance  illustrating the past and present valuation based on earnings achievements as reported  Future forecasts for earnings growth are based on the consensus of leading analysts  Although with just a quick glance you can know a lot about the company  it s imperative that the reader conducts their own due diligence in order to validate whether the consensus estimates seem reasonable or not Disclosure  No position at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation  A comprehensive due diligence effort is recommended ,2013-03-01,F.A.S.T. Graphs,https://www.investing.com/analysis/mckesson-corp:-in-value-stock-based-on-historical-earnings-157309,157309
128249,349764,MCK,S P 500 Range Bound,opinion,"They say the trend is your friend  While the S P 500 may be going up  it has yet to really go anywhere in 2014  Every time it sells off the bears jump on the sell side  it sells off  and then stops  That s what it did last Friday and that s what it s done all year  As of Friday s close the S P is up 1 63   the Dow is up fractionally  0 04   while the NASDAQ Composite is down  2 51  
Rotations
At some point the S P will sell off  but until then it seems very range bound  Whether you re a bull or a bear  it s always important to keep an eye on the overall price action of the S P  Yes  the Russell and Nasdaq were weak  but it looked like the mutual funds were buying the Dow and S P and selling the Nasdaq and Russel  As weak as the markets may have been acting  the Dow rose to a record close on Friday while at the same time the Nasdaq ended its worst week in a month 
Friday to Friday

If you get the feeling that the S P isn t going anywhere right now  you re right  On Friday  May 2  the E mini  CME  ESM14  settled at 1874 50  and last Friday  May 9  the ESM14 settled at 1873 50  After all the hundreds of handles of up and down  the S P closed 1 handle  point  lower from the prior week  After all the thrashing  the S P didn t go anywhere 
Fridays  Mondays and Tuesdays
Clearly there are days when the S P goes up  like Turnaround Tuesday  and there are days the S P goes down  Recently Fridays have not been good  in fact  the S P has closed lower 6 out of the last 8 Fridays while 9 of the 17 Mondays this year have closed higher  with the last 4 all up  But the big day this year has been Turnaround Tuesday  of the 18 Tuesdays so far this year 15 have closed higher and 3 have closed lower  with 5 of the last 6 closing higher 
The Asian markets majors closed sharply higher overnight  Shanghai Comp   2 08    Hang Seng  1 82   after China s Xi said that China must adapt to  new normal  of slower growth  and in Europe 8 out of 12 markets are trading higher  This week s economic calendar includes 20 separate economic releases  9 T bill or T bond announcements or auctions and a whirlwind of Fed speak which includes 6 Federal Reserve governors and 2 appearances by Janet Yellen   Today s economic schedule starts with the Gallup US Consumer Spending Measure  PMI Services index  ISM Non Mfg Index and earnings from McKesson Corporation  NYSE MCK   NII Holdings  NASDAQ NIHD   and Babcock   Wilcox  NYSE BWC  
Our view
Our call was right on last Friday  as was the S P cash study showing it being an up day  We are going to keep it simple  the S P cash study shows the Monday of the May expiration as being up 21   down 9 of the last 30 occasions and Tuesday shows a down day  up 12   down 18 of the last 30 occasions  Overall Fridays have been down lately and Mondays have been up  We lean to selling the early rallies and buying weakness today 
As always please keep an eye on the 10 handle rule and please use stops when trading futures and options 
In Asia  6 of 11 markets closed higher  Shanghai Comp   2 08   Hang Seng  1 82   Nikkei  0 35  
In Europe  8 of 12 markets are trading higher  DAX  0 91   FTSE  0 42 
Morning headline   S P 500 futures seen higher ahead of PMI and ISM index releases 
Fair value  S P  4 17  Nasdaq  4 85   Dow  47 93
Total volume  1 47mil ESM and 3 8K SPM traded
Economic and earnings calendar  Gallup US Consumer Spending Measure  PMI Services index  ISM Non Mfg Index and earnings from McKesson Corp   NII Holdings and Babcock   Wilcox 

E mini S P 500 1888 75 15 25    0 81 
Crude 102 15 0 02    0 02 
Shanghai Composite 0 00N A   N A
Hang Seng 22261 609 398 619    1 82 
Nikkei 225 14149 52 50 07    0 35 
DAX 9695 48 114 03    1 19 
FTSE 100 6847 25 32 68    0 48 
Euro 1 376",2014-05-12,Danny Riley,https://www.investing.com/analysis/s-p-500-range-bound-212510,212510
128250,349765,MCK,Company Notes Digest  Retailers Stick To The Same Script,opinion,"It s half way through May and we re still talking about the weather
Every retailer pretty much stuck to the same script  business was weak in Q1 because of the weather
 Like other retailers in the United States  the unseasonably cold and disruptive winter weather negatively impacted our U S  sales and drove operating expenses higher than expected for the company   Wal Mart Stores Inc  NYSE WMT  
 we were expecting sales to be stronger than they were at both Bloomingdale s and Macy s  and as I just stated  the weather clearly played a major role in the weakness   Macy s Inc  NYSE M  
 We had very tough business in February and March like everyone else  we were down something like  40 million to plan at one point just from weather   JC Penney Company Inc Holding  NYSE JCP  
Even online shopping is apparently not immune from the grip of cold weather
 Obviously  E Comm was also affected by some of the difficulty from a weather perspective in the quarter   Kohl s Corporation  NYSE KSS  
Everyone agrees that things got better when the weather warmed up though
 once the weather warmed up  there was a significant change in the trend  So  again  a couple of weeks doesn t a quarter or a year make  But it is encouraging to see that and particularly in the northern climate  So that s part of why we re feeling confident   Macy s Inc  NYSE M  
 I m encouraged by the sales momentum in the back half of the quarter   Wal Mart Stores Inc  NYSE WMT  
 I am encouraged by the consistent improvement that we saw as the quarter progressed   Kohl s Corporation  NYSE KSS  
 we had a great recovery in April   JC Penney Company Inc Holding  NYSE JCP  
 Our business did get better as the quarter went on  First month was  February was the toughest month of the quarter for us and last month was the best   Nordstrom Inc  NYSE JWN  
But here s the rub  Q1 for retailers lasts Feb April  Bad weather affected only two out of thirteen weeks
 As we indicated in February  we realized negative comp sales during the first two weeks of the fiscal year from severe winter storms  A solid start to the spring season and a strong Easter holiday drove positive comps over the remaining 11 weeks of the quarter    WMT  
And April got a strong boost because Easter shifted later in the year
 April was very  very strong because of the shift in the Easter holiday    JCP  
When Macy s was pushed  they admitted they couldn t be sure it was all weather related
 While we aren t sure that all of the weakness in the quarter was weather related  we continue to believe that the underlying customer demand is strong enough to enable us to achieve our annual guidance    M  
And conceded that they planned for a so so consumer and that s what they re seeing
 when we gave our guidance at the beginning of the year  We were not expecting the consumer to be all that strong  So that really hasn t changed with anything we ve seen in the first quarter  Obviously  could make it a little more challenging but we still think that the consumer is okay but not great    M  
Walmart makes an emphatic statement on accelerating inflation
 Q1 was marked by a rapid acceleration in inflation  as cost inflation was approximately 160 basis points  compared to 30 basis points in Q4    WMT  
If the weather is unfavorable  food inflation could get worse  uggh  more weather 
 even though supplies appear to be adequate  global grain and oil seed demands remain strong  Unfavorable growing conditions in any part of the world would hurt production  reduce the stock to use ratio and result in prices quickly moving higher    DE  
Consumer
You have to invest heavily to stay on top of the pack in e commerce
 I don t know how a retailer could compete going forward without a really strong online presence and investing heavily to keep up with all that s happening technologically in that world    M  
 An important element is our technology investments  which represent  1 2 billion or 30  of our capital plan    JWN  
Home was a weak category for Macy s after a long run of strength
 it stood out for us too because as you know  home has been so strong for so long  So I m hoping it s just an outlier and by the second quarter that would no longer be the case  Early May is making us feel a lot better  But there s really nothing we re seeing on the competitive front that would lead us to be concerned about home longer term    M  
JC Penney may have steadied the ship
 as I go to stores I don t hear from associates that we re in misalignment at this point  I think we re back to running the business properly    JCP  
 I think we put to bed a lot of the previous anxieties and frankly our results will only enhance that we are going forward    JCP  
Millenials shop both online and in store
 There is sort of assumption that many people have that it s all online  is actually not the case  Millennials love shopping in stores as well as online and browsing in one channel and shopping in another  so both have been doing well    M  
Online shopping has made pricing much more competitive
 the competitive issue has been  it s been made more dramatic by the fact that the online business has really made things much more transparent and really better for customers if all the choices are out there    JWN  
Online and off price outlets are a way to generate new customer relationships
 we re not interested in isolating the channels  The reason we ve invested the way we have is because we want to have a complete offering online  in store  regular price and off pricing  We believe that that s going to allow us to engage with more customers and we also believe particularly in the online and off price segment that it s a great vehicle for us to acquire new customers  And we find that a lot of those customers do migrate to a regular price offering as time goes on  and we also have regular price customers that periodically look to shop at the Rack  And as long as we can continue to offer that more robust offering  we believe we re going to create more lifelong customers    JWN  
Healthcare
The healthcare landscape is shifting  everyone more focused on better quality of care at lower cost
 Pharmacies are increasingly positioning themselves as convenient alternative sites for primary care and offering services to patients to assist them in managing their health  Payers and providers are collaborating in innovative ways to design effective value based reimbursement programs that will slowly shift our fee for service based approach to a care delivery to our payment for value approach tied to outcomes delivered by providers  And consumers are more engaged in understanding the cost and quality of healthcare than ever before    MCK  
Materials  Industrials  Energy
Still too many dry bulk ships to balance the market
 we still say the same thing that the numbers of that available in the waters are too many  We have still vessels coming into the water demolition has been slowing down since its peak in 2012   Diana Shipping inc  NYSE DSX  
Diana is sorry for being right that everyone was overly optimistic
 We regret to say that we were once again correct in our way of thinking at the previous conference call where everyone was over optimistic about the market  And we said to you read the sign better and see that the market is not   the things are not so good as they were presented to you being    DSX  
The Dry Bulk market will improve eventually  but unlikely to get better in the next 12 24 months
 even though we assure that the market will improve eventually and it will improve significantly from the level at that we re now  we are not very optimistic about the next 12 to 24 months as regard to rate  which does not exclude spike in rate  especially spot rate  due to seasonal reasons or other disruptions in the supply stream of ships    DSX  
Private equity money is distorting the market
 big chunks of money that are coming into the picture from private investors and together with the capital market but they have distorted the way of thinking and they create a kind of not normal optimism about the market but influences everybody    DSX  
Low interest rates are also delaying the equilibrium
 there is also the very low cost of the money  If you have interest rates very low  then the equilibrium between the values does not come quickly stronger    DSX  
Farm income expected to decline slightly in 2014
 While remaining near long term averages  grain prices and farm income are expected to decrease in 2014  As a result  farm machinery demand is expected to be lower for the year   DAX 
Miscellaneous Nuggets of Wisdom
Forecasting is a part of business  You do the best you can with the information you have 
 Like any other estimate that we have to make  whether it s brand inflation or generic inflation or generic launches  et cetera  what we attempt to do is use the best resources we have internal to the company and whatever resources are available externally to create those views It certainly could be wrong  and the manufacturers don t typically tell us what they re going to do   McKesson Corporation  NYSE MCK  
Enter new markets with an underdog mentality
 We go in with a lot of humility  it s not easy to go to another country and we have to win with the customer  So we re going in with an underdog mentality   Nordstrom Inc  NYSE JWN  

Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-05-16,Investing.com,https://www.investing.com/analysis/company-notes-digest:-retailers-stick-to-the-same-script-213147,213147
128251,349766,MCK,Summer Slog Likely To Keep A Lid On Further Stock Gains ,opinion,"Stock investors entered the Fourth of July holiday on a high note  pushing the Dow Jones Industrials Index above 17 000 and the Wilshire 5000 Total Market Index above 21 000  and even pushing the S P 500 to a smidge above the upper trend line of its long standing bullish ascending channel that has been in place for nearly three years  However  with the Independence Day cheer behind us  persistently overbought technical conditions  and two months of summer doldrums ahead until the Labor Day holiday  I don t think stocks are likely to muster much in the way of further progress over the near term  This may give bears a chance to make their long stymied move   Although bulls should be able to maintain the upper hand in the longer term  I expect bears will finally have their window of opportunity to drive prices down  at least a little  before summer is over 
Last week I reported that among the ten U S  business sectors  defensive and income oriented Utilities displayed the best first half performance  But last week was harsh on Utilities  allowing Energy to become the new leader  while Utilities fell into a virtual dead heat with Healthcare and Technology for second place  Basic Materials also has shown good strength of late  This recent action might suggest some early signs of positioning for rising inflation and interest rates on the horizon 
Although the U S  10 Year Treasury bond continues to remain strong with a low yield of 2 66   this is actually a bit of a spike from the prior week s close of 2 53   Nevertheless  some top bond fund managers are still predicting that the 10 year yield could fall as low as 2 2  this year 
While the CPI is showing no signs of inflation  there s no doubt that healthcare and housing costs are rising  But with the labor force participation rate on a downtrend and capacity utilization still relatively low  wage pressures and GDP will gradually rise  As a result  assuming the Fed starts raising interest rates by the end of next year  some  like Guggenheim Partners  are predicting 10 year Treasury yields to approach 4  over the next few years  Much of this capital should rotate into equities 
The CBOE Market Volatility Index  VIX   a k a  fear gauge  continues on its slow trek toward the depths of single digits  closing the short week on Thursday at 10 32  While some observers have been predicting single digits for the VIX  others expect an imminent reversion to the mean  perhaps all the way up to test resistance at 15  But short of a major black swan event  catalysts for such a volatility spike seem scarce 
Indeed  investor sentiment is definitely not overly bullish  which means from a contrarian basis that there is plenty of fuel available to fill the tank  For example  there has been three straight months of outflows from U S  equity funds  Also  short interest in S P 500 stocks has been rising  trading volume is moribund  and individual investor participation remains low 
Furthermore  corporate stock buybacks continue in earnest  and with persistently low interest rates and wage inflation  central banks can continue their liquidity programs without constraint  This means that equity prices and P E multiples still have plenty of room to the upside 
Economists are expecting strong economic growth in the second half of 2014  Sell side analysts are anticipating record earnings per share for both the second quarter and the calendar year  Companies in the S P 500 are estimated to achieve 7 1  EPS growth compared with last quarter s actual of 3 4   However  top line revenues are only projected to grow at 2 6   indicating cost cutting and productivity gains as the key drivers  At some point  revenues will have to become the driver for earnings growth  Notably  all ten business sectors are expected to report positive growth 
SPY chart review 
The SPDR S P 500 Trust  ARCA SPY  closed the short week on Thursday at 198 20  The upper line of the long standing bullish rising channel has been extremely tough resistance  but on Thursday SPY showed some desire to want to break through during the low volume  holiday shortened week  However  even if it succeeds this week  I believe the writing is on the wall for a failed breakout and a cycle back down to test the 50 day simple moving average and the lower Bollinger Band as we slog through the summer doldrums  Oscillators RSI  MACD  and Slow Stochastic are all acting fatigued at these heights and wanting to cycle back down  A successful test of the 50 day SMA  around 192 or so  would be healthy for bullish conviction by attracting fresh capital to make a new run at the 200 level  which is both psychologically attractive and ominous  Now that would be a test of resistance that I would really like to see 

By the way  the Russell 2000 small cap index has rallied from a May double bottom formation back above the 1200 level  but now might be forming a bearish double top formation 
Latest sector rankings 
Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 
In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 
Outlook score is forward looking while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs is used  We use the iShares that represent the ten major U S  business sectors  Financial  iShares US Financials  NYSE IYF    Technology  iShares Dow Jones US Technology  NYSE IYW    Industrial  iShares US Industrials  NYSE IYJ    Healthcare  iShares US Healthcare  NYSE IYH    Consumer Goods  iShares US Consumer Goods  NYSE IYK    Consumer Services  iShares US Consumer Services  NYSE IYC    Energy  iShares DJ US Energy Sector Fund  NYSE IYE    Basic Materials  iShares US Basic Materials  NYSE IYM    Telecommunications  iShares US Telecommunications  NYSE IYZ    and Utilities  iShares US Utilities  NYSE IDU    Whereas the Select Sector SPDRs only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each   
Here are some of my observations on this week s scores 
1   Technology remains in first place with a strong Outlook score of 87  although Energy is catching up fast at 82  Technology continues to display generally solid factor scores across the board  with a strong forward long term growth rate  a reasonable forward P E  the highest return ratios  and good sentiment among Wall Street analysts  upward revisions to earnings estimates   Energy displays the most upward revisions from Wall Street  the second lowest forward P E  and the strongest insider sentiment  open market buying  this week  Healthcare takes third place  scoring 61  with solid sell side sentiment and a strong forward long term growth rate  while Financial and Industrial round out the top five  However  Financial and Industrial are both scoring well below the 50 mid point  so only three sectors are scoring above mid point  which is concerning  Notably  Utilities continues to fall  as well 
2   Basic Materials is in the cellar this week with an Outlook score of 14  as it displays the worst sentiment among both Wall Street analysts  downward revisions to earnings estimates  and insiders  open market selling   Telecommunications takes a rare trip out of the bottom spot but remains in the bottom two with a score of 20 
3   Looking at the Bull scores  Technology is the leader with a relatively low score of 52  followed by Industrial at 51  while Utilities is the clear laggard at 35  The top bottom spread is 17 points  reflecting lower sector correlations on particularly strong market days  It is generally desirable in a healthy market to see a top bottom spread of at least 20 points  which indicates that investors have clear preferences in the stocks they want to hold  rather than the all boats lifted in a rising tide mentality that dominated 2013 
4   Looking at the Bear scores  Utilities is the clear leader with a 64  which means that stocks within this sector have been the preferred safe havens on weak market days  Industrial displays the lowest score of 44  The top bottom spread is up to 20 points  reflecting lower sector correlations on particularly weak market days  Again  it is generally desirable in a healthy market to see a top bottom spread of at least 20 points  so this is promising 
5   Technology displays the best all weather combination of Outlook Bull Bear scores  while Telecom is the worst  Looking at just the Bull Bear combination  Energy is the leader  indicating superior relative performance  on average  in extreme market conditions  whether bullish or bearish   Telecom scores the lowest  indicating general investor avoidance during extreme conditions 
6   Overall  this week s fundamentals based Outlook rankings still look neutral  On the one hand  economically sensitive sectors Technology  Financial  and Industrial are all in the top five  while defensive sector Utilities continues to fall  But on the other hand  only three of the ten sectors hold an Outlook score above 50  and none of sectors are displaying very high Bull scores 
These Outlook scores represent the view that the Technology and Energy sectors are relatively undervalued  while Basic Materials and Telecom may be relatively overvalued based on our 1 3 month forward look 
Stock and ETF Ideas 
Our Sector Rotation model  which appropriately weights Outlook  Bull  and Bear scores in accordance with the overall market s prevailing trend  bullish  neutral  or bearish   suggests continuing to hold Technology  Energy  and Healthcare  in that order  in the prevailing bullish climate   Note  In this model  we consider the bias to be bullish from a rules based standpoint because SPY is still above its 50 day simple moving average while also remaining above its 200 day SMA  
Other highly ranked ETFs from the Technology  Energy  and Healthcare sectors include First Trust NASDAQ Technology Dividend Index Fund  NASDAQ TDIV   PowerShares Dynamic Energy E P Portfolio  NYSE PXE   and ProShares Ultra Health Care  NYSE RXL  
For an enhanced sector portfolio that enlists top ranked stocks  instead of ETFs  from within Technology  Energy  and Healthcare  some long ideas include Skyworks Solutions  NASDAQ SWKS   OmniVision Technologies  NASDAQ OVTI   Valero Energy  NYSE VLO   EOG Resources  NYSE EOG   McKesson Corp NYSE MCK   and Questcor Pharmaceuticals  NASDAQ QCOR   All are highly ranked in the Sabrient Ratings Algorithm and also score in the top two quintiles  lowest accounting related risk  of our   a pure accounting based risk assessment signal based on the forensic accounting expertise of our subsidiary Gradient Analytics  We have found it quite valuable for helping to avoid performance offsetting meltdowns in our model portfolios 
If you are more comfortable with a neutral bias  the model still suggests holding Technology  Energy  and Healthcare  in that order   But if you have a bearish outlook on the market  the model suggests holding Energy  Utilities  and Technology  in that order  
Disclosure  Author has no positions in stocks or ETFs mentioned   Disclaimer  This newsletter is published solely for informational purposes and is not to be construed as advice or a recommendation to specific individuals  Individuals should take into account their personal financial circumstances in acting on any rankings or stock selections provided by Sabrient  Sabrient makes no representations that the techniques used in its rankings or selections will result in or guarantee profits in trading  Trading involves risk  including possible loss of principal and other losses  and past performance is no indication of future results ",2014-07-07,Scott Martindale,https://www.investing.com/analysis/summer-slog-likely-to-keep-a-lid-on-further-stock-gains-218547,218547
